0001493152-24-045032.txt : 20241113 0001493152-24-045032.hdr.sgml : 20241113 20241113131217 ACCESSION NUMBER: 0001493152-24-045032 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 43 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241113 DATE AS OF CHANGE: 20241113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VIVOS INC CENTRAL INDEX KEY: 0001449349 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 800138937 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53497 FILM NUMBER: 241452864 BUSINESS ADDRESS: STREET 1: 719 JADWIN AVENUE CITY: RICHLAND STATE: WA ZIP: 99352 BUSINESS PHONE: 509-736-4000 MAIL ADDRESS: STREET 1: 719 JADWIN AVENUE CITY: RICHLAND STATE: WA ZIP: 99352 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED MEDICAL ISOTOPE Corp DATE OF NAME CHANGE: 20081103 10-Q 1 form10-q.htm
false --12-31 Q3 0001449349 P3Y P3Y P2Y 0001449349 2024-01-01 2024-09-30 0001449349 2024-11-13 0001449349 2024-09-30 0001449349 2023-12-31 0001449349 RDGL:SeriesAConvertiblePreferredStockMember 2024-09-30 0001449349 RDGL:SeriesAConvertiblePreferredStockMember 2023-12-31 0001449349 RDGL:SeriesBConvertiblePreferredStockMember 2024-09-30 0001449349 RDGL:SeriesBConvertiblePreferredStockMember 2023-12-31 0001449349 RDGL:SeriesCConvertiblePreferredStockMember 2024-09-30 0001449349 RDGL:SeriesCConvertiblePreferredStockMember 2023-12-31 0001449349 2023-01-01 2023-09-30 0001449349 2024-07-01 2024-09-30 0001449349 2023-07-01 2023-09-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-12-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember 2022-12-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-12-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember 2022-12-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-12-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember 2022-12-31 0001449349 us-gaap:CommonStockMember 2022-12-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001449349 us-gaap:RetainedEarningsMember 2022-12-31 0001449349 2022-12-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-03-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember 2023-03-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-03-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember 2023-03-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2023-03-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember 2023-03-31 0001449349 us-gaap:CommonStockMember 2023-03-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001449349 us-gaap:RetainedEarningsMember 2023-03-31 0001449349 2023-03-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-06-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember 2023-06-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-06-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember 2023-06-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2023-06-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember 2023-06-30 0001449349 us-gaap:CommonStockMember 2023-06-30 0001449349 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001449349 us-gaap:RetainedEarningsMember 2023-06-30 0001449349 2023-06-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-12-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember 2023-12-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-12-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember 2023-12-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2023-12-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember 2023-12-31 0001449349 us-gaap:CommonStockMember 2023-12-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001449349 us-gaap:RetainedEarningsMember 2023-12-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-03-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember 2024-03-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-03-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember 2024-03-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2024-03-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember 2024-03-31 0001449349 us-gaap:CommonStockMember 2024-03-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001449349 us-gaap:RetainedEarningsMember 2024-03-31 0001449349 2024-03-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-06-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember 2024-06-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-06-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember 2024-06-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2024-06-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember 2024-06-30 0001449349 us-gaap:CommonStockMember 2024-06-30 0001449349 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001449349 us-gaap:RetainedEarningsMember 2024-06-30 0001449349 2024-06-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-03-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember 2023-01-01 2023-03-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-03-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember 2023-01-01 2023-03-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2023-01-01 2023-03-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember 2023-01-01 2023-03-31 0001449349 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001449349 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001449349 2023-01-01 2023-03-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-04-01 2023-06-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember 2023-04-01 2023-06-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-04-01 2023-06-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember 2023-04-01 2023-06-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2023-04-01 2023-06-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember 2023-04-01 2023-06-30 0001449349 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001449349 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001449349 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001449349 2023-04-01 2023-06-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-07-01 2023-09-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember 2023-07-01 2023-09-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-07-01 2023-09-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember 2023-07-01 2023-09-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2023-07-01 2023-09-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember 2023-07-01 2023-09-30 0001449349 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001449349 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001449349 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-03-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember 2024-01-01 2024-03-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-03-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember 2024-01-01 2024-03-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2024-01-01 2024-03-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember 2024-01-01 2024-03-31 0001449349 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001449349 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001449349 2024-01-01 2024-03-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-04-01 2024-06-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember 2024-04-01 2024-06-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-04-01 2024-06-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember 2024-04-01 2024-06-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2024-04-01 2024-06-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember 2024-04-01 2024-06-30 0001449349 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001449349 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001449349 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001449349 2024-04-01 2024-06-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-07-01 2024-09-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember 2024-07-01 2024-09-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-07-01 2024-09-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember 2024-07-01 2024-09-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2024-07-01 2024-09-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember 2024-07-01 2024-09-30 0001449349 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001449349 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001449349 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-09-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember 2023-09-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-09-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember 2023-09-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2023-09-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember 2023-09-30 0001449349 us-gaap:CommonStockMember 2023-09-30 0001449349 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001449349 us-gaap:RetainedEarningsMember 2023-09-30 0001449349 2023-09-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-09-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember 2024-09-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-09-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember 2024-09-30 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2024-09-30 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember 2024-09-30 0001449349 us-gaap:CommonStockMember 2024-09-30 0001449349 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001449349 us-gaap:RetainedEarningsMember 2024-09-30 0001449349 us-gaap:PrivatePlacementMember 2023-01-01 2023-12-31 0001449349 us-gaap:WarrantMember 2023-12-31 0001449349 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001449349 us-gaap:WarrantMember 2024-09-30 0001449349 us-gaap:CommonStockMember srt:MaximumMember 2024-07-17 2024-07-17 0001449349 RDGL:BrachytherapyProductLineMember 2024-01-01 2024-09-30 0001449349 RDGL:RadionuclideTherapyProductLineMember 2024-01-01 2024-09-30 0001449349 us-gaap:PreferredStockMember 2024-01-01 2024-09-30 0001449349 us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001449349 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001449349 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001449349 us-gaap:StockOptionMember 2024-01-01 2024-09-30 0001449349 us-gaap:StockOptionMember 2023-01-01 2023-12-31 0001449349 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001449349 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001449349 2023-01-01 2023-12-31 0001449349 srt:ChiefExecutiveOfficerMember 2023-09-30 0001449349 RDGL:SeriesAConvertiblePreferredStockMember 2015-06-30 0001449349 RDGL:SeriesAConvertiblePreferredStockMember 2016-03-30 0001449349 RDGL:SeriesAConvertiblePreferredStockMember 2016-03-31 0001449349 RDGL:SeriesAConvertiblePreferredStockMember 2015-06-30 2015-06-30 0001449349 RDGL:SeriesBConvertiblePreferredStockMember 2018-10-10 0001449349 RDGL:SeriesBConvertiblePreferredStockMember 2018-10-10 2018-10-10 0001449349 RDGL:SeriesCConvertiblePreferredStockMember 2019-03-27 0001449349 RDGL:SeriesCConvertiblePreferredStockMember 2019-03-27 2019-03-27 0001449349 RDGL:CommonStockandWarrantsMember 2024-01-01 2024-09-30 0001449349 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001449349 us-gaap:CommonStockMember 2023-04-01 2023-04-30 0001449349 RDGL:SeriesAWarrantMember 2023-04-01 2023-04-30 0001449349 RDGL:SeriesBWarrantMember 2023-04-01 2023-04-30 0001449349 srt:MinimumMember 2023-12-31 0001449349 srt:MaximumMember 2023-12-31 0001449349 srt:MinimumMember 2024-09-30 0001449349 srt:MaximumMember 2024-09-30 0001449349 srt:MinimumMember 2022-12-31 0001449349 srt:MaximumMember 2022-12-31 0001449349 2022-01-01 2022-12-31 0001449349 srt:MinimumMember 2023-09-30 0001449349 srt:MaximumMember 2023-09-30 0001449349 us-gaap:StockOptionMember 2024-07-01 2024-09-30 0001449349 us-gaap:StockOptionMember 2024-01-01 2024-09-30 0001449349 us-gaap:StockOptionMember 2023-07-01 2023-09-30 0001449349 us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001449349 us-gaap:WarrantMember 2023-04-01 2023-04-30 0001449349 us-gaap:WarrantMember 2024-01-01 2024-01-31 0001449349 us-gaap:WarrantMember 2024-04-01 2024-04-01 0001449349 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001449349 RDGL:RestrictedStockUnitsMember srt:ChiefExecutiveOfficerMember 2024-01-01 2024-01-01 0001449349 RDGL:RestrictedStockUnitsMember srt:ChiefExecutiveOfficerMember 2024-01-01 2024-09-30 0001449349 us-gaap:RestrictedStockUnitsRSUMember RDGL:ConsultantsMember 2024-05-01 2024-05-31 0001449349 us-gaap:WarrantMember 2023-12-31 0001449349 us-gaap:WarrantMember srt:MinimumMember 2023-12-31 0001449349 us-gaap:WarrantMember srt:MaximumMember 2023-12-31 0001449349 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001449349 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001449349 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001449349 us-gaap:WarrantMember 2024-09-30 0001449349 us-gaap:WarrantMember 2022-12-31 0001449349 us-gaap:WarrantMember srt:MinimumMember 2022-12-31 0001449349 us-gaap:WarrantMember srt:MaximumMember 2022-12-31 0001449349 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001449349 us-gaap:WarrantMember 2023-09-30 0001449349 us-gaap:WarrantMember srt:MinimumMember 2023-09-30 0001449349 us-gaap:WarrantMember srt:MaximumMember 2023-09-30 0001449349 RDGL:RestrictedStockUnitsMember 2023-12-31 0001449349 RDGL:RestrictedStockUnitsMember 2024-01-01 2024-09-30 0001449349 RDGL:RestrictedStockUnitsMember 2024-09-30 0001449349 RDGL:RestrictedStockUnitsMember 2022-12-31 0001449349 RDGL:RestrictedStockUnitsMember 2023-01-01 2023-09-30 0001449349 RDGL:RestrictedStockUnitsMember 2023-09-30 0001449349 RDGL:EmploymentAgreementMember RDGL:DrMichaelKKorenkoMember 2019-06-04 2019-06-04 0001449349 RDGL:EmploymentAgreementMember RDGL:DrMichaelKKorenkoMember 2024-01-01 2024-01-01 0001449349 us-gaap:RestrictedStockUnitsRSUMember RDGL:DrMichaelKKorenkoMember 2024-01-01 2024-01-01 0001449349 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2024-11-12 2024-11-12 0001449349 us-gaap:SubsequentEventMember us-gaap:WarrantMember 2024-11-12 2024-11-12 0001449349 us-gaap:SubsequentEventMember RDGL:ExpireDecemberThirtyFirstTwoThousandAndTwentyFourMember 2024-11-12 2024-11-12 0001449349 us-gaap:SubsequentEventMember RDGL:ExpireDecemberThirtyFirstTwoThousandAndTwentyFourMember 2024-11-12 0001449349 us-gaap:SubsequentEventMember RDGL:ExpireDecemberThirtyFirstTwoThousandAndTwentySevenMember 2024-11-12 2024-11-12 0001449349 us-gaap:SubsequentEventMember RDGL:ExpireDecemberThirtyFirstTwoThousandAndTwentySevenMember 2024-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE QUARTERLY PERIOD ENDED: SEPTEMBER 30, 2024

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM __________ TO __________

 

Commission File Number 000-53497

 

VIVOS INC

(Exact name of registrant as specified in its charter)

 

Delaware   80-0138937

(State or other jurisdiction

of incorporation or organization)

  

(I.R.S. Employer

Identification No.)

 

1030 N Center Parkway,

Kennewick, WA 99336

(Address of principal executive offices, Zip Code)

 

(509) 222-2222

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

  Large accelerated filer ☐ Accelerated filer ☐  
  Non-accelerated filer ☒ Smaller reporting company ☒  
    Emerging growth company ☐  

 

If an emerging growth company, indicate by check mark if the company has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of November 13, 2024, there were 417,592,703 shares of the registrant’s common stock outstanding.

 

 

 

 
 

TABLE OF CONTENTS

 

      Page
  PART I – FINANCIAL INFORMATION    
       
Item 1. Financial Statements    
       
  Condensed Balance Sheets as of September 30, 2024 (unaudited) and December 31, 2023   1
       
  Condensed Statements of Operations for the Nine and Three Months ended September 30, 2024 and 2023 (unaudited)   2
       
  Condensed Statement of Changes in Stockholders’ Equity for the Nine Months ended September 30, 2024 and 2023 (unaudited)   3
       
  Condensed Statements of Cash Flow for the Nine Months ended September 30, 2024 and 2023 (unaudited)   4
       
  Notes to Condensed Financial Statements (unaudited)   5
       
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations   20
       
Item 3. Quantitative and Qualitative Disclosures About Market Risk   26
       
Item 4. Controls and Procedures   26
       
  PART II – OTHER INFORMATION    
       
Item 1. Legal Proceedings   27
       
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   27
       
Item 6. Exhibits   27
       
SIGNATURES   28

 

i
 

 

PART I – FINANCIAL INFORMATION

 

VIVOS INC

CONDENSED BALANCE SHEETS

SEPTEMBER 30, 2024 (UNAUDITED) AND DECEMBER 31, 2023

 

   SEPTEMBER 30,   DECEMBER 31, 
   2024   2023 
    (UNAUDITED)      
           
ASSETS          
           
Current Assets:          
Cash  $1,218,160   $1,592,287 
Accounts receivable   5,000    7,000 
Prepaid expenses   21,165    10,837 
           
Total Current Assets   1,244,325    1,610,124 
           
TOTAL ASSETS  $1,244,325   $1,610,124 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
LIABILITIES          
Current Liabilities:          
Accounts payable and accrued expenses  $48,820   $245,004 
           
Total Current Liabilities   48,820    245,004 
           
Total Liabilities   48,820    245,004 
           
Commitments and contingencies   -    - 
           
STOCKHOLDERS’ EQUITY          
Preferred stock, par value, $0.001, 20,000,000 shares authorized, Series A Convertible Preferred, 5,000,000 shares authorized, 2,071,007 shares issued and outstanding, respectively  
 
 		  
 
 		  
 
2,071		  
 
 		  
 
 		  
 
 		  
 
2,071		  
 
 
Additional paid in capital - Series A Convertible preferred stock   8,842,458    8,842,458 
Series B Convertible Preferred, 5,000,000 shares authorized, 200,363 shares issued and outstanding, respectively  
 		  
 		  
200		  
 		  
 		  
 		  
200		  
 
Additional paid in capital - Series B Convertible preferred stock   290,956    290,956 
Series C Convertible Preferred, 5,000,000 shares authorized, 385,302 shares issued and outstanding, respectively  
 		  
 		  
385		  
 		  
 		  
 		  
385		  
 
Additional paid in capital - Series C Convertible preferred stock   500,507    500,507 
Common stock, par value, $0.001, 950,000,000 shares authorized, 417,592,703 and 387,894,033 issued and outstanding, respectively  
 		  
 		  
417,593		  
 		  
 		  
 		  
387,894		  
 
Additional paid in capital - common stock   75,479,376    73,791,430 
Accumulated deficit   (84,338,041)   (82,450,781)
           
Total Stockholders’ Equity   1,195,505    1,365,120 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $1,244,325   $1,610,124 

 

1

 

 

VIVOS INC

CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)

FOR THE NINE AND THREE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

 

   2024   2023   2024   2023 
   NINE MONTHS ENDED   THREE MONTHS ENDED 
   SEPTEMBER 30,   SEPTEMBER 30,   SEPTEMBER 30,   SEPTEMBER 30, 
   2024   2023   2024   2023 
                 
Revenues, net  $23,000   $19,500   $5,000   $7,000 
Cost of Goods Sold   (20,699)   (16,536)   (3,919)   - 
                     
Gross profit   2,301    2,964    1,081    7,000 
                     
OPERATING EXPENSES                    
Professional fees, including stock-based compensation   1,310,604    1,205,819    627,152    512,856 
Payroll expenses   267,153    214,083    85,400    69,562 
Research and development   223,660    300,586    66,551    80,858 
General and administrative expenses   143,468    132,831    65,123    31,357 
                     
Total Operating Expenses   1,944,885    1,853,319    844,226    694,633 
                     
OPERATING LOSS   (1,942,584)   (1,850,355)   (843,145)   (687,633)
                     
NON-OPERATING INCOME (EXPENSE)                    
Interest income   55,324    31,821    17,882    19,943 
                     
Total Non-Operating Income (Expenses)   55,324    31,821    17,882    19,943 
                     
NET LOSS BEFORE PROVISION FOR INCOME TAXES   (1,887,260)   (1,818,534)   (825,263)   (667,690)
                     
Provision for income taxes   -    -    -    - 
                     
NET LOSS  $(1,887,260)  $(1,818,534)  $(825,263)  $(667,690)
                     
Net loss per share - basic and diluted  $(0.00)  $(0.00)  $(0.00)  $(0.00)
                     
Weighted average common shares outstanding   403,860,277    367,112,957    418,629,728    370,541,528 

 

2

 

 

VIVOS INC

CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY (UNAUDITED)

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

 

           Additional           Additional           Additional                     
           Paid-In           Paid-In           Paid-In       Additional         
   Series A Preferred   Capital -
Series A		   Series B Preferred   Capital -
Series B		   Series C Preferred   Capital -
Series C		   Common Stock   Paid-In
Capital -		   Accumulated     
   Shares   Amount   Preferred   Shares   Amount   Preferred   Shares   Amount   Preferred   Shares   Amount   Common   Deficit   Total 
                                                         
Balance - December 31, 2022   2,071,007   $2,071   $8,842,458    200,363   $200   $290,956    385,302   $385   $500,507    362,541,518   $362,541   $71,217,954   $(79,556,028)  $1,661,044 
                                                                       
Net loss for the period   -    -    -    -    -    -    -    -    -    -    -    -    (248,318)   (248,318)
                                                                       
Balance - March 31, 2023   2,071,007    2,071    8,842,458    200,363    200    290,956    385,302    385    500,507    362,541,518    362,541    71,217,954    (79,804,346)   1,412,726 
                                                                       
Stock issued for:                                                                      
Cash   -    -    -    -    -    -    -    -    -    8,000,000    8,000    632,000    -    640,000 
Warrants purchased for cash   -    -    -    -    -    -    -    -    -    -    -    10,665    -    10,665 
RSUs granted to consultants that have vested   -    -    -    -    -    -    -    -    -    -    -    515,975    -    515,975 
Net loss for the period   -    -    -    -    -    -    -    -    -    -    -    -    (902,526)   (902,526)
                                                                       
Balance - June 30, 2023   2,071,007    2,071    8,842,458    200,363    200    290,956    385,302    385    500,507    370,541,518    370,541    72,376,594    (80,706,872)   1,676,840 
                                                                       
RSUs granted to consultants that have vested   -    -    -    -    -    -    -    -    -    -    -    450,000    -    450,000 
Net loss for the period   -    -    -    -    -    -    -    -    -    -    -    -    (667,690)   (667,690)
                                                                       
Balance - September 30, 2023   2,071,007   $2,071   $8,842,458    200,363   $200   $290,956    385,302   $385   $500,507    370,541,518   $370,541   $72,826,594   $(81,374,562)  $1,459,150 
                                                                       
Balance - December 31, 2023   2,071,007   $2,071   $8,842,458    200,363   $200   $290,956    385,302   $385   $500,507    387,894,033   $387,894   $73,791,430   $(82,450,781)  $1,365,120 
                                                                       
Stock issued for:                                                                      
Cash   -    -    -    -    -    -    -    -    -    2,000,000    2,000    126,000    -    128,000 
Services   -    -    -    -    -    -    -    -    -    139,834    140    9,342    -    9,482 
Warrants purchased for cash   -    -    -    -    -    -    -    -    -    -    -    2,000    -    2,000 
RSUs granted to consultants that have vested   -    -    -    -    -    -    -    -    -    -    -    361,500    -    361,500 
Net loss for the period   -    -    -    -    -    -    -    -    -    -    -    -    (558,539)   (558,539)
                                                                       
Balance - March 31, 2024   2,071,007    2,071    8,842,458    200,363    200    290,956    385,302    385    500,507    390,033,867    390,034    74,290,272    (83,009,320)   1,307,563 
                                                                       
Stock issued for:                                                                      
Cash   -    -    -    -    -    -    -    -    -    11,000,000    11,000    693,000    -    704,000 
Services   -    -    -    -    -    -    -    -    -    22,766    22    3,728    -    3,750 
Cashless exercise of warrants   -    -    -    -    -    -    -    -    -    16,624,612    16,625    (16,625)   -    - 
Warrants purchased for cash   -    -    -    -    -    -    -    -    -    -    -    5,000    -    5,000 
RSUs granted to consultants that have vested   -    -    -    -    -    -    -    -    -    -    -    86,250    -    86,250 
Net loss for the period   -    -    -    -    -    -    -    -    -    -    -    -    (503,458)   (503,458)
                                                                       
Balance - June 30, 2024   2,071,007    2,071    8,842,458    200,363    200    290,956    385,302    385    500,507    417,681,245    417,681    75,061,625    (83,512,778)   1,603,105 
                                                                       
Stock issued for:                                                                      
Cash   -    -    -    -    -    -    -    -    -    -    -    -    -    - 
Services   -    -    -    -    -    -    -    -    -    278,652    279    55,884    -    56,163 
Cashless exercise of warrants   -    -    -    -    -    -    -    -    -    295,306    295    (295)   -    - 
Vested RSUs   -    -    -    -    -    -    -    -    -    500,000    500    (500)   -    - 
Adjustment for vested RSUs   -    -    -    -    -    -    -    -    -    (1,162,500)   (1,162)   1,162    -    - 
RSUs granted to consultants that have vested   -    -    -    -    -    -    -    -    -    -    -    361,500    -    361,500 
Net loss for the period   -    -    -    -    -    -    -    -    -    -    -    -    (825,263)   (825,263)
                                                                       
Balance - September 30, 2024   2,071,007   $2,071   $8,842,458    200,363   $200   $290,956    385,302   $385   $500,507    417,592,703   $417,593   $75,479,376   $(84,338,041)  $1,195,505 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

3

 

 

VIVOS INC

CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

 

   2024   2023 
CASH FLOW FROM OPERTING ACTIVIITES          
Net loss  $(1,887,260)  $(1,818,534)
Adjustments to reconcile net loss to net cash used in operating activities          
Common stock, stock options and warrants for services   69,395    - 
RSUs issued for services   809,250    965,975 
Changes in assets and liabilities          
Accounts receivable   2,000    3,000 
Prepaid expenses and other assets   (10,328)   3,996 
Accounts payable and accrued expenses   (196,184)   15,677 
Total adjustments   674,133    988,648 
           
Net cash used in operating activities   (1,213,127)   (829,886)
           
CASH FLOWS FROM FINANCING ACTIVITES          
Proceeds from short-term advances from related party   -    10,000 
Proceeds from common stock and warrants   839,000    650,665 
Net cash provided by financing activities   839,000    660,665 
           
NET (DECREASE) IN CASH   (374,127)   (169,221)
           
CASH - BEGINNING OF PERIOD   1,592,287    1,706,065 
           
CASH - END OF PERIOD  $1,218,160   $1,536,844 
           
CASH PAID DURING THE PERIOD FOR:          
Interest expense  $-   $- 
           
Income taxes  $-   $- 

 

4

 

 

VIVOS INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(unaudited)

 

NOTE 1: BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

 

The accompanying condensed financial statements of Vivos Inc. (the “Company”) have been prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and disclosures required by accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations. These condensed financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the results of operations of the Company for the period presented. The results of operations for the nine months ended September 30, 2024, are not necessarily indicative of the results that may be expected for any future period or the fiscal year ending December 31, 2024 and should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 18, 2024.

 

Business Overview

 

The Company was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (“SMSC”). On September 6, 2006, the Company changed its name to Advanced Medical Isotope Corporation, and on December 28, 2017, the Company began operating as Vivos Inc. The Company has authorized capital of 950,000,000 shares of common stock (“Common Stock”), $0.001 par value per share, and 20,000,000 shares of preferred stock (“Preferred Stock”), $0.001 par value per share.

 

Our principal place of business is located at 1030 North Center Parkway, Kennewick, WA 99336. Our telephone number is (509) 222-2222. Our corporate website address is http://www.radiogel.com. Our Common Stock is currently quoted on the OTC Pink Marketplace under the symbol “RDGL.”

 

The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device, RadioGel™, for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers, and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer.

 

In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGel ™should be classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas. Additionally, after a legal review, the Company believes that the device classification obtained from the Food and Drug Administration (“FDA”) Center for Veterinary Medicine is not limited to canine and feline sarcomas, but rather may be extended to a much broader population of veterinary cancers, including all or most solid tumors in animals. We expect the result of such classification and label review will be that no additional regulatory approvals are necessary for the use of IsoPet® for the treatment of solid tumors in animals. The FDA does not have premarket authority over devices with a veterinary classification, and the manufacturers are responsible for assuring that the product is safe, effective, properly labeled, and otherwise in compliance with all applicable laws and regulations.

 

Based on the FDA’s recommendation, RadioGel™ will be marketed as “IsoPet®” for use by veterinarians to avoid any confusion between animal and human therapy. The Company already has trademark protection for the “IsoPet®” name. IsoPet® and RadioGel™ are used synonymously throughout this document. The only distinction between IsoPet® and RadioGel™ is the FDA’s recommendation that we use “IsoPet®” for veterinarian usage, and reserve “RadioGel™” for human therapy. Based on these developments, the Company has shifted its primary focus to the development and marketing of Isopet® for animal therapy, through the Company’s IsoPet® Solutions division.

 

IsoPet Solutions

 

The Company’s IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospitals to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. The Company has worked with three different university veterinarian hospitals on IsoPet® testing and therapy. Washington State University treated five cats for feline sarcoma and served to develop the procedures which are incorporated in our label. They concluded that the product was safe and effective in killing cancer cells. Colorado State University demonstrated the CT and PET-CT imaging of IsoPet®. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting in November 2017.

 

5

 

 

The dogs were treated for canine soft tissue sarcoma. Response evaluation criteria in solid tumors (“RECIST”) is a set of published rules that define when tumors in cancer patients improve (respond), stay the same (stabilize), or worsen (progress) during treatment. The criteria were published by an international collaboration including the European Organisation for Research and Treatment of Cancer (“EORTC”), National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group.

 

The testing at the University of Missouri met its objective to demonstrate the safety of IsoPet®. Using its advanced CT and PET equipment it was able to demonstrate that the dose calculations were accurate and that the injections perfused into the cell interstices and did not stay concentrated in a bolus. This results in a more homogeneous dose distribution. There was insignificant spread of Y-90 outside the points of injection demonstrating the effectiveness of the particles and the gel to localize the radiation with no spreading to the blood or other organs nor to urine or fecal material. This confirms that IsoPet® is safe for same day therapy.

 

The effectiveness of IsoPet® for life extension was not the prime objective, but it resulted in valuable insights. Of the cases one is still cancer-free but the others eventually recurred since there was not a strong focus on treating the margins. The University of Missouri has agreed to become a regional center to administer IsoPet® therapy and will incorporate the improvements suggested by the testing program.

 

The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel™ (under the name IsoPet®) and related services, and from licensing to private medical and veterinary clinics in the United States of America (the “USA”, or, the “U.S.”) and internationally. The Company intends to report the results from the IsoPet® Solutions division as a separate operating segment in accordance with generally accepted accounting principles (“GAAP”).

 

Commencing in July 2019, the Company recognized its first commercial sale of IsoPet®. A veterinarian from Alaska brought his cat with a re-occurrent spindle cell sarcoma tumor on his face. The cat had previously received external beam therapy, but now the tumor was growing rapidly. He was given a high dose of 400 Gray with heavy therapy at the margins. This sale met the revenue recognition requirements under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606 – Revenue from Contracts with Customers (“ASC 606”) as the performance obligation was satisfied. The Company completed sales for an additional four animals that received the IsoPet® during 2019.

 

Our plan is to incorporate the data assembled from our work with Isopet® in animal therapy to support the Company’s efforts in the development of our RadioGel™ device candidate, including obtaining approval from the FDA to market and sell RadioGel™ as a Class II medical device. RadioGel™ is an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals. RadioGel™ is comprised of a hydrogel, or a substance that is liquid at room temperature and then gels when reaching body temperature after injection into a tumor. In the gel are small particles, less than two microns, of Y-90. Once injected, these inert particles are locked in place inside the tumor by the gel, delivering a very high local radiation dose. The radiation is beta, consisting of high-speed electrons. These electrons only travel a short distance so the device can deliver high radiation to the tumor with minimal dose to the surrounding tissue. Optimally, patients can go home immediately following treatment without the risk of radiation exposure to family members. Since Y-90 has a half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days.

 

The Company modified its Indication for Use from skin cancel to cancerous tissue or solid tumors pathologically associated with locoregional papillary thyroid carcinoma and recurrent papillary thyroid carcinoma having discernable tumors associated with metastatic lymph nodes or extranodal disease in patients who are not surgical candidates or who have declined surgery, or patients who require post-surgical remnant ablation (for example, after prior incomplete radioiodine therapy). Papillary thyroid carcinoma belongs to the general class of head and neck tumors for which tumors are accessible by intraoperative direct needle injection. The Company’s Medical Advisory Board felt that demonstrating efficacy in clinical trials was much easier with this new indication.

 

In the third quarter of 2024, the Company entered the market of treating exotic animals by treating a ferret. The Company also has established important contacts at zoos and used conferences to communicate the effectiveness of Precision Radionuclide Therapy TM to the zoo community.

 

The Company intends to conduct human trials internationally, initially in Southeast Asia. These trials will be initiated prior to trials in the United States, and will be conducted under a protocol consistent with and complimentary to the IDE and human trial roadmap in the United States.

 

Intellectual Property

 

Our original license with Battelle National Laboratory (the “Battelle License”) reached its end of life in 2022. During the past several years, we have expanded our proprietary knowledge, as well as our trademark and patent protection, in anticipation of the Battelle License reaching the end of its term.

 

6

 

 

Our RadioGel™ trademark protection is in 17 countries. We have expanded our trademark protection from RadioGel™ to now include IsoPet®. We obtained the International Certificate of Registration for ISOPET, which is the first step to file in several countries.

 

We have filed for trademark protection for the term Precision Radionuclide Therapy™. We believe this term will be increasingly important.

 

The Company received the Patent Cooperation Treaty (“PCT”) International Search Report on our patent application (No.1811.191). Seven of our claims were immediately ruled as having novelty, inventive step and industrial applicability. This gives us the basis to extend for many years the patent protection for our proprietary Y-90 phosphate particles utilized in Isopet® and Radiogel™.

 

Our patent team filed our particle patent in more than ten patent offices that collectively cover 63 countries throughout the world. We filed a continuation-in-part applications number 1774054 in the USA to expand the claims on our particle patent. The U.S. Patent office recently gave us the Notice of Allowance for our patent to produce our yttrium phosphate microparticles, U.S. Patent Application Serial No: 16-459,466. We also filed an amendment to correct the wording on our claims at make them consistent with the USE claims. Ref: 4207-0005; European Patent Application NO. 20 834 229.5; VIVOS INC; Our Ref: FS/53791.

 

We filed a hydrogel utility patent in the USA (16309:17/943,311) and internationally (16389:PCT/US22/4374) based on the last 18 months of development work to optimize our hydrogel component. These include reducing the polymer production time and increasing the output by a factor of three. We have also further reduced the level of trace contaminants to be well below the FDA guidelines.

 

We filed a provisional patent (Serial Number 63436562) to protect our innovative improvements in our shipping container, our vial shield, our syringe shield, and our Peltier chiller. Our objectives were to reduce shipping costs, decrease radiation exposure, and enhance sterility. These devices will be preferentially used at Mayo Clinics for human clinical studies at our IsoPet regional treatment centers. The Company filed a utility patent in the fourth quarter of 2023 for this therapy support equipment.

 

We anticipate that Precision Radionuclide Therapy will become increasingly important in the future and expand to other isotope and other indications for use. Therefore, we filed an alternate particle utility patent (Serial number 18/152,137). We will focus our near-term effort on the Y-90 therapy, which we believe is the best beta emitter; however, we leveraged our hydrogel utility patent to incorporate other promising isotopes and compounds for a range of future applications. This includes gamma and alpha particle emitters.

 

We have trademark protection in several countries on IsoPet®, RadioGel®, Precision Radionuclide TherapyTM, BetaGelTM, GammaGelTM, and AlphaGelTM.

 

Going Concern

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $2.5 million annually to maintain current operating activities.

 

Financing and Strategy

 

In November 2019, the SEC qualified the Company’s offering of its Common Stock, under Regulation A of Section 3(6) of the Securities Act of 1933, as amended (the “Securities Act”) (“Regulation A”), which offering was and amended from time to time thereafter (the “2019 Regulation A+ Offering”). In September 2021, the SEC qualified the Company’s offering of Common Stock under Regulation A, which offering was amended from time to time thereafter (together with the 2019 Regulation A+ Offering, the “Prior Regulation A+ Offerings”). During the year ended December 31, 2023, $1,179,245 was raised through the sale of 16,132,000 shares of common stock and the private placement of 18,797,000 warrants. During the nine months ended September 30, 2024, the Company raised $839,000 through the issuance of 13,000,000 shares of common stock and 7,000,000 warrants. The Company’s Prior Regulation A Offerings undertaken pursuant to Regulation A+ have raised approximately $6,000,000 from the sale of shares of common stock.

 

7

 

 

On July 17, 2024, the SEC qualified the Company’s offering under Regulation A to offer up to $60,000,000 shares of its Common Stock (the “July 2024 Regulation A+ Offering”).

 

The Company is using the proceeds generated from the Prior Regulation A+ Offering and the July 2024 Regulation A+ Offering as follows:

 

Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities. The Company may require additional funding of approximately $5 million annually to maintain current operating activities. Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, and clinical trials; (3) activate several regional clinics to administer IsoPet® across the county; (4) create an independent production center within the current production site to create a template for future international manufacturing; and (5) initiate regulatory approval processes outside of the United States. The proceeds to be raised from the Regulation A+ Offerings will be used to continue to fund this development.

 

The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise), and any requirements for additional studies (which may possibly include clinical studies). Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be: (1) the timing of any approvals; (2) the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution, and licensing of those products; and (3) the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements, as well as proceeds to be raised from the Regulation A+ Offerings.

 

Following receipt of required regulatory approvals and necessary financing to fund our working capital requirements, the Company intends to outsource material aspects of manufacturing, distribution, sales, and marketing for operations within the U.S. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.

 

Long-term, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses. These long-term goals are subject to the Company: (1) receiving adequate funding; (2) receiving regulatory approval for RadioGel™ and other brachytherapy products; and (3) being able to successfully commercialize its brachytherapy products.

 

Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.

 

The Company’s headquarters are in Northeast Washington, however, our focus on the animal therapy market has been the Northwestern sector of the U.S. The Company continues its marketing efforts on the animal therapy market and our attempts to increase the exposure to our product, and generate revenue accordingly.

 

As of September 30, 2024, the Company had $1,218,160 cash on hand. There are currently commitments to vendors for products and services purchased. To continue the development of the Company’s products, the current level of cash will not be enough to cover the fixed and variable obligations of the Company.

 

8

 

 

The Company anticipates using the proceeds from the July 2024 Regulation A+ Offering as follows:

 

For the animal therapy market:

 

  ● Expand communication on our website, the Company’s social media presence, conferences, and journals, each intended to increase the number of certified clinics for small animal and equine therapy and to increase the number of patients.
  ● Subsidize some IsoPet® therapies, if necessary, to ensure that all viable candidates are treated; and.
  ● Assist a new regional clinic with their license and certification training.

 

For the human market:

 

  ● Enhance the pedigree of the Quality Management System.
  ● Begin automation of product manufacturing.
  ● Fund liability insurance for human clinical studies; and.
  ● Fund human clinical studies in the US.

 

Research and development of the Company’s precision radionuclide therapy product line has been funded with proceeds from the sale of equity and debt securities, including from the Prior Regulation A+ Offerings. The Company requires additional funding of approximately $2.5 million annually to maintain operating activities. Over the next 36 months, the Company believes it will cost approximately $8.0 to $9.0 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, clinical trials; (3) activate several regional clinics to administer IsoPet® across the U.S.; (4) create an independent production center within the current production site to create a template for future international manufacturing; and (5) initiate regulatory approval processes outside of the United States. The proceeds raised from the Prior Regulation A+ Offerings were used to fund this development and proceeds from the July 2024 Regulation A+ Offering will be used to continue such development efforts.

 

The continued deployment of the precision radionuclide therapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the precision radionuclide therapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s precision radionuclide therapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or from proceeds raised from the Prior Regulation A+ Offering and from the July 2024 Regulation A+ Offering.

 

The Company intends to expand the indications for use in phases: first, for lymph nodes associated with thyroid cancer, secondly, cancerous lung nodules, and finally, all non-sectable solid tumors. It is anticipated that the medical community may begin to use RadioGel off-label, we will support but will not encourage that practice.

 

Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.

 

Long-term, the Company intends to consider resuming research efforts with respect to other products and technologies, such as Gamma Gel and Alpha Gel intended to help improve the diagnosis and treatment of cancer and other illnesses. These long-term goals are subject to the Company: (1) receiving adequate funding; (2) receiving regulatory approval for RadioGel™ and other precision radionuclide therapy products; and (3) being able to successfully commercialize its precision radionuclide therapy products.

 

Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.

 

The Company’s headquarters are in the State of Washington., The initial focus of the animal therapy market has been the Northwestern sector of the United States. The Company has initiated marketing efforts to the animal therapy market in other regions of the United States, attempting to increase the exposure to our product and increase revenue opportunities.

 

9

 

 

There are currently commitments to vendors for products and services purchased. To continue the development of the Company’s products, the current level of cash will not be enough to cover the fixed and variable obligations of the Company. The Company has focused on operating on minimum overhead, including using a virtual office for the last several years and retaining experienced industry consultants available on an as needed basis. This has helped focus the capital received from the Company’s Regulation A+ Offerings on activities that enhance our objectives.

 

There is no guarantee that the Company will be able to raise additional funds or to do so on terms advantageous to the Company’s stockholders.

 

The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There can be no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Use of Estimates

 

The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amount of revenue and expense during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.

 

Financial Statement Reclassification

 

Certain account balances from prior periods have been reclassified in these financial statements so as to conform to current period classifications.

 

Cash Equivalents

 

For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.

 

The Company occasionally maintains cash balances in excess of the FDIC insured limit. The Company does not consider this risk to be material.

 

Fair Value of Financial Instruments

 

Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of September 30, 2024 and December 31, 2023, the balances reported for cash, prepaid expense, accounts receivable, accounts payable, and accrued expense, approximate the fair value because of their short maturities.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ASC”) Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

 

Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

 

Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

10

 

 

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis.

 

Patents and Intellectual Property

 

While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such 10-year period and on a straight-line basis will begin once the patents have been issued and the Company begins utilization of the patents through production and sales, resulting in revenues.

 

The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows.

 

There have been no such capitalized costs in the three and nine months ended September 30, 2024 and 2023, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) filed by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet® commercially available, which it did on or about July 9, 2019. This additional patent protection will strengthen the Company’s competitive position. It is the Company’s intention to further extend this patent protection to several key countries within one year, as permitted under international patent laws and treaties.

 

Revenue Recognition

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated guidance effective January 1, 2018 using the full retrospective method.

 

Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to perform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows.

 

The Company recognized revenue as they (i) identified the contracts with each customer; (ii) identified the performance obligation in each contract; (iii) determined the transaction price in each contract; (iv) were able to allocate the transaction price to the performance obligations in the contract; and (v) recognized revenue upon the satisfaction of the performance obligation. Upon the sales of the product to complete the procedures on the animals, the Company recognized revenue as that was considered the performance obligation.

 

All revenue recognized in the three and nine months ended September 30, 2024 and 2023 relate to the procedures performed with respect to the IsoPet® therapies.

 

Loss Per Share

 

The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive Common Stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the periods ended in the nine months ended September 30, 2024 and 2023, the basic earnings per share equals the diluted earnings per share.

 

11

 

 

The following represent Common Stock equivalents that could be dilutive in the future as of September 30, 2024 and December 31, 2023, which include the following:

 

   September 30, 2024   December 31, 2023 
Preferred stock   9,909,570    9,909,570 
Restricted stock units   12,000,000    1,450,000 
Common stock options   2,252,809    2,252,809 
Common stock warrants   8,100,000    26,134,000 
Total potential dilutive securities   32,262,379    39,746,379 

 

Research and Development Costs

 

Research and developments costs, including salaries, research materials, administrative expense and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed.

 

The Company incurred $66,551 and $80,858 in research and development costs for the three months ended September 30, 2024 and 2023, respectively, and $223,660 and $300,586 in research and development costs for the nine months ended September 30, 2024 and 2023, respectively, all of which were recorded in the Company’s operating expense noted on the statements of operations for the periods then ended.

 

Advertising and Marketing Costs

 

Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. During the three and nine months ended September 30, 2024 and 2023, the Company incurred nominal advertising and marketing costs.

 

Contingencies

 

In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. The Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of September 30, 2024 and December 31, 2023.

 

Income Taxes

 

To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition.

 

The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the three and nine months ended September 30, 2024 and 2023. The Company did not have any deferred tax liability or asset on its balance sheets as of September 30, 2024 and December 31, 2023.

 

Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the three and nine months ended September 30, 2024 and 2023, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months.

 

12

 

 

Stock-Based Compensation

 

The Company recognizes compensation costs under FASB ASC Topic 718, Compensation – Stock Compensation and ASU 2018-07. Companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.

 

Recent Accounting Pronouncements

 

The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

 

NOTE 2: RELATED PARTY TRANSACTIONS

 

In September 2023, our Chief Executive Officer advanced $10,000 to the Company, which amount was repaid October 4, 2023.

 

NOTE 3: STOCKHOLDERS’ EQUITY

 

Common Stock

 

The Company has authorized 950,000,000 shares of Common Stock. As of September 30, 2024 and December 31, 2023, there are 417,592,703 and 387,894,033 shares of Common Stock issued and outstanding, respectively.

 

Preferred Stock

 

The Company has authorized 20,000,000 shares of Preferred Stock. There are currently three series of Preferred Stock outstanding; Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock. The Company’s Board of Directors is authorized to provide for the issuance of shares of Preferred Stock in one or more series, fix or alter the designations, preferences, rights, qualifications, limitations or restrictions of the shares of each series, including the dividend rights, dividend rates, conversion rights, voting rights, term of redemption including sinking fund provisions, redemption price or prices, liquidation preferences and the number of shares constituting any series or designations of such series without further vote or action by the shareholders. The issuance of Preferred Stock may have the effect of delaying, deferring or preventing a change in control of management without further action by the shareholders and may adversely affect the voting and other rights of the holders of Common Stock. The issuance of Preferred Stock with voting and conversion rights may adversely affect the voting power of the holders of Common Stock, including the loss of voting control to others.

 

Series A Convertible Preferred Stock

 

On June 30, 2015, a certificate of designations was filed with the Delaware Secretary of State to designate 2,500,000 shares of the Company’s Preferred Stock as Series A Convertible Preferred Stock, par value $0.001 per share (“Series A Preferred”) (the “Series A COD”). Effective March 31, 2016, the Company amended the Series A COD, increasing the maximum number of shares of Series A Preferred from 2,500,000 shares to 5,000,000 shares. As of September 30, 2024 and December 31, 2023, there are 2,071,007 shares of Series A Preferred issued and outstanding, respectively.

 

The following summarizes the current rights and preferences of the Series A Preferred:

 

Liquidation Preference. The Series A Preferred has a liquidation preference of $5.00 per share.

 

13

 

 

Dividends. Shares of Series A Preferred do not have any separate dividend rights.

 

Conversion. Subject to certain limitations set forth in the Series A COD, each share of Series A Preferred is convertible, at the option of the holder, into that number of shares of Common Stock (the “Series A Conversion Shares”) equal to the liquidation preference thereof, divided by Conversion Price (as such term is defined in the Series A COD), currently $4.00.

 

In the event the Company completes an equity or equity-based public offering, registered with the SEC, resulting in gross proceeds to the Company totaling at least $5.0 million, all issued and outstanding shares of Series A Preferred at that time will automatically convert into Series A Conversion Shares.

 

Redemption. Subject to certain conditions set forth in the Series A COD, in the event of a Change of Control (defined in the Series A COD), or at such time as a third party not affiliated with the Company or any holders of the Series A Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent (50%) of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series A Preferred in cash at a price per share of Series A Preferred equal to 100% of the Liquidation Preference.

 

Voting Rights. Holders of Series A Preferred are entitled to vote on all matters, together with the holders of Common Stock, and have the equivalent of five votes for every Series A Conversion Share issuable upon conversion of such holder’s outstanding shares of Series A Preferred. However, the Series A Conversion Shares, when issued, will have all the same voting rights as other issued and outstanding Common Stock of the Company, and none of the rights of the Series A Preferred.

 

Liquidation. Upon any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary (a “Liquidation”), the holders of Series A Preferred shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the liquidation preference of the Series A Preferred before any distribution or payment shall be made to the holders of any junior securities, and if the assets of the Company are insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of the Series A Preferred shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.

 

Certain Price and Share Adjustments.

 

a) Stock Dividends and Stock Splits. If the Company (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock equivalents; (ii) subdivides outstanding shares of Common Stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Company, then the conversion price shall be adjusted accordingly.

 

b) Merger or Reorganization. If the Company is involved in any reorganization, recapitalization, reclassification, consolidation or merger in which the Common Stock is converted into or exchanged for securities, cash or other property than each share of Series A Preferred shall be convertible into the kind and amount of securities, cash or other property that a holder of the number of shares of Common Stock issuable upon conversion of one share of Series A Preferred prior to any such merger or reorganization would have been entitled to receive pursuant to such transaction.

 

14

 

 

Series B Convertible Preferred Stock

 

On October 10, 2018, a certificate of designation was filed with the Delaware Secretary of State to designate 5,000,000 shares of our Preferred Stock as Series B Convertible Preferred Stock, par value $0.001 per share (“Series B Preferred”) (the “Series B COD”). As of September 30, 2024 and December 31, 2023, there are 200,363 shares of Series B Preferred issued and outstanding, respectively.

 

The following summarizes the current rights and preferences of the Series B Preferred:

 

Liquidation Preference. The Series B Preferred has a liquidation preference of $1.00 per share.

 

Dividends. Shares of Series B Preferred do not have any separate dividend rights.

 

Conversion. Subject to certain limitations set forth in the Series B COD, each share of Series B Convertible is convertible, at the option of the holder, into that number of shares of Common Stock (the “Series B Conversion Shares”) equal to the liquidation preference thereof, divided by the Conversion Price (as such term is defined in the Series B COD), currently $0.08.

 

Redemption. Subject to certain conditions set forth in the Series B COD, in the event of a Change of Control (defined in the Series B COD), or at such as a third party not affiliated with the Company or any holders of the Series B Convertible shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent (50%) of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Preferred in cash at a price per share of Series B Preferred equal to 100% of the Liquidation Preference.

 

Voting Rights. Holders of Series B Preferred are entitled to vote on all matters, together with the holders of Common Stock, and have the equivalent of two votes for every Series B Conversion Share issuable upon conversion of such holder’s outstanding shares of Series B Preferred. However, the Series B Conversion Shares, when issued, will have the same voting rights as other issued and outstanding shares of Common Stock of the Company, and none of the rights of the Series A Preferred.

 

Liquidation. Upon any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary (a “Liquidation”), the holders of Series B Preferred shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the liquidation preference of the Series B Preferred before any distribution or payment shall be made to the holders of any junior securities, and if the assets of the Company are insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of the Series B Preferred shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.

 

Certain Price and Share Adjustments.

 

a) Stock Dividends and Stock Splits. If the Company (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock equivalents; (ii) subdivides outstanding shares of Common Stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Company, then the conversion price shall be adjusted accordingly.

 

b) Merger or Reorganization. If the Company is involved in any reorganization, recapitalization, reclassification, consolidation or merger in which the Common Stock is converted into or exchanged for securities, cash or other property than each share of Series B Preferred shall be convertible into the kind and amount of securities, cash or other property that a holder of the number of shares of Common Stock issuable upon conversion of one share of Series B Preferred prior to any such merger or reorganization would have been entitled to receive pursuant to such transaction.

 

Series C Convertible Preferred Stock

 

On March 27, 2019, a certificate of designation was filed with the Delaware Secretary of State to designate 5,000,000 shares of our Preferred Stock as Series C Convertible Preferred Stock, par value $0.001 per share (“Series C Preferred”) (the “Series C COD”). As of September 30, 2024 and December 31, 2023, there were 385,302 shares of Series C Preferred issued and outstanding, respectively.

 

The following summarizes the current rights and preferences of the Series C Preferred:

 

Liquidation Preference. The Series C Preferred has a liquidation preference of $1.00 per share.

 

Dividends. Shares of Series C Preferred do not have any separate dividend rights.

 

15

 

 

Conversion. Subject to certain limitations set forth in the Series C COD, each share of Series C Preferred is convertible, at the option of the holder, into that number of shares of Common Stock (the “Series C Conversion Shares”) equal to the liquidation preference thereof, divided by Conversion Price (as such term is defined in the Series C COD), currently $0.08.

 

The Series C Preferred will only be convertible at any time after the date that the Company shall have amended its Certificate of Incorporation to increase the number of shares of Common Stock authorized for issuance thereunder or effect a reverse stock split of the outstanding shares of Common Stock by a sufficient amount to permit the conversion of all Series C Preferred into shares of Common Stock (“Authorized Share Approval”) (such date, the “Initial Convertibility Date”), each share of Series C Preferred shall be convertible into validly issued, fully paid and non-assessable shares of Common Stock on the terms and conditions set forth in the Series C COD under the definition “Conversion Rights”.

 

Redemption. Subject to certain conditions set forth in the Series C COD, in the event of a Change of Control (defined in the Series C COD), or at such time as a third party not affiliated with the Company or any holders of the Series C Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent (50%) of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series C Preferred in cash at a price per share of Series C Preferred equal to 100% of the Liquidation Preference.

 

Voting Rights. Holders of Series C Preferred are entitled to vote on all matters, together with the holders of Common Stock, and have the equivalent of thirty-two votes for every Series C Conversion Share issuable upon conversion of such holder’s outstanding shares of Series C Preferred. However, the Series C Conversion Shares, when issued, will have the same voting rights as other issued and outstanding shares of Common Stock of the Company, and none of the rights of the Series C Preferred.

 

Liquidation. Upon any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary (a “Liquidation”), the holders of Series C Preferred shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the liquidation preference of the Series C Preferred before any distribution or payment shall be made to the holders of any junior securities, and if the assets of the Company are insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of the Series C Preferred shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.

 

Certain Price and Share Adjustments.

 

a) Stock Dividends and Stock Splits. If the Company (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock equivalents; (ii) subdivides outstanding shares of Common Stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Company, then the conversion price shall be adjusted accordingly.

 

b) Merger or Reorganization. If the Company is involved in any reorganization, recapitalization, reclassification, consolidation or merger in which the Common Stock is converted into or exchanged for securities, cash or other property than each share of Series C Preferred shall be convertible into the kind and amount of securities, cash or other property that a holder of the number of shares of Common Stock issuable upon conversion of one share of Series C Preferred prior to any such merger or reorganization would have been entitled to receive pursuant to such transaction.

 

Common and Preferred Stock Issuances

 

Common and Preferred Stock Issuances - 2024

 

From January 1, 2024 through September 30, 2024, the Company issued 13,000,000 shares of Common Stock and warrants to purchase 7,000,000 shares of Common Stock pursuant to the Regulation A+ Offerings for cash proceeds of $839,000.

 

The Company issued 441,252 shares of Common Stock for services rendered valued at $69,395.

 

The Company issued 16,919,918 shares of Common Stock in the cashless exercise of 25,034,000 warrants.

 

The Company settled 500,000 RSUs for Common Stock.

 

The Company adjusted their common shares for vested RSUs in prior periods that were cancelled.

 

16

 

 

Common and Preferred Stock Issuances – 2023

 

In April 2023, the Company issued 8,000,000 shares of Common Stock, 2,665,000 Series A warrants and 8,000,000 Series B warrants in their Regulation A+ Offerings for $640,000. The Company sold the warrants for $10,665.

 

NOTE 4: COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS

 

Common Stock Options

 

The Company recognizes in the financial statements compensation related to all stock-based awards, including stock options and warrants, based on their estimated grant-date fair value. The Company has estimated expected forfeitures and is recognizing compensation expense only for those awards expected to vest. All compensation is recognized by the time the award vests.

 

The following schedule summarizes the changes in the Company’s stock options:

 

   Options Outstanding   Weighted Average
Remaining		       Weighted Average 
  

Number Of

Shares

   Exercise Price
Per Share		   Contractual
Life		   Aggregate
Intrinsic Value		   Exercise Price
Per Share		 
Nine Months Ended September 30, 2024                         
                          
Outstanding at January 1, 2024   2,252,809   $0.024-0.04     5.70 years   $78,886   $0.04 
Granted   -   $-    -        $- 
Exercised   -   $-    -        $- 
Expired/canceled   -   $-    -        $- 
Outstanding at September 30, 2024   2,252,809   $0.024-0.04     4.95 years    $284,567   $0.04 
Exercisable at September 30, 2024   2,252,809   $0.024-0.04     4.95 years    $284,567   $0.04 
                          
Nine Months Ended September 30, 2023                         
                          
Outstanding at January 1, 2023   2,252,809   $0.024-0.04    6.70 years    $16,032   $0.04 
Granted   -   $-    -        $- 
Exercised   -   $-    -        $- 
Expired/canceled   -   $-    -        $- 
Outstanding at September 30, 2023   2,252,809   $0.024-0.04    5.95 years   $65,819   $0.04 
Exercisable at September 30, 2023   2,252,809   $0.024-0.04    5.95 years   $65,819   $0.04 

 

During the three and nine months ended September 30, 2024 and the three and nine months ended September 30, 2023, the Company recognized $0 of stock-based compensation expense related to the vesting of stock options.

 

17

 

 

Common Stock Warrants

 

The following schedule summarizes the changes in the Company’s stock warrants:

   Warrants Outstanding   Weighted Average
Remaining		       Weighted Average 
   Number Of
Shares		  

Exercise Price

Per Share

   Contractual
Life		   Aggregate
Intrinsic Value		   Exercise Price
Per Share		 
Nine Months Ended September 30, 2024                         
                          
Outstanding at January 1, 2024   26,134,000   $0.06-0.10    3.54 years   $-   $0.0827 
Granted   7,000,000   $0.075    -   $-   $- 
Exercised   (25,034,000)  $-    -   $-   $- 
Redeemed   (500,000)  $-    -   $-   $- 
Expired/cancelled   -   $-    -   $-   $- 
Outstanding at September 30, 2024   8,100,000   $0.075    3.25 years   $717,660   $0.075 
Exercisable at September 30, 2024   8,100,000   $0.075    3.25 years   $717,660   $0.075 
                          
Nine Months Ended September 30, 2023                         
                          
Outstanding at January 1, 2023   26,737,500   $0.06-0.10    1.52 years   $-   $0.09 
Granted   10,665,000   $0.0775    -   $-   $- 
Redeemed   (500,000)  $-    -   $-   $- 
Expired/cancelled   (11,237,500)  $-    -   $-   $- 
Outstanding at September 30, 2023   25,665,000   $0.06-0.10    1.91 years   $150,573   $0.079 
Exercisable at September 30, 2023   25,665,000   $0.06-0.10    1.91 years   $150,573   $0.079 

 

Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each option/warrant is estimated using the Black-Scholes valuation model. The following assumptions were used for the periods as follows:

 

      Nine Months Ended       Nine Months Ended  
      September 30, 2024       September 30, 2023  
Expected term     -       -  
Expected volatility     - %     - %
Expected dividend yield     -       -  
Risk-free interest rate     - %     - %

 

The Company granted 10,665,000 warrants in their Reg A+ funding in April 2023, with an exercise price of $0.0775 and a three-year term.

 

The Company granted 2,000,000 warrants in their Regulation A+ Offering in January 2024, with an exercise price of $0.075 and a three-year term and 5,000,000 warrants with the same terms on April 1, 2024.

 

The Company issued 16,919,918 shares of Common Stock in the cashless exercise of 25,034,000 warrants.

 

Restricted Stock Units

 

The following schedule summarizes the changes in the Company’s restricted stock units:

 

   Number Of Shares   Weighted Average
Grant Date Fair Value		 
Nine Months Ended September 30, 2024          
           
Outstanding at January 1, 2024   1,450,000   $0.09 
Granted   21,050,000   $0.077 
Vested   (10,500,000)  $- 
Forfeited   -   $- 
Outstanding at September 30, 2024   12,000,000   $0.08 
           
Nine Months Ended September 30, 2023          
           
Outstanding at January 1, 2023   10,262,500   $0.08 
Granted   2,900,000   $0.091 
Vested   (10,725,000)  $- 
Forfeited   (262,500)  $- 
Outstanding at September 30, 2023   2,175,000   $0.09 

 

18

 

 

During the nine months ended September 30, 2024 and 2023, the Company recognized $809,250 and $965,975 in expense related to the vesting of its restricted stock units. As of September 30, 2024, the Company had $951,595 worth of expense yet to be recognized for restricted stock units not yet vested.

 

On January 1, 2024, the Company granted 20,000,000 restricted stock units to its Chief Executive Officer as part of his new employment agreement that vest in four equal installments over a two-year period beginning February 1, 2024. During the nine months ended September 30, 2024, 10,500,000 of these restricted stock units vested. In May 2024, the Company granted 1,050,000 restricted stock units to consultants that vest through December 31, 2025.

 

NOTE 5: COMMITMENT

 

On June 4, 2019, the Company entered into an Executive Employment Agreement (“Employment Agreement”) with Dr. Michael K. Korenko, the Company’s Chief Executive Officer. The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement. On December 31, 2020, the Company extended the Employment Agreement through December 31, 2021 while renegotiating terms of a new Employment Agreement. On May 3, 2021, the Company and the Chief Executive Officer agreed the terms of a new Employment Agreement with an effective date of January 1, 2021 that has a term of three years and expired December 31, 2023. The Company renewed the Employment Agreement for a term of two years expiring December 31, 2025.

 

Under the terms of the Employment Agreement effective January 1, 2024, the Company shall pay to Dr. Korenko a base compensation of $295,500. In addition, there is a discretionary bonus to be earned in the amount of $10,000 per quarter upon the satisfaction of conditions to be determined by the Board of Directors of the Company. In addition, the Company granted Dr. Korenko 20,000,000 restricted stock units on January 1, 2024 that vest over the two year period.

 

NOTE 6: SUBSEQUENT EVENTS

 

On November 12, 2024, the Company entered into agreements for the issuance of 11,950,000 shares of common stock for $1,434,000 under the Regulation A+. The Company additionally entered into agreements for the sale of 11,950,000 warrants, 30% of which expire December 31, 2024 at an exercise price of $0.01 and 70% of which expire December 31, 2027 at an exercise price of $0.15 for $11,950 which were not part of the Regulation A+. The shares and warrants will be issued upon receipt of fully executed agreements and receipt of all funds.

 

19

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Except for statements of historical fact, certain information described in this Quarterly Report on Form 10-Q (“Quarterly Report”) contains “forward-looking statements” that involve substantial risks and uncertainties. You can identify these statements by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will,” “would” or similar words. The statements that contain these or similar words should be read carefully because these statements discuss the Company’s future expectations, including its expectations of its future results of operations or financial position, or state other “forward-looking” information. Vivos Inc. believes that it is important to communicate its future expectations to its investors. However, there may be events in the future that the Company is not able to accurately predict or to control. Further, the Company urges you to be cautious of the forward-looking statements which are contained in this Quarterly Report because they involve risks, uncertainties and other factors affecting its operations, market growth, service, products and licenses. The risk factors in the section captioned “Risk Factors” in Item 1A of the Company’s Annual Report on Form 10-K, filed with the SEC on March 18, 2024, as well as other cautionary language in this Quarterly Report, describe such risks, uncertainties and events that may cause the Company’s actual results and achievements, whether expressed or implied, to differ materially from the expectations the Company describes in its forward-looking statements. The occurrence of any of the events described as risk factors could have a material adverse effect on the Company’s business, results of operations and financial position.

 

Vivos Inc. (the “Company”) was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (“SMSC”). On September 6, 2006, the Company changed its name to Advanced Medical Isotope Corporation, and on December 28, 2017, the Company began operating as Vivos Inc. The Company has authorized capital of 950,000,000 shares of common stock, $0.001 par value per share (“Common Stock”), and 20,000,000 shares of preferred stock, $0.001 par value per share (“Preferred Stock”).

 

Our principal place of business is located at 1030 North Center Parkway, Kennewick, WA 99336. Our telephone number is (509) 222-2222. Our corporate website address is http://www.radiogel.com. Our Common Stock is currently quoted on the OTC Pink Marketplace under the symbol “RDGL.”

 

The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device, RadioGel™, for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers, and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer.

 

In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGel ™should be classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas. Additionally, after a legal review, the Company believes that the device classification obtained from the Food and Drug Administration (“FDA”) Center for Veterinary Medicine is not limited to canine and feline sarcomas, but rather may be extended to a much broader population of veterinary cancers, including all or most solid tumors in animals. We expect the result of such classification and label review will be that no additional regulatory approvals are necessary for the use of IsoPet® for the treatment of solid tumors in animals. The FDA does not have premarket authority over devices with a veterinary classification, and the manufacturers are responsible for assuring that the product is safe, effective, properly labeled, and otherwise in compliance with all applicable laws and regulations.

 

Based on the FDA’s recommendation, RadioGel™ will be marketed as “IsoPet®” for use by veterinarians to avoid any confusion between animal and human therapy. The Company already has trademark protection for the “IsoPet®” name. IsoPet® and RadioGel™ are used synonymously throughout this document. The only distinction between IsoPet® and RadioGel™ is the FDA’s recommendation that we use “IsoPet®” for veterinarian usage, and reserve “RadioGel™” for human therapy. Based on these developments, the Company has shifted its primary focus to the development and marketing of Isopet® for animal therapy, through the Company’s IsoPet® Solutions division.

 

20

 

 

Financing and Strategy

 

In November 2019, the Securities and Exchange Commission (the “SEC”) qualified the Company’s offering of its Common Stock under Regulation A of Section 3(6) of the Securities Act of 1933, as amended (the “Securities Act”)(“Regulation A”), which offering was and amended from time to time thereafter (the “2019 Regulation A+ Offering”). In September 2021, the SEC qualified the Company’s offering of Common Stock under Regulation A, which offering was amended from time to time thereafter (together with the 2019 Regulation A+ Offering, the “Prior Regulation A+ Offerings”). During the year ended December 31, 2023, $1,179,245 was raised through the sale of 16,132,000 shares of Common Stock and the private placement of 18,797,000 warrants. During the period January 1, 2024 through May 10, 2024, the Company raised $834,000 through the issuance of 13,000,000 shares of Common Stock and the private placement of 2,000,000 warrants. During the nine months ended September 30, 2024, the Company raised $839,000 through the issuance of 13,000,000 shares of Common Stock and 7,000,000 warrants. The Company’s Prior Regulation A Offerings undertaken pursuant to Regulation A+ have raised approximately $6,000,000 from the sale of shares of Common Stock.

 

On July 17, 2024, the SEC qualified the Company’s offering under Regulation A to offer up to $60,000,000 shares of its Common Stock (the “July 2024 Regulation A+ Offering”).

 

The Company anticipates using the proceeds from the July 2024 Regulation A+ Offering as follows:

 

For the animal therapy market:

 

  ● Expand communication on our website, our social media presence, conference, and journals, each to increase the number of certified clinics for small animal and equine therapy and to increase the number of patients;
  ● Subsidize some IsoPet® therapies, if necessary, to ensure that all viable candidates are treated; and
  ● Assist a new regional clinic with their license and certification training.

 

For the human market:

 

  ● Enhance the pedigree of the Quality Management System;
  ● Begin automation of product manufacturing;
  ● Fund liability insurance for human clinical studies; and
  ● Fund human clinical studies in the U.S.

 

Research and development of the Company’s precision radionuclide therapy product line has been funded with proceeds from the sale of equity and debt securities, including from the Prior Regulation A+ Offerings. The Company requires additional funding of approximately $2.5 million annually to maintain operating activities. Over the next 36 months, the Company believes it will cost approximately $8.0 to $9.0 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, clinical trials; (3) activate several regional clinics to administer IsoPet® across the county; (4) create an independent production center within the current production site to create a template for future international manufacturing; and (5) initiate regulatory approval processes outside of the United States. The proceeds raised from the Prior Regulation A+ Offerings were used to fund this development and proceeds from the July 2024 Regulation A+ Offering will used to continue such development efforts.

 

The continued deployment of the precision radionuclide therapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the precision radionuclide therapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s precision radionuclide therapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution, and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or from proceeds raised from the Prior Regulation A+ Offering and from the July 2024 Regulation A+ Offering.

 

The Company intends to expand the indications for use in phases: first, for lymph nodes associated with thyroid cancer, secondly, cancerous lung nodules, and finally, all non-sectable solid tumors. It is anticipated that the medical community may begin to use RadioGel off-label, we will support but will not encourage that practice.

 

Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales, and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.

 

21

 

 

Long-term, the Company intends to consider resuming research efforts with respect to other products and technologies, such as Gamma Gel and Alpha Gel intended to help improve the diagnosis and treatment of cancer and other illnesses. These long-term goals are subject to the Company: (1) receiving adequate funding; (2) receiving regulatory approval for RadioGel™ and other precision radionuclide therapy products; and (3) being able to successfully commercialize its precision radionuclide therapy products.

 

Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.

 

The Company’s headquarters are in the State of Washington., The initial focus of the animal therapy market has been the Northwestern sector of the U.S. The Company has initiated marketing efforts to the animal therapy market in other regions of the U.S., attempting to increase the exposure to our product and increase revenue opportunities.

 

As of September 30, 2024, the Company had $1,218,160 cash on hand. There are currently commitments to vendors for products and services purchased. To continue the development of the Company’s products, the current level of cash will be insufficient to cover the fixed and variable obligations of the Company. The Company has focused on operating on minimum overhead, including using a virtual office for the last several years and retaining experienced industry consultants available on an as needed basis. This has helped focus the capital received from the Company’s Regulation A+ Offerings on activities that enhance our objectives.

 

No assurances can be given that the Company will be able to raise additional funds or to do so on terms advantageous to the Company or its stockholders.

 

The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financings and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There is no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Available Information

 

The Company prepares and files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and certain other information with the SEC. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at http://www.sec.gov. Moreover, the Company maintains a website at http://www.radiogel.com that contains important information about the Company, including biographies of key management personnel, as well as information about the Company’s business. This information is publicly available and is updated regularly.

 

Results of Operations

 

Comparison of the Nine Months Ended September 30, 2024 and 2023

 

The following table sets forth information from our statements of operations for the nine months ended September 30, 2024 and 2023:

 

   Nine Months Ended
September 30, 2024		   Nine Months Ended
September 30, 2023		 
Revenues  $23,000   $19,500 
Cost of goods sold   (20,699)   (16,536)
Gross profit   2,301    2,964 
Operating expense   (1,944,885)   (1,853,319)
Operating loss   (1,942,584)   (1,850,355)
Non-operating income   55,324    31,821 
Net loss  $(1,887,260)  $(1,818,534)

 

22

 

 

Revenues and Cost of Goods Sold

 

Revenue was $23,000 and $19,500 for the nine months ended September 30, 2024 and 2023, respectively. All revenue recognized in the nine months ended September 30, 2024 and 2023 relate to consulting income with respect to the IsoPet® therapies.

 

Management does not anticipate that the Company will generate sufficient revenue to sustain operations until such time as the Company secures multiple revenue-generating arrangements with respect to RadioGel™ and/or any of our other brachytherapy technologies.

 

Operating Expense

 

Operating expense for the nine months ended September 30, 2024 and 2023, respectively consists of the following:

 

   Nine months ended
September 30, 2024		   Nine months ended
September 30, 2023		 
Professional fees, including stock-based compensation  $1,310,604   $1,205,819 
Payroll expense   267,153    214,083 
Research and development   223,660    300,586 
General and administrative expense   143,468    132,831 
Total operating expense  $1,944,885   $1,853,319 

 

Operating expense for the nine months ended September 30, 2024 and 2023 was $1,944,885 and $1,853,319, respectively. The increase in operating expense from 2023 to 2024 can be attributed to an increase in professional fees from $1,205,819 for the nine months ended September 30, 2023 to $1,310,604 for the nine months ended September 30, 2024, partially attributable to the stock based compensation expense related to the restricted stock units; an increase in general and administrative expense from $132,831 for the nine months ended September 30, 2023 to $143,468 for the nine months ended September 30, 2024; a decrease in research and development expense from $300,586 for the nine months ended September 30, 2023 to $223,660 for the nine months ended September 30, 2024 as the Company ramped up the development of their products in 2023 to include studies that are required to continue to have their products accepted by the FDA, and completed some of those studies for the 2024 period; and an increase in payroll expense related to the CEO’s employment contract and bonus, to $267,153 for the nine months ended September 30, 2024 from $214,083 for the nine months ended September 30, 2023.

 

Non-Operating Income (Expense)

 

Non-operating income (expense) for the nine months ended September 30, 2024 and 2023 consists of the following:

 

   Nine months ended
September 30, 2024		   Nine months ended
September 30, 2023		 
Interest income  $55,324   $31,821 
Non-operating income (expense)  $55,324   $31,821 

 

Non-operating income (expense) for the nine months ended September 30, 2024 and 2023 related to interest earned on the Company’s cash accounts.

 

Net Loss

 

Our net loss for the nine months ended September 30, 2024 and 2023 was $(1,887,260) and $(1,818,534), respectively.

 

23

 

 

Comparison of the Three Months Ended September 30, 2024 and 2023

 

The following table sets forth information from our statements of operations for the three months ended September 30, 2024 and 2023:

 

   Three Months Ended
September 30, 2024		   Three Months Ended
September 30, 2023		 
Revenues  $5,000   $7,000 
Cost of goods sold   (3,919)   - 
Gross profit   1,081    7,000 
Operating expense   (844,226)   (694,633)
Operating loss   (843,145)   (687,633)
Non-operating income (expense)   17,882    19,943 
Net loss  $(825,263)  $(667,690)

 

Revenues and Cost of Goods Sold

 

Revenue was $5,000 and $7,000 for the three months ended September 30, 2024 and 2023, respectively. All revenue recognized in the three months ended September 30, 2024 and 2023 relate to consulting income with respect to the IsoPet® therapies.

 

Management does not anticipate that the Company will generate sufficient revenue to sustain operations until such time as the Company secures multiple revenue-generating arrangements with respect to RadioGel™ and/or any of our other brachytherapy technologies.

 

Operating Expense

 

Operating expense for the three months ended September 30, 2024 and 2023, respectively consists of the following:

 

   Three months ended
September 30, 2024		   Three months ended
September 30, 2023		 
Professional fees, including stock-based compensation  $627,152   $512,856 
Payroll expense   85,400    69,562 
Research and development   66,551    80,858 
General and administrative expense   65,123    31,357 
Total operating expense  $844,226   $694,633 

 

Operating expense for the three months ended September 30, 2024 and 2023 was $844,226 and $694,633, respectively. The increase in operating expense from 2023 to 2024 can be attributed to an increase in professional fees from $512,856 for the three months ended September 30, 2023 to $627,152 for the three months ended September 30, 2024, attributable to the stock based compensation expense related to the restricted stock units; an increase in general and administrative expense from $31,357 for the three months ended September 30, 2023 to $65,123 for the three months ended September 30, 2024 related to attendance at various conferences and a marketing campaign commenced in this quarter; a decrease in research and development expense from $80,858 for the three months ended September 30, 2023 to $66,551 for the three months ended September 30, 2024 as the Company ramped up the development of their products in 2023 to include studies that are required to continue to have their products accepted by the FDA, and completed some of those studies for the 2024 period; and an increase in payroll expense related to the CEO’s employment contract and bonus to $85,400 for the three months ended September 30, 2024 from $69,562 for the three months ended September 30, 2023.

 

Non-Operating Income (Expense)

 

Non-operating income (expense) for the three months ended September 30, 2024 and 2023 consists of the following:

 

   Three months ended
September 30, 2024		   Three months ended
September 30, 2023		 
Interest income  $17,882   $19,943 
Non-operating income (expense)  $17,882   $19,943 

 

Non-operating income (expense) for the three months ended September 30, 2024 and 2023 related to interest earned on the Company’s cash accounts.

 

Net Loss

 

Our net loss for the three months ended September 30, 2024 and 2023 was $(825,263) and $(667,690), respectively.

 

24

 

 

Liquidity and Capital Resources

 

At September 30, 2024, the Company had working capital of $1,195,505, as compared to working capital of $1,365,120 at December 31, 2023. During the nine months ended September 30, 2024 and 2023, the Company experienced negative cash flow from operations of $1,213,127 and $829,886 and had no cash from investing activities. In both 2024 and 2023, there were no investing activities, and in 2024 and 2023, the Company raised $839,000 and $650,665 from the sales of Common Stock and warrants as part of our Regulation A+ Offerings. We also received $10,000 in September 2023 from advances from our CEO that was repaid in October 2023.As of September 30, 2024, the Company did not have any commitments for capital expenditures.

 

Cash used in operating activities increased from $829,886 for the nine months ended September 30, 2023 to $1,213,127 for the nine months ended September 30, 2024. Cash used in operating activities was primarily a result of the Company’s non-cash items, such as loss from operations, stock-based compensation, as well as the changes in accounts receivable, prepaid expense and accounts payable in 2024 compared to only having net changes from current assets and liabilities and stock-based compensation in 2023.

 

The Company has generated material operating losses since inception. The Company had a net loss of $1,887,260 and $1,818,534 for the nine months ended September 30, 2024 and 2023, respectively. The Company expects to continue to experience net operating losses for the foreseeable future. Historically, the Company has relied upon investor funds to maintain its operations and develop the Company’s business. The Company anticipates raising additional capital within the next twelve months for working capital as well as business expansion, although no assurances can be given that such additional capital will be available on terms acceptable to the Company, if at all. If the Company is unable to obtain additional financing to meet its working capital requirements, it may have to curtail its business or cease all operations.

 

The Company requires funding of at least $5 million per year to maintain current operating activities. Over the next 24 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, and clinical trials; (3) activate several regional clinics to administer IsoPet® across the county; (4) create an independent production center within the current production site to create a template for future international manufacturing; and (5) initiate regulatory approval processes outside of the United States.

 

The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies, which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or additional capital raises.

 

Although the Company is seeking to raise additional capital and has engaged in numerous discussions with investment bankers and investors, to date the Company has not received firm commitments for the required funding. Based upon its discussions, the Company anticipates that if the Company is able to obtain the funding required to retire outstanding debt, pay past due payables and maintain its current operating activities, that the terms and conditions associated with such future funding will result in material dilution to existing shareholders.

 

Recent geopolitical events, including the inherent instability and volatility in global capital markets, as well as the lack of liquidity in the capital markets, could also impact the Company’s ability to obtain financing and its ability to execute its business plan.

 

Our Chief Executive Officer currently works from his home office in virtual communication with key personnel. Cadwell Laboratories, which is controlled by Carl Cadwell, a director of the Company, provides office space to management on an as-needed basis until such time as the Company leases permanent office space.

 

25

 

 

Accounting Policies and Estimates

 

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from these estimates under different assumptions or conditions. During the period ended September 30, 2024, we believe there have been no significant changes to the items disclosed as significant accounting policies in management’s notes to the financial statements in our annual report on Form 10-K for the year ended December 31, 2023, filed on March 18, 2024.

 

Off-Balance Sheet Arrangements

 

The Company does not have any off-balance sheet arrangements that are reasonably likely to have a current or future effect on the Company’s financial condition, revenues, results of operations, liquidity or capital expenditures.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

This item is not applicable to us because we are a smaller reporting company as defined by Rule 12b-2 under the Securities Exchange Act of 1934.

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures

 

Based on an evaluation as of the date of the end of the period covered by this report, the Company’s Chief Executive Officer and Interim Chief Financial Officer conducted an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures, as required by Exchange Act Rule 13a-15. Based on that evaluation, the Company’s Chief Executive Officer and Interim Chief Financial Officer concluded that, because of material weakness related to proper segregation of duties, the Company’s disclosure controls and procedures were ineffective as of the end of the period covered by this report to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms.

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in the Company’s reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the Company’s reports filed under the Exchange Act is accumulated and communicated to management, including the Company’s Chief Executive Officer and the Company’s Interim Chief Financial Officer, to allow timely decisions regarding required disclosure.

 

Changes in Internal Control Over Financial Reporting

 

There have been no changes in the Company’s internal control over financial reporting that occurred during the period ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

The term “internal control over financial reporting” is defined as a process designed by, or under the supervision of, the registrant’s principal executive and principal financial officers, or persons performing similar functions, and effected by the registrant’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

 

  (a) Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the registrant;
     
  (b) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the registrant are being made only in accordance with authorizations of management and directors of the registrant; and
     
  (c) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the registrant’s assets that could have a material effect on the financial statements.

 

26

 

 

PART II

 

Item 1. Legal Proceedings

 

The Company may, from time to time, be involved in various legal proceedings incidental to the conduct of our business. Historically, the outcome of all such legal proceedings has not, in the aggregate, had a material adverse effect on our business, financial condition, results of operations or liquidity.

 

Item 2. Unregistered Sales of Equity Securities

 

From January 1, 2024 through September 30, 2024, the Company issued 13,000,000 shares of Common Stock and warrants to purchase 7,000,000 shares of Common Stock pursuant to the Regulation A+ Offering for cash proceeds of $839,000.

 

The Company issued 441,252 shares of Common Stock for services rendered valued at $69,395.

 

The Company issued 16,919,918 shares of Common Stock in the cashless exercise of 25,034,000 warrants.

 

The Company settled 500,000 RSUs for common stock.

 

Item 6. Exhibits.

 

Exhibit

Number

   Description
     
31.1*   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes – Oxley Act of 2002
     
31.2*   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes – Oxley Act of 2002
     
32.1*   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350
     
101.INS   Inline XBRL Instance Document
     
101.SCH   Inline XBRL Taxonomy Extension Schema
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

 

27

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Vivos Inc.
     
Date: November 13, 2024 By: /s/ Michael Korenko
  Name: Michael K. Korenko
  Title: Chief Executive Officer
    (Principal Executive Officer)

 

Date: November 13, 2024 By: /s/ Michael Pollack
  Name: Michael Pollack
  Title: Interim Chief Financial Officer
    (Interim Principal Financial and Accounting Officer)

 

28

 

 EX-31.1 2 ex31-1.htm

 

EXHIBIT 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Michael K. Korenko, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Vivos Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 13, 2024  
   
/s/ Michael K. Korenko  
Michael K. Korenko  
Chief Executive Officer  
(Principal Executive Officer)  

 

 

 

 EX-31.2 3 ex31-2.htm

 

EXHIBIT 31.2

 

CERTIFICATION OF INTERIM CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Michael Pollack, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Vivos Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 13, 2024  
   
/s/ Michael Pollack  
Michael Pollack  
Interim Chief Financial Officer  
(Interim Principal Financial Officer)  

 

 

 

 EX-32.1 4 ex32-1.htm

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the accompanying quarterly report of Vivos Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2024 (the “Report”), the undersigned, Michael Korenko, Chief Executive Officer of the Company, and Michael Pollack, Interim Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 13, 2024  
   
/s/ Michael K. Korenko  
Name: Michael K. Korenko  
Title: Chief Executive Officer  

 

/s/ Michael Pollack  
Name: Michael Pollack  
Title: Interim Chief Financial Officer  

 

 

 

 EX-101.SCH 5 rdgl-20240930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statement of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - COMMITMENT link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SCHEDULE OF DILUTIVE EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SCHEDULE OF CHANGES IN STOCK OPTION (Details) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - SCHEDULE OF CHANGES IN STOCK WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - COMMITMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 rdgl-20240930_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 rdgl-20240930_def.xml XBRL DEFINITION FILE EX-101.LAB 8 rdgl-20240930_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Series A Preferred Stock [Member] Additional Paid-In Capital - Series A Preferred [Member] Series B Preferred Stock [Member] Additional Paid-In Capital - Series B Preferred [Member] Series C Preferred Stock [Member] Additional Paid-In Capital - Series C Preferred [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Sale of Stock [Axis] Private Placement [Member] Warrant [Member] Statistical Measurement [Axis] Maximum [Member] Product and Service [Axis] Brachytherapy Product Line [Member] Radionuclide Therapy Product Line [Member] Antidilutive Securities [Axis] Restricted Stock Units (RSUs) [Member] Equity Option [Member] Title and Position [Axis] Chief Executive Officer [Member] Common Stock and Warrants [Member] Award Type [Axis] Series A Warrant [Member] Series B Warrant [Member] Minimum [Member] Derivative Instrument [Axis] Restricted Stock Units [Member] Consultants [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Employment Agreement [Member] Dr. Michael K. Korenko [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Expire December 31, 2024 [Member] Expire December 31, 2027 [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS Current Assets: Cash Accounts receivable Prepaid expenses Total Current Assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ EQUITY LIABILITIES Current Liabilities: Accounts payable and accrued expenses Total Current Liabilities Total Liabilities Commitments and contingencies STOCKHOLDERS’ EQUITY Preferred stock value Additional paid in capital Common stock, par value, $0.001, 950,000,000 shares authorized, 417,592,703 and 387,894,033 issued and outstanding, respectively Additional paid in capital - common stock Accumulated deficit Total Stockholders’ Equity TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues, net Cost of Goods Sold Gross profit OPERATING EXPENSES Professional fees, including stock-based compensation Payroll expenses Research and development General and administrative expenses Total Operating Expenses OPERATING LOSS NON-OPERATING INCOME (EXPENSE) Interest income Total Non-Operating Income (Expenses) NET LOSS BEFORE PROVISION FOR INCOME TAXES Provision for income taxes NET LOSS Net loss per share - basic Net loss per share - diluted Weighted average common shares outstanding - basic Weighted average common shares outstanding - diluted Balance Balance, shares Net loss for the period Cash Cash, shares Warrants purchased for cash RSUs granted to consultants that have vested Services Services, shares Cashless exercise of warrants Cashless exercise of warrants, shares Vested RSUs Vested RSUs, shares Adjustment for vested RSUs Adjustment for vested RSUs, shares Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOW FROM OPERTING ACTIVIITES Net loss Adjustments to reconcile net loss to net cash used in operating activities Common stock, stock options and warrants for services RSUs issued for services Changes in assets and liabilities Accounts receivable Prepaid expenses and other assets Accounts payable and accrued expenses Total adjustments Net cash used in operating activities CASH FLOWS FROM FINANCING ACTIVITES Proceeds from short-term advances from related party Proceeds from common stock and warrants Net cash provided by financing activities NET (DECREASE) IN CASH CASH - BEGINNING OF PERIOD CASH - END OF PERIOD CASH PAID DURING THE PERIOD FOR: Interest expense Income taxes Accounting Policies [Abstract] BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Equity [Abstract] STOCKHOLDERS’ EQUITY COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS Commitments and Contingencies Disclosure [Abstract] COMMITMENT Subsequent Events [Abstract] SUBSEQUENT EVENTS Business Overview IsoPet Solutions Intellectual Property Going Concern Financing and Strategy Use of Estimates Financial Statement Reclassification Cash Equivalents Fair Value of Financial Instruments Patents and Intellectual Property Revenue Recognition Loss Per Share Research and Development Costs Advertising and Marketing Costs Contingencies Income Taxes Stock-Based Compensation Recent Accounting Pronouncements SCHEDULE OF DILUTIVE EARNINGS PER SHARE SCHEDULE OF CHANGES IN STOCK OPTION SCHEDULE OF CHANGES IN STOCK WARRANTS SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total potential dilutive securities Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Current operating activities Number of common stock shares issued, value Number of common stock shares issued, shares Number of warrants issued Sale of common stock Current operating activities Offering term Cash on hand Economic life of the patent Research and development costs Advance from officer Number of Options Outstanding Beginning Balance Exercise Price Per Share Outstanding Beginning Balance Weighted Average Remaining Contractual Life (in years) Outstanding Aggregate Intrinsic Value Outstanding Beginning Weighted Average Exercise Price Per Share Outstanding Beginning Number of Options granted Exercise Price Per Share granted Weighted Average Exercise Price Per Share Options granted Number of Options exercised Exercise Price Per Share exercised Weighted Average Exercise Price Per Share Options exercised Number of Options expired/cancelled Exercise Price Per Share expired/cancelled Weighted Average Exercise Price Per Share Options expired/cancelled Number of Options Outstanding Ending Balance Weighted Average Exercise Price Per Share Outstanding Ending Aggregate Intrinsic Value Outstanding Ending Weighted Average Exercise Price Per Share Outstanding Ending Number of Options Exercisable Exercise Price Per Share Exercisable Weighted Average Remaining Contractual Life (in years) Exercisable Aggregate Intrinsic Value Exercisable Weighted Average Exercise Price Per Share Exercisable Stock, Class of Stock [Table] Class of Stock [Line Items] Preferred stock shares authorized Preferred stock shares outstanding Preferred stock, liquidation preference per share Conversion price per share Gross proceeds from preferred stock Preferred stock redemption, description Redemption percentage Voting percentage Preferred stock shares issued Number of shares issued Warrant purchase Proceeds from issuance or sale of equity Issued for services, shares Issued for services, value Issued for common stock warrant exercise Issued for cashless exercise, warrants Issued for common stock RSU Number of shares issued, value Proceeds from issuance of warrants Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of Shares, Warrants Outstanding Beginning Exercise Price Per Share Warrants Outstanding Beginning Weighted Average Remaining Contractual Life Warrants Outstanding Ending Aggregate Intrinsic Value Outstanding Beginning Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable Beginning Number of Shares, Warrants granted Exercise Price Per Share Warrants granted Weighted Average Exercise Price Per Share Exercise Price Warrants granted Number of Shares, Warrants exercised Exercise Price Per Share Warrants exercised Number of Shares, Warrants redeemed Number of Shares, Warrants expired/cancelled Exercise Price Per Share Warrants expired/cancelled Number of Shares, Warrants Outstanding Ending Exercise Price Per Share Warrants Outstanding Ending Aggregate Intrinsic Value Outstanding Ending Weighted Average Exercise Price Per Share Exercise Price Warrants Ending Number of Shares, Warrants Exercisable Ending Exercise Price Per Share Warrants Exercisable Ending Weighted Average Remaining Contractual Life Warrants Exercisable Aggregate Intrinsic Value Exercisable Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable Expected term Expected volatility Expected dividend yield Risk-free interest rate Number of Shares, RSU's Beginning balance Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning Number of Shares, RSU's granted Weighted Average Grant Date Fair Value, RSU's granted Number of Shares, RSU's vested Weighted Average Grant Date Fair Value, RSU's vested Number of Shares, RSU's forfeited Weighted Average Grant Date Fair Value, RSU's forfeited Number of Shares, RSU's Ending balance Weighted Average Grant Date Fair Value, RSU's Outstanding Ending Number of Shares, RSU's forfeited Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Stock based compensation Number of Shares, warrants granted Exercise price per share warrants granted Vest period Number of shares issued Number of Shares, Warrants exercised Restricted stock expense vesting Restricted stock expenses yet to be recognized Number of restricted shares unit granted Restricted stock units vested Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Agreement term description Compensation amount Discretionary bonus Granted restricted stock units Subsequent Event [Table] Subsequent Event [Line Items] Number of share issued Number of share issued, value Warrants percentage Warrants exercise price Business Overview [Policy Text Block] Intellectual Property [Policy Text Block] Going Concern [Policy Text Block] Financing and Strategy [Policy Text Block] Brachytherapy Product Line [Member] Offering term. Series C Convertible Preferred Stock [Member] Radionuclide Therapy Product Line [Member] Series A Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Common Stock and Warrants [Member] Stock issued during period shares stock options warrant exercised. Additional Paid-In Capital - Series A Preferred [Member] Additional Paid-In Capital - Series C Preferred [Member] Stock issued during period shares reverse stock units. Series A Warrant [Member] Series B Warrant [Member] Share based compensation arrangement by share based payment award options exercisable weighted average exercisable price. Stock Option Plans Exercise Price. Weighted Average Exercise Price Per Share Options granted. Weighted Average Exercise Price Per Share Options Exercised. Weighted average exercise price per share option expired. Exercisable Weighted Average Exercise Price Per Shares. Stock issued during period value cashless exercise of warrants. Stock issued during period shares cashless exercise of warrants. The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan. Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan. Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity. Weighted average price at which non-option equity holders acquired shares when converting their non-option equity into shares. Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price. Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average exercisable price. Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Sharebased compensation arrangement by sharebased payment award non options outstanding intrinsic value. Stock issued during period value adjustment for vested restricted stock award. Sharebased compensation arrangement by sharebased payment award non options exercisable intrinsic value. Exercise Price Warrant Exercisable. Weighted Average Exercise Price Per Share Exercise Price Warrants Granted. Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning Ending. Stock issued during period shares adjustment for vested restricted stock award. Restricted stock units issued for services. Restricted Stock Units [Member] Restricted stock expenses yet to be recognized. Consultants [Member] Agreement term description. Employment Agreement [Member] Dr. Michael K. Korenko [Member] Discretionary bonus. Stock issued during period shares settled. Additional Paid-In Capital - Series B Preferred [Member] Expire December 31, 2024 [Member] Expire December 31, 2027 [Member] Assets, Current Assets Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Cost of Goods and Services Sold Gross Profit Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shares, Outstanding Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Equity [Text Block] Net Cash Provided by (Used in) Operating Activities, Continuing Operations Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisablePrice Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricePerShares Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations ExercisePriceMinimum ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisablePrice SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1 Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value EX-101.PRE 9 rdgl-20240930_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Cover - shares
 9 Months Ended
Sep. 30, 2024
Nov. 13, 2024
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2024  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2024  
Current Fiscal Year End Date --12-31  
Entity File Number 000-53497  
Entity Registrant Name VIVOS INC  
Entity Central Index Key 0001449349  
Entity Tax Identification Number 80-0138937  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 1030 N Center Parkway  
Entity Address, City or Town Kennewick  
Entity Address, State or Province WA  
Entity Address, Postal Zip Code 99336  
City Area Code (509)  
Local Phone Number 222-2222  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   417,592,703
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Balance Sheets - USD ($)
Sep. 30, 2024
Dec. 31, 2023
Current Assets:    
Cash $ 1,218,160 $ 1,592,287
Accounts receivable 5,000 7,000
Prepaid expenses 21,165 10,837
Total Current Assets 1,244,325 1,610,124
TOTAL ASSETS 1,244,325 1,610,124
Current Liabilities:    
Accounts payable and accrued expenses 48,820 245,004
Total Current Liabilities 48,820 245,004
Total Liabilities 48,820 245,004
Commitments and contingencies
STOCKHOLDERS’ EQUITY    
Common stock, par value, $0.001, 950,000,000 shares authorized, 417,592,703 and 387,894,033 issued and outstanding, respectively 417,593 387,894
Additional paid in capital - common stock 75,479,376 73,791,430
Accumulated deficit (84,338,041) (82,450,781)
Total Stockholders’ Equity 1,195,505 1,365,120
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY 1,244,325 1,610,124
Series A Convertible Preferred Stock [Member]    
STOCKHOLDERS’ EQUITY    
Preferred stock value 2,071 2,071
Additional paid in capital 8,842,458 8,842,458
Series B Convertible Preferred Stock [Member]    
STOCKHOLDERS’ EQUITY    
Preferred stock value 200 200
Additional paid in capital 290,956 290,956
Series C Convertible Preferred Stock [Member]    
STOCKHOLDERS’ EQUITY    
Preferred stock value 385 385
Additional paid in capital $ 500,507 $ 500,507
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2024
Dec. 31, 2023
Mar. 27, 2019
Oct. 10, 2018
Mar. 31, 2016
Mar. 30, 2016
Jun. 30, 2015
Preferred stock, par value $ 0.001 $ 0.001          
Preferred stock, shares authorized 20,000,000 20,000,000          
Common stock, par value $ 0.001 $ 0.001          
Common stock, shares authorized 950,000,000 950,000,000          
Common stock, shares issued 417,592,703 387,894,033          
Common stock, shares outstanding 417,592,703 387,894,033          
Series A Convertible Preferred Stock [Member]              
Preferred stock, par value             $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000     5,000,000 2,500,000 2,500,000
Preferred stock, shares issued 2,071,007 2,071,007          
Preferred stock, shares outstanding 2,071,007 2,071,007          
Series B Convertible Preferred Stock [Member]              
Preferred stock, par value       $ 0.001      
Preferred stock, shares authorized 5,000,000 5,000,000   5,000,000      
Preferred stock, shares issued 200,363 200,363          
Preferred stock, shares outstanding 200,363 200,363          
Series C Convertible Preferred Stock [Member]              
Preferred stock, par value     $ 0.001        
Preferred stock, shares authorized 5,000,000 5,000,000 5,000,000        
Preferred stock, shares issued 385,302 385,302          
Preferred stock, shares outstanding 385,302 385,302          
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Revenues, net $ 5,000 $ 7,000 $ 23,000 $ 19,500
Cost of Goods Sold (3,919) (20,699) (16,536)
Gross profit 1,081 7,000 2,301 2,964
OPERATING EXPENSES        
Professional fees, including stock-based compensation 627,152 512,856 1,310,604 1,205,819
Payroll expenses 85,400 69,562 267,153 214,083
Research and development 66,551 80,858 223,660 300,586
General and administrative expenses 65,123 31,357 143,468 132,831
Total Operating Expenses 844,226 694,633 1,944,885 1,853,319
OPERATING LOSS (843,145) (687,633) (1,942,584) (1,850,355)
NON-OPERATING INCOME (EXPENSE)        
Interest income 17,882 19,943 55,324 31,821
Total Non-Operating Income (Expenses) 17,882 19,943 55,324 31,821
NET LOSS BEFORE PROVISION FOR INCOME TAXES (825,263) (667,690) (1,887,260) (1,818,534)
Provision for income taxes
NET LOSS $ (825,263) $ (667,690) $ (1,887,260) $ (1,818,534)
Net loss per share - basic $ (0.00) $ (0.00) $ (0.00) $ (0.00)
Net loss per share - diluted $ (0.00) $ (0.00) $ (0.00) $ (0.00)
Weighted average common shares outstanding - basic 418,629,728 370,541,528 403,860,277 367,112,957
Weighted average common shares outstanding - diluted 418,629,728 370,541,528 403,860,277 367,112,957
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)
Preferred Stock [Member]
Series A Preferred Stock [Member]
Preferred Stock [Member]
Additional Paid-In Capital - Series A Preferred [Member]
Preferred Stock [Member]
Series B Preferred Stock [Member]
Preferred Stock [Member]
Additional Paid-In Capital - Series B Preferred [Member]
Preferred Stock [Member]
Series C Preferred Stock [Member]
Preferred Stock [Member]
Additional Paid-In Capital - Series C Preferred [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2022 $ 2,071 $ 8,842,458 $ 200 $ 290,956 $ 385 $ 500,507 $ 362,541 $ 71,217,954 $ (79,556,028) $ 1,661,044
Balance, shares at Dec. 31, 2022 2,071,007   200,363   385,302   362,541,518      
Net loss for the period (248,318) (248,318)
Balance at Mar. 31, 2023 $ 2,071 8,842,458 $ 200 290,956 $ 385 500,507 $ 362,541 71,217,954 (79,804,346) 1,412,726
Balance, shares at Mar. 31, 2023 2,071,007   200,363   385,302   362,541,518      
Balance at Dec. 31, 2022 $ 2,071 8,842,458 $ 200 290,956 $ 385 500,507 $ 362,541 71,217,954 (79,556,028) 1,661,044
Balance, shares at Dec. 31, 2022 2,071,007   200,363   385,302   362,541,518      
Net loss for the period                   (1,818,534)
Balance at Sep. 30, 2023 $ 2,071 8,842,458 $ 200 290,956 $ 385 500,507 $ 370,541 72,826,594 (81,374,562) 1,459,150
Balance, shares at Sep. 30, 2023 2,071,007   200,363   385,302   370,541,518      
Balance at Mar. 31, 2023 $ 2,071 8,842,458 $ 200 290,956 $ 385 500,507 $ 362,541 71,217,954 (79,804,346) 1,412,726
Balance, shares at Mar. 31, 2023 2,071,007   200,363   385,302   362,541,518      
Net loss for the period (902,526) (902,526)
Cash $ 8,000 632,000 640,000
Cash, shares             8,000,000      
Warrants purchased for cash 10,665 10,665
RSUs granted to consultants that have vested 515,975 515,975
Balance at Jun. 30, 2023 $ 2,071 8,842,458 $ 200 290,956 $ 385 500,507 $ 370,541 72,376,594 (80,706,872) 1,676,840
Balance, shares at Jun. 30, 2023 2,071,007   200,363   385,302   370,541,518      
Net loss for the period (667,690) (667,690)
RSUs granted to consultants that have vested 450,000 450,000
Balance at Sep. 30, 2023 $ 2,071 8,842,458 $ 200 290,956 $ 385 500,507 $ 370,541 72,826,594 (81,374,562) 1,459,150
Balance, shares at Sep. 30, 2023 2,071,007   200,363   385,302   370,541,518      
Balance at Dec. 31, 2023 $ 2,071 8,842,458 $ 200 290,956 $ 385 500,507 $ 387,894 73,791,430 (82,450,781) 1,365,120
Balance, shares at Dec. 31, 2023 2,071,007   200,363   385,302   387,894,033      
Net loss for the period (558,539) (558,539)
Cash $ 2,000 126,000 128,000
Cash, shares             2,000,000      
Warrants purchased for cash 2,000 2,000
RSUs granted to consultants that have vested 361,500 361,500
Services $ 140 9,342 9,482
Services, shares             139,834      
Balance at Mar. 31, 2024 $ 2,071 8,842,458 $ 200 290,956 $ 385 500,507 $ 390,034 74,290,272 (83,009,320) 1,307,563
Balance, shares at Mar. 31, 2024 2,071,007   200,363   385,302   390,033,867      
Balance at Dec. 31, 2023 $ 2,071 8,842,458 $ 200 290,956 $ 385 500,507 $ 387,894 73,791,430 (82,450,781) 1,365,120
Balance, shares at Dec. 31, 2023 2,071,007   200,363   385,302   387,894,033      
Net loss for the period                   (1,887,260)
Services                   $ 69,395
Services, shares                   441,252
Balance at Sep. 30, 2024 $ 2,071 8,842,458 $ 200 290,956 $ 385 500,507 $ 417,593 75,479,376 (84,338,041) $ 1,195,505
Balance, shares at Sep. 30, 2024 2,071,007   200,363   385,302   417,592,703      
Balance at Mar. 31, 2024 $ 2,071 8,842,458 $ 200 290,956 $ 385 500,507 $ 390,034 74,290,272 (83,009,320) 1,307,563
Balance, shares at Mar. 31, 2024 2,071,007   200,363   385,302   390,033,867      
Net loss for the period (503,458) (503,458)
Cash $ 11,000 693,000 704,000
Cash, shares             11,000,000      
Warrants purchased for cash 5,000 5,000
RSUs granted to consultants that have vested 86,250 86,250
Services $ 22 3,728 3,750
Services, shares             22,766      
Cashless exercise of warrants $ 16,625 (16,625)
Cashless exercise of warrants, shares             16,624,612      
Balance at Jun. 30, 2024 $ 2,071 8,842,458 $ 200 290,956 $ 385 500,507 $ 417,681 75,061,625 (83,512,778) 1,603,105
Balance, shares at Jun. 30, 2024 2,071,007   200,363   385,302   417,681,245      
Net loss for the period (825,263) (825,263)
Cash
RSUs granted to consultants that have vested 361,500 361,500
Services $ 279 55,884 56,163
Services, shares             278,652      
Cashless exercise of warrants $ 295 (295)
Cashless exercise of warrants, shares             295,306      
Vested RSUs $ 500 (500)
Vested RSUs, shares             500,000      
Adjustment for vested RSUs $ (1,162) 1,162
Adjustment for vested RSUs, shares             (1,162,500)      
Balance at Sep. 30, 2024 $ 2,071 $ 8,842,458 $ 200 $ 290,956 $ 385 $ 500,507 $ 417,593 $ 75,479,376 $ (84,338,041) $ 1,195,505
Balance, shares at Sep. 30, 2024 2,071,007   200,363   385,302   417,592,703      
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
CASH FLOW FROM OPERTING ACTIVIITES    
Net loss $ (1,887,260) $ (1,818,534)
Adjustments to reconcile net loss to net cash used in operating activities    
Common stock, stock options and warrants for services 69,395
RSUs issued for services 809,250 965,975
Changes in assets and liabilities    
Accounts receivable 2,000 3,000
Prepaid expenses and other assets (10,328) 3,996
Accounts payable and accrued expenses (196,184) 15,677
Total adjustments 674,133 988,648
Net cash used in operating activities (1,213,127) (829,886)
CASH FLOWS FROM FINANCING ACTIVITES    
Proceeds from short-term advances from related party 10,000
Proceeds from common stock and warrants 839,000 650,665
Net cash provided by financing activities 839,000 660,665
NET (DECREASE) IN CASH (374,127) (169,221)
CASH - BEGINNING OF PERIOD 1,592,287 1,706,065
CASH - END OF PERIOD 1,218,160 1,536,844
CASH PAID DURING THE PERIOD FOR:    
Interest expense
Income taxes
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.3
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

NOTE 1: BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

 

The accompanying condensed financial statements of Vivos Inc. (the “Company”) have been prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and disclosures required by accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations. These condensed financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the results of operations of the Company for the period presented. The results of operations for the nine months ended September 30, 2024, are not necessarily indicative of the results that may be expected for any future period or the fiscal year ending December 31, 2024 and should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 18, 2024.

 

Business Overview

 

The Company was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (“SMSC”). On September 6, 2006, the Company changed its name to Advanced Medical Isotope Corporation, and on December 28, 2017, the Company began operating as Vivos Inc. The Company has authorized capital of 950,000,000 shares of common stock (“Common Stock”), $0.001 par value per share, and 20,000,000 shares of preferred stock (“Preferred Stock”), $0.001 par value per share.

 

Our principal place of business is located at 1030 North Center Parkway, Kennewick, WA 99336. Our telephone number is (509) 222-2222. Our corporate website address is http://www.radiogel.com. Our Common Stock is currently quoted on the OTC Pink Marketplace under the symbol “RDGL.”

 

The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device, RadioGel™, for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers, and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer.

 

In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGel ™should be classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas. Additionally, after a legal review, the Company believes that the device classification obtained from the Food and Drug Administration (“FDA”) Center for Veterinary Medicine is not limited to canine and feline sarcomas, but rather may be extended to a much broader population of veterinary cancers, including all or most solid tumors in animals. We expect the result of such classification and label review will be that no additional regulatory approvals are necessary for the use of IsoPet® for the treatment of solid tumors in animals. The FDA does not have premarket authority over devices with a veterinary classification, and the manufacturers are responsible for assuring that the product is safe, effective, properly labeled, and otherwise in compliance with all applicable laws and regulations.

 

Based on the FDA’s recommendation, RadioGel™ will be marketed as “IsoPet®” for use by veterinarians to avoid any confusion between animal and human therapy. The Company already has trademark protection for the “IsoPet®” name. IsoPet® and RadioGel™ are used synonymously throughout this document. The only distinction between IsoPet® and RadioGel™ is the FDA’s recommendation that we use “IsoPet®” for veterinarian usage, and reserve “RadioGel™” for human therapy. Based on these developments, the Company has shifted its primary focus to the development and marketing of Isopet® for animal therapy, through the Company’s IsoPet® Solutions division.

 

IsoPet Solutions

 

The Company’s IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospitals to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. The Company has worked with three different university veterinarian hospitals on IsoPet® testing and therapy. Washington State University treated five cats for feline sarcoma and served to develop the procedures which are incorporated in our label. They concluded that the product was safe and effective in killing cancer cells. Colorado State University demonstrated the CT and PET-CT imaging of IsoPet®. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting in November 2017.

 

 

The dogs were treated for canine soft tissue sarcoma. Response evaluation criteria in solid tumors (“RECIST”) is a set of published rules that define when tumors in cancer patients improve (respond), stay the same (stabilize), or worsen (progress) during treatment. The criteria were published by an international collaboration including the European Organisation for Research and Treatment of Cancer (“EORTC”), National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group.

 

The testing at the University of Missouri met its objective to demonstrate the safety of IsoPet®. Using its advanced CT and PET equipment it was able to demonstrate that the dose calculations were accurate and that the injections perfused into the cell interstices and did not stay concentrated in a bolus. This results in a more homogeneous dose distribution. There was insignificant spread of Y-90 outside the points of injection demonstrating the effectiveness of the particles and the gel to localize the radiation with no spreading to the blood or other organs nor to urine or fecal material. This confirms that IsoPet® is safe for same day therapy.

 

The effectiveness of IsoPet® for life extension was not the prime objective, but it resulted in valuable insights. Of the cases one is still cancer-free but the others eventually recurred since there was not a strong focus on treating the margins. The University of Missouri has agreed to become a regional center to administer IsoPet® therapy and will incorporate the improvements suggested by the testing program.

 

The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel™ (under the name IsoPet®) and related services, and from licensing to private medical and veterinary clinics in the United States of America (the “USA”, or, the “U.S.”) and internationally. The Company intends to report the results from the IsoPet® Solutions division as a separate operating segment in accordance with generally accepted accounting principles (“GAAP”).

 

Commencing in July 2019, the Company recognized its first commercial sale of IsoPet®. A veterinarian from Alaska brought his cat with a re-occurrent spindle cell sarcoma tumor on his face. The cat had previously received external beam therapy, but now the tumor was growing rapidly. He was given a high dose of 400 Gray with heavy therapy at the margins. This sale met the revenue recognition requirements under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606 – Revenue from Contracts with Customers (“ASC 606”) as the performance obligation was satisfied. The Company completed sales for an additional four animals that received the IsoPet® during 2019.

 

Our plan is to incorporate the data assembled from our work with Isopet® in animal therapy to support the Company’s efforts in the development of our RadioGel™ device candidate, including obtaining approval from the FDA to market and sell RadioGel™ as a Class II medical device. RadioGel™ is an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals. RadioGel™ is comprised of a hydrogel, or a substance that is liquid at room temperature and then gels when reaching body temperature after injection into a tumor. In the gel are small particles, less than two microns, of Y-90. Once injected, these inert particles are locked in place inside the tumor by the gel, delivering a very high local radiation dose. The radiation is beta, consisting of high-speed electrons. These electrons only travel a short distance so the device can deliver high radiation to the tumor with minimal dose to the surrounding tissue. Optimally, patients can go home immediately following treatment without the risk of radiation exposure to family members. Since Y-90 has a half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days.

 

The Company modified its Indication for Use from skin cancel to cancerous tissue or solid tumors pathologically associated with locoregional papillary thyroid carcinoma and recurrent papillary thyroid carcinoma having discernable tumors associated with metastatic lymph nodes or extranodal disease in patients who are not surgical candidates or who have declined surgery, or patients who require post-surgical remnant ablation (for example, after prior incomplete radioiodine therapy). Papillary thyroid carcinoma belongs to the general class of head and neck tumors for which tumors are accessible by intraoperative direct needle injection. The Company’s Medical Advisory Board felt that demonstrating efficacy in clinical trials was much easier with this new indication.

 

In the third quarter of 2024, the Company entered the market of treating exotic animals by treating a ferret. The Company also has established important contacts at zoos and used conferences to communicate the effectiveness of Precision Radionuclide Therapy TM to the zoo community.

 

The Company intends to conduct human trials internationally, initially in Southeast Asia. These trials will be initiated prior to trials in the United States, and will be conducted under a protocol consistent with and complimentary to the IDE and human trial roadmap in the United States.

 

Intellectual Property

 

Our original license with Battelle National Laboratory (the “Battelle License”) reached its end of life in 2022. During the past several years, we have expanded our proprietary knowledge, as well as our trademark and patent protection, in anticipation of the Battelle License reaching the end of its term.

 

 

Our RadioGel™ trademark protection is in 17 countries. We have expanded our trademark protection from RadioGel™ to now include IsoPet®. We obtained the International Certificate of Registration for ISOPET, which is the first step to file in several countries.

 

We have filed for trademark protection for the term Precision Radionuclide Therapy™. We believe this term will be increasingly important.

 

The Company received the Patent Cooperation Treaty (“PCT”) International Search Report on our patent application (No.1811.191). Seven of our claims were immediately ruled as having novelty, inventive step and industrial applicability. This gives us the basis to extend for many years the patent protection for our proprietary Y-90 phosphate particles utilized in Isopet® and Radiogel™.

 

Our patent team filed our particle patent in more than ten patent offices that collectively cover 63 countries throughout the world. We filed a continuation-in-part applications number 1774054 in the USA to expand the claims on our particle patent. The U.S. Patent office recently gave us the Notice of Allowance for our patent to produce our yttrium phosphate microparticles, U.S. Patent Application Serial No: 16-459,466. We also filed an amendment to correct the wording on our claims at make them consistent with the USE claims. Ref: 4207-0005; European Patent Application NO. 20 834 229.5; VIVOS INC; Our Ref: FS/53791.

 

We filed a hydrogel utility patent in the USA (16309:17/943,311) and internationally (16389:PCT/US22/4374) based on the last 18 months of development work to optimize our hydrogel component. These include reducing the polymer production time and increasing the output by a factor of three. We have also further reduced the level of trace contaminants to be well below the FDA guidelines.

 

We filed a provisional patent (Serial Number 63436562) to protect our innovative improvements in our shipping container, our vial shield, our syringe shield, and our Peltier chiller. Our objectives were to reduce shipping costs, decrease radiation exposure, and enhance sterility. These devices will be preferentially used at Mayo Clinics for human clinical studies at our IsoPet regional treatment centers. The Company filed a utility patent in the fourth quarter of 2023 for this therapy support equipment.

 

We anticipate that Precision Radionuclide Therapy will become increasingly important in the future and expand to other isotope and other indications for use. Therefore, we filed an alternate particle utility patent (Serial number 18/152,137). We will focus our near-term effort on the Y-90 therapy, which we believe is the best beta emitter; however, we leveraged our hydrogel utility patent to incorporate other promising isotopes and compounds for a range of future applications. This includes gamma and alpha particle emitters.

 

We have trademark protection in several countries on IsoPet®, RadioGel®, Precision Radionuclide TherapyTM, BetaGelTM, GammaGelTM, and AlphaGelTM.

 

Going Concern

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $2.5 million annually to maintain current operating activities.

 

Financing and Strategy

 

In November 2019, the SEC qualified the Company’s offering of its Common Stock, under Regulation A of Section 3(6) of the Securities Act of 1933, as amended (the “Securities Act”) (“Regulation A”), which offering was and amended from time to time thereafter (the “2019 Regulation A+ Offering”). In September 2021, the SEC qualified the Company’s offering of Common Stock under Regulation A, which offering was amended from time to time thereafter (together with the 2019 Regulation A+ Offering, the “Prior Regulation A+ Offerings”). During the year ended December 31, 2023, $1,179,245 was raised through the sale of 16,132,000 shares of common stock and the private placement of 18,797,000 warrants. During the nine months ended September 30, 2024, the Company raised $839,000 through the issuance of 13,000,000 shares of common stock and 7,000,000 warrants. The Company’s Prior Regulation A Offerings undertaken pursuant to Regulation A+ have raised approximately $6,000,000 from the sale of shares of common stock.

 

 

On July 17, 2024, the SEC qualified the Company’s offering under Regulation A to offer up to $60,000,000 shares of its Common Stock (the “July 2024 Regulation A+ Offering”).

 

The Company is using the proceeds generated from the Prior Regulation A+ Offering and the July 2024 Regulation A+ Offering as follows:

 

Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities. The Company may require additional funding of approximately $5 million annually to maintain current operating activities. Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, and clinical trials; (3) activate several regional clinics to administer IsoPet® across the county; (4) create an independent production center within the current production site to create a template for future international manufacturing; and (5) initiate regulatory approval processes outside of the United States. The proceeds to be raised from the Regulation A+ Offerings will be used to continue to fund this development.

 

The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise), and any requirements for additional studies (which may possibly include clinical studies). Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be: (1) the timing of any approvals; (2) the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution, and licensing of those products; and (3) the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements, as well as proceeds to be raised from the Regulation A+ Offerings.

 

Following receipt of required regulatory approvals and necessary financing to fund our working capital requirements, the Company intends to outsource material aspects of manufacturing, distribution, sales, and marketing for operations within the U.S. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.

 

Long-term, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses. These long-term goals are subject to the Company: (1) receiving adequate funding; (2) receiving regulatory approval for RadioGel™ and other brachytherapy products; and (3) being able to successfully commercialize its brachytherapy products.

 

Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.

 

The Company’s headquarters are in Northeast Washington, however, our focus on the animal therapy market has been the Northwestern sector of the U.S. The Company continues its marketing efforts on the animal therapy market and our attempts to increase the exposure to our product, and generate revenue accordingly.

 

As of September 30, 2024, the Company had $1,218,160 cash on hand. There are currently commitments to vendors for products and services purchased. To continue the development of the Company’s products, the current level of cash will not be enough to cover the fixed and variable obligations of the Company.

 

 

The Company anticipates using the proceeds from the July 2024 Regulation A+ Offering as follows:

 

For the animal therapy market:

 

  ● Expand communication on our website, the Company’s social media presence, conferences, and journals, each intended to increase the number of certified clinics for small animal and equine therapy and to increase the number of patients.
  ● Subsidize some IsoPet® therapies, if necessary, to ensure that all viable candidates are treated; and.
  ● Assist a new regional clinic with their license and certification training.

 

For the human market:

 

  ● Enhance the pedigree of the Quality Management System.
  ● Begin automation of product manufacturing.
  ● Fund liability insurance for human clinical studies; and.
  ● Fund human clinical studies in the US.

 

Research and development of the Company’s precision radionuclide therapy product line has been funded with proceeds from the sale of equity and debt securities, including from the Prior Regulation A+ Offerings. The Company requires additional funding of approximately $2.5 million annually to maintain operating activities. Over the next 36 months, the Company believes it will cost approximately $8.0 to $9.0 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, clinical trials; (3) activate several regional clinics to administer IsoPet® across the U.S.; (4) create an independent production center within the current production site to create a template for future international manufacturing; and (5) initiate regulatory approval processes outside of the United States. The proceeds raised from the Prior Regulation A+ Offerings were used to fund this development and proceeds from the July 2024 Regulation A+ Offering will be used to continue such development efforts.

 

The continued deployment of the precision radionuclide therapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the precision radionuclide therapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s precision radionuclide therapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or from proceeds raised from the Prior Regulation A+ Offering and from the July 2024 Regulation A+ Offering.

 

The Company intends to expand the indications for use in phases: first, for lymph nodes associated with thyroid cancer, secondly, cancerous lung nodules, and finally, all non-sectable solid tumors. It is anticipated that the medical community may begin to use RadioGel off-label, we will support but will not encourage that practice.

 

Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.

 

Long-term, the Company intends to consider resuming research efforts with respect to other products and technologies, such as Gamma Gel and Alpha Gel intended to help improve the diagnosis and treatment of cancer and other illnesses. These long-term goals are subject to the Company: (1) receiving adequate funding; (2) receiving regulatory approval for RadioGel™ and other precision radionuclide therapy products; and (3) being able to successfully commercialize its precision radionuclide therapy products.

 

Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.

 

The Company’s headquarters are in the State of Washington., The initial focus of the animal therapy market has been the Northwestern sector of the United States. The Company has initiated marketing efforts to the animal therapy market in other regions of the United States, attempting to increase the exposure to our product and increase revenue opportunities.

 

 

There are currently commitments to vendors for products and services purchased. To continue the development of the Company’s products, the current level of cash will not be enough to cover the fixed and variable obligations of the Company. The Company has focused on operating on minimum overhead, including using a virtual office for the last several years and retaining experienced industry consultants available on an as needed basis. This has helped focus the capital received from the Company’s Regulation A+ Offerings on activities that enhance our objectives.

 

There is no guarantee that the Company will be able to raise additional funds or to do so on terms advantageous to the Company’s stockholders.

 

The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There can be no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Use of Estimates

 

The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amount of revenue and expense during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.

 

Financial Statement Reclassification

 

Certain account balances from prior periods have been reclassified in these financial statements so as to conform to current period classifications.

 

Cash Equivalents

 

For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.

 

The Company occasionally maintains cash balances in excess of the FDIC insured limit. The Company does not consider this risk to be material.

 

Fair Value of Financial Instruments

 

Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of September 30, 2024 and December 31, 2023, the balances reported for cash, prepaid expense, accounts receivable, accounts payable, and accrued expense, approximate the fair value because of their short maturities.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ASC”) Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

 

Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

 

Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

 

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis.

 

Patents and Intellectual Property

 

While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such 10-year period and on a straight-line basis will begin once the patents have been issued and the Company begins utilization of the patents through production and sales, resulting in revenues.

 

The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows.

 

There have been no such capitalized costs in the three and nine months ended September 30, 2024 and 2023, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) filed by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet® commercially available, which it did on or about July 9, 2019. This additional patent protection will strengthen the Company’s competitive position. It is the Company’s intention to further extend this patent protection to several key countries within one year, as permitted under international patent laws and treaties.

 

Revenue Recognition

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated guidance effective January 1, 2018 using the full retrospective method.

 

Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to perform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows.

 

The Company recognized revenue as they (i) identified the contracts with each customer; (ii) identified the performance obligation in each contract; (iii) determined the transaction price in each contract; (iv) were able to allocate the transaction price to the performance obligations in the contract; and (v) recognized revenue upon the satisfaction of the performance obligation. Upon the sales of the product to complete the procedures on the animals, the Company recognized revenue as that was considered the performance obligation.

 

All revenue recognized in the three and nine months ended September 30, 2024 and 2023 relate to the procedures performed with respect to the IsoPet® therapies.

 

Loss Per Share

 

The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive Common Stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the periods ended in the nine months ended September 30, 2024 and 2023, the basic earnings per share equals the diluted earnings per share.

 

 

The following represent Common Stock equivalents that could be dilutive in the future as of September 30, 2024 and December 31, 2023, which include the following:

 

   September 30, 2024   December 31, 2023 
Preferred stock   9,909,570    9,909,570 
Restricted stock units   12,000,000    1,450,000 
Common stock options   2,252,809    2,252,809 
Common stock warrants   8,100,000    26,134,000 
Total potential dilutive securities   32,262,379    39,746,379 

 

Research and Development Costs

 

Research and developments costs, including salaries, research materials, administrative expense and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed.

 

The Company incurred $66,551 and $80,858 in research and development costs for the three months ended September 30, 2024 and 2023, respectively, and $223,660 and $300,586 in research and development costs for the nine months ended September 30, 2024 and 2023, respectively, all of which were recorded in the Company’s operating expense noted on the statements of operations for the periods then ended.

 

Advertising and Marketing Costs

 

Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. During the three and nine months ended September 30, 2024 and 2023, the Company incurred nominal advertising and marketing costs.

 

Contingencies

 

In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. The Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of September 30, 2024 and December 31, 2023.

 

Income Taxes

 

To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition.

 

The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the three and nine months ended September 30, 2024 and 2023. The Company did not have any deferred tax liability or asset on its balance sheets as of September 30, 2024 and December 31, 2023.

 

Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the three and nine months ended September 30, 2024 and 2023, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months.

 

 

Stock-Based Compensation

 

The Company recognizes compensation costs under FASB ASC Topic 718, Compensation – Stock Compensation and ASU 2018-07. Companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.

 

Recent Accounting Pronouncements

 

The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

 
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.3
RELATED PARTY TRANSACTIONS
 9 Months Ended
Sep. 30, 2024
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 2: RELATED PARTY TRANSACTIONS

 

In September 2023, our Chief Executive Officer advanced $10,000 to the Company, which amount was repaid October 4, 2023.

 
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.3
STOCKHOLDERS’ EQUITY
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 3: STOCKHOLDERS’ EQUITY

 

Common Stock

 

The Company has authorized 950,000,000 shares of Common Stock. As of September 30, 2024 and December 31, 2023, there are 417,592,703 and 387,894,033 shares of Common Stock issued and outstanding, respectively.

 

Preferred Stock

 

The Company has authorized 20,000,000 shares of Preferred Stock. There are currently three series of Preferred Stock outstanding; Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock. The Company’s Board of Directors is authorized to provide for the issuance of shares of Preferred Stock in one or more series, fix or alter the designations, preferences, rights, qualifications, limitations or restrictions of the shares of each series, including the dividend rights, dividend rates, conversion rights, voting rights, term of redemption including sinking fund provisions, redemption price or prices, liquidation preferences and the number of shares constituting any series or designations of such series without further vote or action by the shareholders. The issuance of Preferred Stock may have the effect of delaying, deferring or preventing a change in control of management without further action by the shareholders and may adversely affect the voting and other rights of the holders of Common Stock. The issuance of Preferred Stock with voting and conversion rights may adversely affect the voting power of the holders of Common Stock, including the loss of voting control to others.

 

Series A Convertible Preferred Stock

 

On June 30, 2015, a certificate of designations was filed with the Delaware Secretary of State to designate 2,500,000 shares of the Company’s Preferred Stock as Series A Convertible Preferred Stock, par value $0.001 per share (“Series A Preferred”) (the “Series A COD”). Effective March 31, 2016, the Company amended the Series A COD, increasing the maximum number of shares of Series A Preferred from 2,500,000 shares to 5,000,000 shares. As of September 30, 2024 and December 31, 2023, there are 2,071,007 shares of Series A Preferred issued and outstanding, respectively.

 

The following summarizes the current rights and preferences of the Series A Preferred:

 

Liquidation Preference. The Series A Preferred has a liquidation preference of $5.00 per share.

 

 

Dividends. Shares of Series A Preferred do not have any separate dividend rights.

 

Conversion. Subject to certain limitations set forth in the Series A COD, each share of Series A Preferred is convertible, at the option of the holder, into that number of shares of Common Stock (the “Series A Conversion Shares”) equal to the liquidation preference thereof, divided by Conversion Price (as such term is defined in the Series A COD), currently $4.00.

 

In the event the Company completes an equity or equity-based public offering, registered with the SEC, resulting in gross proceeds to the Company totaling at least $5.0 million, all issued and outstanding shares of Series A Preferred at that time will automatically convert into Series A Conversion Shares.

 

Redemption. Subject to certain conditions set forth in the Series A COD, in the event of a Change of Control (defined in the Series A COD), or at such time as a third party not affiliated with the Company or any holders of the Series A Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent (50%) of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series A Preferred in cash at a price per share of Series A Preferred equal to 100% of the Liquidation Preference.

 

Voting Rights. Holders of Series A Preferred are entitled to vote on all matters, together with the holders of Common Stock, and have the equivalent of five votes for every Series A Conversion Share issuable upon conversion of such holder’s outstanding shares of Series A Preferred. However, the Series A Conversion Shares, when issued, will have all the same voting rights as other issued and outstanding Common Stock of the Company, and none of the rights of the Series A Preferred.

 

Liquidation. Upon any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary (a “Liquidation”), the holders of Series A Preferred shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the liquidation preference of the Series A Preferred before any distribution or payment shall be made to the holders of any junior securities, and if the assets of the Company are insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of the Series A Preferred shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.

 

Certain Price and Share Adjustments.

 

a) Stock Dividends and Stock Splits. If the Company (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock equivalents; (ii) subdivides outstanding shares of Common Stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Company, then the conversion price shall be adjusted accordingly.

 

b) Merger or Reorganization. If the Company is involved in any reorganization, recapitalization, reclassification, consolidation or merger in which the Common Stock is converted into or exchanged for securities, cash or other property than each share of Series A Preferred shall be convertible into the kind and amount of securities, cash or other property that a holder of the number of shares of Common Stock issuable upon conversion of one share of Series A Preferred prior to any such merger or reorganization would have been entitled to receive pursuant to such transaction.

 

 

Series B Convertible Preferred Stock

 

On October 10, 2018, a certificate of designation was filed with the Delaware Secretary of State to designate 5,000,000 shares of our Preferred Stock as Series B Convertible Preferred Stock, par value $0.001 per share (“Series B Preferred”) (the “Series B COD”). As of September 30, 2024 and December 31, 2023, there are 200,363 shares of Series B Preferred issued and outstanding, respectively.

 

The following summarizes the current rights and preferences of the Series B Preferred:

 

Liquidation Preference. The Series B Preferred has a liquidation preference of $1.00 per share.

 

Dividends. Shares of Series B Preferred do not have any separate dividend rights.

 

Conversion. Subject to certain limitations set forth in the Series B COD, each share of Series B Convertible is convertible, at the option of the holder, into that number of shares of Common Stock (the “Series B Conversion Shares”) equal to the liquidation preference thereof, divided by the Conversion Price (as such term is defined in the Series B COD), currently $0.08.

 

Redemption. Subject to certain conditions set forth in the Series B COD, in the event of a Change of Control (defined in the Series B COD), or at such as a third party not affiliated with the Company or any holders of the Series B Convertible shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent (50%) of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Preferred in cash at a price per share of Series B Preferred equal to 100% of the Liquidation Preference.

 

Voting Rights. Holders of Series B Preferred are entitled to vote on all matters, together with the holders of Common Stock, and have the equivalent of two votes for every Series B Conversion Share issuable upon conversion of such holder’s outstanding shares of Series B Preferred. However, the Series B Conversion Shares, when issued, will have the same voting rights as other issued and outstanding shares of Common Stock of the Company, and none of the rights of the Series A Preferred.

 

Liquidation. Upon any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary (a “Liquidation”), the holders of Series B Preferred shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the liquidation preference of the Series B Preferred before any distribution or payment shall be made to the holders of any junior securities, and if the assets of the Company are insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of the Series B Preferred shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.

 

Certain Price and Share Adjustments.

 

a) Stock Dividends and Stock Splits. If the Company (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock equivalents; (ii) subdivides outstanding shares of Common Stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Company, then the conversion price shall be adjusted accordingly.

 

b) Merger or Reorganization. If the Company is involved in any reorganization, recapitalization, reclassification, consolidation or merger in which the Common Stock is converted into or exchanged for securities, cash or other property than each share of Series B Preferred shall be convertible into the kind and amount of securities, cash or other property that a holder of the number of shares of Common Stock issuable upon conversion of one share of Series B Preferred prior to any such merger or reorganization would have been entitled to receive pursuant to such transaction.

 

Series C Convertible Preferred Stock

 

On March 27, 2019, a certificate of designation was filed with the Delaware Secretary of State to designate 5,000,000 shares of our Preferred Stock as Series C Convertible Preferred Stock, par value $0.001 per share (“Series C Preferred”) (the “Series C COD”). As of September 30, 2024 and December 31, 2023, there were 385,302 shares of Series C Preferred issued and outstanding, respectively.

 

The following summarizes the current rights and preferences of the Series C Preferred:

 

Liquidation Preference. The Series C Preferred has a liquidation preference of $1.00 per share.

 

Dividends. Shares of Series C Preferred do not have any separate dividend rights.

 

 

Conversion. Subject to certain limitations set forth in the Series C COD, each share of Series C Preferred is convertible, at the option of the holder, into that number of shares of Common Stock (the “Series C Conversion Shares”) equal to the liquidation preference thereof, divided by Conversion Price (as such term is defined in the Series C COD), currently $0.08.

 

The Series C Preferred will only be convertible at any time after the date that the Company shall have amended its Certificate of Incorporation to increase the number of shares of Common Stock authorized for issuance thereunder or effect a reverse stock split of the outstanding shares of Common Stock by a sufficient amount to permit the conversion of all Series C Preferred into shares of Common Stock (“Authorized Share Approval”) (such date, the “Initial Convertibility Date”), each share of Series C Preferred shall be convertible into validly issued, fully paid and non-assessable shares of Common Stock on the terms and conditions set forth in the Series C COD under the definition “Conversion Rights”.

 

Redemption. Subject to certain conditions set forth in the Series C COD, in the event of a Change of Control (defined in the Series C COD), or at such time as a third party not affiliated with the Company or any holders of the Series C Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent (50%) of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series C Preferred in cash at a price per share of Series C Preferred equal to 100% of the Liquidation Preference.

 

Voting Rights. Holders of Series C Preferred are entitled to vote on all matters, together with the holders of Common Stock, and have the equivalent of thirty-two votes for every Series C Conversion Share issuable upon conversion of such holder’s outstanding shares of Series C Preferred. However, the Series C Conversion Shares, when issued, will have the same voting rights as other issued and outstanding shares of Common Stock of the Company, and none of the rights of the Series C Preferred.

 

Liquidation. Upon any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary (a “Liquidation”), the holders of Series C Preferred shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the liquidation preference of the Series C Preferred before any distribution or payment shall be made to the holders of any junior securities, and if the assets of the Company are insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of the Series C Preferred shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.

 

Certain Price and Share Adjustments.

 

a) Stock Dividends and Stock Splits. If the Company (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock equivalents; (ii) subdivides outstanding shares of Common Stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Company, then the conversion price shall be adjusted accordingly.

 

b) Merger or Reorganization. If the Company is involved in any reorganization, recapitalization, reclassification, consolidation or merger in which the Common Stock is converted into or exchanged for securities, cash or other property than each share of Series C Preferred shall be convertible into the kind and amount of securities, cash or other property that a holder of the number of shares of Common Stock issuable upon conversion of one share of Series C Preferred prior to any such merger or reorganization would have been entitled to receive pursuant to such transaction.

 

Common and Preferred Stock Issuances

 

Common and Preferred Stock Issuances - 2024

 

From January 1, 2024 through September 30, 2024, the Company issued 13,000,000 shares of Common Stock and warrants to purchase 7,000,000 shares of Common Stock pursuant to the Regulation A+ Offerings for cash proceeds of $839,000.

 

The Company issued 441,252 shares of Common Stock for services rendered valued at $69,395.

 

The Company issued 16,919,918 shares of Common Stock in the cashless exercise of 25,034,000 warrants.

 

The Company settled 500,000 RSUs for Common Stock.

 

The Company adjusted their common shares for vested RSUs in prior periods that were cancelled.

 

 

Common and Preferred Stock Issuances – 2023

 

In April 2023, the Company issued 8,000,000 shares of Common Stock, 2,665,000 Series A warrants and 8,000,000 Series B warrants in their Regulation A+ Offerings for $640,000. The Company sold the warrants for $10,665.

 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.3
COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS

NOTE 4: COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS

 

Common Stock Options

 

The Company recognizes in the financial statements compensation related to all stock-based awards, including stock options and warrants, based on their estimated grant-date fair value. The Company has estimated expected forfeitures and is recognizing compensation expense only for those awards expected to vest. All compensation is recognized by the time the award vests.

 

The following schedule summarizes the changes in the Company’s stock options:

 

   Options Outstanding   Weighted Average
Remaining		       Weighted Average 
  

Number Of

Shares

   Exercise Price
Per Share		   Contractual
Life		   Aggregate
Intrinsic Value		   Exercise Price
Per Share		 
Nine Months Ended September 30, 2024                         
                          
Outstanding at January 1, 2024   2,252,809   $0.024-0.04     5.70 years   $78,886   $0.04 
Granted   -   $-    -        $- 
Exercised   -   $-    -        $- 
Expired/canceled   -   $-    -        $- 
Outstanding at September 30, 2024   2,252,809   $0.024-0.04     4.95 years    $284,567   $0.04 
Exercisable at September 30, 2024   2,252,809   $0.024-0.04     4.95 years    $284,567   $0.04 
                          
Nine Months Ended September 30, 2023                         
                          
Outstanding at January 1, 2023   2,252,809   $0.024-0.04    6.70 years    $16,032   $0.04 
Granted   -   $-    -        $- 
Exercised   -   $-    -        $- 
Expired/canceled   -   $-    -        $- 
Outstanding at September 30, 2023   2,252,809   $0.024-0.04    5.95 years   $65,819   $0.04 
Exercisable at September 30, 2023   2,252,809   $0.024-0.04    5.95 years   $65,819   $0.04 

 

During the three and nine months ended September 30, 2024 and the three and nine months ended September 30, 2023, the Company recognized $0 of stock-based compensation expense related to the vesting of stock options.

 

 

Common Stock Warrants

 

The following schedule summarizes the changes in the Company’s stock warrants:

   Warrants Outstanding   Weighted Average
Remaining		       Weighted Average 
   Number Of
Shares		  

Exercise Price

Per Share

   Contractual
Life		   Aggregate
Intrinsic Value		   Exercise Price
Per Share		 
Nine Months Ended September 30, 2024                         
                          
Outstanding at January 1, 2024   26,134,000   $0.06-0.10    3.54 years   $-   $0.0827 
Granted   7,000,000   $0.075    -   $-   $- 
Exercised   (25,034,000)  $-    -   $-   $- 
Redeemed   (500,000)  $-    -   $-   $- 
Expired/cancelled   -   $-    -   $-   $- 
Outstanding at September 30, 2024   8,100,000   $0.075    3.25 years   $717,660   $0.075 
Exercisable at September 30, 2024   8,100,000   $0.075    3.25 years   $717,660   $0.075 
                          
Nine Months Ended September 30, 2023                         
                          
Outstanding at January 1, 2023   26,737,500   $0.06-0.10    1.52 years   $-   $0.09 
Granted   10,665,000   $0.0775    -   $-   $- 
Redeemed   (500,000)  $-    -   $-   $- 
Expired/cancelled   (11,237,500)  $-    -   $-   $- 
Outstanding at September 30, 2023   25,665,000   $0.06-0.10    1.91 years   $150,573   $0.079 
Exercisable at September 30, 2023   25,665,000   $0.06-0.10    1.91 years   $150,573   $0.079 

 

Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each option/warrant is estimated using the Black-Scholes valuation model. The following assumptions were used for the periods as follows:

 

      Nine Months Ended       Nine Months Ended  
      September 30, 2024       September 30, 2023  
Expected term     -       -  
Expected volatility     - %     - %
Expected dividend yield     -       -  
Risk-free interest rate     - %     - %

 

The Company granted 10,665,000 warrants in their Reg A+ funding in April 2023, with an exercise price of $0.0775 and a three-year term.

 

The Company granted 2,000,000 warrants in their Regulation A+ Offering in January 2024, with an exercise price of $0.075 and a three-year term and 5,000,000 warrants with the same terms on April 1, 2024.

 

The Company issued 16,919,918 shares of Common Stock in the cashless exercise of 25,034,000 warrants.

 

Restricted Stock Units

 

The following schedule summarizes the changes in the Company’s restricted stock units:

 

   Number Of Shares   Weighted Average
Grant Date Fair Value		 
Nine Months Ended September 30, 2024          
           
Outstanding at January 1, 2024   1,450,000   $0.09 
Granted   21,050,000   $0.077 
Vested   (10,500,000)  $- 
Forfeited   -   $- 
Outstanding at September 30, 2024   12,000,000   $0.08 
           
Nine Months Ended September 30, 2023          
           
Outstanding at January 1, 2023   10,262,500   $0.08 
Granted   2,900,000   $0.091 
Vested   (10,725,000)  $- 
Forfeited   (262,500)  $- 
Outstanding at September 30, 2023   2,175,000   $0.09 

 

 

During the nine months ended September 30, 2024 and 2023, the Company recognized $809,250 and $965,975 in expense related to the vesting of its restricted stock units. As of September 30, 2024, the Company had $951,595 worth of expense yet to be recognized for restricted stock units not yet vested.

 

On January 1, 2024, the Company granted 20,000,000 restricted stock units to its Chief Executive Officer as part of his new employment agreement that vest in four equal installments over a two-year period beginning February 1, 2024. During the nine months ended September 30, 2024, 10,500,000 of these restricted stock units vested. In May 2024, the Company granted 1,050,000 restricted stock units to consultants that vest through December 31, 2025.

 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.3
COMMITMENT
 9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENT

NOTE 5: COMMITMENT

 

On June 4, 2019, the Company entered into an Executive Employment Agreement (“Employment Agreement”) with Dr. Michael K. Korenko, the Company’s Chief Executive Officer. The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement. On December 31, 2020, the Company extended the Employment Agreement through December 31, 2021 while renegotiating terms of a new Employment Agreement. On May 3, 2021, the Company and the Chief Executive Officer agreed the terms of a new Employment Agreement with an effective date of January 1, 2021 that has a term of three years and expired December 31, 2023. The Company renewed the Employment Agreement for a term of two years expiring December 31, 2025.

 

Under the terms of the Employment Agreement effective January 1, 2024, the Company shall pay to Dr. Korenko a base compensation of $295,500. In addition, there is a discretionary bonus to be earned in the amount of $10,000 per quarter upon the satisfaction of conditions to be determined by the Board of Directors of the Company. In addition, the Company granted Dr. Korenko 20,000,000 restricted stock units on January 1, 2024 that vest over the two year period.

 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.3
SUBSEQUENT EVENTS
 9 Months Ended
Sep. 30, 2024
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 6: SUBSEQUENT EVENTS

 

On November 12, 2024, the Company entered into agreements for the issuance of 11,950,000 shares of common stock for $1,434,000 under the Regulation A+. The Company additionally entered into agreements for the sale of 11,950,000 warrants, 30% of which expire December 31, 2024 at an exercise price of $0.01 and 70% of which expire December 31, 2027 at an exercise price of $0.15 for $11,950 which were not part of the Regulation A+. The shares and warrants will be issued upon receipt of fully executed agreements and receipt of all funds.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.3
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Business Overview

Business Overview

 

The Company was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (“SMSC”). On September 6, 2006, the Company changed its name to Advanced Medical Isotope Corporation, and on December 28, 2017, the Company began operating as Vivos Inc. The Company has authorized capital of 950,000,000 shares of common stock (“Common Stock”), $0.001 par value per share, and 20,000,000 shares of preferred stock (“Preferred Stock”), $0.001 par value per share.

 

Our principal place of business is located at 1030 North Center Parkway, Kennewick, WA 99336. Our telephone number is (509) 222-2222. Our corporate website address is http://www.radiogel.com. Our Common Stock is currently quoted on the OTC Pink Marketplace under the symbol “RDGL.”

 

The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device, RadioGel™, for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers, and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer.

 

In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGel ™should be classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas. Additionally, after a legal review, the Company believes that the device classification obtained from the Food and Drug Administration (“FDA”) Center for Veterinary Medicine is not limited to canine and feline sarcomas, but rather may be extended to a much broader population of veterinary cancers, including all or most solid tumors in animals. We expect the result of such classification and label review will be that no additional regulatory approvals are necessary for the use of IsoPet® for the treatment of solid tumors in animals. The FDA does not have premarket authority over devices with a veterinary classification, and the manufacturers are responsible for assuring that the product is safe, effective, properly labeled, and otherwise in compliance with all applicable laws and regulations.

 

Based on the FDA’s recommendation, RadioGel™ will be marketed as “IsoPet®” for use by veterinarians to avoid any confusion between animal and human therapy. The Company already has trademark protection for the “IsoPet®” name. IsoPet® and RadioGel™ are used synonymously throughout this document. The only distinction between IsoPet® and RadioGel™ is the FDA’s recommendation that we use “IsoPet®” for veterinarian usage, and reserve “RadioGel™” for human therapy. Based on these developments, the Company has shifted its primary focus to the development and marketing of Isopet® for animal therapy, through the Company’s IsoPet® Solutions division.

 
IsoPet Solutions

IsoPet Solutions

 

The Company’s IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospitals to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. The Company has worked with three different university veterinarian hospitals on IsoPet® testing and therapy. Washington State University treated five cats for feline sarcoma and served to develop the procedures which are incorporated in our label. They concluded that the product was safe and effective in killing cancer cells. Colorado State University demonstrated the CT and PET-CT imaging of IsoPet®. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting in November 2017.

 

 

The dogs were treated for canine soft tissue sarcoma. Response evaluation criteria in solid tumors (“RECIST”) is a set of published rules that define when tumors in cancer patients improve (respond), stay the same (stabilize), or worsen (progress) during treatment. The criteria were published by an international collaboration including the European Organisation for Research and Treatment of Cancer (“EORTC”), National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group.

 

The testing at the University of Missouri met its objective to demonstrate the safety of IsoPet®. Using its advanced CT and PET equipment it was able to demonstrate that the dose calculations were accurate and that the injections perfused into the cell interstices and did not stay concentrated in a bolus. This results in a more homogeneous dose distribution. There was insignificant spread of Y-90 outside the points of injection demonstrating the effectiveness of the particles and the gel to localize the radiation with no spreading to the blood or other organs nor to urine or fecal material. This confirms that IsoPet® is safe for same day therapy.

 

The effectiveness of IsoPet® for life extension was not the prime objective, but it resulted in valuable insights. Of the cases one is still cancer-free but the others eventually recurred since there was not a strong focus on treating the margins. The University of Missouri has agreed to become a regional center to administer IsoPet® therapy and will incorporate the improvements suggested by the testing program.

 

The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel™ (under the name IsoPet®) and related services, and from licensing to private medical and veterinary clinics in the United States of America (the “USA”, or, the “U.S.”) and internationally. The Company intends to report the results from the IsoPet® Solutions division as a separate operating segment in accordance with generally accepted accounting principles (“GAAP”).

 

Commencing in July 2019, the Company recognized its first commercial sale of IsoPet®. A veterinarian from Alaska brought his cat with a re-occurrent spindle cell sarcoma tumor on his face. The cat had previously received external beam therapy, but now the tumor was growing rapidly. He was given a high dose of 400 Gray with heavy therapy at the margins. This sale met the revenue recognition requirements under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606 – Revenue from Contracts with Customers (“ASC 606”) as the performance obligation was satisfied. The Company completed sales for an additional four animals that received the IsoPet® during 2019.

 

Our plan is to incorporate the data assembled from our work with Isopet® in animal therapy to support the Company’s efforts in the development of our RadioGel™ device candidate, including obtaining approval from the FDA to market and sell RadioGel™ as a Class II medical device. RadioGel™ is an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals. RadioGel™ is comprised of a hydrogel, or a substance that is liquid at room temperature and then gels when reaching body temperature after injection into a tumor. In the gel are small particles, less than two microns, of Y-90. Once injected, these inert particles are locked in place inside the tumor by the gel, delivering a very high local radiation dose. The radiation is beta, consisting of high-speed electrons. These electrons only travel a short distance so the device can deliver high radiation to the tumor with minimal dose to the surrounding tissue. Optimally, patients can go home immediately following treatment without the risk of radiation exposure to family members. Since Y-90 has a half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days.

 

The Company modified its Indication for Use from skin cancel to cancerous tissue or solid tumors pathologically associated with locoregional papillary thyroid carcinoma and recurrent papillary thyroid carcinoma having discernable tumors associated with metastatic lymph nodes or extranodal disease in patients who are not surgical candidates or who have declined surgery, or patients who require post-surgical remnant ablation (for example, after prior incomplete radioiodine therapy). Papillary thyroid carcinoma belongs to the general class of head and neck tumors for which tumors are accessible by intraoperative direct needle injection. The Company’s Medical Advisory Board felt that demonstrating efficacy in clinical trials was much easier with this new indication.

 

In the third quarter of 2024, the Company entered the market of treating exotic animals by treating a ferret. The Company also has established important contacts at zoos and used conferences to communicate the effectiveness of Precision Radionuclide Therapy TM to the zoo community.

 

The Company intends to conduct human trials internationally, initially in Southeast Asia. These trials will be initiated prior to trials in the United States, and will be conducted under a protocol consistent with and complimentary to the IDE and human trial roadmap in the United States.

 
Intellectual Property

Intellectual Property

 

Our original license with Battelle National Laboratory (the “Battelle License”) reached its end of life in 2022. During the past several years, we have expanded our proprietary knowledge, as well as our trademark and patent protection, in anticipation of the Battelle License reaching the end of its term.

 

 

Our RadioGel™ trademark protection is in 17 countries. We have expanded our trademark protection from RadioGel™ to now include IsoPet®. We obtained the International Certificate of Registration for ISOPET, which is the first step to file in several countries.

 

We have filed for trademark protection for the term Precision Radionuclide Therapy™. We believe this term will be increasingly important.

 

The Company received the Patent Cooperation Treaty (“PCT”) International Search Report on our patent application (No.1811.191). Seven of our claims were immediately ruled as having novelty, inventive step and industrial applicability. This gives us the basis to extend for many years the patent protection for our proprietary Y-90 phosphate particles utilized in Isopet® and Radiogel™.

 

Our patent team filed our particle patent in more than ten patent offices that collectively cover 63 countries throughout the world. We filed a continuation-in-part applications number 1774054 in the USA to expand the claims on our particle patent. The U.S. Patent office recently gave us the Notice of Allowance for our patent to produce our yttrium phosphate microparticles, U.S. Patent Application Serial No: 16-459,466. We also filed an amendment to correct the wording on our claims at make them consistent with the USE claims. Ref: 4207-0005; European Patent Application NO. 20 834 229.5; VIVOS INC; Our Ref: FS/53791.

 

We filed a hydrogel utility patent in the USA (16309:17/943,311) and internationally (16389:PCT/US22/4374) based on the last 18 months of development work to optimize our hydrogel component. These include reducing the polymer production time and increasing the output by a factor of three. We have also further reduced the level of trace contaminants to be well below the FDA guidelines.

 

We filed a provisional patent (Serial Number 63436562) to protect our innovative improvements in our shipping container, our vial shield, our syringe shield, and our Peltier chiller. Our objectives were to reduce shipping costs, decrease radiation exposure, and enhance sterility. These devices will be preferentially used at Mayo Clinics for human clinical studies at our IsoPet regional treatment centers. The Company filed a utility patent in the fourth quarter of 2023 for this therapy support equipment.

 

We anticipate that Precision Radionuclide Therapy will become increasingly important in the future and expand to other isotope and other indications for use. Therefore, we filed an alternate particle utility patent (Serial number 18/152,137). We will focus our near-term effort on the Y-90 therapy, which we believe is the best beta emitter; however, we leveraged our hydrogel utility patent to incorporate other promising isotopes and compounds for a range of future applications. This includes gamma and alpha particle emitters.

 

We have trademark protection in several countries on IsoPet®, RadioGel®, Precision Radionuclide TherapyTM, BetaGelTM, GammaGelTM, and AlphaGelTM.

 
Going Concern

Going Concern

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $2.5 million annually to maintain current operating activities.

 
Financing and Strategy

Financing and Strategy

 

In November 2019, the SEC qualified the Company’s offering of its Common Stock, under Regulation A of Section 3(6) of the Securities Act of 1933, as amended (the “Securities Act”) (“Regulation A”), which offering was and amended from time to time thereafter (the “2019 Regulation A+ Offering”). In September 2021, the SEC qualified the Company’s offering of Common Stock under Regulation A, which offering was amended from time to time thereafter (together with the 2019 Regulation A+ Offering, the “Prior Regulation A+ Offerings”). During the year ended December 31, 2023, $1,179,245 was raised through the sale of 16,132,000 shares of common stock and the private placement of 18,797,000 warrants. During the nine months ended September 30, 2024, the Company raised $839,000 through the issuance of 13,000,000 shares of common stock and 7,000,000 warrants. The Company’s Prior Regulation A Offerings undertaken pursuant to Regulation A+ have raised approximately $6,000,000 from the sale of shares of common stock.

 

 

On July 17, 2024, the SEC qualified the Company’s offering under Regulation A to offer up to $60,000,000 shares of its Common Stock (the “July 2024 Regulation A+ Offering”).

 

The Company is using the proceeds generated from the Prior Regulation A+ Offering and the July 2024 Regulation A+ Offering as follows:

 

Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities. The Company may require additional funding of approximately $5 million annually to maintain current operating activities. Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, and clinical trials; (3) activate several regional clinics to administer IsoPet® across the county; (4) create an independent production center within the current production site to create a template for future international manufacturing; and (5) initiate regulatory approval processes outside of the United States. The proceeds to be raised from the Regulation A+ Offerings will be used to continue to fund this development.

 

The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise), and any requirements for additional studies (which may possibly include clinical studies). Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be: (1) the timing of any approvals; (2) the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution, and licensing of those products; and (3) the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements, as well as proceeds to be raised from the Regulation A+ Offerings.

 

Following receipt of required regulatory approvals and necessary financing to fund our working capital requirements, the Company intends to outsource material aspects of manufacturing, distribution, sales, and marketing for operations within the U.S. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.

 

Long-term, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses. These long-term goals are subject to the Company: (1) receiving adequate funding; (2) receiving regulatory approval for RadioGel™ and other brachytherapy products; and (3) being able to successfully commercialize its brachytherapy products.

 

Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.

 

The Company’s headquarters are in Northeast Washington, however, our focus on the animal therapy market has been the Northwestern sector of the U.S. The Company continues its marketing efforts on the animal therapy market and our attempts to increase the exposure to our product, and generate revenue accordingly.

 

As of September 30, 2024, the Company had $1,218,160 cash on hand. There are currently commitments to vendors for products and services purchased. To continue the development of the Company’s products, the current level of cash will not be enough to cover the fixed and variable obligations of the Company.

 

 

The Company anticipates using the proceeds from the July 2024 Regulation A+ Offering as follows:

 

For the animal therapy market:

 

  ● Expand communication on our website, the Company’s social media presence, conferences, and journals, each intended to increase the number of certified clinics for small animal and equine therapy and to increase the number of patients.
  ● Subsidize some IsoPet® therapies, if necessary, to ensure that all viable candidates are treated; and.
  ● Assist a new regional clinic with their license and certification training.

 

For the human market:

 

  ● Enhance the pedigree of the Quality Management System.
  ● Begin automation of product manufacturing.
  ● Fund liability insurance for human clinical studies; and.
  ● Fund human clinical studies in the US.

 

Research and development of the Company’s precision radionuclide therapy product line has been funded with proceeds from the sale of equity and debt securities, including from the Prior Regulation A+ Offerings. The Company requires additional funding of approximately $2.5 million annually to maintain operating activities. Over the next 36 months, the Company believes it will cost approximately $8.0 to $9.0 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, clinical trials; (3) activate several regional clinics to administer IsoPet® across the U.S.; (4) create an independent production center within the current production site to create a template for future international manufacturing; and (5) initiate regulatory approval processes outside of the United States. The proceeds raised from the Prior Regulation A+ Offerings were used to fund this development and proceeds from the July 2024 Regulation A+ Offering will be used to continue such development efforts.

 

The continued deployment of the precision radionuclide therapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the precision radionuclide therapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s precision radionuclide therapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or from proceeds raised from the Prior Regulation A+ Offering and from the July 2024 Regulation A+ Offering.

 

The Company intends to expand the indications for use in phases: first, for lymph nodes associated with thyroid cancer, secondly, cancerous lung nodules, and finally, all non-sectable solid tumors. It is anticipated that the medical community may begin to use RadioGel off-label, we will support but will not encourage that practice.

 

Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.

 

Long-term, the Company intends to consider resuming research efforts with respect to other products and technologies, such as Gamma Gel and Alpha Gel intended to help improve the diagnosis and treatment of cancer and other illnesses. These long-term goals are subject to the Company: (1) receiving adequate funding; (2) receiving regulatory approval for RadioGel™ and other precision radionuclide therapy products; and (3) being able to successfully commercialize its precision radionuclide therapy products.

 

Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.

 

The Company’s headquarters are in the State of Washington., The initial focus of the animal therapy market has been the Northwestern sector of the United States. The Company has initiated marketing efforts to the animal therapy market in other regions of the United States, attempting to increase the exposure to our product and increase revenue opportunities.

 

 

There are currently commitments to vendors for products and services purchased. To continue the development of the Company’s products, the current level of cash will not be enough to cover the fixed and variable obligations of the Company. The Company has focused on operating on minimum overhead, including using a virtual office for the last several years and retaining experienced industry consultants available on an as needed basis. This has helped focus the capital received from the Company’s Regulation A+ Offerings on activities that enhance our objectives.

 

There is no guarantee that the Company will be able to raise additional funds or to do so on terms advantageous to the Company’s stockholders.

 

The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There can be no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 
Use of Estimates

Use of Estimates

 

The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amount of revenue and expense during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.

 
Financial Statement Reclassification

Financial Statement Reclassification

 

Certain account balances from prior periods have been reclassified in these financial statements so as to conform to current period classifications.

 
Cash Equivalents

Cash Equivalents

 

For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.

 

The Company occasionally maintains cash balances in excess of the FDIC insured limit. The Company does not consider this risk to be material.

 
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of September 30, 2024 and December 31, 2023, the balances reported for cash, prepaid expense, accounts receivable, accounts payable, and accrued expense, approximate the fair value because of their short maturities.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ASC”) Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

 

Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

 

Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

 

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis.

 
Patents and Intellectual Property

Patents and Intellectual Property

 

While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such 10-year period and on a straight-line basis will begin once the patents have been issued and the Company begins utilization of the patents through production and sales, resulting in revenues.

 

The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows.

 

There have been no such capitalized costs in the three and nine months ended September 30, 2024 and 2023, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) filed by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet® commercially available, which it did on or about July 9, 2019. This additional patent protection will strengthen the Company’s competitive position. It is the Company’s intention to further extend this patent protection to several key countries within one year, as permitted under international patent laws and treaties.

 
Revenue Recognition

Revenue Recognition

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated guidance effective January 1, 2018 using the full retrospective method.

 

Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to perform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows.

 

The Company recognized revenue as they (i) identified the contracts with each customer; (ii) identified the performance obligation in each contract; (iii) determined the transaction price in each contract; (iv) were able to allocate the transaction price to the performance obligations in the contract; and (v) recognized revenue upon the satisfaction of the performance obligation. Upon the sales of the product to complete the procedures on the animals, the Company recognized revenue as that was considered the performance obligation.

 

All revenue recognized in the three and nine months ended September 30, 2024 and 2023 relate to the procedures performed with respect to the IsoPet® therapies.

 
Loss Per Share

Loss Per Share

 

The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive Common Stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the periods ended in the nine months ended September 30, 2024 and 2023, the basic earnings per share equals the diluted earnings per share.

 

 

The following represent Common Stock equivalents that could be dilutive in the future as of September 30, 2024 and December 31, 2023, which include the following:

 

   September 30, 2024   December 31, 2023 
Preferred stock   9,909,570    9,909,570 
Restricted stock units   12,000,000    1,450,000 
Common stock options   2,252,809    2,252,809 
Common stock warrants   8,100,000    26,134,000 
Total potential dilutive securities   32,262,379    39,746,379 

 
Research and Development Costs

Research and Development Costs

 

Research and developments costs, including salaries, research materials, administrative expense and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed.

 

The Company incurred $66,551 and $80,858 in research and development costs for the three months ended September 30, 2024 and 2023, respectively, and $223,660 and $300,586 in research and development costs for the nine months ended September 30, 2024 and 2023, respectively, all of which were recorded in the Company’s operating expense noted on the statements of operations for the periods then ended.

 
Advertising and Marketing Costs

Advertising and Marketing Costs

 

Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. During the three and nine months ended September 30, 2024 and 2023, the Company incurred nominal advertising and marketing costs.

 
Contingencies

Contingencies

 

In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. The Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of September 30, 2024 and December 31, 2023.

 
Income Taxes

Income Taxes

 

To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition.

 

The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the three and nine months ended September 30, 2024 and 2023. The Company did not have any deferred tax liability or asset on its balance sheets as of September 30, 2024 and December 31, 2023.

 

Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the three and nine months ended September 30, 2024 and 2023, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months.

 

 
Stock-Based Compensation

Stock-Based Compensation

 

The Company recognizes compensation costs under FASB ASC Topic 718, Compensation – Stock Compensation and ASU 2018-07. Companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.3
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
SCHEDULE OF DILUTIVE EARNINGS PER SHARE

The following represent Common Stock equivalents that could be dilutive in the future as of September 30, 2024 and December 31, 2023, which include the following:

 

   September 30, 2024   December 31, 2023 
Preferred stock   9,909,570    9,909,570 
Restricted stock units   12,000,000    1,450,000 
Common stock options   2,252,809    2,252,809 
Common stock warrants   8,100,000    26,134,000 
Total potential dilutive securities   32,262,379    39,746,379 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.3
COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Tables)
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
SCHEDULE OF CHANGES IN STOCK OPTION

The following schedule summarizes the changes in the Company’s stock options:

 

   Options Outstanding   Weighted Average
Remaining		       Weighted Average 
  

Number Of

Shares

   Exercise Price
Per Share		   Contractual
Life		   Aggregate
Intrinsic Value		   Exercise Price
Per Share		 
Nine Months Ended September 30, 2024                         
                          
Outstanding at January 1, 2024   2,252,809   $0.024-0.04     5.70 years   $78,886   $0.04 
Granted   -   $-    -        $- 
Exercised   -   $-    -        $- 
Expired/canceled   -   $-    -        $- 
Outstanding at September 30, 2024   2,252,809   $0.024-0.04     4.95 years    $284,567   $0.04 
Exercisable at September 30, 2024   2,252,809   $0.024-0.04     4.95 years    $284,567   $0.04 
                          
Nine Months Ended September 30, 2023                         
                          
Outstanding at January 1, 2023   2,252,809   $0.024-0.04    6.70 years    $16,032   $0.04 
Granted   -   $-    -        $- 
Exercised   -   $-    -        $- 
Expired/canceled   -   $-    -        $- 
Outstanding at September 30, 2023   2,252,809   $0.024-0.04    5.95 years   $65,819   $0.04 
Exercisable at September 30, 2023   2,252,809   $0.024-0.04    5.95 years   $65,819   $0.04 
SCHEDULE OF CHANGES IN STOCK WARRANTS

The following schedule summarizes the changes in the Company’s stock warrants:

   Warrants Outstanding   Weighted Average
Remaining		       Weighted Average 
   Number Of
Shares		  

Exercise Price

Per Share

   Contractual
Life		   Aggregate
Intrinsic Value		   Exercise Price
Per Share		 
Nine Months Ended September 30, 2024                         
                          
Outstanding at January 1, 2024   26,134,000   $0.06-0.10    3.54 years   $-   $0.0827 
Granted   7,000,000   $0.075    -   $-   $- 
Exercised   (25,034,000)  $-    -   $-   $- 
Redeemed   (500,000)  $-    -   $-   $- 
Expired/cancelled   -   $-    -   $-   $- 
Outstanding at September 30, 2024   8,100,000   $0.075    3.25 years   $717,660   $0.075 
Exercisable at September 30, 2024   8,100,000   $0.075    3.25 years   $717,660   $0.075 
                          
Nine Months Ended September 30, 2023                         
                          
Outstanding at January 1, 2023   26,737,500   $0.06-0.10    1.52 years   $-   $0.09 
Granted   10,665,000   $0.0775    -   $-   $- 
Redeemed   (500,000)  $-    -   $-   $- 
Expired/cancelled   (11,237,500)  $-    -   $-   $- 
Outstanding at September 30, 2023   25,665,000   $0.06-0.10    1.91 years   $150,573   $0.079 
Exercisable at September 30, 2023   25,665,000   $0.06-0.10    1.91 years   $150,573   $0.079 
SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT

 

      Nine Months Ended       Nine Months Ended  
      September 30, 2024       September 30, 2023  
Expected term     -       -  
Expected volatility     - %     - %
Expected dividend yield     -       -  
Risk-free interest rate     - %     - %
SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS

The following schedule summarizes the changes in the Company’s restricted stock units:

 

   Number Of Shares   Weighted Average
Grant Date Fair Value		 
Nine Months Ended September 30, 2024          
           
Outstanding at January 1, 2024   1,450,000   $0.09 
Granted   21,050,000   $0.077 
Vested   (10,500,000)  $- 
Forfeited   -   $- 
Outstanding at September 30, 2024   12,000,000   $0.08 
           
Nine Months Ended September 30, 2023          
           
Outstanding at January 1, 2023   10,262,500   $0.08 
Granted   2,900,000   $0.091 
Vested   (10,725,000)  $- 
Forfeited   (262,500)  $- 
Outstanding at September 30, 2023   2,175,000   $0.09 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.3
SCHEDULE OF DILUTIVE EARNINGS PER SHARE (Details) - shares
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential dilutive securities 32,262,379 39,746,379
Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential dilutive securities 9,909,570 9,909,570
Restricted Stock Units (RSUs) [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential dilutive securities 12,000,000 1,450,000
Equity Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential dilutive securities 2,252,809 2,252,809
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential dilutive securities 8,100,000 26,134,000
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.3
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 17, 2024
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Property, Plant and Equipment [Line Items]            
Common stock, shares authorized   950,000,000   950,000,000   950,000,000
Common stock, par value   $ 0.001   $ 0.001   $ 0.001
Preferred stock, shares authorized   20,000,000   20,000,000   20,000,000
Preferred stock, par value   $ 0.001   $ 0.001   $ 0.001
Current operating activities       $ 2,500,000    
Sale of common stock       6,000,000    
Current operating activities       (1,213,127) $ (829,886)  
Cash on hand   $ 1,218,160   $ 1,218,160    
Economic life of the patent   10 years   10 years    
Research and development costs   $ 66,551 $ 80,858 $ 223,660 $ 300,586  
Brachytherapy Product Line [Member]            
Property, Plant and Equipment [Line Items]            
Current operating activities       $ 5,000,000    
Offering term       Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, and clinical trials; (3) activate several regional clinics to administer IsoPet® across the county; (4) create an independent production center within the current production site to create a template for future international manufacturing; and (5) initiate regulatory approval processes outside of the United States. The proceeds to be raised from the Regulation A+ Offerings will be used to continue to fund this development.    
Radionuclide Therapy Product Line [Member]            
Property, Plant and Equipment [Line Items]            
Current operating activities       $ 2,500,000    
Offering term       Over the next 36 months, the Company believes it will cost approximately $8.0 to $9.0 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, clinical trials; (3) activate several regional clinics to administer IsoPet® across the U.S.; (4) create an independent production center within the current production site to create a template for future international manufacturing; and (5) initiate regulatory approval processes outside of the United States.    
Warrant [Member]            
Property, Plant and Equipment [Line Items]            
Number of warrants issued   7,000,000   7,000,000   18,797,000
Common Stock [Member]            
Property, Plant and Equipment [Line Items]            
Number of common stock shares issued, value       $ 839,000    
Number of common stock shares issued, shares       13,000,000    
Common Stock [Member] | Maximum [Member]            
Property, Plant and Equipment [Line Items]            
Number of common stock shares issued, value $ 60,000,000          
Private Placement [Member]            
Property, Plant and Equipment [Line Items]            
Number of common stock shares issued, value           $ 1,179,245
Number of common stock shares issued, shares           16,132,000
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.3
RELATED PARTY TRANSACTIONS (Details Narrative)
Sep. 30, 2023
USD ($)
Chief Executive Officer [Member]  
Advance from officer $ 10,000
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.3
SCHEDULE OF CHANGES IN STOCK OPTION (Details) - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Number of Options Outstanding Beginning Balance 2,252,809 2,252,809 2,252,809  
Weighted Average Remaining Contractual Life (in years) Outstanding 4 years 11 months 12 days 5 years 11 months 12 days 5 years 8 months 12 days 6 years 8 months 12 days
Aggregate Intrinsic Value Outstanding Beginning $ 78,886 $ 16,032 $ 16,032  
Weighted Average Exercise Price Per Share Outstanding Beginning $ 0.04 $ 0.04 $ 0.04  
Number of Options granted    
Exercise Price Per Share granted    
Weighted Average Exercise Price Per Share Options granted    
Number of Options exercised    
Exercise Price Per Share exercised    
Weighted Average Exercise Price Per Share Options exercised    
Number of Options expired/cancelled    
Exercise Price Per Share expired/cancelled    
Weighted Average Exercise Price Per Share Options expired/cancelled    
Number of Options Outstanding Ending Balance 2,252,809 2,252,809 2,252,809 2,252,809
Aggregate Intrinsic Value Outstanding Ending $ 284,567 $ 65,819 $ 78,886 $ 16,032
Weighted Average Exercise Price Per Share Outstanding Ending $ 0.04 $ 0.04 $ 0.04 $ 0.04
Number of Options Exercisable 2,252,809 2,252,809    
Weighted Average Remaining Contractual Life (in years) Exercisable 4 years 11 months 12 days 5 years 11 months 12 days    
Aggregate Intrinsic Value Exercisable $ 284,567 $ 65,819    
Weighted Average Exercise Price Per Share Exercisable $ 0.04 $ 0.04    
Minimum [Member]        
Exercise Price Per Share Outstanding Beginning Balance 0.024 0.024 0.024  
Weighted Average Exercise Price Per Share Outstanding Ending 0.024 0.024 0.024 0.024
Exercise Price Per Share Exercisable 0.024 0.024    
Maximum [Member]        
Exercise Price Per Share Outstanding Beginning Balance 0.04 0.04 0.04  
Weighted Average Exercise Price Per Share Outstanding Ending 0.04 0.04 $ 0.04 $ 0.04
Exercise Price Per Share Exercisable $ 0.04 $ 0.04    
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.3
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Mar. 27, 2019
Oct. 10, 2018
Jun. 30, 2015
Apr. 30, 2023
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Mar. 31, 2016
Mar. 30, 2016
Class of Stock [Line Items]                          
Common stock, shares authorized         950,000,000       950,000,000   950,000,000    
Common stock, shares issued         417,592,703       417,592,703   387,894,033    
Common stock, shares outstanding         417,592,703       417,592,703   387,894,033    
Preferred stock shares authorized         20,000,000       20,000,000   20,000,000    
Preferred stock, par value         $ 0.001       $ 0.001   $ 0.001    
Proceeds from issuance or sale of equity                 $ 839,000 $ 650,665      
Issued for services, shares                 441,252        
Issued for services, value         $ 56,163 $ 3,750 $ 9,482   $ 69,395        
Number of shares issued, value         $ 704,000 $ 128,000 $ 640,000          
Restricted Stock Units (RSUs) [Member]                          
Class of Stock [Line Items]                          
Issued for common stock RSU                 500,000        
Common Stock and Warrants [Member]                          
Class of Stock [Line Items]                          
Number of shares issued                 13,000,000        
Warrant [Member]                          
Class of Stock [Line Items]                          
Warrant purchase         7,000,000       7,000,000   18,797,000    
Issued for common stock warrant exercise                 16,919,918        
Issued for cashless exercise, warrants         25,034,000       25,034,000        
Common Stock [Member]                          
Class of Stock [Line Items]                          
Number of shares issued       8,000,000   11,000,000 2,000,000 8,000,000          
Issued for services, shares         278,652 22,766 139,834            
Issued for services, value         $ 279 $ 22 $ 140            
Issued for common stock warrant exercise                 16,919,918        
Issued for common stock RSU         500,000                
Number of shares issued, value       $ 640,000 $ 11,000 $ 2,000 $ 8,000          
Proceeds from issuance of warrants       $ 10,665                  
Series A Convertible Preferred Stock [Member]                          
Class of Stock [Line Items]                          
Preferred stock shares authorized     2,500,000   5,000,000       5,000,000   5,000,000 5,000,000 2,500,000
Preferred stock, par value     $ 0.001                    
Preferred stock shares outstanding         2,071,007       2,071,007   2,071,007    
Preferred stock, liquidation preference per share     5.00                    
Conversion price per share     $ 4.00                    
Gross proceeds from preferred stock     $ 5,000,000.0                    
Preferred stock redemption, description     Subject to certain conditions set forth in the Series A COD, in the event of a Change of Control (defined in the Series A COD), or at such time as a third party not affiliated with the Company or any holders of the Series A Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent (50%) of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series A Preferred in cash at a price per share of Series A Preferred equal to 100% of the Liquidation Preference.                    
Redemption percentage     100.00%                    
Voting percentage     Holders of Series A Preferred are entitled to vote on all matters, together with the holders of Common Stock, and have the equivalent of five votes for every Series A Conversion Share issuable upon conversion of such holder’s outstanding shares of Series A Preferred. However, the Series A Conversion Shares, when issued, will have all the same voting rights as other issued and outstanding Common Stock of the Company, and none of the rights of the Series A Preferred.                    
Preferred stock shares issued         2,071,007       2,071,007   2,071,007    
Series B Convertible Preferred Stock [Member]                          
Class of Stock [Line Items]                          
Preferred stock shares authorized   5,000,000     5,000,000       5,000,000   5,000,000    
Preferred stock, par value   $ 0.001                      
Preferred stock shares outstanding         200,363       200,363   200,363    
Preferred stock, liquidation preference per share   1.00                      
Conversion price per share   $ 0.08                      
Preferred stock redemption, description   Subject to certain conditions set forth in the Series B COD, in the event of a Change of Control (defined in the Series B COD), or at such as a third party not affiliated with the Company or any holders of the Series B Convertible shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent (50%) of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Preferred in cash at a price per share of Series B Preferred equal to 100% of the Liquidation Preference                      
Redemption percentage   100.00%                      
Voting percentage   Holders of Series B Preferred are entitled to vote on all matters, together with the holders of Common Stock, and have the equivalent of two votes for every Series B Conversion Share issuable upon conversion of such holder’s outstanding shares of Series B Preferred. However, the Series B Conversion Shares, when issued, will have the same voting rights as other issued and outstanding shares of Common Stock of the Company, and none of the rights of the Series A Preferred.                      
Preferred stock shares issued         200,363       200,363   200,363    
Series C Convertible Preferred Stock [Member]                          
Class of Stock [Line Items]                          
Preferred stock shares authorized 5,000,000       5,000,000       5,000,000   5,000,000    
Preferred stock, par value $ 0.001                        
Preferred stock shares outstanding         385,302       385,302   385,302    
Preferred stock, liquidation preference per share 1.00                        
Conversion price per share $ 0.08                        
Preferred stock redemption, description Subject to certain conditions set forth in the Series C COD, in the event of a Change of Control (defined in the Series C COD), or at such time as a third party not affiliated with the Company or any holders of the Series C Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent (50%) of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series C Preferred in cash at a price per share of Series C Preferred equal to 100% of the Liquidation Preference                        
Redemption percentage 100.00%                        
Voting percentage Holders of Series C Preferred are entitled to vote on all matters, together with the holders of Common Stock, and have the equivalent of thirty-two votes for every Series C Conversion Share issuable upon conversion of such holder’s outstanding shares of Series C Preferred. However, the Series C Conversion Shares, when issued, will have the same voting rights as other issued and outstanding shares of Common Stock of the Company, and none of the rights of the Series C Preferred.                        
Preferred stock shares issued         385,302       385,302   385,302    
Series A Warrant [Member]                          
Class of Stock [Line Items]                          
Number of shares issued       2,665,000                  
Series B Warrant [Member]                          
Class of Stock [Line Items]                          
Number of shares issued       8,000,000                  
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.3
SCHEDULE OF CHANGES IN STOCK WARRANTS (Details) - Warrant [Member] - USD ($)
 1 Months Ended 9 Months Ended 12 Months Ended
Apr. 01, 2024
Jan. 31, 2024
Apr. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Number of Shares, Warrants Outstanding Beginning   26,134,000   26,134,000 26,737,500 26,737,500  
Weighted Average Remaining Contractual Life Warrants Outstanding Ending       3 years 3 months 1 year 10 months 28 days 3 years 6 months 14 days 1 year 6 months 7 days
Aggregate Intrinsic Value Outstanding Beginning      
Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable Beginning   $ 0.0827   $ 0.0827 $ 0.09 $ 0.09  
Number of Shares, Warrants granted 5,000,000 2,000,000 10,665,000 7,000,000 10,665,000    
Exercise Price Per Share Warrants granted   $ 0.075 $ 0.0775 $ 0.075 $ 0.0775    
Weighted Average Exercise Price Per Share Exercise Price Warrants granted          
Number of Shares, Warrants exercised       (25,034,000)      
Exercise Price Per Share Warrants exercised          
Number of Shares, Warrants redeemed         (500,000)    
Number of Shares, Warrants expired/cancelled       (11,237,500)    
Exercise Price Per Share Warrants expired/cancelled          
Number of Shares, Warrants Outstanding Ending       8,100,000 25,665,000 26,134,000 26,737,500
Exercise Price Per Share Warrants Outstanding Ending       $ 0.075      
Aggregate Intrinsic Value Outstanding Ending       $ 717,660 $ 150,573
Weighted Average Exercise Price Per Share Exercise Price Warrants Ending       $ 0.075 $ 0.079    
Number of Shares, Warrants Exercisable Ending       8,100,000 25,665,000    
Exercise Price Per Share Warrants Exercisable Ending       $ 0.075      
Weighted Average Remaining Contractual Life Warrants Exercisable       3 years 3 months 1 year 10 months 28 days    
Aggregate Intrinsic Value Exercisable       $ 717,660 $ 150,573    
Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable       $ 0.075 $ 0.079 $ 0.0827 $ 0.09
Minimum [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Exercise Price Per Share Warrants Outstanding Beginning   0.06   0.06 0.06 0.06  
Exercise Price Per Share Warrants Outstanding Ending         0.06 0.06 0.06
Exercise Price Per Share Warrants Exercisable Ending         0.06    
Maximum [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Exercise Price Per Share Warrants Outstanding Beginning   $ 0.10   $ 0.10 0.10 0.10  
Exercise Price Per Share Warrants Outstanding Ending         0.10 $ 0.10 $ 0.10
Exercise Price Per Share Warrants Exercisable Ending         $ 0.10    
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.3
SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT (Details)
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Equity [Abstract]    
Expected term
Expected volatility
Expected dividend yield
Risk-free interest rate
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.3
SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS (Details) - Restricted Stock Units [Member] - $ / shares
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of Shares, RSU's Beginning balance 1,450,000 10,262,500
Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning $ 0.09 $ 0.08
Number of Shares, RSU's granted 21,050,000 2,900,000
Weighted Average Grant Date Fair Value, RSU's granted $ 0.077 $ 0.091
Number of Shares, RSU's vested (10,500,000) (10,725,000)
Weighted Average Grant Date Fair Value, RSU's vested
Number of Shares, RSU's forfeited 262,500
Weighted Average Grant Date Fair Value, RSU's forfeited
Number of Shares, RSU's Ending balance 12,000,000 2,175,000
Weighted Average Grant Date Fair Value, RSU's Outstanding Ending $ 0.08 $ 0.09
Number of Shares, RSU's forfeited (262,500)
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.3
COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Apr. 01, 2024
Jan. 01, 2024
May 31, 2024
Jan. 31, 2024
Apr. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Restricted stock expense vesting               $ 809,250 $ 965,975
Restricted stock expenses yet to be recognized               $ 951,595  
Warrant [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Number of shares issued               16,919,918  
Number of Shares, Warrants exercised               25,034,000  
Warrant [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Number of Shares, warrants granted 5,000,000     2,000,000 10,665,000     7,000,000 10,665,000
Exercise price per share warrants granted       $ 0.075 $ 0.0775     $ 0.075 $ 0.0775
Vest period       3 years 3 years        
Number of Shares, Warrants exercised               25,034,000  
Restricted Stock Units [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Number of restricted shares unit granted               21,050,000 2,900,000
Restricted stock units vested               10,500,000 10,725,000
Restricted Stock Units [Member] | Chief Executive Officer [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Vest period   2 years              
Number of restricted shares unit granted   20,000,000              
Restricted stock units vested               10,500,000  
Restricted Stock Units (RSUs) [Member] | Consultants [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Number of restricted shares unit granted     1,050,000            
Equity Option [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Stock based compensation           $ 0 $ 0 $ 0 $ 0
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.3
COMMITMENT (Details Narrative) - Dr. Michael K. Korenko [Member] - USD ($)
Jan. 01, 2024
Jun. 04, 2019
Employment Agreement [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Agreement term description   The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement. On December 31, 2020, the Company extended the Employment Agreement through December 31, 2021 while renegotiating terms of a new Employment Agreement. On May 3, 2021, the Company and the Chief Executive Officer agreed the terms of a new Employment Agreement with an effective date of January 1, 2021 that has a term of three years and expired December 31, 2023. The Company renewed the Employment Agreement for a term of two years expiring December 31, 2025.
Compensation amount $ 295,500  
Discretionary bonus $ 10,000  
Vest period 2 years  
Restricted Stock Units (RSUs) [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Granted restricted stock units 20,000,000  
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.3
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended
Nov. 12, 2024
Apr. 30, 2023
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2023
Subsequent Event [Line Items]            
Number of share issued, value     $ 704,000 $ 128,000 $ 640,000
Common Stock [Member]            
Subsequent Event [Line Items]            
Number of share issued   8,000,000   11,000,000 2,000,000 8,000,000
Number of share issued, value   $ 640,000 $ 11,000 $ 2,000 $ 8,000
Subsequent Event [Member] | Expire December 31, 2024 [Member]            
Subsequent Event [Line Items]            
Warrants percentage 30.00%          
Warrants exercise price $ 0.01          
Subsequent Event [Member] | Expire December 31, 2027 [Member]            
Subsequent Event [Line Items]            
Warrants percentage 70.00%          
Warrants exercise price $ 0.15          
Subsequent Event [Member] | Common Stock [Member]            
Subsequent Event [Line Items]            
Number of share issued 11,950,000          
Number of share issued, value $ 1,434,000          
Subsequent Event [Member] | Warrant [Member]            
Subsequent Event [Line Items]            
Number of share issued 11,950,000          
Number of share issued, value $ 11,950          
EXCEL 37 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 38 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 39 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 41 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 228 201 1 false 38 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://radiogel.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets Sheet http://radiogel.com/role/BalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://radiogel.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://radiogel.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statement of Changes in Stockholders' Equity (Unaudited) Sheet http://radiogel.com/role/StatementOfChangesInStockholdersEquity Condensed Statement of Changes in Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://radiogel.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Sheet http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPolicies BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 00000008 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://radiogel.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 8 false false R9.htm 00000009 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://radiogel.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 9 false false R10.htm 00000010 - Disclosure - COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS Sheet http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnits COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS Notes 10 false false R11.htm 00000011 - Disclosure - COMMITMENT Sheet http://radiogel.com/role/Commitment COMMITMENT Notes 11 false false R12.htm 00000012 - Disclosure - SUBSEQUENT EVENTS Sheet http://radiogel.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 12 false false R13.htm 00000013 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 13 false false R14.htm 00000014 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPolicies 14 false false R15.htm 00000015 - Disclosure - COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Tables) Sheet http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsTables COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Tables) Tables http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnits 15 false false R16.htm 00000016 - Disclosure - SCHEDULE OF DILUTIVE EARNINGS PER SHARE (Details) Sheet http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails SCHEDULE OF DILUTIVE EARNINGS PER SHARE (Details) Details 16 false false R17.htm 00000017 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables 17 false false R18.htm 00000018 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://radiogel.com/role/RelatedPartyTransactions 18 false false R19.htm 00000019 - Disclosure - SCHEDULE OF CHANGES IN STOCK OPTION (Details) Sheet http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails SCHEDULE OF CHANGES IN STOCK OPTION (Details) Details 19 false false R20.htm 00000020 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://radiogel.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://radiogel.com/role/StockholdersEquity 20 false false R21.htm 00000021 - Disclosure - SCHEDULE OF CHANGES IN STOCK WARRANTS (Details) Sheet http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails SCHEDULE OF CHANGES IN STOCK WARRANTS (Details) Details 21 false false R22.htm 00000022 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT (Details) Sheet http://radiogel.com/role/ScheduleOfAssumptionsUsedInFairValueMeasurementDetails SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT (Details) Details 22 false false R23.htm 00000023 - Disclosure - SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS (Details) Sheet http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS (Details) Details 23 false false R24.htm 00000024 - Disclosure - COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Details Narrative) Sheet http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Details Narrative) Details http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsTables 24 false false R25.htm 00000025 - Disclosure - COMMITMENT (Details Narrative) Sheet http://radiogel.com/role/CommitmentDetailsNarrative COMMITMENT (Details Narrative) Details http://radiogel.com/role/Commitment 25 false false R26.htm 00000026 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://radiogel.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://radiogel.com/role/SubsequentEvents 26 false false All Reports Book All Reports form10-q.htm rdgl-20240930.xsd rdgl-20240930_cal.xml rdgl-20240930_def.xml rdgl-20240930_lab.xml rdgl-20240930_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 true true JSON 44 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-q.htm": { "nsprefix": "RDGL", "nsuri": "http://radiogel.com/20240930", "dts": { "inline": { "local": [ "form10-q.htm" ] }, "schema": { "local": [ "rdgl-20240930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "rdgl-20240930_cal.xml" ] }, "definitionLink": { "local": [ "rdgl-20240930_def.xml" ] }, "labelLink": { "local": [ "rdgl-20240930_lab.xml" ] }, "presentationLink": { "local": [ "rdgl-20240930_pre.xml" ] } }, "keyStandard": 167, "keyCustom": 34, "axisStandard": 11, "axisCustom": 0, "memberStandard": 15, "memberCustom": 17, "hidden": { "total": 257, "http://fasb.org/us-gaap/2024": 214, "http://radiogel.com/20240930": 39, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 228, "entityCount": 1, "segmentCount": 38, "elementCount": 326, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 753, "http://xbrl.sec.gov/dei/2024": 26 }, "report": { "R1": { "role": "http://radiogel.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R2": { "role": "http://radiogel.com/role/BalanceSheets", "longName": "00000002 - Statement - Condensed Balance Sheets", "shortName": "Condensed Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R3": { "role": "http://radiogel.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Condensed Balance Sheets (Parenthetical)", "shortName": "Condensed Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://radiogel.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Condensed Statements of Operations (Unaudited)", "shortName": "Condensed Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R5": { "role": "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "longName": "00000005 - Statement - Condensed Statement of Changes in Stockholders' Equity (Unaudited)", "shortName": "Condensed Statement of Changes in Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-03-31_us-gaap_RetainedEarningsMember", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R6": { "role": "http://radiogel.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R7": { "role": "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPolicies", "longName": "00000007 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES", "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R8": { "role": "http://radiogel.com/role/RelatedPartyTransactions", "longName": "00000008 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R9": { "role": "http://radiogel.com/role/StockholdersEquity", "longName": "00000009 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "shortName": "STOCKHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R10": { "role": "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnits", "longName": "00000010 - Disclosure - COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS", "shortName": "COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R11": { "role": "http://radiogel.com/role/Commitment", "longName": "00000011 - Disclosure - COMMITMENT", "shortName": "COMMITMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:CommitmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:CommitmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R12": { "role": "http://radiogel.com/role/SubsequentEvents", "longName": "00000012 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R13": { "role": "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies", "longName": "00000013 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "13", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "RDGL:BusinessOverviewPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "RDGL:BusinessOverviewPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R14": { "role": "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables", "longName": "00000014 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "14", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R15": { "role": "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsTables", "longName": "00000015 - Disclosure - COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Tables)", "shortName": "COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "15", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R16": { "role": "http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails", "longName": "00000016 - Disclosure - SCHEDULE OF DILUTIVE EARNINGS PER SHARE (Details)", "shortName": "SCHEDULE OF DILUTIVE EARNINGS PER SHARE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "16", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R17": { "role": "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "longName": "00000017 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "17", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "RDGL:GoingConcernPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R18": { "role": "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "00000018 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "18", "firstAnchor": { "contextRef": "AsOf2023-09-30_srt_ChiefExecutiveOfficerMember", "name": "us-gaap:OtherLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30_srt_ChiefExecutiveOfficerMember", "name": "us-gaap:OtherLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R19": { "role": "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails", "longName": "00000019 - Disclosure - SCHEDULE OF CHANGES IN STOCK OPTION (Details)", "shortName": "SCHEDULE OF CHANGES IN STOCK OPTION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "19", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R20": { "role": "http://radiogel.com/role/StockholdersEquityDetailsNarrative", "longName": "00000020 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "20", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember20425156", "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R21": { "role": "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails", "longName": "00000021 - Disclosure - SCHEDULE OF CHANGES IN STOCK WARRANTS (Details)", "shortName": "SCHEDULE OF CHANGES IN STOCK WARRANTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_WarrantMember20425890", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-09-30_us-gaap_WarrantMember20425921", "name": "RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R22": { "role": "http://radiogel.com/role/ScheduleOfAssumptionsUsedInFairValueMeasurementDetails", "longName": "00000022 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT (Details)", "shortName": "SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": null, "uniqueAnchor": null }, "R23": { "role": "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails", "longName": "00000023 - Disclosure - SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS (Details)", "shortName": "SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "AsOf2023-12-31_custom_RestrictedStockUnitsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_custom_RestrictedStockUnitsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R24": { "role": "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "longName": "00000024 - Disclosure - COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Details Narrative)", "shortName": "COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:RestrictedStockExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:RestrictedStockExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R25": { "role": "http://radiogel.com/role/CommitmentDetailsNarrative", "longName": "00000025 - Disclosure - COMMITMENT (Details Narrative)", "shortName": "COMMITMENT (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "From2019-06-042019-06-04_custom_EmploymentAgreementMember_custom_DrMichaelKKorenkoMember", "name": "RDGL:AgreementTermDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2019-06-042019-06-04_custom_EmploymentAgreementMember_custom_DrMichaelKKorenkoMember", "name": "RDGL:AgreementTermDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R26": { "role": "http://radiogel.com/role/SubsequentEventsDetailsNarrative", "longName": "00000026 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-11-122024-11-12_us-gaap_SubsequentEventMember_custom_ExpireDecemberThirtyFirstTwoThousandAndTwentyFourMember", "name": "RDGL:WarrantsPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://radiogel.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r35", "r36" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://radiogel.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r527" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r113", "r114", "r294", "r295", "r296", "r297", "r298", "r299" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r113", "r114", "r294", "r295", "r296", "r297", "r298", "r299" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://radiogel.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid in capital - common stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r44" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r358", "r516", "r517", "r518", "r519", "r539", "r594" ] }, "us-gaap_AdditionalPaidInCapitalPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalPreferredStock", "crdr": "credit", "calculation": { "http://radiogel.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid in capital", "documentation": "Value received from shareholder in nonredeemable preferred stock-related transaction in excess of par value, value contributed to entity and value received from other stock-related transaction. Includes, but is not limited to, preferred stock redeemable solely at option of issuer. Excludes common stock." } } }, "auth_ref": [ "r44" ] }, "RDGL_AdditionalPaidInCapitalSeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://radiogel.com/20240930", "localname": "AdditionalPaidInCapitalSeriesAPreferredStockMember", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-In Capital - Series A Preferred [Member]", "documentation": "Additional Paid-In Capital - Series A Preferred [Member]" } } }, "auth_ref": [] }, "RDGL_AdditionalPaidInCapitalSeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://radiogel.com/20240930", "localname": "AdditionalPaidInCapitalSeriesBPreferredStockMember", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-In Capital - Series B Preferred [Member]", "documentation": "Additional Paid-In Capital - Series B Preferred [Member]" } } }, "auth_ref": [] }, "RDGL_AdditionalPaidInCapitalSeriesCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://radiogel.com/20240930", "localname": "AdditionalPaidInCapitalSeriesCPreferredStockMember", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-In Capital - Series C Preferred [Member]", "documentation": "Additional Paid-In Capital - Series C Preferred [Member]" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "RSUs granted to consultants that have vested", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Warrants purchased for cash", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r6", "r22", "r68" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "crdr": "debit", "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Total adjustments", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities", "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method." } } }, "auth_ref": [ "r59" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Advertising and Marketing Costs", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r91" ] }, "RDGL_AgreementTermDescription": { "xbrltype": "stringItemType", "nsuri": "http://radiogel.com/20240930", "localname": "AgreementTermDescription", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Agreement term description", "documentation": "Agreement term description." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r502" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Total potential dilutive securities", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r147" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r16" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r277" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://radiogel.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r78", "r88", "r104", "r124", "r150", "r154", "r159", "r160", "r165", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r278", "r280", "r293", "r320", "r395", "r459", "r460", "r471", "r487", "r532", "r533", "r551" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://radiogel.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r101", "r109", "r124", "r165", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r278", "r280", "r293", "r471", "r532", "r533", "r551" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r502" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails", "http://radiogel.com/role/StockholdersEquityDetailsNarrative", "http://radiogel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r221", "r222", "r223", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r245", "r246", "r247", "r248", "r249" ] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r60" ] }, "RDGL_BrachytherapyProductLineMember": { "xbrltype": "domainItemType", "nsuri": "http://radiogel.com/20240930", "localname": "BrachytherapyProductLineMember", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Brachytherapy Product Line [Member]", "documentation": "Brachytherapy Product Line [Member]" } } }, "auth_ref": [] }, "RDGL_BusinessOverviewPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://radiogel.com/20240930", "localname": "BusinessOverviewPolicyTextBlock", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Business Overview", "documentation": "Business Overview [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "calculation": { "http://radiogel.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r90", "r323", "r369", "r390", "r471", "r487", "r510" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash on hand", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r13", "r103", "r452" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r14" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "CASH - BEGINNING OF PERIOD", "periodEndLabel": "CASH - END OF PERIOD", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r13", "r57", "r122" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "NET (DECREASE) IN CASH", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r57" ] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "auth_ref": [ "r526" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://radiogel.com/role/BalanceSheets", "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r98", "r105", "r106", "r107", "r124", "r141", "r142", "r144", "r146", "r152", "r153", "r165", "r178", "r180", "r181", "r182", "r185", "r186", "r189", "r190", "r193", "r196", "r203", "r293", "r350", "r351", "r352", "r353", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r370", "r382", "r404", "r424", "r440", "r441", "r442", "r443", "r444", "r508", "r514", "r520" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r105", "r106", "r107", "r152", "r189", "r190", "r191", "r193", "r196", "r201", "r203", "r350", "r351", "r352", "r353", "r462", "r508", "r514" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://radiogel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r204" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of warrants issued", "verboseLabel": "Warrant purchase", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r204" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issued for cashless exercise, warrants", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r277" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://radiogel.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r40", "r80", "r322", "r381" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Contingencies", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": [ "r21", "r446" ] }, "us-gaap_CommitmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsDisclosureTextBlock", "presentation": [ "http://radiogel.com/role/Commitment" ], "lang": { "en-us": { "role": { "label": "COMMITMENT", "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights." } } }, "auth_ref": [ "r62" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative", "http://radiogel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r477", "r478", "r479", "r481", "r482", "r483", "r484", "r516", "r517", "r519", "r539", "r590", "r594" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r43" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r43", "r382" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r43" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r6", "r43", "r382", "r401", "r594", "r595" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://radiogel.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, par value, $0.001, 950,000,000 shares authorized, 417,592,703 and 387,894,033 issued and outstanding, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r43", "r325", "r471" ] }, "RDGL_CommonStockandWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://radiogel.com/20240930", "localname": "CommonStockandWarrantsMember", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock and Warrants [Member]", "documentation": "Common Stock and Warrants [Member]" } } }, "auth_ref": [] }, "RDGL_ConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://radiogel.com/20240930", "localname": "ConsultantsMember", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consultants [Member]", "documentation": "Consultants [Member]" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Cost of Goods Sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r51", "r52", "r316" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion price per share", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r63", "r187" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Redemption percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r84" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r371", "r373", "r387", "r388", "r389", "r391", "r392", "r393", "r394", "r396", "r397", "r398", "r399", "r412", "r413", "r414", "r415", "r418", "r419", "r420", "r421", "r435", "r436", "r437", "r438", "r477", "r479", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r32", "r33", "r34", "r77", "r371", "r373", "r387", "r388", "r389", "r391", "r392", "r393", "r394", "r396", "r397", "r398", "r399", "r412", "r413", "r414", "r415", "r418", "r419", "r420", "r421", "r435", "r436", "r437", "r438", "r454", "r477", "r479", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548" ] }, "RDGL_DiscretionaryBonus": { "xbrltype": "monetaryItemType", "nsuri": "http://radiogel.com/20240930", "localname": "DiscretionaryBonus", "crdr": "credit", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Discretionary bonus", "documentation": "Discretionary bonus." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r501" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r499", "r501", "r502" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r500" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r488" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r501" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r501" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r503" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r491" ] }, "RDGL_DrMichaelKKorenkoMember": { "xbrltype": "domainItemType", "nsuri": "http://radiogel.com/20240930", "localname": "DrMichaelKKorenkoMember", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dr. Michael K. Korenko [Member]", "documentation": "Dr. Michael K. Korenko [Member]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per share - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r116", "r130", "r131", "r132", "r133", "r134", "r135", "r139", "r141", "r144", "r145", "r146", "r149", "r273", "r276", "r290", "r291", "r318", "r331", "r456" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per share - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r116", "r130", "r131", "r132", "r133", "r134", "r135", "r141", "r144", "r145", "r146", "r149", "r273", "r276", "r290", "r291", "r318", "r331", "r456" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Loss Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r16", "r17", "r148" ] }, "RDGL_EmploymentAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://radiogel.com/20240930", "localname": "EmploymentAgreementMember", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employment Agreement [Member]", "documentation": "Employment Agreement [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r494" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r490" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r490" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r507" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r490" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r504" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r502" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r490" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r490" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r490" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r490" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r505" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative", "http://radiogel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r6", "r99", "r113", "r114", "r115", "r125", "r126", "r127", "r129", "r134", "r136", "r138", "r151", "r166", "r167", "r173", "r205", "r267", "r268", "r270", "r271", "r272", "r274", "r275", "r276", "r282", "r283", "r284", "r285", "r286", "r287", "r289", "r294", "r295", "r296", "r297", "r298", "r299", "r301", "r302", "r304", "r330", "r342", "r343", "r344", "r358", "r424" ] }, "RDGL_ExcercisePriceWarrantsGrantedMinimum": { "xbrltype": "perShareItemType", "nsuri": "http://radiogel.com/20240930", "localname": "ExcercisePriceWarrantsGrantedMinimum", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Per Share Exercise Price Warrants granted", "documentation": "Weighted Average Exercise Price Per Share Exercise Price Warrants Granted." } } }, "auth_ref": [] }, "RDGL_ExercisePriceMinimum": { "xbrltype": "perShareItemType", "nsuri": "http://radiogel.com/20240930", "localname": "ExercisePriceMinimum", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average Exercise Price Per Share Exercise Price Warrants Ending", "documentation": "Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning Ending.", "label": "ExercisePriceMinimum" } } }, "auth_ref": [] }, "RDGL_ExpireDecemberThirtyFirstTwoThousandAndTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://radiogel.com/20240930", "localname": "ExpireDecemberThirtyFirstTwoThousandAndTwentyFourMember", "presentation": [ "http://radiogel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expire December 31, 2024 [Member]", "documentation": "Expire December 31, 2024 [Member]" } } }, "auth_ref": [] }, "RDGL_ExpireDecemberThirtyFirstTwoThousandAndTwentySevenMember": { "xbrltype": "domainItemType", "nsuri": "http://radiogel.com/20240930", "localname": "ExpireDecemberThirtyFirstTwoThousandAndTwentySevenMember", "presentation": [ "http://radiogel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expire December 31, 2027 [Member]", "documentation": "Expire December 31, 2027 [Member]" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r5" ] }, "RDGL_FinancingAndStrategyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://radiogel.com/20240930", "localname": "FinancingAndStrategyPolicyTextBlock", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Financing and Strategy", "documentation": "Financing and Strategy [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Economic life of the patent", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative expenses", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r55", "r406" ] }, "RDGL_GoingConcernPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://radiogel.com/20240930", "localname": "GoingConcernPolicyTextBlock", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Going Concern", "documentation": "Going Concern [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Patents and Intellectual Property", "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined." } } }, "auth_ref": [ "r170", "r171", "r172" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r49", "r53", "r87", "r124", "r165", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r293", "r458", "r459", "r521", "r522", "r523", "r524", "r525", "r532" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "NET LOSS BEFORE PROVISION FOR INCOME TAXES", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r50", "r82", "r87", "r319", "r328", "r458", "r459", "r521", "r522", "r523", "r524", "r525" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Provision for income taxes", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r89", "r96", "r137", "r138", "r150", "r157", "r160", "r259", "r260", "r269", "r332", "r466" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r112", "r257", "r258", "r261", "r262", "r263", "r266", "r349" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income taxes", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r15", "r121", "r264", "r265" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r2" ] }, "RDGL_IntellectualPropertyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://radiogel.com/20240930", "localname": "IntellectualPropertyPolicyTextBlock", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Intellectual Property", "documentation": "Intellectual Property [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount of interest income (expense) classified as operating." } } }, "auth_ref": [ "r317", "r522" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest expense", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r117", "r119", "r120" ] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Common stock, stock options and warrants for services", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r3" ] }, "us-gaap_LaborAndRelatedExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LaborAndRelatedExpense", "crdr": "debit", "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Payroll expenses", "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit." } } }, "auth_ref": [ "r513" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://radiogel.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r11", "r35", "r36", "r37", "r38", "r39", "r40", "r41", "r124", "r165", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r279", "r280", "r281", "r293", "r380", "r457", "r487", "r532", "r551", "r552" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAbstract", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://radiogel.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r48", "r81", "r327", "r471", "r515", "r528", "r549" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://radiogel.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r37", "r102", "r124", "r165", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r279", "r280", "r281", "r293", "r471", "r532", "r551", "r552" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r174", "r175", "r176", "r177", "r217", "r254", "r292", "r315", "r340", "r341", "r347", "r372", "r373", "r431", "r432", "r433", "r434", "r439", "r447", "r448", "r461", "r462", "r464", "r467", "r468", "r469", "r470", "r473", "r534", "r553", "r554", "r555", "r556", "r557", "r558" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r174", "r175", "r176", "r177", "r217", "r254", "r292", "r315", "r340", "r341", "r347", "r372", "r373", "r431", "r432", "r433", "r434", "r439", "r447", "r448", "r461", "r462", "r464", "r467", "r468", "r469", "r473", "r534", "r553", "r554", "r555", "r556", "r557", "r558" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r118" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Current operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r57", "r58", "r59" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOW FROM OPERTING ACTIVIITES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Current operating activities", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r57", "r58", "r59" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://radiogel.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StatementsOfCashFlows", "http://radiogel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "NET LOSS", "label": "Net loss for the period", "verboseLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r54", "r59", "r83", "r100", "r110", "r111", "r115", "r124", "r128", "r130", "r131", "r132", "r133", "r134", "r137", "r138", "r143", "r165", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r273", "r276", "r291", "r293", "r329", "r403", "r422", "r423", "r485", "r532" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total Non-Operating Income (Expenses)", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r56" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "NON-OPERATING INCOME (EXPENSE)" } } }, "auth_ref": [] }, "RDGL_OfferingTerm": { "xbrltype": "stringItemType", "nsuri": "http://radiogel.com/20240930", "localname": "OfferingTerm", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Offering term", "documentation": "Offering term." } } }, "auth_ref": [] }, "us-gaap_OfficersCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficersCompensation", "crdr": "debit", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Compensation amount", "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [ "r513" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total Operating Expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "OPERATING LOSS", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r87", "r458", "r521", "r522", "r523", "r524", "r525" ] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilities", "crdr": "credit", "presentation": [ "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Advance from officer", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r79", "r321", "r376", "r377", "r487", "r560", "r591" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r501" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r495" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r497" ] }, "us-gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockLiquidationPreference", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, liquidation preference per share", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share." } } }, "auth_ref": [ "r26", "r27", "r42", "r514", "r535" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": [ "http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r477", "r478", "r481", "r482", "r483", "r484", "r590", "r594" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r42", "r189" ] }, "us-gaap_PreferredStockRedemptionTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockRedemptionTerms", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock redemption, description", "documentation": "The redemption terms of preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity. The redemption features of this capital stock are solely within the control of the issuer." } } }, "auth_ref": [ "r25", "r26" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "verboseLabel": "Preferred stock shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r42", "r382" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "verboseLabel": "Preferred stock shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r42", "r189" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "verboseLabel": "Preferred stock shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r42", "r382", "r401", "r594", "r595" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://radiogel.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock value", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r42", "r324", "r471" ] }, "us-gaap_PreferredStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockVotingRights", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Voting percentage", "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": [ "r26", "r42" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://radiogel.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r108", "r168", "r169", "r453" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Financial Statement Reclassification", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r509" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of common stock", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r1" ] }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "crdr": "debit", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross proceeds from preferred stock", "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation." } } }, "auth_ref": [ "r1" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r1" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from common stock and warrants", "verboseLabel": "Proceeds from issuance or sale of equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r1", "r350" ] }, "us-gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from short-term advances from related party", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": [ "r12" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r161", "r316", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r451", "r463", "r472", "r473", "r474", "r475", "r476", "r530", "r531", "r537", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r161", "r316", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r451", "r463", "r472", "r473", "r474", "r475", "r476", "r530", "r531", "r537", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589" ] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfessionalFees", "crdr": "debit", "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Professional fees, including stock-based compensation", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": [ "r459", "r485", "r592", "r593" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r303" ] }, "RDGL_RadionuclideTherapyProductLineMember": { "xbrltype": "domainItemType", "nsuri": "http://radiogel.com/20240930", "localname": "RadionuclideTherapyProductLineMember", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Radionuclide Therapy Product Line [Member]", "documentation": "Radionuclide Therapy Product Line [Member]" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r174", "r175", "r176", "r177", "r216", "r217", "r246", "r247", "r248", "r254", "r292", "r313", "r314", "r315", "r340", "r341", "r347", "r372", "r373", "r431", "r432", "r433", "r434", "r439", "r447", "r448", "r461", "r462", "r464", "r467", "r468", "r469", "r470", "r473", "r479", "r529", "r534", "r540", "r554", "r555", "r556", "r557", "r558" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "auth_ref": [ "r174", "r175", "r176", "r177", "r216", "r217", "r246", "r247", "r248", "r254", "r292", "r313", "r314", "r315", "r340", "r341", "r347", "r372", "r373", "r431", "r432", "r433", "r434", "r439", "r447", "r448", "r461", "r462", "r464", "r467", "r468", "r469", "r470", "r473", "r479", "r529", "r534", "r540", "r554", "r555", "r556", "r557", "r558" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://radiogel.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r305", "r306", "r307", "r308", "r309", "r355", "r356", "r357", "r407", "r408", "r409", "r428", "r430" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development", "verboseLabel": "Research and development costs", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r256", "r449", "r459", "r559" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Costs", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r255" ] }, "us-gaap_RestrictedStockExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockExpense", "crdr": "debit", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted stock expense vesting", "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "RDGL_RestrictedStockExpensesYetToBeRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://radiogel.com/20240930", "localname": "RestrictedStockExpensesYetToBeRecognized", "crdr": "debit", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted stock expenses yet to be recognized", "documentation": "Restricted stock expenses yet to be recognized." } } }, "auth_ref": [] }, "RDGL_RestrictedStockUnitsIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://radiogel.com/20240930", "localname": "RestrictedStockUnitsIssuedForServices", "crdr": "debit", "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "RSUs issued for services", "documentation": "Restricted stock units issued for services." } } }, "auth_ref": [] }, "RDGL_RestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://radiogel.com/20240930", "localname": "RestrictedStockUnitsMember", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units [Member]", "documentation": "Restricted Stock Units [Member]" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative", "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://radiogel.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r45", "r68", "r326", "r345", "r346", "r354", "r383", "r471" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r99", "r125", "r126", "r127", "r129", "r134", "r136", "r138", "r166", "r167", "r173", "r267", "r268", "r270", "r271", "r272", "r274", "r275", "r276", "r282", "r284", "r285", "r287", "r289", "r301", "r302", "r342", "r344", "r358", "r594" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenues, net", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r85", "r86", "r150", "r155", "r156", "r158", "r160", "r161", "r162", "r163", "r214", "r215", "r316" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "IsoPet Solutions", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r97", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r450" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r405", "r450", "r455" ] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of common stock shares issued, value", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of common stock shares issued, shares", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF DILUTIVE EARNINGS PER SHARE", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r277" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r4", "r303" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r219", "r220", "r221", "r222", "r223", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r245", "r246", "r247", "r248", "r249" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r70" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF CHANGES IN STOCK OPTION", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r9", "r10", "r70" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r76" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r23", "r24", "r26", "r27", "r28", "r29", "r64", "r66", "r67", "r68", "r105", "r106", "r107", "r152", "r189", "r190", "r191", "r193", "r196", "r201", "r203", "r350", "r351", "r352", "r353", "r462", "r508", "r514" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF CHANGES IN STOCK WARRANTS", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r30" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r489" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r493" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r492" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r498" ] }, "RDGL_SeriesAConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://radiogel.com/20240930", "localname": "SeriesAConvertiblePreferredStockMember", "presentation": [ "http://radiogel.com/role/BalanceSheets", "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series A Convertible Preferred Stock [Member]", "documentation": "Series A Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r511", "r512", "r536" ] }, "RDGL_SeriesAWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://radiogel.com/20240930", "localname": "SeriesAWarrantMember", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series A Warrant [Member]", "documentation": "Series A Warrant [Member]" } } }, "auth_ref": [] }, "RDGL_SeriesBConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://radiogel.com/20240930", "localname": "SeriesBConvertiblePreferredStockMember", "presentation": [ "http://radiogel.com/role/BalanceSheets", "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series B Convertible Preferred Stock [Member]", "documentation": "Series B Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesBPreferredStockMember", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": [ "r511", "r512", "r536" ] }, "RDGL_SeriesBWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://radiogel.com/20240930", "localname": "SeriesBWarrantMember", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series B Warrant [Member]", "documentation": "Series B Warrant [Member]" } } }, "auth_ref": [] }, "RDGL_SeriesCConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://radiogel.com/20240930", "localname": "SeriesCConvertiblePreferredStockMember", "presentation": [ "http://radiogel.com/role/BalanceSheets", "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series C Convertible Preferred Stock [Member]", "documentation": "Series C Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_SeriesCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesCPreferredStockMember", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Series C Preferred Stock [Member]", "documentation": "Series C preferred stock." } } }, "auth_ref": [ "r511", "r512", "r536" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative", "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vest period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r465" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Number of Shares, RSU's forfeited", "negatedLabel": "Number of Shares, RSU's forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r238" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Grant Date Fair Value, RSU's forfeited", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r238" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative", "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Number of Shares, RSU's granted", "verboseLabel": "Number of restricted shares unit granted", "terseLabel": "Granted restricted stock units", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r236" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Grant Date Fair Value, RSU's granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r236" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Shares, RSU's Beginning balance", "periodEndLabel": "Number of Shares, RSU's Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r233", "r234" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning", "periodEndLabel": "Weighted Average Grant Date Fair Value, RSU's Outstanding Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r233", "r234" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Shares, RSU's vested", "label": "Restricted stock units vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r237" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Grant Date Fair Value, RSU's vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r237" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://radiogel.com/role/ScheduleOfAssumptionsUsedInFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Expected dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r247" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://radiogel.com/role/ScheduleOfAssumptionsUsedInFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r246" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://radiogel.com/role/ScheduleOfAssumptionsUsedInFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r248" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r219", "r220", "r221", "r222", "r223", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r245", "r246", "r247", "r248", "r249" ] }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://radiogel.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Number of Shares, Warrants Exercisable Ending", "documentation": "The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Shares, Warrants exercised", "label": "Number of Shares, Warrants exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": [ "r8" ] }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://radiogel.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Per Share Warrants exercised", "documentation": "Weighted average price at which non-option equity holders acquired shares when converting their non-option equity into shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Shares, Warrants expired/cancelled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations", "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed." } } }, "auth_ref": [ "r73" ] }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://radiogel.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Per Share Warrants expired/cancelled", "documentation": "Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Number of Shares, Warrants granted", "verboseLabel": "Number of Shares, warrants granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r7" ] }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://radiogel.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Per Share Warrants granted", "verboseLabel": "Exercise price per share warrants granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Number of Shares, Warrants redeemed", "documentation": "Other increase (decrease) in number of shares reserved for issuance under non-option equity instrument agreements that is not separately disclosed." } } }, "auth_ref": [] }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://radiogel.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life Warrants Exercisable", "documentation": "Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Shares, Warrants Outstanding Beginning", "periodEndLabel": "Number of Shares, Warrants Outstanding Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r71", "r72" ] }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisablePrice": { "xbrltype": "perShareItemType", "nsuri": "http://radiogel.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisablePrice", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Exercise Price Per Share Warrants Exercisable Ending", "documentation": "Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average exercisable price.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisablePrice" } } }, "auth_ref": [] }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://radiogel.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Exercise Price Per Share Warrants Outstanding Beginning", "periodEndLabel": "Exercise Price Per Share Warrants Outstanding Ending", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" } } }, "auth_ref": [] }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding": { "xbrltype": "durationItemType", "nsuri": "http://radiogel.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life Warrants Outstanding Ending", "documentation": "Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://radiogel.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Aggregate Intrinsic Value Outstanding Beginning", "periodEndLabel": "Aggregate Intrinsic Value Outstanding Ending", "documentation": "Sharebased compensation arrangement by sharebased payment award non options outstanding intrinsic value.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Number of Options Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r227" ] }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisablePrice": { "xbrltype": "perShareItemType", "nsuri": "http://radiogel.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisablePrice", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Exercise Price Per Share Exercisable", "documentation": "Share based compensation arrangement by share based payment award options exercisable weighted average exercisable price.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisablePrice" } } }, "auth_ref": [] }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricePerShares": { "xbrltype": "perShareItemType", "nsuri": "http://radiogel.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricePerShares", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average Exercise Price Per Share Exercisable", "documentation": "Exercisable Weighted Average Exercise Price Per Shares.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricePerShares" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Options expired/cancelled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r232" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "lang": { "en-us": { "role": { "label": "Number of Options granted", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r538" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Aggregate Intrinsic Value Outstanding Beginning", "periodEndLabel": "Aggregate Intrinsic Value Outstanding Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Options Outstanding Beginning Balance", "periodEndLabel": "Number of Options Outstanding Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r225", "r226" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Exercise Price Per Share Outstanding Beginning Balance", "periodEndLabel": "Weighted Average Exercise Price Per Share Outstanding Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r225", "r226" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails", "http://radiogel.com/role/StockholdersEquityDetailsNarrative", "http://radiogel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r221", "r222", "r223", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r245", "r246", "r247", "r248", "r249" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Per Share exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r230" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Per Share expired/cancelled", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r232" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Per Share granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r229" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r218", "r224", "r243", "r244", "r245", "r246", "r249", "r250", "r251", "r252", "r253" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://radiogel.com/role/ScheduleOfAssumptionsUsedInFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Expected term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r245" ] }, "RDGL_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://radiogel.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Aggregate Intrinsic Value Exercisable", "documentation": "Sharebased compensation arrangement by sharebased payment award non options exercisable intrinsic value.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Aggregate Intrinsic Value Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r31" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life (in years) Outstanding", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r74" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life (in years) Exercisable", "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r75" ] }, "RDGL_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://radiogel.com/20240930", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price Per Share Outstanding Beginning", "periodEndLabel": "Weighted Average Exercise Price Per Share Outstanding Ending", "documentation": "Stock Option Plans Exercise Price.", "label": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice" } } }, "auth_ref": [] }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnits" ], "lang": { "en-us": { "role": { "label": "COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS", "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } }, "auth_ref": [ "r65", "r69" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r496" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://radiogel.com/role/BalanceSheets", "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r98", "r105", "r106", "r107", "r124", "r141", "r142", "r144", "r146", "r152", "r153", "r165", "r178", "r180", "r181", "r182", "r185", "r186", "r189", "r190", "r193", "r196", "r203", "r293", "r350", "r351", "r352", "r353", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r370", "r382", "r404", "r424", "r440", "r441", "r442", "r443", "r444", "r508", "r514", "r520" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative", "http://radiogel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r6", "r43", "r46", "r47", "r99", "r113", "r114", "r115", "r125", "r126", "r127", "r129", "r134", "r136", "r138", "r151", "r166", "r167", "r173", "r205", "r267", "r268", "r270", "r271", "r272", "r274", "r275", "r276", "r282", "r283", "r284", "r285", "r286", "r287", "r289", "r294", "r295", "r296", "r297", "r298", "r299", "r301", "r302", "r304", "r330", "r342", "r343", "r344", "r358", "r424" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://radiogel.com/role/BalanceSheets", "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r125", "r126", "r127", "r151", "r302", "r316", "r348", "r370", "r374", "r375", "r376", "r377", "r378", "r379", "r382", "r385", "r386", "r387", "r388", "r389", "r391", "r392", "r393", "r394", "r396", "r397", "r398", "r399", "r400", "r402", "r405", "r406", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r424", "r480" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://radiogel.com/role/BalanceSheets", "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r125", "r126", "r127", "r151", "r164", "r302", "r316", "r348", "r370", "r374", "r375", "r376", "r377", "r378", "r379", "r382", "r385", "r386", "r387", "r388", "r389", "r391", "r392", "r393", "r394", "r396", "r397", "r398", "r399", "r400", "r402", "r405", "r406", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r424", "r480" ] }, "RDGL_StockIssuedDuringPeriodSharesAdjustmentForVestedRestrictedStockAward": { "xbrltype": "sharesItemType", "nsuri": "http://radiogel.com/20240930", "localname": "StockIssuedDuringPeriodSharesAdjustmentForVestedRestrictedStockAward", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Adjustment for vested RSUs, shares", "documentation": "Stock issued during period shares adjustment for vested restricted stock award." } } }, "auth_ref": [] }, "RDGL_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://radiogel.com/20240930", "localname": "StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Cashless exercise of warrants, shares", "documentation": "Stock issued during period shares cashless exercise of warrants." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Services, shares", "verboseLabel": "Issued for services, shares", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative", "http://radiogel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash, shares", "verboseLabel": "Number of shares issued", "terseLabel": "Number of share issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r6", "r42", "r43", "r68", "r350", "r424", "r441" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vested RSUs, shares", "verboseLabel": "Issued for common stock RSU", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r6", "r68" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r6", "r42", "r43", "r68", "r230" ] }, "RDGL_StockIssuedDuringPeriodSharesStockOptionsWarrantExercised": { "xbrltype": "sharesItemType", "nsuri": "http://radiogel.com/20240930", "localname": "StockIssuedDuringPeriodSharesStockOptionsWarrantExercised", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issued for common stock warrant exercise", "verboseLabel": "Number of shares issued", "documentation": "Stock issued during period shares stock options warrant exercised." } } }, "auth_ref": [] }, "RDGL_StockIssuedDuringPeriodValueAdjustmentForVestedRestrictedStockAward": { "xbrltype": "monetaryItemType", "nsuri": "http://radiogel.com/20240930", "localname": "StockIssuedDuringPeriodValueAdjustmentForVestedRestrictedStockAward", "crdr": "credit", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Adjustment for vested RSUs", "documentation": "Stock issued during period value adjustment for vested restricted stock award." } } }, "auth_ref": [] }, "RDGL_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://radiogel.com/20240930", "localname": "StockIssuedDuringPeriodValueCashlessExerciseOfWarrants", "crdr": "credit", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Cashless exercise of warrants", "documentation": "Stock issued during period value cashless exercise of warrants." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Services", "verboseLabel": "Issued for services, value", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative", "http://radiogel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash", "label": "Number of shares issued, value", "terseLabel": "Number of share issued, value", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r6", "r42", "r43", "r68", "r358", "r424", "r441", "r486" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Vested RSUs", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r6", "r42", "r43", "r68" ] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r479" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://radiogel.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://radiogel.com/role/BalanceSheets", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total Stockholders\u2019 Equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r43", "r46", "r47", "r61", "r384", "r401", "r425", "r426", "r471", "r487", "r515", "r528", "r549", "r594" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://radiogel.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "STOCKHOLDERS\u2019 EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r65", "r123", "r188", "r190", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r202", "r205", "r288", "r427", "r429", "r445" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://radiogel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r300", "r311" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://radiogel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r300", "r311" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://radiogel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r300", "r311" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://radiogel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r300", "r311" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://radiogel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r300", "r311" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://radiogel.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r310", "r312" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH PAID DURING THE PERIOD FOR:" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative", "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r526", "r550" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative", "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r277" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r18", "r19", "r20", "r92", "r93", "r94", "r95" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails", "http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails", "http://radiogel.com/role/StockholdersEquityDetailsNarrative", "http://radiogel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r477", "r478", "r481", "r482", "r483", "r484" ] }, "RDGL_WarrantsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://radiogel.com/20240930", "localname": "WarrantsPercentage", "presentation": [ "http://radiogel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants percentage" } } }, "auth_ref": [] }, "RDGL_WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable": { "xbrltype": "perShareItemType", "nsuri": "http://radiogel.com/20240930", "localname": "WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable Beginning", "periodEndLabel": "Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable", "documentation": "Exercise Price Warrant Exercisable.", "label": "WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable" } } }, "auth_ref": [] }, "RDGL_WeightedAverageExercisePricePerShareOptionsExercised": { "xbrltype": "perShareItemType", "nsuri": "http://radiogel.com/20240930", "localname": "WeightedAverageExercisePricePerShareOptionsExercised", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Per Share Options exercised", "documentation": "Weighted Average Exercise Price Per Share Options Exercised." } } }, "auth_ref": [] }, "RDGL_WeightedAverageExercisePricePerShareOptionsExpired": { "xbrltype": "perShareItemType", "nsuri": "http://radiogel.com/20240930", "localname": "WeightedAverageExercisePricePerShareOptionsExpired", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Per Share Options expired/cancelled", "documentation": "Weighted average exercise price per share option expired." } } }, "auth_ref": [] }, "RDGL_WeightedAverageExercisePricePerShareOptionsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://radiogel.com/20240930", "localname": "WeightedAverageExercisePricePerShareOptionsGranted", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Per Share Options granted", "documentation": "Weighted Average Exercise Price Per Share Options granted." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding - diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r140", "r146" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding - basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r139", "r146" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://radiogel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r506" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r451": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r452": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r455": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r456": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r457": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r458": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r459": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r460": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r461": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r462": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r463": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r464": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r465": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r467": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r468": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r469": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r470": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r471": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r472": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r474": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r475": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r476": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r477": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r479": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r485": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r486": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r487": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r488": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r489": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r490": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r492": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r494": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r495": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r496": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r497": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r498": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r499": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r500": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r501": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r502": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r503": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r505": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r506": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r507": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r508": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r509": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r510": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r511": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 45 0001493152-24-045032-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-045032-xbrl.zip M4$L#!!0 ( (9I;5G:A>M;CP@ "5, * 97@S,2TQ+FAT;>U<;7/: MN!;^WIG^!UUF=B>=@0#)YGX FAD"SH;9;,A-W$[[4=@R:&-+KB1#V5]_SY%L M($#:=)>DD-#.),'6RW,DG4?/.19N7?A_7IZ^?=.Z\-I=^$WP7\OO^9?>::OJ M?L/=:GZ[==;O?B:W_N=+[WTIDL(T2+V6&N+SA&ERQ2;D1B94E-V%,KEEBDC[:LYG\S![!T^JL8Z+39JF*#&[!E#6;% MAZ/B$A__;- MG3ZEM6Z&GL6TIY^Z9S2FX]WXO?->I^WW^E=OW_3/2>>BYYT3[Y/7 M^>#W/GJD?PZWO9L78N_UAYO;#^TK6)5^G]QZ'32;'->.P$SB7WCDMGUSUK[R M;BO]3Y?>9]+N^'CGJ%8[>HX!^$G.^O0K^J],&QY-G\6:7OGMFS]Y,*(L)G\< MDC^D8N).EF&0%6(@9D1-XTF,W9:9\]MGEQ[I>)>7M]?M3N_J]_>E6LE^OFYW MN\7G'S9XPD,SPJ*U7\ XJ4*FT+"8IAH %7^5K!9H^3<_WL$89RB@<;%J8(,N MY:QQDHW[@8([HF!'%QIQ- M6 B+GVOR):,*^":>PO54*D.D(.=2)5"Q\C\B(_*1CZ4F/1$<-A?MAA\W+W%V ME[QH9V9X%?=+G:&C'?2_,ZI9Z*""?R53\I M9]MGZ/C%40XC$1?@S\@/<_\M ]^$1,)MM7"?BP@$ 34X0J9ND W)L/8H9N2Q@0T2#F M>H0UL%@""@A5$'X.N0YBJ3.HA]I(R=CQ0JIDP$*XK!V: ^""D &Y.([ROD+P M+X:,M$%VW&0QF%@_II7ZR0%S4.HGH?OD/G),O@A'2M@)05FRP%6.-A#0 QTY M%"N]1?=ZBZ WM'B9QJ $AFB-U[#F]ZST%#,TR\S8O--SS=<_!WFT893T 2;= MME7491J:+@2:#:.^SW!E#/,"FH&P>VP5#/0&#(C*=9<';S)3T HI#'7J+MF M,2$3MC%,B\[CQT7]IUA,+?U!X?OL5:AYPJCE9P M%VA:12JPI4QCW&=WC9S&,5RT$E-J!J@,Z$.LF5)TEBRFJ#7!0(MD'D1"#1>7 M+L;4\-> 84%0@E"?A5OKO%OJKEL*ZY4S_9;.RB9A#7:7S!^M(UQ MQ&LYU>T-]XK.DPH.CA7X7W/3TDRE0.S:I@F"0*K0HK YPB$3$/C'P.]PAZ6X M>V"13!C'X;#+\!24]=XQ7P2L/8MOXZQL$E:P(RSNC6FQ(5]3A4!/FL7<)S(#/S'1B/"1?HK#3#O&[T_0$=[N.R K>7:)&? "> MIW#MG;7\^P.:&3,;,@@RA=RWD$%8;=7!2:0V9"5C/(,(LU";J32LZR#O0#M)@DWAK%O*/.!I,HJWY #2-O(@(JJ&1^OD7(TA-J:S93<@[28IVBA"G";5$#--OC7, (Z2Q*JP'1K4:ZEUQ[I MV@?V+PO6GFVW<59>XV.QML@/FT<*!%L9N(]9K0GL:0^'YS1;=I$O%V,9CQF& MOX(.\X/N*I>G+$EC.65P=S*23I#2>R0.I/N-!$&167@D2Q^N7]Q5^UVJT]W] MPN/^&V*/ 'Q2^V6CV2U8Y0V'Z@K66S* )5<_+I.CVM%OFSU,M6'@>YK?.EC/ M,0&YIQ:O/SB+@99('5JWA[DB5;OM*JK#NKJMWE;U=[IACPII2$>@IA9 M7[>][_B,_HP9RV?)85FVGY:=9>G#M M#C057Y%:F9MW.S4YFY+(._E&BXUN>4MP_U.ID'/.XK!!KB$Z:D+%+QD3 59H MDGYJL]0-[2:QSU_E#'++(U9AZPT/1\JHLU6:S'5A5&HAB4A:&LXEBZ\7JR);'C M+\E96HC%_[7OX2J&/[>XBJ_Y#_1]02P,$% @ AFEM61_D,;V; M" <4X H !E>#,Q+3(N:'1M[5QM;^*X%OX^TOP'7Z1==20HE$[O!V J M4:#;2 STTNQJYZ-)'/!M8C-V L/^^CW'3L)K9SJ[?4M+I0))_/((& M.:G-8N+RB&DR8 LRDA$597NB3&Z8XD$)*D+5ZZQ>S+[%%1KRB6@0CXF8J2:) MJ)IP48GEK$%J^>%8QK&,X$SI_%;B6@$0^7C1^U;,IJ_A>S0*"E"Q@\_,<6SQ\%M.*3:7:*"Y]A@[7C,RZ: M9$R]VXF2B? KG@RE:I#%E,?L@07L_7GE7#CN^W>G)\?UQY8V6R9/(%JVT%Z% M,)W>R'4NG4[;=8:#]^^&E\09N+V1\YETKIS>);ET!NU!QVGWR? 2BO5&KT3N MZ]]'-[^W![ ZW2&YZ750?'):JX.8Q+WJD9OVZ*(]Z-U4AG_V>U](N^/BE7JM M5G\E _#XJ_C_B8YYL'P2:9SR^W>?N3>E+"37,@RAQS*,ID( ))[2N/$DDCX3 MV>Z?2[=]T>^13J_?O[EN=YS!;Y]*M9(YOFYWN]GQ3X_"@OOQ%(O6?@'AI/*9 M0L%".M, */M5,JY"RQW]? =SG#:/AMGH@LDOI8Y'R^W^?'M[9NHA!__D.!]X MM[N&LS/$<1]\*M7_P2 _,F;'PIS2.2.*S3E;,!_4A&OR-:$**"AVW$X!P3RF-55+BP+*1?260>=K#6LXYP,BZ#?$ ML ,[P@(>5UX203$!;0 M!F;RB83+:NTZ%P$X&33FT X77ICXH-' )FL:708ZXNB8S( ,D,R0Y,(P9RN+ M(R4*O=4_L*+/L?4REDA"* 4)8%"3)_:@/*HGI(@E N=\9=B$ZYC1:$WBB(!:7F,@G2$RD#-^.C#1@8F*.6T?"\A$[I1E^I]I[*]*?TUD4Z=A9X;'/M1=*G4 ] M]+>4#"V#S)3TF ^GM45S!*SA,Z ARV:];]Z4B@DC;7!E1DD((IZ% " \3& MFU6$ W\]SK2E&:0T/_:,D_C/D=>? CJ]@XA?VGKK,@U-9YZ@B>Q^3)!EC#P] MFH '>=\J&'N.&?"<[2Z-)V6BH %PQ>96$^LQ_P6I> M),4^8"V,]3A,58YU7%P#<6_7=L=.W-\IOLM<9#!6-@.+@IV95;U"85.B$":9H"#8#KK 96B0LDHC8V@6P7'P&SOY!A8N@ M&L7&>EA6+Q2K5Q#+T)O3,$&O>G5;AP4!\V(^!YK3>Q*Q>5KG'O&"/5SE9C=< M:8P;H"*X^=IF@,*%:_(%S>M>28)^A#3[;:[LY?2?\.TQJR,]+U'( MIVO9D]U6+9Q(ZA@NX@Y+:%##4LWV.I&C.] $8"+ X=XJG:+W@+/-?@K<:B&2 M'-P'"VU*=9YT0E?=6!/FI]DI\/7-R*21QI*$_);!E]EEU>ETYL$B0>VDJS7GL2_?L).-SB#3Q M>2R5SI,KY@2T&T4\CAG[3K PEE099]SG -(T@M)A%L.M>D$4Q*VFR]S7:@W[U?>V.0JIS.]SB2U(?:FN5^ MY)VLFB:RH0I0HU3 [":=H6$$=!)%5('H1J+4D]^[:^^0JBB4JA4;ZV%9O5"L M1;DAV1;ITPR! A^R#'S*C/L+C&R>/DBINVQC>2[F,IPS#.@%G:1/4JC48V;1 M+)1+!E<74VE]9+IA&(#(OY/RR'(E]V3^X_UJ4#7/^IV_MJ=1#T\P;@ ^J_WR MH/DZ6.4-BVH ZRT:PY([.2V3>JW^\6'WRSTP\)=M$%XH]Q=_ E)-S5[Y<8$/ M>9,3:-ULS;,PGWHD6LYY5539)CS;FY]KN+(.9V9FC M#X6:I(=RE@OY-I8'-7Y;$"0\K-,EP9E+H#=*G M.B:52K90NLX?&9JMEWK]%V7XOM4'$*L@83THV X:-GV(76]_*RK8E76EVGL4 M=G.H0Q:8&KD&K#6]FNIL36;KL56%D<@&96THJSB6=KS^S9)(WYR&0[K][K0G M>=U9)O;N:\"J^,HX^PXY?-7VJUU(D0*DU^A8PD&Z MVGXTB0'?)G::F+[IZRO9:VGYHB!./GV?F\7AL13]UO@Z[Y9)^ M:AH#O(+ZTQW+&9I=O9Y>\6D]>ZSW[,$Y3)WSH7E72 M0:O6_-7,\L@] [4\5#M!IF].'.O$ZAN.98_*I?'99'IFH&W'WA&"S<_ETEEM M6NO78&KV%4MH'APUM!VA9TS+)6-@CQUS +L7O"QBY=*7QB>P3\ Y-6%J3'K& MR)Q6[>]#\QR,OJ.>M!J-UHZ0_O7YY:]5+-G\)FMDW*/*9*-VQ/BS,+1XN>0* MSJDKF>!PQ>02Y)("<5T1A(3?,+Z BQ6)T.7^#40T%)$$,8=O[%+$8'&W!GNJ M@VYU/_K>Q4IT^FG'CU%RI]>M[CZ@Z1,1!3AH]4\$$25C9&:!(FNO7)K24-)@ MA@T'#0U5U#K$2Y "FI\A3WR9HY/$!R0&X@FD[=UY/7LIG6O9 %,2S0BG<=6^ M]ND-&&X2!377E ^(;.^R2G=_'NXU]\LE!^.<:ASF*Q^GFYJ#/D-#ZWD9T8L5 MBVB \&(E@'BMISV"TRR"YM&>MY\J*\2^+IGY5%N+".= Q*2R:%ZCTOF"YDIJ M?CDX5-W*)1(D$[*C)L0NN_P-B*J5B8IQS+D!292"V5X2AJD26Q-1Y(HC3&7X M,**Q$I>F'A/?1W8J 6+&PP#_(]@M@2 L_#?9]1#=9_T>C,1V M-FOS ZV>JCNAB2/%PF=>"OFYO8(U=SVNI[#7!74MKZE5Z5U((#L0$L_#+<:: M?;/8X[QGCNY_3=]''XHD/<(*KEU0?#* A\4B7&^S%*Y-716)^:A1*.:7+:4B MF3I,^@4)J-#S4;4#3Y'U(+=73L6>SL5[FM9L;-#K/?E^GVY M+FZY7HOJ?:U^ >O,"UVKLU/S%,M/CLY?'.@WN&:_4C+;-'ZK5E%?U/?:,"8+ MVL&.%RO*7=6A W:8'$*V84AB"=5JKK:!]2U'L_51R2?%[?%5'D'<%CR;!YWB:L!]+0W1#X=)[T6$^C#=.W$LB%G8M:KZ,GY=^8<2+2R)!F_!V.< MD+'!,3C;%XY C5$L)"();W_]VRT6LP@06KNAYLP\CVU 5%?]:NFJZNJ/_^]I M:' /R'9TR_SG_X2W_/]QR.Q9FF[>_?-_E5:U7O^__W?ZYN/ Q6_#;S6=?TX& MKCMZ_^[=X^/CVT?IK67?O1/*Y?*[)_*>D\F;WC_YOD_D>>'=CZO+5F^ AFI> M-QU7-7MH_B%#-^\W/Y^\.G]KUS;TI;>2O\R^1'JW]FC\JO;Z@<4W%]Y-7EQZ MJ^O[5F7R5G?V5MVQ9%$H;J-C\H[Y!YXVO5<@-.,5HA]G-Y>O;W?]W__ZUG>N MK9I.W[*'JHM%2)ZDY'DQ+Q86'I)W4&_I0?CWMW?6P\[GE/*2,'O.FG"65TI> M[JK.G.,:6F'W[#OQ"_@3HCQ[X]C)WZGJ:/[FONITO<=.7UA]LVT9R/%]M_?* MTMLUU\Z[SR/D^!..7WY'7B:?$?.\M+#:GC4V7?O9?PG3%Y>^RK'==:+P'Y?> M='/^Z7+^+EO5=.L.&6][UM![%U^6^!.B;$C53M]PY)^/KNX:Z/3CN\G_O_DX M1*[*D0?DT9^Q_O#/2=4R762Z^39>QPG7F_SVSXF+GMQWGD:^PY]Z-WGDQ__* MY[D+'1G:>ZZ%W ]<0QVB]]R3]O2!JY][/W3X(M_Y)"P\J3JV;?(FIQD^DVC53.U== MU)F\?-GBGZYT_N7JZS__A*3UW.J-A_.ON$:V;FD7^&].YZNTQR//%AY9,S'P MGJOXH;9JU$T-/?V+GCL\MN.R7);D1TQ([G ";/<+R_[?$8@M#SZ^FCI#6"(CV[W+D>VZ@C+SYDA/\R>437TIXY MQWTVT#\G?:RJ[SF!'[E<6Q_B+VF@1^[&&JIF;O*''/X:6^\3BZ#I#[./:;HS M,M3G]YQIF8B\IC^])]J-;&PRO%]T34,FL1_D-_RN!@:%K?;+A.O$W\OTM\O*<%$5OMA(@H+!*Q4;M.3K]*"1%07"3 5Q=/3E^5<3,1 M%S9^(G;KTZ=-/>O[JC4))<-B'PS\=.2=+!%><9G^52(QW42K$'8W3GO3=W ;L@>(^*!XJ9$FLA]G9)"=$H0T[+,K03/QE*>;Z(93CYR8\Y0JD4E:0Z#LB'J*T^U9Y&R'30&3)17W=] MZ=F(J5>*1(5/DR)I0M%F#HF*D#*'IA+;R!\Q9?YL1Y"H2%'I:2!W0M*EY3B[ MI40"X<[TLYUK&_41MK]:R[5Z]U=HV$7V_$7BH9!3\7O/ZC(D(;*88U\&MMXN MCC KFJ:3K\-F7=6UNEE51[JK&GLM+C)F$I;16;!ET >U(#(*N#B9NL4MRZ@: M;!F1O6TF,@JXN,@./,KB2!ABF5OI*V9)WP8&;Z(U+OBO;)Q#?)\#07LU>+W)W)D?Y+:\N+S,W)D/Y.13(.9:#FR_Z%* MI@$7'=DO92338"9=CNROJ))IP$5']F-)+/H&N:IN(JVFVB9^HK.)^')4XBO: M;\Q*;S_?MC:P\[MJVZKI3I:8E1-1(NM>)DN-SZ$HD;63 ED'L[-*9)VD5M8! M&1 Y>*5 UL'LKQ(Y]J56U@$90+T-W[W9*D1.5":]AH .M1 Y:@^R$*^B=:8Z M2,.L)7E'KY1_@QS7UGON%"ZWF SGAA2/'=U%T_SV)+2X03WKSO2>G)4[+J3B MC2AC5'S.O)"*AZ.,?6%"@4(JGI R1L472!12\:Z4L2],&%)(Q0M3QJCX@IAB M*@% =NS;'0(5(R9 P "JF$Y=*NGP)GI[0NS+B"_X**93&DDZ-"A&]FV9 MR"C@XB+[HX1E%,POE"+[A4QD%'!QZ?1)A'9)I71:'3;0MU\)M!39;U#B/I=; MA&+W3#)_*#O'?1@5F^^3^4/93X;'62 ')/.'LG.,&V,L(/L.9=NY@7T[HQPY>D,GW1P(MO&64^J93#J\2:EM+YO@(WJ?7\(R M"N;;A'3VIMDX;C&='6O2;E5,9V^:C=,3T]G8AG9)8CI)T WT[;7QEL4,>QKE M>?^TG-!9%CEZH36UY<7G9Z(733.2:3 3';VH295, RXZLM/-2*;!3'KT B)5 M,@VXZ P/1FQ>=, -1S%1QS'Y\X5ESP[V9N5 HA=B4E]F?(XD>ODF8QD'LZW1 M"SE4RCC@XA,]J)2"C(/9VN@%)BIE''#Q5-OJ@ ZG1$E3? I.IYQ*3C/VI<;G M>,JIE(,3EG4P^UNFY&!39@ZH3,G!IA2<4)F2@TV9.:(R]39\=W:O3,F)I:@. M5>$/HO2:O#M6^(-H3LK*F2M\*AZ.,O:%" 44_B .56452"B'T1J7?!BB'$83 M7%9!C'(8K7$10B#E,+K;(@=0:0S*2R&\2:-U*+/@(XTA;"F$!FF,6\O,<:?1 M])6"6TVCO2LSIY=&TU<4EY1&W]9F^O;JN5&B-V=%JOO*\S4DD)2#3@(O.MH\JO$R#F70YVSZJN&4:<-'9]E%M6'3 M#4?T@>>QU'&3=B#1QY^EOLSX'$GT@6@9RSB8;8T^]HQ*&0=;?/1Y:1G+.)BM M+=#15Y6-HXD^2B[)Q0=T..''O)'KP;:NH*HZ P,Y3NT)V3W=0J^S\9U1K\>,FD&["Z2E:CW0P&=?_D@QMZDX([3.5U &:/B<^;IG$V@ MC'UA0H%T3C90QJCX HETSD50QKXP84@ZAR\H8U1\04SY4!HWPX9 A8,Y]!(I M@"KP*8Q02CZ\*40_,1'[,F(+/@K1SS,D+*- OJT0_;1!)C(*N+AT>CX3=JN% MZ W]F<@HV.*BCYB-LKC=+BFE8P0;Z-NK=;40?=IJI/:IXGP-B8P?+42_932U MY<7G9Z+?+)J13(.9Z.BWB5(ETX"+SK9U-;Q,@YGT9)OD4I=IP$5GV[JZ8=&[ M_5NRW6YAZ=[/[R7;RA9V#0$W>\FVHNU)_#IU=$SF2CJTB'YC:NK+C"_$2'8, M;PHR#N9UDQV\FYF, RZ>CL;UI$./9 ?Q9B;C8(M/=DQOU,4'=(=4-3TF[7:H M:I/+QOF$[[ZC2M[!K'#XD;T,R#L@"VAJ8D_:'84?W\N O .R@ %['M UA6\H M3'PIZ[0F&NRNU$HKCZJM?;*WI+>3=J316\XR6VY\KC3Z8&)*9![,DT0?0TRU MS ,R(=&:2(HR#^9-HK?\42WS@$Q(-%\3%Q,".M7H34\)+F:5VF+X!J6=(8W_#="/-C_J,/&PQ_)Q8FE8>F[,MAF]NHHD?(?QN,7SG$TTKC\T%%\.W M4-'$CQ#>N!B^OXJFE4[KK6"3^4V?!)>_?H0SX9 M9%1\P4#TX:(,LB],[!!]4"F#C(HOU(@^1Y5!]H6)3*(/<6604?$%,M'O\*:; M?3O;XHK1;PFGFP,!(S\QG2,\28!Q-&1790B^PV2+U#-'FKV)UD 4YM5 MQ!=:T)IVU5#UH?]:I/F% -*&]$#T(OFU;?40TASRE3?(4+'/OE9M]_D<==UM MMQ2XUN:L12EZUJ*.O]?&4001%19Z:$JB0RX()3L%58H!3A[NV^H3%3@)KDWPVP0E<>D*W>H5EKSC4.S5'XA:Z YWK?Q7H9U6VD M8>*]9RZN:?LEI=L)+D$>9=O(X[\4IQ;/5A*=Y:5!N9FB:K2-90*WV2R<. MJ!C$H\0%J8C&J_8TTFWO,]$M6+%(!^;65I0,ZJ):A?U1AQ<6 7.K;<>982Z MP]SE]P5A*8W.JKO8:'6L,SI,IICUW%54\-& MKVZZV/8Y>L]K%%E>6,5I]KWE".+B38_3%-$D*27RLJB4RNN+C7CDK/;46Q## M+"LU=1U7NJD/Q\-M<8I/O[C@%BSIKS^K%EG2>:[K&UY>:'J]J31%V]GA_-0%9'NEC:RAT*X5>R,:$629*1@#7'[U&VT?+,, M_!@#@_9&=4/G]L2E3.;UV$;L+"\ +$IT+NYV6VU+^ MEH*EW>C._86-T*R^'4UN$J.+"R W.?C2MMM[>?Y% MCQ5.3J^EGQ_?+5&_EQ>>_10XO"5'?S-;3]S06PNPFNX V>V!.MLH3,X#;8BW MO*#\'"-SCN" NZ9IQYA?EZT_UR6AD/56>B>K+BR[C_0%;B7'C%(:6=RHC,"6 MQLD.,*OG-"@$3!RZM;ZAV9]5$C.Z%1Y29/>1XKQNZ M>?_>Z0W04,45>O_GISR/"_(PYKZ^M?@J'_PN?(2M^_6YM\1.S/R]^^^QO4U9N M9.\T92CG!2$O2.RP5#=)0M0]?:5]_OSI*W$RAS&\+3%G"3GQ,V=:4&22.5/: M$T?.S%=,SRA5+1,[0U?O&LCWF$4FK'PU5NB.N)'7OT]?T3 E3R-#[^G3K1:G MZ?B-#G9(BWTXV"Z1CU<-U7%F)Q&>=.?D=))C#L2!"95K7[A ZCM?6AG1%8 # M$W#(QCJ<'3T<=G'@J*P#P(%2.&1C':I'#X=='#@JZP!PH!0.R5F'C74D9C9@ M2]D0*40V1$HL&[)Q3!J;S)VN@Y)4TRMRBP>"W+V9FQQR-[3^A9X'!U$$,);Q.3 YF_9+(&,')>8=%@;"*'A1_T ;I/$K1=X[2^5 MH\9RD,E.@-KTK*VO!(X:H>&'=@%NL[6V@.4P,]H M>E96U\)'#5"PX_? ]QF M:VV/&LOKTQ8/'XYK:SX686\?77GX@M^Z_F,!P8:!UX6(9^>-6KIS:?3@5#(I].)6[;R MZ71@&?+I6:.6WGPZ'0B%?#J=N&4KGYXZEB&??D3"AGPZ??GTU$$ ^70:\NEI MB9W)?'H:S"G$G"P+(IU.23T]%[*SFTY-F#LQ[82!VHSF?GO@)"ICWPBQN6,9-6GI3QG0@%%+&=.*6K91QZEB&E/$1 M"1M2QO2EC%,' :2,:4@9IR5V)ENPTV .C#2A/W:C.I^>["&!0 B%?#J=N&4N MGTX!EB&?GC5JJ M+I8AGWY$PH9\.I7Y]'1! /ET2O+IJ8B=U7QZ0LRYL*WA9&:*@/^%RS=9B>(H MRZQC/-KN.:;V]!5,\\?/7UO]%#*UA<\L5HQFKV2&<,C,TXE[!C+S!Z<+D-G/ M&O649?8/#N%0&: 3]PQ4!@Y.%Z"RD#7J*:LL'!S"H3)!)^X9J$RPK M0V0"P M! 8+5$8HJ8RP#"*HK&1666$0-NQ49IA@KCQG+IR4H#_VI;R>(X= ^&+%,G.$ M0SV'3MPS6,]A7A>@GI,UZBFOYS"/<*CGT(E[!NLYS.L"U'.R1CWE]1SF$0[U M'#IQSV ]AR5=@'H.@"4P6*">0VD]AR4003V'FGH. [!AMYY#)7.+<^:6H9Y# M?>Q+>3VG& +A99H0#O4<.G'/8#V'>5V >D[6J*>\GL,\PJ&>0R?N&:SG,*\+ M4,_)&O64UW.81SC4<^C$/8/U')9T >HY ); 8(%Z#J7U')9 !/4<:NHY],%& MGI_/@1 )^Y9*SD<@BY R2%KU--<LKK.P7H.\[H ]9RL44]Y/8=YA$,]AT[<,UC/ M84D7H)X#8 D,%JCG4%K/80E$4,^AII[# &S8K>=0R=SBG+DP$HS^V)?R>L[> M)]#D%$Z@[8-PJ.?0B7L&ZSG,ZP+4<[)&/>7U'.81#O4<.G'/8#V'>5V >D[6 MJ*>\GL,\PJ&>0R?N&:SGL*0+4,\!L 0&"]1S**WGL 0BJ.=04\^A"#85[/5] MYL=!H8'*H(RR0H-N8O3B1ZP/K9N]DC)"H5! )VX9*!10AV5(]&>-6LH2_=0A M%!+U=.*6@40]=5B&1'O6J*4LT4X=0B%13B=N&4B49XEE2'0?D; A44U)HCI+ M$$"B.;-$=Q[0 ,.XZNJ:K]G-+ M-9!OV.J_Z#2%O]2U+X6X^&$JQ]?OCK]K?QDHWU7;5@\"'\$,Q-)Z,ZNS+0DY M?KNP='4*A((TG2$,#0@V-]&!"$"<_+]C6K>H=V6IO M\.P.D*V.GJ]M2QOWW$L*/-?NS),HULEL#U49GS_X/B*$0<%2 VY:V <"Q#3BZDCX[+=P-8&0MY5[8/."V3R X.%!D#$KZ+&N.2)R -@%@MT:Q\#: M!;-V #5VH<:853N81'XJ,,NL#,"R-0.(L0_K/62SJ[\D&=[67=(05#C^2;044 ME.F=?-,JR/1H7]4R'Y#MZET#'5J.<5=?># .9 .'F;22@T,ASTL !U;@,)56 MTG 0 X,P2&Y1L&9^0&WP0(P%@/-5<<1)-!<_4SL@:90R@L\_G<91&='#Z)= M',C(NDREE9QUF7X! (,%8"Q9EQ5H!+(N*Y^)W[J4B3<4B\L@JAX]B'9Q("/K M,I56D!:=O:H482 M0XN5R,NB(B@%EH%4>51MK?T\0BQTIE )'BG/R[/J!_X)SNM1 M!-,$RW+.YF!JL@$S--1459F#RMF10>4,H+)IF@[/IBE$>:%; S0Q&2&F-I )-)%A(8K@$Q,7HIBT.17! M)S(LQ.E&1IQGUT2FVT/%$-DG,?-]@;28C8#=R8B>4@F;GZ#]S'X\O3-?L 9(!R8S:9&6.9"7P<,?7$Q:F M,S;YA M%+YC%7-0>T-EI3U[++%>?Z<"2U04_!/N:PHX6=%S/V7^$$\)TI'IH&ML7XBT M6%G,J"7N",!!Y99KF -"4=2>%T:K("$:H4#H1Y;V7LEP D"RM@JIY3M!U%F+.O%L MPWHQ"X2>O0.@LL0% *'%*B0]#8.,?"_D>?GUIYG0:\.183V3I53N;.0=IUEN M*#ZWK_3>0$7&O_]:-C+O+?8A0=#0[%?([O+.6_$"-#;R([8-Z+:^X@W,SLIL MS<"RC]E:_4R*IY8 RX#EC5AFX-R2L'B&-]!IC^,!-#UG/P#7@7 M"'BG\_K3 MZ\23<==!?\9XN;6'5P-]F'Z8\FB4'R/WS)[U.REI>>3 M9_D_O#50;>1L>OZ42]Y[0GX!)NW:_TN\K-FZ82"?;(R'R%9=:QU+P=>^2I[/ M,Q>^\1R9UE W=WSG3GZL?JG/8VZS@>U3'Z/S/2?P(Y=K8\5UN 9Z MY&ZLH6KF)G_(<>2ZO_X';JC:=[KYGB-OG?]WZ^COZ#)UY^<_N]_"P7^P\=WY(&G']^-3N.E<_+ _\KGN0L=&=I[[F9LH/RU M>H>X?/[T(^;,[+LF3\B[ULA[RNR1^:[E8B=70[_!+/>Q 2$ 0"^TE3WS=T]M&O5T[?]-J5]JUUL=WW5-F M5]*J56]OZNUZK?6FTCCG:C^JGRN-3S6NVKRZJK=:]6:#R>6)T^5]K[0^UQN? MVLU&[LWYV^I;3N05$L(QN*1#T)N+YLW5F\D3B2-]TIXZ95[N( WI^?RYU1L/ MIQ%OIT=B.%[@A4['^ZDL\9T7JVG_,OAOUQ??#?PX["A-R_1"";W'3<.V&]1? M+=6ZUFO#YLED2Z[V7)Y$]-()9ZHD[,<$O%_\_I-3@<]_]9SQZW>\8@;@LXOV MWW@#I_>?XR3^KRO5OG_3--'?C"Z :>ZO:FUI16N_CE4;H]5XOD$CRW;]%;C[ MO=?[==&[OKI60RMPW[*'JOO/B?[DON]:EH'POLX>HQ7-EOTT>X5&(I%R42Y\ MV*#G;[[>5F[:M9O+G]Q-[;IYT^:N;V]:MY5&FVLW.>PYV]@]%LJ2S"@"&/4]'NW8\;PADGF5Z'7MIM[$ 4_C MO';^GEM%-[^"[FLO45";9,/\L5W[]^OGTI"7556*!=L:J9[BSPTT]?D9X5VN MN0)QQ0_B2X2>X/#NNEV[.JO=+P3XW'"!;]UK)!RXN5T-OKC#7]F$:DL:UGSADVZ#\HQGZV&T[9J.CJY MO&F;9Y:T?WOC^T_W_PJ#.#US7S6<5==<] VZ5ZB<^F9YHV]NWU0:K;KG@<$Y MLVTV9LYY0:13[WQQT[SB.O-_B&1??V-SL2P+BC0=Z@ZI%;VYT W$89TD%22\ ML5_Z#H\(#?4L6R4*_9X;FQJ.NG43K5NKPM1:U;PR#WGJY*'^5JKUMT2^O2'*YN"O"@'Q )NFD35'[1)(WZ$YW7-);V, R]@=4 M=2@T1J-?_7(/Q8.H\CJBENDX.?U6_]9LO:DWJ@>77OJK]H3Y\(8P@+/ZG#U? M.*IXMS5CUJ18-:UP M?G2UE4K9QF+8WBN2R_])6DP^5D)2W+56MLNO9SU=(V& WU M7]Y"9;&EW<<2*^<=U"/-.2X:V=8#49[5K;[(KUN5K72?G)XC0WU4215ZMXUQ MM351[RU*,7%)KBB<#]$'B<^V^E2?=AKU/%EOBX^4WX^%2JEU]C*,Q9N)PCKN M-M!S!0 M_??8UAU-[Q'!+?HNCVNL,,#J>_3JBQ;06Z)]IYKZB_?[8E01T<)E;=8.$<+U MMS=O6V_WPO#D;#1I*&04MLMFTZ.]8;U= ^K<++[SPLE3MD-B5FCW\ZB01_'VR<-6VE^FU\?U>,QPF+ZT[8AQC2L2#Q;QI,-=ZW: M]X_J\P9?G&-WD^DC*=E/4E7\8]-N6X^FOYS*I;-SH:SU^MUXFDE$::.<7DDY M.?T7F29ZU'OWFR2SUA\C^*W.BP&:]C7>,6 _N&&C\OO7KUIC4'3,R_ ER:4E MRAN7N$+/R>GWRH8%;JQ"+CWOVL([(N.7/MJ\#7LH-YYNC&^]-HI)@,K&U2U1 M?R?>'@*_YJ9_M__+HE" M\8/SQD4&&I'5P';9U5T?.FTEB M'=E(XT9CVQF3#+MKX4]Z^WI.$/_J_DT2\'C+SU5Z>%4-+% V,X)'??B'>5^[ZZ6 >P&^VYMF62'+7QS*$' M9#]S=<)>#!0239^KKLIY710KVOWZC$7;3@YUO9%YA2@P=MMC8Y+U;.7;2:OR MA)ZYAB+G[[<;CW#,2E/S99)53N'OKW_]7P^#GX5ZN^KE+V/0/Y\"O#\]H'^' MI7^ZPZF<@0E%G-KK8?VS5:)$!+(V<3Z^?^6P[/.^+SA#K+CX6^R9U7[3LX9X M9<_$U>*G8?]$>'+'W=G6HSO@IJ^^Q:M!'FD:ZNNFU]'H$*4E$;;(?]A$H/>R M\&'VMK4W3%_/O9F^88V\&0'S)Q%W.WWS!EIG[]1-S[Q@F]'-B[, 8A8UD #R M+?=7U>,_#B/_?G\XFG @_1JN-0I?^%P@]S]TUK5>R_'Q4GA)5-$C:DW;UHP^ MA>177HGV2$N.\,21$6LG0"1MH%,#DCPN(*TUX-I5C*D[RW[VC]CN!M)O^_*K M_!0A8EOM?IH,>?$0W)M^^6H/E.33 [5$[F1K)7[%AM$WSC=> MOQY^EYUXI@ML\0 ^?4R+- 8.V@#@:0&\XO7L-*R'R41/0?+(&WLC@B5EJ!I;P,8',\U"Q70ST=[RA.N.D/SC\G]<;%"4?F M*WJ/G(V[E(5B3BF+N2(OS7 [(WB^'9S,DISIM+W6'$'L 5X)%IE%U^UJ&Y M:ZCH[/6"!Z[76L5B;6*U=K'\#>M%AY7BQ'IV\#6/X9.=6.:#@?K>)^;;NB5= MG$E]MM&:[;*F,VW7>&(C]3[?1=C$8V)&'A\7M?!PF;"HXRFJ-UOAV5]NJX:S6F(0E9JR*]E*:D58\#W46'IE-T4@5HSQSM5/F0NHN&'AW" M6]I ?S&K]'C$S.\K==@$%SN4@M&G _\L8XA._AVC@4\*15%3T:N[!''7+J%J MF1HRG6GGX)EJ8.> N-8 (=1YT7:^$L0=V5Y1S@G_6P^OH>\D[B812<$[B8A2D5P-RR82UKAPPK_ MP-W0ZV[DD.Z&>)NJUZ'JD 96KQ=O8!D:LIUI=E1P3NAR)*)7 _ M+)A/6N'#,J61T'[!]U?44=KF>AN4BQR/3M;BY'^+F-?]%;P2N)'E*%7 9X#*.D])C M=!GSMB^1NK:O5T>B3IJ'KU13O?-5:?>AJ-BJL:SHWO[EE<\-' DXDN.D]*@=B42Y(Q%/3K^2>3 ZWE>0 M"<_$)^ _&+/?B4LQ+&=,9@Q4NM;8Y:Y4^QZYW(WNW(.?B-U/%,!/@)\X3DJ/ MVD_(E/L)R2N+N+9E.)Z/N+:M'M*(6P G $Z 5G-+)U6 =' ";,J+W.2WY!;D M$^^,.E=_/:#>;'^NW2P?3B<.H@M.XC!4!QS% 6.('4J/T5%0?"I]V2TH)Z>7 MZ$XU)ML$[W(OV"?$OT\H@OD'\W^].ETX.;TU%^[[;:D&\DK,T_,: M"_>\DES2K4/N:9_Y"G 4X"BH-XL^\AY';M6;3TR=+\6:D[S,? MG:V5!Q!;US*TD/[/Y]:H6&^)6A::.!?:M_JW9NM-O5%E=6'59N.\UFC5SM^< M52XQX&IV>9;9E8$27^X(@M!YN3?;MOC)+OSB[[#?&0\Q MB<_>6]XO#!S*+QRY79ZD&N(2FV!>;?42FUU7T\3&3/*HY1@Z_XCTN\$4IO%) M;3%B7]P=S40DE_F%*T._C<:?B\.SQNA&.=E(7,SWS/*M5OG^LYR:-!;-3#:"6,\=T**5'[BIT9M;?2&2U0\(CH#; MK:210:S$!D[YL,6'GM3T]>CE)%$DIZ#J[)?@^[Z4. M&COY.U4=Y?,5Q\'[]DK7<6VUYW;TL\Z+-$1?AL9CZ:XDG^ROY_9=]R^1EW.B M5,J)BO+W>I';UY5U3RNM5FUV\>\41POIYMTX6,Q-;Y7C[C?Z/9 B8N(TP]0N MDBIB?-6HNJ9&U;%M8T"_:A,O8'TJ])[,Y\9%01T7$]>GB!9DN@!NLISW8-=I MM>L@#(J$X6L="@O6@4Q#)L:@WAFJE>K+[UJQ\](HGKGME['TYR6,E_WNWS\V MS9@72!EXED,@ZYWO\T(;!KR"#;R=?J?XGT1WX[-:P']BW7#^S_8U"865KXL* MTH_ZTWO3,B^(=R"CY4QUB)\PQ?A[_RAO0D59QFGZ3S\GPY+TWK M-1?XLSS^1Q9/R'#MH>K^_-\5"S7 WU]*%JG'#3'QROSC,V]6BM2A MRM<^GRU&;[T>-JZNQT*K=?OI]\:OKR!=EE/SNB+ B9D,^ M6RIGS]<*@44$[=H&G3ULN1)6ZY0<_GA0C8.8E&GH^!OL0ECH%.F!CJ^%KBU8 MZ&L;C51=JSV-2-O)!M/<_'(__%:X"*K O:M.2%J"4'93Z>YER MZ&T!GRM)@?<$&: T2C9]9FH!"C$CA"D@#$:%X1LSEM=BQM=@ M<1(C%G]JUM=^2?\QTN.+$0/T4Z^'C>);)5J0V&Q7+CU*9CUW@>QJU*\-Z7V] MK^4T:]PU4"IEVCVI2,/][A$8RID%AAZ+L@L- 9YTP=,_+ Q=Z(P<%J8"3P@, M(18!83 JC)U=WI>ZVM4-;R)OQ=1:KM6['^"8#=G.9&+OPC&*9-*(LR$7/B>VF-;WYEJM]O:VW?U+87T\5,U%S]6ZEN#6+8(Q6E!>< ^TN@<0!D7"\+4& M)7]KL'XL2\1&8?S"7TM_Q&KA,DP^)Y-C60MK@K-9U$(3A$&1,':?W)QVX5ZK MSZ0%%\?U^"_V&&GK!@0;#HGTFUY67YSF;>?E7CBKW?3-P=FW =O]IC,>>+2, M)HSPKAQ1)ZPXXB;4O;)PV11H@P,X>!JY$+JK7"[E2F+@MG)H+@#8AH.M;WJY M4 S=3"V3DS30=%^';GV%O M^,VY_24=6K/J A>.SV?EBW0YNT65[:'8S;F--,J"$0)(I+QT\ M@BR&/E<"$21@,S9L^H>.H6=G0>@(TZ2R[U(8VL5 M?QLV+\CL34));\C2:P19L5V,5\3N+2X'0+K=*RY^ M,.^@7EY_R@]T34/XX1@WHO[4M0WLZI23T_R<'K O+(FND+'H()1@$%T02H P M-H82XD(HL>U4#"_$>"XF0,XIPM*W'9\!;-*)31 &1<+8V7A[;:,^LFTT.4?W M337&B*2MZYW1B!_QG<&"19E>/%PU5,=I]KWW5YYTI]/IC1UL-/!;,!G(J>"- MBV=6N@9:?OH5&G:1C7 \C/G[MO%R6OA4&OX2281IQ-?_[Y&?B&@8[60G^ M,%Y*CANI-O= V)7C_F?RU!F#RTMC+)99<*W:3=MCI>;Q^AK9K8%J8YYCCNM: MI_=ZN?"M7?O2M>1'JR*><*[N$HHW4S%;VBL12B0BIG?JUB_Z=?ZA>/^K(04C M8M?XRP!D!$]#EX*.6:@W+I:3?=?>-SD)$NR;FRP%;>C=3##_EN<%GQ3EIIRE M]W\YHADK^. WXF/R596Q.[!L_05I/N"\'A7/;YYO'K[W-\/"\1[#J?/GK&.T M&(J&*3:_?+$M^5-+T?[\WH^(/42^2L8>V PZ47A9U&%P&8A(7SR6@[99^!,I M\F1X^88!YEL!N2Z7B:7%?ZIP"PZ$FZ\TMP;@BP@ [B3@UU[&S5*_*5>ZMZ5N M)*T(M[")5B2RL-I(^C*J&E=W=UN\0(J:-EU )QC]*Y /6KI,5R\C+2F<&YPM M28E3B?>U\'7'&:>FH$-1NK[\^N"(5_<[<:Q[A*TKY^;@>;*@YMAU7-4DD6=* MJSJ[4^^N*]IG[?-N9VR]4K>^M%T1P;JL$K0Y0JGR[:(F*(/:EO!WAZS$<+)* M<%5]R_A<*]X^7C8'>\IJ;[LSD59B9C1<)!O>C"[(*K$UI1VR;1%1=+<@\-&" MN_A%%,>:HGEO,<<7!>SJ_&Y""/&'Y>J-GVN<6":O +J@SF0[AE\=(?R@!V0\ MKR2\8DRA=>UWIV\H?-;K2A//@[')@GASCO3P8!^KXB59DC+VI3UFMSL]E:QS MO6&,F).M[6* <3!HQR=L,&C[&K08L@"E/7JRP:!%P?BDJK:Y^%[1-)TP3C6N M55VKFU5UI+OXER41IE=E^R/<_]):1O6Y>I?&2>5X9N',61Z$RYZ MA.3]D\6CY9TTE*4C6*Y ($XH.!/X/>:G;[)EI5Q)%G.R4J+C =$;PY]L)LCGC&TK M:>FS= N7.\7P\JOGHJM;IUU],B(5+@OI%BYW+\RJ&KWGT>W-^8B.%H%EF[2+ M_F6;)*2=S@U3N-QS2=&RN8D6+O"5KJEKM75:M]? M/A5HJUON:7*B]4JD5+?<2!((ENZAAEZG&H9PP.D _JU(]0 M/?WJ2>64ZTE[Y.H^/PZD;T_UY\>'PZLGG4$]B;I\?@S!@1A';;S,Y\I*@8YL M/J OTVK2GNC;8R(9$^CSK25MSL+%44NJ!O=/%:,EV898^=UDMI14#5I*VG4: M)>92TDXIO$C?AW=77^[^//?V/"JVLK"4S\#M7IAZUBRT?YV9;DNEL)2TB_X5 M@T3GV=0H2Y*B)=@2+26=IU=*VHUCY_&B:96UMEF5TZY/)+BJ/\7&@]Y2[_Z] MW+VJK;6D708UQEK2[E45'[X7VR.WA0:]T+(JI5Q+VKVJNONI-;H]*[1[N[L- M4JXE[6ESTCY*'*J6M.>:TJZ/[5M+VG,YM!U3C&--T;RW5%)R$B]"+0F2U0>9 MK(XC/HZA_1.KV4$FJT$]03UCKR7MJ9Y[7(M[;.KI5TO:W/J7CKRUW4TO82TNM M_C3;WYM_^G?;T;"I'VCUPM&EK]W:N/7RN]3]]Z$OV^IG9?MW[]&ULV'EP6%8 M2'(LQC8&[4%BM#XA62CFE+*8*_*!#@ O-6&0MHN OG%[?]O+]UO)OA>5VOV% M$ YX6[]V:Q?:2Z_X M]MBP[#&L85FCBTI.+I9S4I&2DZJ HE10Y+_["!U_%:5 M(%?53:355-O$UM2I]'KCX=@@B=-SU-=[NKMJS,\;QEW)+G:+XB"NI/_>=OVU M(W+R3?A]T89LO*[:(T>;+'V#R.+][MW*VK5L#=GSKSLS,%?)EW*.9>CQ7EN_ M59GWH2.JLO^U7=MWPS:XSRCNT]B(%_?/27YM8K:7G[%13;,12K(/\& M[!X8=GT]57&?\3 ;L$M&O?.Y8HE2["ZXL*A;!PC0$@W0 G\11,L'+0S?H'.Q MBNV%XP/+P!;9J?T9Z^XS"3+;L_;&H7I9P='FTV.O,W1G82>JEOXTY/I+?:BG M$':*7MCI\>$1$4F0AQL^_BKN2+1MS3(,BTSZW_\NB4+Q S=A%KCVS%S[=L^^ MCNL]HM 8VIZ%G%!6<@J__8!@BIY\J]P KXS@U3_RC.&DN9"3"DI.$ ,G2S+ M*X2?$/& ,%@2QL[P\U)7N[JAN^1R-5/S#4:%UV#4G0>C+^W+,^GGZ!MJ5&*[ MZVM)T*'B3?&M$BWB;+8KEQXEE_7*6?VRWJ[76ERE<UF]8\ M OUZ6V__#&B>HY(6TJ=[7\MIUKAKH%C=P__LX]$W4Y&L4]^%[CU"TAB..P@Y M499SDA@Z)/78F%U0"A!F!<+^46H,P_N%7$'@<92ZO=LC:PC/O-X[5\72.GWS MYLW'T>*C)Z6T[0_^P U5^T['])&WSO];)OWWV''U_C.F_MWH-/'O",>A:>K& MT5_0[.30"LM&'H?^*Y_G+G1D:.^Y:_4.8[R%_HR1V<.?DCYPS1&1LO.>?$L+ M38":ST\56-,?@F[H)@N>OU[P#(HG)JZ'#&,*%P]YY'=,86_V^_(WX$#"4$<. MIF[VTP?N4=?< 5DD_Q^?56_9MKC6R!>3_F%:#V&%LY>^#K]W@7\SSGW@VL\C M_/T5&^MP[P/7P)H]X6[#(MP3%C_T;O8I\LHKCF<@_O@.<]F'WS92[_-=A!4; M/WKD"6[*8[RH&8/GR%S VRL,1DL/7R2)D.J).3X%2AC'8>CTD^TB#[W\YPIP MHYS \\-F=Z'3_K[#\]+)S*)^JW]KMM[4&]6/[[JG![+6:K-Q7FNT:N=O6NU* MNW95:[1;7/.":U[7;BKM>K/1XOZZ;51NS^OMVOG?![3PB^;-F_;G&M>H-VK> MOJ+]^:96XZZ:C?;G%E?#7,%;C=HU9LE9[8:3^!Q' E+OG<2MQ\*)8*N.^/A$ M79J_Y@?S(K-ML,07.H(@=5YJE=\_;^\?W*^/O[&/&0\Q_<_>6[ =GTV4X/)D MNH^&3 =IKW]U.*N/'2.R5<\W8LB:ZEC37:3]?;(_WX+YM9.5!%R@813;+^J9 M:$-2FPB??7QJR6[,0?+7?T[$5[G+9:GC'883>*'3>3T6]Z=U6ZQ_4KM5EWX]Y/UW"S3)%30U#W,KS07ZE13C?[Y;[G\Z4'%K*!(J#1I M:M#JV^9^CHVEPF1#@ R8M8[! C6P\F+_2<3OD>E%_?2P#@2WL3JTL%>C4G+A M+42&^X'D?4^PBF+D9<_W[1X1>.^>"0> U\Y6>B\79 [Q>3"ZF'U1[IZWR;OXM)@BP=DCM&%;0VK M^*M(R]YWW1U4O>G?R*X]]8PQ,985QT'X7ZVM/G6&:O6E4'4Z+\VK9ET=]Y[$ MET3ZO*>U;:GPGT!G#",(8LH%_ <3;1IG,:5&_$^B;:ZS>OY_4FEGG7V;^)\T M^U9#8&ZYE95\!_76M39W8I]. R4=HP%7@K&^,5VM9H#]!(&QJE"1HG M/_E@<8_Q*2N-U>6< E@$+.YG&8L3+/K;Q3W&H:QURB MMS)#CDHH^@;>-R(H],JP^YZV;(ZN%:0>T#M[:C-"04?@>(Q!6HG ^ M5RB7:9EZ +/B#@6RNT+U/6[/6PG5"SE%"CP9%P +@ UL8[?&\WN<0%\9T)XK M"V!@ :_+'\P[J)?7G_(#7=,0?CB.8D7]J6L;&&JED]/\G-Y,8!+S]*'->6B* M$_LP^P:$ <( 88 P#ED8OLFDQ3MF/MF6XUS;5I_F.!%$Y="U7S)4+H0=D 4@!I,&30N7015XAQ]-SRP6 E&F0[BC_EM,I_T)* M"O9ZE._U0!@@#! &"(-R8?BFI"H+*:GIT#OSKO8T(D/QG$K7\;K'.OI9YZ5_ M\>^P/+CX]K562C4A%8$)T\&3C4]<[<[I_L"(8=)5=429[[R\-*_O[(N[PL67WXF44WI]WD'BD.N-21AA$IV]P#H"(F:54B%*L^(?.CR MC)"3!#Y7X -GO\$>,@>?[643D0]_!"XG\DJN%+Q5$<##''BVES/PG\."IR 6 MD(!).F!4GVW+,#@TS2B!0D50*'^0A(P&PY_L*A";+-&A M6 "AQ""T*R(,?=)*%.0<7P( '3J =D6%H4\^E92<'+R! /##*'YVA89[7'RY MLJLHYY0")9L*W\B07YKRY2#5[@TPS\[1 S*L$;FDRC= ?/IU\>]U6W9?I# ! M8N;)Q=E*.=74L/CF:P5]BZ!O6^$3+G04PO=YBU*N4 #+?21(VA%!"J%SBA+/ MYY02)7M[P%$*%FE;("F$3R\6&@#8!W3_#NBIW# MS[F2Q%Q)@C-B -T$[>[6<#UTWK>@Y 0Q<-T D O(W=_H;MTAA,XX2T).4HH4 M(Q>./#*X08:>=! &" .$ <+8*QM6VW;DD>2_)M.X2 +,&^A.IG$YXQH_N&T_ MM'O=C!-A8K1$6-MRIVFP^=*Y&F2_Z(YEUU :+M\E1C@!4I;E7*FD4!S" F!9 M ^R.')<8XWFT7#9;J].](&:EYM(L'VR&S&'MT;/E MX)7]=SN2F7MT:ZU$;4EA<])"C4I6$ M\ZC=E=': MHU-K VI+LI039, L8#9&2[LUL;5'C]8&S!9*19HR7']OV@5 <@MVC2 ,$ 8( M X3!NC!\DUO*0G*K89G6K>LS*COM%LY%_GU-<; MU>95C?MK.J]^-5X%Q%*#6! &" .$ <*@7!B^CK6TX%CK>(=M(\==[<5 MEJ1]"DL;P"L4 %X [QZ6=UN%2=JGPK0)O.5<6::FPA1S#_5*&@WV MEH>ZMP1A@#! &" ,RH6Q\][CC;6EUV$ )/TU;Z!^N..OG"\_AF?J'3UIL-CF M F!NO+:2Y&%(?+CLFAAP5 3@Q0FQ!J=R3%Y/ 3Y2$5 M!IA-S-)NRX7)H<<&0 8,,)N8 DS$CBK'?QA4S1K*"7KU?5@OH[D<19PIW:M;8W M98 [JUTT;VK<]4WS6[U5;S8\,O"?9MW;[@5"KFQ$SN/X2#!$S!<5>>*Y9Q D(IITB!\[0 QF,%XZX$5@Q3 D0%V\4L M;H0'*#(%Q5UYJ1@._Q>*N4(Y>Q<->2A65 1VVR ,$ 8( X2Q5QY*6,M#X?!@ M6I,Z0R;JZZYW_8J7.+(O/GVZ/2ORPF6&'5<1F')M6P^Z0^(G')Y,3QER+@F' MH&":7<%T\8-Y!_7R^E-^H&L:P@_'(!7UIZYM\*+"GYSFY_324J@$K%")%0&P M E@)B!41L )8"8@5B4:L0)("HG\0!@@#A '"8%T8ODF*\\538LA=OUC#RTY\ M=OKWA=OQG\M&,MF) &TMZPD+\:T2*5YKU-K[WJL1]2M#AHC>UW*:->X:*-:( MYW_V"1 W4Y%P#6X)E^&:6Y0,FEM\P9/)L'> +9VPW=$$HV30! .@!=!&NE)# M2;U9!B +D(UTHX:2>E--VI"%-!;L#T$8( P0!@B#=6$D=17[P9?[,OS^Q/.U5U""D;.!M3@R-A0'6?RO:.!Z79NI9N!]NF;^^N[ MPM>K_-U7L3S^]>G;N"=^NZ]?-/B?/VZ,[O=O8^WSU5U7_'G7ELZ,WO""5[^7 MQ[WGBO7MNS+0OM^,\#/N__U:Z:PO[F++XLXG -Z\/&$TMC__D;OZ9WG[\J:J MD,8"=VQ%? 48+F-9"#J=JMZXV+ MN?9H<'8-SM@@F)!D!QWV$H!L_BWOMZ/: MM,7:IW5@NN%*T@!M2AJ :6;%-$N!3;,TMUW2Q';QVJ<+X\>5-*YV*37-YWN8 MYK7E_2HZ-S=/GV19[!^>:=Z1E2_(-!KF740'+26 60:S3+E95O:(F(LK(:4K MW%YKC^.F*5!JEBM[1E9^&QH8@]2LUR=:]H>65Y98P=I=5B MC.F 6(/EK43'&.$?DE6&*C*49T 8( P0!@B#=6%D7T6.>R/SW7LZTCQ:5+P: M]0[AX&:4?C_L=BDVMK7-UCU!;V&#-A5B9R;(R' M760W^Y.HLODJQAT5XK-VZW MV^J@^?/GQ=WGW^'8D>(.;?MN9R]\A*OD%O%$=]E3'C+L1@W-?8 MT5.*/R^,>O-7%8S[CFIP::^R0P:F?1?]>V45U^B7"L6<((BYL@*&'0Q[1,-> MB"%J7RGCJGV[WV_?#2TMI"6CHM\S?-2^P@[3_>R,1.&R^0<=O6'?44\N[56Y MR"9FWTI_M#V'+)1R!;&<*XHE,.Q@V*,9]DH,$?M*(?CF^[C:__?\O(4DQ@R[ M%$O$OL(._6NS\;G6;=S^"KF!.2##OJ,D78J6RD@E8M]&?SG:CD,J\CE%%G(* MVX9]5G1XYZK8?)V^P?]\'"T^^STG\-B\;7WR!VZHVG)CY8>OD@2(=43CTD^TB#WEB.5: RT>( MT_RPV5UPR?<=GI=/9I;M6_U;L_6FWJA^?-<]/9"U5IN-\UJC53M_TVI7VK6K M6J/--2^XZN=*XU.MQ=4;7*O=K/[[N7EY7KMI_>]_ET2A^(&K?;VMMW]R?]TV M*K?G]7;M_.\#8LE%\^9-^W.-:]0;->ZJV6A_;G$US*5SKE6[QBPZJ]UP$I_C MR-:*JS3.R0\2%PL#@BTVC<ISU8%JWF%:=1/_ MW>K=#RP#NS+G_[C:G['N/F-DF^I8TW%0]O?)_GP.YAA/ K5%^+<\A-6G!&W^ M>C[A%6)+K>[ <'?M2?3%%]0O5T$MWNT2@=N][B)W&'*SK-RNU5_ MHW4W^/HT?"Y8J 8P!;=+]6YW X)_OOSIG?^TZX:QBF!*^ YN%]PNRZQE@L@= MIDS>VY15O>:L)4MS442_2HTK='MK +; 5T:L8FSP=3.P/4C#3S_Y)^M.'M#I MUE@6)A.ZL0-Q%WLC[@:YJFXB;39/: :URLN7Q]']W>!;\P[LVA$1N0-@Y4&H/H!^%"C30 M2#43K&6"2)#_L530'LGU+WE,'ID,8UJ/MCI:GX"_=GL-W;Z3WC5M"[5V#>") M@PG)KG?2Z.JML<+-VUT/7::'N*88HT%:%CEM4/-6EO_8M=]-%CG!+% MXIJ.QIJ>@35E>4U'9TW/#EVBA[BFH[&F5;"F+*_IZ*QI]= E>HAK.FQK.CE> M-@$I.6-VZ-(\Q#4=H!V=U8KG%G1J6+%1/7!A'N*:#A"@E5YO/!P;JGN$H2?; MRXFG(D;O^@Y,7)15V3*79H1V"%^)9J=L,0?/"6<=O&M2#D@RC)-_,,"J#*VQ MZ1Z09!@G_V" %7-JE KA,$[^P6 +O"%=Y!\,L, ;TD7^P0 +O"%UY!\,ML ; MTD7^P0 +O"%=Y!\,L, ;4D?^P6 +O"%=Y!\,L, ;TD7^P0!KT@-U0))AG/R# M =8YZNL]'4P6->0?#++:EIOJOS M8JC%RU&Y]'SYKQSB\+5_P><#UU5[]W>V-3:U/):K9;_G[+ON7R(OYT2IE!,5 MY>]( W9US1V\YV3Y/W$R^DPU5+.'N#QWCGK>1;B<).0XS$HQ^JGN"<5"K 1O M4:;P!"Z7(0W43Z&./0-QN<0O M9K7VN.7<=535($)7@=Z9HOSH->??SZOGGG MY>*-[CZ/J1JJXS3[WKM6'D%6B9R*[Y->]$+YYK;UJ5UO:2>\>73[,4MO)Q<07R!*>%Y'HO[!)-K#U7WGQ/]R7UO MCH>:Y6JHIP]5XX2;_N#\14S/%%(M\ZD^@BZ"+H(N^NMB;^S@ MD+KS>D^KU< !!?-!XP9>7*T&\$BV(Y_F<5)# ((%!@K A'I44RW+H$)[G01-! M$T$3PP?P0?0SJ,MKH3OQ4CANU12]=X;%;;@M7U[\AXO:,RAJ35D+I M /\ ?X8Y"-@#_ '^"/ M0<8!_@!_],@6\ ?X _PQR$; '^ /\,<@XP!_@#]Z9 OX _P!_AAD(^ /\)?L M%&J^M'#ZJ('(&^$W6UID?&1WR>_T\<$N]J40ZDDO(7:+DD\"+$P8:@#YT8!\Z4EY M!_7R^E-^H&L:PM^&W9&H/W5M@Y<$85$A0"] +T O/+T002] +XY'+R H I ? M/,@#&W\)C#_H!>C%FE[(H!>@%\>C%Q 4 <@/'N2!C;\"QA_T O1B32\*H!>@ M%\>C%Q 4 <@/'N2!C7\1C#_H!>C%FEZ40"] +XY'+W8,-%SJ]EL>K'9A6T,R M9CS/"_C?R4_2OE,-A3VFB&Z8:BC*I9R4Q*#LU+4W^G!#4%Q0W-"*NZR98O1Y MHX>JF3 G$3P6)7YB=N'Y7;4=O=5Z$&VW8Y[]TE2_WC,Q0C).Y M9ZJAFCW$Y;DKU>X-.$G(<81WH.XQJ=(,G^5291&+ ]5&3G/L.JYJDFXZ L61 MKOE"N+, 8=5%0V2Z$_Q6K>'(,O&O3N5)=Q;>=VVC/K)MI'F8G[3^^CVF:JB. MT^Q[[UIY!%DEK7'VIW,'"YUU.2 O9ZUAL7"TV>$Y)/3L4<7Q1R/%^,O].3 M>N<(9H;.J"*62^.3T391#'OKO*=HH&2@9$>G9+VQ@X/:3D73=/)-JG&MZEK= MK*HCW56-X*H7U-&MJ5XI5Y+%G*PD<)J!>A2!^JV'TA*#H?29?RA]+HHOWXV7 MA[ZC0BB]U;G[,G EE%:BA=(\GY,*$AB9(S8R3*E:8H%T %T3Y="!-,^#BH&* M'9V*!0FC@RA>4">WKGAE/E=6"J!\1ZQ\KT%TE<$@NNH?1'\3Y:M1N=H=_^Y# M$+W5L?LR<"6(+D8*HJ62DI-X$8S,$1L9IE0ML2 Z@*Z)A;"^'*L9J!BHV-&I M6) @.HCB!75R:XJG\'Q.@6KK42O?:Q MIA=$XQ>&EKD4]TJ"7>BJ-W?WO'+, M<>\:9U8"VJ!C[C8$M 4QI\A"3DEBF!8H/3-*SY0>A?.X.Q1)+(6.5BF0+^ /\ ?XR9V,Z/4#QC?Q- MED%>1QFG.\X8::0][#WH*@UZ +H*^ /\,F0+^ /\ M ?X89"/@#_ '^&.0<8 _P!\]L@7\ ?X ?PRR$? '^ /\,<@XP!_@CQ[9 OX M?X"_S-GH=]DX+Z]>+%[WNF?.Q[9NWEWCAUO:-]48(_S-WBM.Y\66?VAUQ1B( MSWJB%XU'G#ST@1NI&AF]FR>\G?$E/@Y756< ^DV#[L2NWWG65!N@=RC06WI2 MWD&]O/Z4'^B:AO"W89,MZD]=V^ E65B$*: 5T$HU6D5 *Z U:[2"6P?HT6XH M)3"4@%9FT"H#6@&M6:,5W#I CW9#J8"A!+0R@]8"H/48T?IZ&^3%[JK0Y%;! MU[)0HO=#MK^>C1[%'U\DYWY^/R2IOS!Z.60@CBY?AG)A6\/)92ARGASX]4Q.?1=S"50+5"MHU:M M/6ZQ:?%M MW3Q?V*17M-]CQR6;:Z=M;?"EWU7;5DUW(J'.RSTR;^J/1;=5$!)MXV1E>-R4 M/0XW&MN]@>I,1LAQ/6CS/%1S!H4C@![E<9\"%79 *SMHA3(GH#5SM();!^C1 M;BBAP@YH90>M14 KH#5KM();!^C1;BA+8"@!K#0#)]>>1?H)P[1H"GRL4%.:[-4#G#D;G@GH(F&\":,T> MK5EXB!7;+QVY[??MU)/V[-3S3EV=D18TR[2O$[+6\P^ MYP;]&>N.[B),XH/>0Y.6RQO4L^Y,[\F=%[EQWOWQ:+;0BT;WN,8D)773NG6X M.X)MI'&N19#MC V7]/MY!+L#U>4&Z@/""W;P>\!"'J2%A&0#0(_V4!)ZJ "M M[* 5&ED K9FC%=PZ0(]V0PD]5(!6=M *C2R ULS1"FX=H$>[H80>*D K,V@M M0B,+H#5SM();!^C1;BCA=B5 :_9HC=S/$6,C07+]@L6@HVG7>D840G$H>A%G8Q#H!>@%Y7H!01& _.!!'MCXQ]EG!WH!>G$H>A%G6Q7H M!>@%Y7H!01& _.!!'M3XE^+L4@2] +TX%+V(LRD-] +T@G*]@* (0'[P( ]L M_..<, =Z 7IQ*'H19R,EZ 7H!>5Z\=?VGLVE;K\]6_9OD*OJ)M)JJFUB-#E^ MO?JE/1HN'F0+^ /\ ?X89"/@ M#_"7[)Q$J=+ID78JOL@+G8[W4UGB%V8G>M,K!Y:A(=NI_1GK[G-';W5>1H6S M+Z4?LO&++S,R0S%.YIZIAFKV$)?GOHQ-Q$E\CB.L VV/29-F\"R7RHM0)(-6 MG>;8=5S5),UT!(DC7?-%<&#<%4HYS MO+6%4*4,A^.NR6.Y9[."F>338NW+G-F+6QBXW.I9+@5L]:PW+A9Z/"8?2K!"-SQ$:&*55++(C>K6M260CKR[&:@8J!BAV=B@4) MHH,H7OA;JGD^IT"U]:B5[S6(+J471.,7AI:Y'/<.Y8=/J"CUGGX?<]R[QIF5 M@#;HE+L- 6T1*[PLY!0!RD_'K/1,Z5$XC[M=D:2R%#I:G>@0Z _HSR'KSX:H MU%>70M]U7Q1S4K&04\HRJ!.H$R7JM&,>:DA]"C+#N!Q]4FJ)SQ7Y0JY49"QK M&75B,2@3G=,-WINXZ-^C/6'=T%V$2'_0>NL:46MH- MZEEWIO?DSHMZ7;J1W-MZJZ8R,H4X6:'=M&X=[LY63E0WJ8&1P,(#6S-'* MGH-9<1U[3.L[3-?AVWIXOM!ZV$!NW>Q90W1I.4[GI=%[=,^1<6_?)]L8&'%@ MV3H?/W C52,SO/.3+\5/63.XD9B+&<49F$<>R1A4G#M W,A#:610)$SZ;IO8 MM6P-V?/O/S.PP @5G&,9NC9Y))7X3GH)%&8W?,#"A*L"D!\-R .'N7&VAX%> M@%X@%Z0;E>0% $(#]XD @%X??H [D64Q^IW(A4(Q5R@GT&Z9NO9& MO249%!<4-X+BKFCF'A@W)U$J=7JDLXHO\D*GX_U4EOB%V8G> M],J!96C(=FI_QKK[W-%KG1?7['[MUYW>YVN![AF*JRU8XELEWE[#,]50S1[B M\O@=(]=K'>4D/N=13/@9>Q-9["L(V2WIT<%IUKAK(+H;)F=H+Y=JB\@F8K_'5 W5<9I][UTKCR"K1$[%]TDO/QPL$_731:G<.^% MVDX2EU_*XWC71+;<,%K!?/3I[_;EW^S%+3Q>[C.5R@'[3.N-BX4&TPG))Z=B MCB\*.9XO)M]EZ@F6"2<-IBWX4OYGGS9P%G5[+=!(4;G%4M@AVIY>@TZ#3H-. M)ZO3O;&#F;'I4I7@FA[4C:]I>BE7DL6#XG%20P;((Q)=>06Y,D M[O8!C0:-!HW>=V,21,^#NO!U/2_SN;)2 %T'74]B6U)A<%M2]=^6M$8E\TF\ MM3V9;PZ6U+\ M#RUS:29Q]:]R7A//B M4W4 .XFMQFF->2M;A*"#-3=L$8K8R,A"3A&@+ N&!H**^(**'7HKR:'C_XG* M@KJ"NH*ZQJ:N&^)\7]7=8Y;ULNH6Q5Q)+.24L@S:"]I[G-J[8YYU2/4-,H-> MBC[INB3DI**<4PJ'D52/?Q ]Z.XAZVZF0+^-L\A5[P3FK) MO# ]J27S$O[;]BGTK"3C5.>6 Y&!D*C0RX]]#W M H2^[221X>&@7:!=]&I73(.\E? #^Y,:Y UZ1Z'>[0J=+Q@,G3?,W:[>G0D_ MBW?W;OD.0N>HDW<+02?OICQ4&XP,A48&G'M8-5-"W\>1R(!KT"[0+GJU*Z9A MTTKHH?*)#9L&O:-0[W:%SG)ZH;//;.A?I1]M\8J_>_FD'G.TNV. ;"'H -E- M86PQ5RK+.2PV4/JC4/IC=+8[=$@)?3G#5'U =4!U#E1U]AB(K(2>95Z4U"G$H$?4Z5&< M:K2B)WL,\5X=%"P5E)P@LN]J8"(P6(QL& \*UD7NYF'[G.R%IX2TH[M]I!T]Q>6 M0 *4"(E(PH[Y];>J]M8$PL88C(1KK=.GW39(>WAJV%5/U6;\I6=O&7^O2 =Z M80_?S:X*,.\,OX8?XR_#"XCXX_QQ_C+X,(Q_AA_ MZ=E;QA_CC_&W]65,NC*\4)N]'KQ-[)GCB6-8@TMXN*U]5EWX^CH/_:&,50T[[N[C,OM+M+[%/E+=(8MZ&L1H[:*^GS4I M9^CM"O1B3]IW]=Z^\6M_:&B:#F\#[5TR?G4=LU"IU:(P9;0R6E.-UCJCE=&Z M;;2R66?HI5U1-EA1,EHS@]8FHY71NFVTLEEGZ*5<4=8+K"@9K9E!:Y'1^A;1 MNN#^].0$D;A,,,P0;?1:R%JA.FCW_OQZ6^T'UT)B_B6C=T(NM:+Q>U%.'7N$ M:[I?*,+_Q$_E9UQW5Z^_Z,K(4AX>@O]D_@(55A [8\Y6$;)X7GO-,K;R%.&=T4,V9^6O3\U>\?+CZ._-LCE?W#ANLQ1. M?T%87>VDNN+$$$,O[7X=9] 9K9E!:X/3F(S6K:.5S3I#+^V*DC/HC-;LH+7$ M:&6T;ANM;-89>FE7E&56E(S6S*"5V#C+CF,UNVC];6- MPXS:;ZRN]BN-[*O]1*KG<>0@W]*^3UP/#][NC;W GGY3'4>U/+$AG>GYGX72 M?>WRG\%5)3/-.S>Y[')Y7&4\<7I#U147!RL][NBYJTJ-DTL,O91[?TW.PC-: MLX-63H4R6K>.5C;K#+VT*TK.PC-:LX/6*J.5T;IMM+)99^BE75'R_1N,UNR@ ME3.+C-:MHY7-.D,O[8J2[]]@M&X?K8]2,)Y- -@<1Z_9Y(ZG+'([(7++&8AJ M@5N@,%JWC]9M&(B8ZJ\6BF];]2?R],K/Y.E1#=8A$M"P?$ZW7!4_=*6[GF/T M/%TCMN4MK)Y[I?^<&*[AZ9);*6B75WK/'ECTY,[T]/K,U-U6H_QCLRR_%S=U MW.1.75W?NLH H:UKBF MVCU)9E Q6K.#5J:Q,%JWCE8VZPR]M"M*9E Q6K.#5J:Q,%JWCE8VZPR]M"M* M9E Q6K.#5J:Q,%JWCE8VZPR]M"M*OG^)T;I]M+Z8SK%&(L'&V(+5XK*-:N/UNP9F!G347KKIB.1;]B(\ W/=:]M M]>R1?F:[;F?Z3_MGNSCZ?#CMU3+;\R^\_UF\'YXRIWM?M,ZP9HH)RT5#QA: MWE!7Q@38%^-CPT-_6CUV;4?3G>#]AR;L'8Y"<6W3T,0C4PGU34\AA8&.!+!D MPFHQR-\,R)?V>-?)%&.Y8+G8%;E8)S&(Y8+E(N5RP4X1@WSG0;ZT\E\GSX[E M@N5B5^1BG;0JE@N6BY3+!3M%#/*=!_G2RG^=+$66"Y:+79&+=9+26"Y8+E(N M%^P4,R9E_TKW M5,/2M1/5L0!-;A)7O_0,PJ4+*P"R.\N\K%8;^6JYN7[FY:M+[WL67!;<[0GN MC&2663(72&:$([U!QO,+^Y^FSJW@HHUT%FUL8(RI7$;&'^./\9?!A6/\,?[2 ML[>,/\8?XR^#R\CX8_PQ_C*X<(P_QE]Z]I;QQ_AC_&5P&1E_C#_&7P87CO'' M^$O/WC+^&'^,OPPN(^./\;?9/HGEPTX/Z52%2J'8Z=!/M7(ATCN1NE<.;5/3 M'??DY\3P'CK&=6?Z5Z'XY]F)UKH^RT@+Q76N[:%JJE9/5_:5+ZK3&RKE8E[! MI6-I7Y,D^?!L-II1*&*C5?=BXKF>:B&9#I$X-K1$!'1#5L%\S?I,4>FZKH7??K4S"-PEKK;2GS2U/KSUXG^ MX%5;M=Z>XAD>KIU$4EYQ:6XKR-(6F^/.[4>K;/3R,<3S'DO0^E?*%>S!<*]'7U':2M55>TR3 MH+&0L9"].2'K35QP:A== K*\Z"UKZ.9$KY%O5$KY2K7!XO>&Q2]TI5L9=*4/ MDUWI3V>:ZOUI:>V_V9-^U+8GKM^,)]UXF2==*.3+M3+KF#>L8S(E:AOSHY>0 MM5)]93]Z!^YI81%C$=N$%[V,X"UKY.8%KUG(-ZLU%KXW+'RA#UW.H ]]E.Q# MU_ZTC!OC5_>D6V8G^E'#GKB %^F7??,M^[]S*S#BTRS:Y6^#0PJFY4"[G&S46^K;+ MA7J^N@/L&&X?S+IB=W1%-LOW&'^,OVPM(^./\0'O8[RVH:Y(!EE?''^,O@,C+^&'^, MOPPN'../\9>>O67\,?X8?QE<1L8?XX_QE\&%8_PQ_M*SMXP_QA_C+X/+R/AC M_#'^,KAPC#_&7WKVEO''^&/\;7T9DZX:+]1FKQ5O$WOF>.(8UN 2'FYK7U5S MHL.;Z2]N9_KGMV+OQ-9_==7>1N\9?V'GH3^4L:IAZ]U]7%M_7=:WPD>J.V3Y M3H/LK%V^][,FV@R]78%>[$G[KM[;-W[M#PU-T^%MH+)+QJ^N8Q:JE4H4IHQ6 M1FNJT5IEM#):MXU6-NL,O;0KRAHK2D9K9M!:9[0R6K>-5C;K#+VT*\H&*TI& M:V;0VF2TOD6TAK=!EI[."HE;!<.TT$;OA]3/K$/[M/E/Z4<]N!\2\R\9O1QR MJ16-7X9RZM@C<1D*_*\H?JKMP_HN>>5=M?JBNR.+Q3P\!?_)_+4IK"%VQIZM M(F7Q;/::A6SERYB%?+%LL6R]6=EZQIV3U97O;ZTURRQH+&AI$K0E#V75$A_* M&*U;1^MKF849A?^,NU%G+ADN5'9"X2>2-YM+DC?%KT]M!UYX9_20Q'D_Z X> M2A^OU6ICHR3.=;:.VRR?TU\;UEP[J;DX2\302[N+Q^ET1FMVT,HY34;KUM'* M9IVAEW9%R>ET1FMFT%HK,%H9K=M&*YMUAE[:%661%26C-3-HY?3AFT1KR.EL M+5"0>;%K25*0FE$LL7R]>;EZ]G\#UKE55EK9ROEQHL;BQN:1&W M98]KW#"'T;I]M+ZV<9A1^[47J/WJCG(^ZQV]-W$]>_0XY1.K(TW==4]^Z4[/ MF;NO[9[58?M"_--]Z T]<(D67:Z38?>5>KA)KM)W4:)Q7 M8NBEW/6KT9H=M'(6E-&Z=;2R66?HI5U1<@*>T9H=M)89K8S6;:.5S3I# M+^V*LL**DM&:&;1R6O%-HC5D@3:>3!\)*N C^:.-LD&;U[6;[V?JC[.'>*?/ MA8F:;%%$KXX_GCW.#UV\\.OEKS66[:&VH"%H+5\K5?*U(I/9WK)BR;K,/9$K M7Z_(U5?F,Y"T55G26-)2(FGOMBUJSV"/UNO+BYT+RP4>]"[(WWL6O9T4O:7/ M>MR?A]&:';1FN$E*(D_S.%)NV=*^PYD;#\3NC;W AEW*CU> L.:,U.VCE M5"6C=>MH9;/.T$N[HN0L.:,U.VBM,5H9K=M&*YMUAE[:%25?K\%HS0Y:.7W' M:-TZ6MFL,_32KB@SG#EFM.X,6A]ME?5L L#FV'#-E>^HK^[$1:HL?BUZ8 H:_)7>LP<6/;DS+7RYFOY9[OXX*V[V%NX7 M=V+.5C;K#+VT*TIF4#%:LX-6IK$P6K>.5C;K#+VT M*TIF4#%:LX-6IK$P6K>.5C;K#+UT*\I:@>]'8K1N'ZTOIG.LD4BP,;9@K;!L ME]@YRDBCEB_MP!V<++$[(['+VA>^J(?1NGVT9L^^S%B.\ANW'(ELPT:$;7BN M>VVK9X_T,]MU.].SJZ_=KXVJ-KW7,]OQ+[RR6;P?GC*G>E^TSK!FB@G+14/& M!H#>4%?&A-<7XV/#0W]:.W9M1].=X/V')NP=CD)Q;=/0Q"-3"?5-3R&%88X$ ML&3":#'(WPS(EW9XU\D38[E@N=@5N5@G+8CE@N4BY7+!3A&#?.=!OK3R7R?+ MCN6"Y6)7Y&*=I"J6"Y:+E,L%.T4,\IT'^=+*?YT<198+EHL=D8OB.BEI+!?GJTON>!9<%=WN".R.9 M%9;,!9(9X4AOD/'\PNZGJ7,KN&8CG34;&QAC*I>1\,/\8?XR^#R\CX8_QMMD]B^;#30SI5H5XH=CKT4[-.<=V9?K^]'-2:D]'#N)J1'HKK7-Q#U52MGJ[L*Y\GEJZ4"WD%EXZE M?4V2Y,.SV2A%H8A]5MV+B>=ZJH5D.D3BV- 2$=R)(%CU=.S@*N"+/5IM"QNZ MMGX9;N1SEX[>UQU']FL5S-^DQQR9JNM>].E3,X_ 6>IN*_%)TW/G2_7OUH_S MTJ"[IWB&AVLG@9177)K;"J*TQ=ZX<_L1YVRV8)$2*-:)B^/_\9$%C%,]2_4E MJ9[M\],(QU,,>>]#*5^H%_.%0CWSS6]9S>R*4_&$L,W9X5>4MF)MU1;3)&@L M9"QD;T[(>A,7?-I%5X L+WK+&KKY[N[Y1J6TF6*&U*.(Q6_>E3[,H"M]F.Q* M/_S9NS"^W!R.SVKL2C]JW!,7<,:5;K[,E2X4\N5:F97,&U8RF1*UC3G22\A: ML;&R(UW(_D4M+&(L8IMPHY<1O&6-W+S@-0OY9K7&PO>&A2]THD\SZ$0?)3O1 M'XN'S=O*/X?3"XV=Z$<->^("QO5+>=GK.Y.=Z'*CFB\72JQDWK"2R92H;M:N.[S1=JQ7RMQ.:(Q2DMXO1$/]05 MY6F9'L:EEW=*;93SU6(I7Z]GC%_TTH[%+$SI%*9URM*,L%17M3I@< KE?+&0 M?:.36#O46*UVJ- X+>E_?:W^^7=IA8.V9KAC4X59P7+J.U-*Q$II[5&F2@93 MM0M*APKVM*)?_!J:+>8[OKB8H;)L,0.7#K&:>7N^SYJEK;RR\\2E0RQD;U/( MUE0Z5%ZY:H]+AUC\=K1TR#Z\J]C#5N7^D%WI%YPMBMB:2H?*J]?L<>G0FQ>^T(FN9M")7E Z]&UZU3Y6V]I]DTN' M7ES.4%VVG(%+AUC)L(5_69G>RF7 7#K$(O8616Q-I4.5E6OVN'2(A2]THEM; M+1WZYZ_IY\N*VNA=E]^RW_M$Q4-UV8H'+AUBH7_3%O<)0:JL7&_+I4,L/V] M?IY1.E19N0R/2X=8G%(G3MLK':H\HP:/2X=8F#(@3)LK':H\H\YNITN'L'#H MV0-=OK;GV]#P]'04]+#9W6%-D\OX8_PQ_C*XC(P_QA_C+X,+Q_AC_*5G M;QE_C#_&W]:7,=(\>(,\OX8_PQ_K:^C$D7C1?F+A5O$WOF>.(8UN 2 M'FYK7U5SHL.;Z2]N9_JM_= O7MX4BWA]RP991R_L//2',E8U;+R[CVOKK\OZ M5OA(=82%'2W)"Q._/K4=>.&=T4-^6/?X?C+X6/BS?ZEOE!^VSJY4FZ6* M^6O#2F(GE02?5!EZ:;=/3,!AM&8'K43,!AM&8'K43,!AM&8&K75F0;Q)M/K)HF9CB631]5!U='<^6S0VM$ZO M5"A5"O5"L=.AGYKE0J<3>:#JZ2/=\DY^3@SOX<@>C6T+_M-M_3+E,_QQ\.RZ=>'>-'\,]Q3,\7 C_S7G%I2&MD*+:K-09OWZW;.O4 M47N>85N*I8[@D7*6OS]O=?>4'CP>1GNE]_^W=^K8(US?_4)]OU 4/S7W8:WE MPSMS*[A'>WP*(RD40,YK>S!<9Z1Z_]LS?GF_6Y.19GN:WC-&JKFGR!_<_^VU MST_WE(EEB->*L>U]*-4;^5JU]-_?XA-DE?&&5,8.B%IRUGO-DE9<4M(*$3F[ MO3Y&(6NR@+& O7D!:VF:@:]4S4O5T-K6D3HV/-5,%+;2JL)6K>8;C0K+&\M; M6N1MV1-;AMEJC-:=0>MK6X<9O5]96>_7\L5:.?-Z/Y'W>=S1>Q/7LT>/TSZQ M^9VIN^[)+]WI&:Y^T?^F.HX*I_+.='#>^'&LG=]6/O?>>G] 7")%EVNDV'WE M7JX2J[2=5&F<6V+HI=WWXR0\HS4[:.5,**-UZVAEL\[02[FB;' 2GM&:';1R M*P)&Z];1RF:=H9=V1H[1\W2-/M6"XZSVT;%=MS,U M[DNUD7WF_?RWGN'VG)O=CJ^P?+I&X[VZOF6VYFYJ$<[_,/12;L":G"AGM&8' MK9RM9+1N':ULUAEZ:5>4G"AGM&8'K15&*Z-UVVAEL\[02[NBY%LV&*W902NG M\MXD6D.V9GW9OIV+TTD;96O^6_SZI?S-=3^>=@.VIDC-4%HF6]S,I5IX+ESH MM;+%ZH5E>YXELS.KA4(>'I,MY@IKD5VV>2OWDGH=B:LUZRMWFV)!8T%+C: M MX&>^IJ0]@Z'9;+R8H9DY\6.&YFY*WM+'.FZ9PVC-"EKKA0SW+4ED:#Y= 4G& ML*5]AT_AL?C4=L29-LD^=J;WO8$[N+TLG;5_I+N;YB87/UPM-.FFW7)P59[1F!ZVFE7E)P59[1F!ZT9+G!EM.X* M6MFL,_32KBCYV@M&:W;0RCF\-XG6D)IYN&0CS67S2!OE:7Z=_NU^/"]=&'BQZ*W?=%+E>0M3_*L%XNK4JLS*'SL<.^R!"YY/"QRGQU& M:W;0FN%F)XD4STJD;#*T?NZ-O?BTNMA=F]DKOV0.+GMR9%KN'WL6OJU+CJI&9]IV;W#2,*"@#[/2M:XIG MHY?A3DP/.W_3@+VAZBE#]4Z7(0A61CNIC#@%Q=!+NQWD7#VC-3MHY80IHW7K M:&6SSM!+NZ+D7#VC-3-H+66XWI;1NBMH9;/.T$N[HN2;-QBMV4$K9P09K5M' M*YMUAE[:%66&D]&,UIU!ZZ--%%^94[ Y9EYIY4OIR[5B]CCI++*[++++&AAN MM,)HW3Y:LV=@9DQ'[:V;CB?O_S[7O;;5LT?Z&=WK7;MO-J;&RDII#"ZD0"63)@J!OF; ?G2;NXZZ6$L%RP7NR(7ZV0# ML5RP7*1<+M@I8I#O/,B75?[E=9+K6"Y8+G9%+M;)I6*Y8+E(N5RP4\0@WWF0 M+ZW\UTE-9+E@N=@5N5@G$XWE@N4BY7+!3A&#?.=!OK3RK[#R9[E@N9B3BW6R M)UDN6"Y2+A<+VEW[1,T8Q>^9//TKW5,-2]=.5,<"-+E)!/WR,UB6"QI8-TK5 M?*E67C_=\M6E]Z5]K5EP67!?(+@SDEEGR5P@F1%B] 9ISNOK?YHZ#X.+-M)9 MM+&!,:9R&1E_C#_&7P87CO''^$O/WC+^&'^,OPPN(^./\KF&AZJI6CU=V8=/C#VBCBKE0IY&C.NY=A+9VF>P(EN2QJ%H]J1K MZNDF3/IH;S:B%Y)3WU;W8N*YGFKA"B.PQX:6*!"=B$"HL,NZY0EIP)ZOMH4- M8EN_##?RN4M'[^N.(_N_"DYQTF..3-5U+_KTJ9E'X"QUMY7XI.EQY?BA6?4^ MEH[Z>XIG>+AV$HMYQ:6Y[6U\_UZY'>_:?O\-$(P%4/>^U#*%^K%/#QG\RQ3VMA,&&E6;1=F> M4;C+S56;:)-Q,7%F/1I2I+2WIE63,^)^F-?*-2RE>J#99V MEO9-'$Z.,W@X.4P^G%Q<%CSKLWWE5,I\.'FI_Y*XQC.'D]++#B>%0K[\&@5P MK-AV4;&Q&[-!T:X45SZ:;.)N'Y9HEFB6Z.<>3):1\V5-^+R<-POY9K7&LLZR MOHEC22F#QY*CY&-)^_+G_>>3ZYIS6>1CR4M]E\0UGCF6+'NM;?*QI-RHYLN% M$BLV5FSLQ+SFL60)T<; SHK7CC:J+-$LT2S1VS^6+"/G*]],7RT4\E7F.["L M;^984GB]8PG\861;L9/$/U/5O'#;E^I/9E\]KISF%F_FB+!L8\WD(T*E6,]7 MFZ5\O<#9"U8T[%2LSZEX0FXKU57] B&R+*XLKBRNZQ/7!7Y^HN@^HY=U7'3K MU7REWLR7ZYQL8.E]H]+[1#_K%<5WF1[TE35TNJ[DR^5&OE#9#&+9:7&ULM/3EENI=J_+MCM8H>Q4,]RQ MJ<*L8)7UG:Q"97V8H@CE:0:)$PN*3<_.ST;=GR>3ATF7PYVO4(]66[8>C8M- M6;6QJY0K^XI<;,HRS3*=$O+$,I*^'WW\V^##R2M4I-67K4CC8E-6;.S&I.9HLH1HUU;NCL'%IBS1+-&I M.)@L(^>K%Y5SL2G+^N:.)8T,'DL6%)N.)[^_F-CR6O49%67[8BC8M- M6;&Q$Y.:8\D2HEU;N3<&%YNR1+-$I^)8LHR_ MK?:I93[4W1J?)%Y2M%9?MFB-BTU9T;!3D9IBT]K*32BXV)3%E<5UB\6FM97K MQ+G8E*7WK4OO]HI-:\\H$N=B4Y9=EMU-6MX9V7Q&(?A;+#:%_UH,#!@M?C3X)SZ1[Q/7,_H/,)??QA\V_0Y_EN,7S6??L\?TON 7_D85 M9K>IIP,,G75NU,U0SZF]GCV"!SX 2!3+]N !JJ,K\ 8#7C=P5!,@Y'B*W5>\ MH>[J@%QU FZFKJ%<:+KEPD]]PU*MG@&?=?UPFGL0 .!E*[3DCF\*O3CXW'__ MG_U]Y=303>UWY5(=@#*[UG].=*L'WZHJ^_M2GVO&W:/ZL @3<&W3T.8VNT:: MB<0#]MDTI=22JL#_AL'T_/^.OZ%GFZ8Z=F$@_D]_*/>&Y@UQ/H7_)"E S_&? M,5MJ#6!,5 VAXID'9.QU\-G(4OF+](=R\S"&][<6*A3RWTQY%)4PL< #""+2BDAQ] M>'1(.%3:YO7A>,.0766<27N[A)9:JW'NRH>A7?W1*12J>[X)_-K^>G&=:Y\? M_?>W[H<=F>O1Q?GQR?GUR7'N^J9U<_+EY/SF6KDX58Y:UY^4T[.+;]?*N]OS MUNUQ^^;D^/T.3?STXBIW\^E$.6^?GRA?+LYO/ETK)[ 6Q\KUR24LQ.')%=[6 M33=U*ZWS8_RAO);Y+S?7F<=O?]>QU,$/L[4YEWB8E2'1@]G,&3:^W M* 5G: MX<,M2$W;NACKCNK!VUIP4+LS/*P\[;H>GMLZQF%G:DY_?&JWF^-"_?O>X^A. MZFSC#+KO2H5*OE1NY$O5ZOOD)C>/+)-PW ([HIQ>77Q1+BY/KF[:YQ^5UM%- M^VL;C,JUOX2)6YT@;.*YR:A*.+8__<&D!Z9H,(GP*,?AT;;@"*6?V:[;,0#_ M(_7\Z/+P=EINE3M3K]'V57_"P"FVM$10*>%II?\DQHR>B-+&=BX>Y3EU M[)&(\A3A?YZ]*.+3>$9=UH)H;#'?:-3SI5I2F5;BMA23MR5I0=_SSB[8V;+8 M6?%3PKX^HPYG\;X6&_EJN;*Y?4W43=$"\I:&\1'R[6[L*QW6H6>8>FQU;NQG M&[="$KI[ MX1R9JC%".UD".]FZN3IO3XWS<6=ZYWVI3OIM>_"]NSX[^12(2@0B07*![\"P M\^)? !$455=1+4VYE_- C:"X$&21Q5Q@4K@ O5N;KH7GQO7SL_:^DS6EHZQ'"VZQ'*XV_58EEC/U91T\QE$Q@5'M5*^D-@E)17PWM"Z M/J6M7TXS*Z]A59\,SL[/_]+1QZJA',IJJ[RB/*_>L;^0+Y>2 M&C,^A;CW*1/AE1?W*:%^AC^[4*B;S23>]XN%NK24\;U4'U"CP5+ ;QQP2L]" MGP>%.GYDTFK-BMUUNMU#_95-\9.A]\ ^C\6,2.!5,:= "RR1WGI1R'992#_G M.:LJE&5V>"6%TBBL(9;;K.6+C:CHY.IH^M7PP-9$[$O]N%]M7Q7^'%[U M7C7XN8"X*Y7RQM#;/*\M>]&:W\RFS\8P( MRZ(2TE(SWV@\'0A8F<_"IB,5IN/D:=-Q*DJ_%O)@KXQ6K_1/M?7G6'OM+%E8 M1$'LU]/V>>O\**2_,OMU-5#4(Z -/1T77-1\USIINKIVJ7J> _'>M>+D6&' MGXX[T\%?AWKE^]&_/V[4+>;&_#$K?1BTX@YMQ]OW=&<$I],[9-7(/SAB.E3] M^) .5DJC6%Z5E;*EX/9C^%C%=A57/MH6"YO*1QTOD(> I>5<'^/:5Y5F[N4*L6\K7:T_RE=46<3U=RVN1YWPL54_3L/[WZ]]?%Y/C3\-OW M_K;*F9928:5"+!PPEA-7N@]^DX)="0FL=(1,V/@5E=GJW$A69J^WCT\HM=+* MI,Q:[364VDN]H?2>K%(UF">YL0A!_ ?-YQT84N*7^41A_$/+TN*_B'SR4G<, M6YM/#??,"4+CY%>/Z*Q7<#@XZ?=UC!O<=,;CPK@ YBAB@MKZ;>/[>?7HRTI\ MVS55U)Z?W"COCD^.KDY:UR?OE?8Y]6K8+CWK=7=G-7M1>D:^WH4-U1]E(6&: MT^G]RGXJU9KY42FHSN.0^L2E(A2FHKLL4!& ]-MRQ M[:KF1]BR,7P#_ANQ:E@379-I#MN",\FU- 33_NF_=L7\,3BNKT+.74GY)_J0 M%%3>5PY//K;/SS&6?'&J7)Y?Z"H M9G.2>&U J;$1-A@C8?U(*"4BX3FU"@N14"_4\@4^T.RP%2MNS8J==*:G7UNM MF]KE]>7DU>)G"]H:2PMVX]Q8GVYJQY7^_2\\S6\K4D9VYK+5/E:. M;Z_PI(3]/H6Y44XOKGY/X2:D:C!/(J*-C1!!9^%=+^>ZH-M,O_2;M^?JW>FG M[BHU;RN3":162:(3^,/TR]HR;F:69.J4*XN9.F_++B^[8-4U+QBS2=.FO [C M-;[V2+]1?^EN3']]_=C^Z\+Y?M'0UEA7\$+]A2-5/!SJ&Q'%1WI?L>Y*6K#& MAG17<&'*;ER9DKH;#YZ[0(_?!%+CFT!>>A-()3,W@61:5EY-6C;SEO7?A#1W M[TAM_MZ1@S7>/_'ZTSN_N#FYSMU<*,&=(WY!3.M,"6\?R?0.D9-[4ST>."Q G^-!T@/5==P+_J7<%+'$!.% ME"SM&N9H],$N6)YLY &FYQ+L5L_0W1L8PZ%I]WZ0.O7=_$8L1O&2QW:F3N5' M\V2J3^Y:8>U8VK6M%+5<\7&ZIVN='7=4L;8'> JIO+PRGCA8 MZ^#E/!MOZE.PN?V!%'[YMZ#U;3C+6I@5&IL+AR>/;8L'#*L(J "G %\3-YNC#1 MTGNZZZK. XYF+/2=TE<-!V8)7\W!;R:FV'D[2!7YVR%WG%HJXW^/B>KG/T;7 M#I0;W-'$1_C?L0Q+5T8 S*&KZ!;6/%SCTN(5PL%56C34G&5[P7 ![3 Y#72Q M9\!BR_'X;\+)PTP?8!,H?(O),7HA#7;BP7[[8Y6CZ!M(L5 >=-7!4>#&'\.K MQ"B*\D(OV*&<"]@U-7PP^.NT_[!!WR>6R-XAMJ,K@P@LUO]PE99E3>#Y5_K8 MQDLI+>44< A"N/]GL!#^NV&HLZ\NYV& II0=VA9 -S[EB^H ?HH-,< =NKIR M_:Y#:2_:+_IPX@+N7/?B#GM#Z_=DQ1\6N :59M@&_8DO=J:5Z^*@6_[S^P^W ME"7C/V/T:^7.U!V9[6OCY$PK-,#HRWGG_(F_LC'/1#!F:S;<5\3W*G;7[MD. MJ!FJ I_ 6X5Z,=5[4L''.OR$FA_41Z!G4,,4FTU0<:YRK=YAL. +&D"TF=>H MLES0:.*A41L+1O_ZR_51U.(?Y"ZLB :OH68JP/]'S84PVJ \X;$HDVAZ6J*( M75.^Z*C53:7MVAZ8B^A[\Z*_;'3+RT(PE <3-&]1H_GH(2^FV@D=TC'9G;&B=7GC#WG Z M_'PS:%JV 2K),SS<\)F[.^@AD8$\20M9/(#EJ3R596O2V^>G$1Z'>.'>AV:5 M*M,7U,213/D3@^6,E6/[\)&K0//P\9-7_L_LTE>3E_Y2=2X<\KBTKZHYT2]U MA\:&6Q!9_N/>Z?C'Y/ROCV?U!ODSEG]9^F=\^6^OCR_] M+2@<% I)50JT^+E@6NCJB*T0 C2[OO'&&+)[[T)T1Y;V1^NO6T/31L?G@V!I M@P>L#.['A_",!5Z6JI:,[])SX#V.SSI >+@:3X&\M' 3EL3YMZG7NOKG^Y^] M0G/Q9BP-]>6&L/QF5)>MV%P1[4H"VE_3'=ZTD=^YR,/%Q,G)HS48W+&I]N@4 MUY5NIF*X"OC3Y,/ 6:Y8*!>4<_!#AG"4QZB. I#\<:\^Y)4_=6 MTFR6R[4#!9X.XS?U\="&TR6 #9T%>.2[:J'Y7BF52OOP3XD^EPN\)>5>[[IP MCH=SM.;(,0P];_S[;[_=W]\?.*IFV /=/ !;)MX0M5_XX=X$),;RX&CZL''M=^Z)Z8;.B9N0^CKFWFI,K X\F!5!0[M-\[!^"HVPU[ MKRJ(#^$>VQ;R.@8/RDCZLIJ.]P\I,LX&A_R!.@B#1_!7W;3'=,,UB !ZQ0^> MYQB3T7ZSH'15C/UT0=\-'["/OCI^D,_+*U<(R8^Z^5]W,D8/O-(HX1+#?^1S M?EC!# M97![!OP5?R8? J8 ']<=^ ME;;NV]+4I0H&<3D\?&#UT0CR+/F;X;&2P-+A* ML"SR:V#8<:%!ZZ >[E L>^$) #YF8M@E*<0274:]W\=#2\S9]S^8 ML^\HBJ?<&10P-.BVQ8%I=RFTIX_&]CU(YGCXX!H]0\5W^ON(2X<1%YH0#1%& M1>&V[H/LV8$3A-&-Q$* 9H+GBX.,I_>&%N("YX<1JIS=[Z.M4ONBC[Y.U:\8 MS@KV3(3)>G@R%\VA#GD>%J<(M_*K#3X:%?Z<#+@8] M+QU;F_0\YT$K M&:1.9N(.I\>M6*+A\;7.@9!C^-@T1A2H!X&7\\57S2Q''KP0#_0?W6,31)$] M$9J%;ZK*"*/V7<=6T82/[;&,V>/2WH4O%V(;57TY5#LPPI'M2AZ-5,%T)1IM M$RSV-S]H'8EIXZ,I5S"S@'2!F@K++;N4/1< NT;8LG _J8-@N1;-UL0N4'X$C MTXCF18*=@VF]#9(76W<_K[$+VLG/37 :R!5X%W,X\ XIK$W&*7 M*Q ] 6L\N+A^=G1.D,17I/8BB*+(@1<1P!T]#\R)JG>VH5'B"L[:_0FY+%W= MN\?THM3L"+3A!*;IZ_AXD%,U,54E@IV@2362.P2YIXNCOR_.2PTVAX&"@X6J M -QL\*6ED/A!"]3JS MGX1/>9YT8T<&-V9Y<[C)[M#H>S*^#D[T2&CVWH07_CDOSQA;MS;9L3D0+6#.&"[U+>\K=8XO+#VO.8U=(L!>H*-M.:Z/BX M(W@\!L:^@4DZHH2E[CR>V8Q>2OB\!W6FC?+5W3]:_Q_/:F8YTWG4F?XS_-R; MG#\4C9,ZN/*$VUP 4TYTILY:1V(O@0H7VZ;,:Q=*BNHN1CP,=RC"+E]4.J?5 M4"$*S2A-?\3;#*,XI!WS)':F'[V17F\NB%K$3;E8XTZBBX0P O_)P -(Y)P?(]FST\,O"L GR<& M06;QAAYZ>7*S#S_"'@Y".YNTEAB-ZTGU*\8%DN5O6N1%\(0O<$R'21HA;OQ# M?/1@C[0V. '3[PS-1?*80YL%LSN'$Y=(I!>*=3Z@K']" 9E)_T78^_!8(4Z= M"W%>6HA3S4HA#CF*/BA8VE+#I-+L =@4,(FAB1(1^ 7!T0/E2L2:=$7'_+,X M0/8< TVHBCHV%A>+1#"O3H[:US>Q(";ED5P=,P/*>.+[*X(>3#9+T_LXCOLA M'/[#2)NT34$RPAAA=$]7WHDPF/8^CTK_020;D6_U#KTAPX2IPY]@>N 7N/#$ M=_"U 68^WRL:A1F&1D 4\NKFYBW+,\J /Y=OGI-IAB MPYMX@<,4(VJ'$<1'OP>_4S55.2*O2C5S-[ "X Y1G)YM9HHGA/(<>*:>O_]) M#M0(3@X8+;&[W_T4G!UUY:3H]'7QO86NVZU+CA4F27T^H_#_[N9$Z8-&P7C2#.@:ZY;P6BEVC^UQ)G2",-R 5D]_ *6CPZ%@9&,U MA#UQQ3@Q/.<873IZD:Z #PDRJAL632GNF$CSL(+_[#<+.7OBN88F%G=L&[+ M))A*9%E\Q1&XYL01D3*-.6:CYY=0X&\&NHG+B@025'(BCQ*DYT5FUI:C(34G MUJEKVJ(B@$+]\ ,H)\Q8./@P5(BZ0H<43 7C60SU@%PBC,T:SDBJZ47'))EL M($U'BE@36IG.2SLD>#NI2>:PMVB7<7=-HR^3AD$( H5-G#GA7:&F$=E&4 A" MRH3\D2>!RH'D9XA,A@L">ZZGND@Y!"@BF#Q,.0CSO]_'\WQW(EY""'85C.AY M$^(U.#K1D\#]-M C]@(1Q7&I2-FP0 MQ&&]JU/W$1438-(?$ E:S&C(I"[:V47Q!!D;H8N;#-)>(4V+])UP<2@ GG,G M@P&H>>&(B+"(*VNWP)]11RQ:*9Y0E$<%-L) 0J#G^[M^K99C]PW,=!A]S(3E M@U0;'%N-.Y\^H!D.)LU=U12DW$=20.]"]AT5("S X?N67F M$P?7![%C!+XXYHR;,QE!_*.E4;S1$15IT>JY@(NQ2#J#&&LNB+&JXN0"IAA7 M("R]N= M(3+7,'R=-!#:>@?M7!?YDT&"%.VQ9=\+JX1/S:')'3CV/8( MH'$!<#[I^53*5'J#F ML;L@ O(80#%_SW"1-!?3CSEB]Q"%0Q@3D?J.]3TWU5.24Z:.NZ7L?" C,KPF,+B)1!+RX0(2I"< X M,,*S+ K)9%[ %<>7/N+F^*1+D$<#QJQ'6=B">DFA$4D&C) PCULX+I'X%&7O MJ!X?X_6@_2#YX@XU#H\+O/2?=/\_MXB$?!BU'?<^$Q/D8^%&<@ M#$>$8=&Q;H,4DS<4#AR&06# MR #GRXN&3N#)2.L0YT]1HH*'3QF>$191'J]H233=Q',@ 0A,L/.0(ZM%,9=( ML 6MF&P#$?P.5JZK>RJ6#L ;7)]XA-_?=\=X@M2QIP5.@[Z*L77_%X(-!N;@ M#I=#7(--T2=2[ZZ=BY*-5? MPOZPFF-,Q!,/.@BXXXL&-D;%\&2*Z*=,?:YOFZ:P]"%8_?8G9)P-]X=?:R'& MI?\:4SL2(B:0\@)AP@PMK,0U'=QQ3\5A&_[?[.]3I &>43JH8SA)TL&H>D/> M%_J0 QB/29%5_^-7F-B. ;H6YBN*Y@0"X51 SV#;E.()10_,(W*PI._4IU*3YS.7-?N&70")D$!";?] MJ$YN#!ZL:5+[F.&#@TS5'OC0AN73-V34R4)5L_B30_4.A02[\: 3'98FS;T< MW%H5N]\8/<5\&(TQCJOI+AR*T0%W5/@O%&%0X:K@:0C^T!=<=0]X3AR87 M&D:7LF#P$:*F:SJ>U='[@P^"9B/]'WN2]* 5$%;8'/FX'+C4%H:Y80+2Y>W3 MP%3T)OVR"3 PMD,>A? QA:@:L)&6[CL%[P^4RT>6JPLN@#4(V)SR("WH\1B3 M&V*0'5??TGL__)7LTPR1*^,OK4@F@/$@FGR7P@*.*L_NN PBGF*!0C8C&8;$ MHJJ@;4-+NS-<+#$01X:^;GI^ZC(:S >W!C[>>Z#TI4RL@9*DQ!HZYE1A 9MH MZ(Y/5\(2#BRG"E#.6BK%$VI;9(EAVP %/R?@9V!&I2_;.44C !07UOU*#O(X M,;'CQY_U7S9*NW_6ZCZ$?U(5JE'W9NGNKDT&,L+YRQDC]+!1.)%;16=)P.34 MMB6[#GT^S.$@%ZXGF'@8A)@@,*73/Q?_OP3Q$-$O\BJM"0 9W*4;Z=B3BWGS MQ8]HDZSFX(W^@[U73?DP6)>MY0UCH]AZ#=F!DHLOM--,8!6/5(9GD*7$9CG@ MVH'Z=3VEY1JJ[[WZBDU&K<4WJ!4<&0.B[^$GGJ_IB"UCXJ%7* M239];]IW,D55']4IT?4KHL4;12>.3Z(U(_AJ!8O91NH8QI:;&T$,I]F!Z0Y) MU\:K"BJQ[FAX]XF))ZZ):EY2,9SW\'@=027LD+;$ESM39U37?WRY:X^KW[-< M.U#J3"^_7-X<__7U\V14%9?&^'//^9/G H+4*7R,[P4G8)'$DUFI0]6C+0PI M86=^EX*'V=1<\-DS\818\)FB/?)DIEL44:*C.JAXO!'T0#F6%#MBL& ]L$Y] M":@/) S]7A>'$?T73!I)ZQCKP\I4Q]!)F?^P['M3UZC*#+E!6('JTJ?"(C_9 MHX#.7T&]7UY$(66J5=0MTS!FYQ-&K,C_$9/ ^8 %Y*3ZMMGB#6:+OY0M7F.V M^!N6MK5:DT<2"XDUUP:E*(IUA=*FV &'&C_,J_SDBFV,ZR6],B?>"8X^9IU% MMF=A.I+>&+3@H)-!C,*-7;-%_I8BS%?Z(&S%@>&D]O7%Y!2]IZE+P&/M ] K>"(H$H7J M@12/;[K?+D8$^>@QX5&YYV 8T!J8#V$0AWV/%$\H&DR)D2(NA2-Z9 ==X$6% MQT.4QW%Y%"^)B6ND:U$<$K91)Z=8/%>V7Q&!]W/[H-@H%@^*S>+[@]PULDG\ M?'G/5(V1)--'DG6RXY+J^MD(R[[338\"/,BBQ8@X:37!KM,FK@B<^%U?#!,C M>H*!@SP>5YD(A=C%NT1 %^9$#R$2EQ$N#CGZDL$^XZ+3AV8=?LK\C;$>=X@: M.88@ M ^B6_WL;LRT^IQ;==1'(-K'P Y/CM7)HF./-6'3DM)@:>0KTWIRJR+O#2=)@ MUOLXBJCTN7[#S6*]7BE4*P'C]9I8)<*[$84I0A0#.8[-1K+-#ZX/?,TAID%* M!;MLY@9HG*24G6.6@-R4%N;^OT6]EC,2)11)T(B16Q=[P*?I=7O]6+=>;1=8%*9X0N&027@$[2:A_L**A M$O"E[5VQ5BXT?R_6?VM6ROERL9C(#:>/-9J_@^G][?:Z5/JM4JY7WLO&H[(O MAHD1JF+#OZC%[N>B3#3BO0'&;>3&8,$5HCH8'^8@;,N7:,K+BV.)HX,P^N&E ML6T^C"@_3BT9B*2#A3)BP+X7*(I;)MX8M%/W 901]GVS'5$*YNAZ>(@2HCAQ MJ)2+WB3=$!,'+E*,*C5EM3S8#$S.:N5*N5:ME=Y+RX"^%R'7L,#W$QR(:)V1(GN*N$-C M/):79='9VB$@4!CP-UYMHU*17+)?LO!-4>H5<-Q&HBS>B"38H M66TAL1K,79PQ4)9G3!%BH.RZSYD-:FI9+E,\(9#+L+9+N*%/L"L2NF^F,)/A46L6 ML[Y"\?W=QF_%:BE?+-??DQVB.W*%P7 MZ^4&U $DO\KR!] VJ,NP>[!<\(C'+\^]TK## 5@=20*@:H)O'2Z@'#M;T31/ MR(_[)0>N$X*YC[0&F^N8&OW3$L%"GT"5SQT"]OW'!+]5/B+2YG^-T&LA]&;_ MM.O VSA3I!9CBGRT06\<8?<(QWJ<(=(*&2*/?*DSO?_V[7JD#UJU4B7+S)"C MSG1Q-N(FWK29<9XO%S\K EN4!F9O%1#5".*BXURQ!<18674L-+9L;"0D32O MX\8NS#E06MCXU[ZW_(\^.9LX#9<:!T^H&Z1/VT?$FK;KZA&2;+2=2T]UAV0/ MI"_NEY:$%^^) A3_0H^$^C;Q##B\&'Y65!#T,=)GZ/X=N?3X7-+7PPME#^*] MHV8*Y9*^&[]3Q6\%21TH<3%HF_L32L12"(Z:3NJ:FPOJY/SB9#R$> _RO5VD M\H37%(?4'"R0%]:RKPPPXTK[W7/>. M8#$OZ1H273M\N(7]:EL7_FZT@LTX$@%<^-U%L'P=X[PSMJI6K:,9\EJQ8J'8 MZ807C-4][YM7_E@:_S+"B_1D<4?2EC]UQ=C+QKNWM"V+6:]E[X3;KX+Q@;,N MC!<,'H(>?A>_F&SO0^F@NO ^LA'V#04Q5NGB7_-!U%,:XDK-WB/+MDND\$T[ M([5"S!F11>P '4N[%E<0/4%;/0Z=DB6^W)F>W7\LUKI?!Y5/F79.&IWI:;WM M#II_=_\=?=_[$,R=^IWXLV2MO*15OVREX:>!GX3] RHA0PT4RB79'GKN6!K_RN]MXWH=>!8F18B\URF0BHE.R" MU\]P9,-O*/"-6&H_V@LS\NYX1T?A1 7COY=-C>7;I"DVQ!W"XM\8S!&E=C-# MP06+S?+_4R[DVOIEN)'/7(HN M3)=8P8[>WQ<:+:AN_=/E7]V''U]NBX'[(A,!L_<3RWM=J3I6.UCNPM1G33/1 M>2D+VT<_%4O[,''Y[$[RE&9,86E)SZ8PZ\44\\5Z,U^J+/9E$)J.BGT1A"^<*NQP& M2Q?8C"-PG?%H(#_GR@^Z_MW'/QCV9]^N'^I MW&@-;A(N99H_;82'#7$H\M0?&$V?.*@B*-P; M/YM0Q%W:BB>"H=&[S"YEK!9%IBW53UL4ZE_BM04]?QC)L4YC=.3=?QX>=+RSOK7-ZY:U*T\5H+*T>-BHOUZ)GE&0'6A%@JTM'PS\J$2B+G[%;KA2>> M>K$N;1?]M 8?N.,ZWO[^%1*^Q&?IO[^H8'LG(]]-4NNN4W :QLGT1VI/1?7] M8CW\:;&?C!/LQ.8W8VB7/57/&]K",YSFV=!\;B:"+7MHERK+A+'9,*=#I<2: M2V%58%#Q()U#V<#/"P+_6"OY2)@^B+H]!0=,RX@6I.[OC(9TH,$GJ>0V3%)1 MGD%2H?* (# W4@,J2JSC^=*DE,)*I!3)/DD,ZY#YN11SOW"NQ3T=W]?/Z],-A;GL?R MPNUMQM@MT7F"HPIG+&+$6?!JI5C"M:SX]7GQ2+LL)'#IUCFZ,,IVO5DA;OJ, M)7C0[\J[XGL2^*#^+>@13_K%C;9'S,U4!XE6AG\H[TKO@PZ*ET.L5VKGE;%A MVIZ@9\]_H?Q>""!FDGR.>7A_E*Q'>N("*=D 1>TYMBOXEL12![W^K@+CH3L] M1<=Y31_KI.6C)8?REBI4I9)&&?0O#C_D&AYEYOVG*3[!4UQB3>41N?AMF+!" M$V1V4L;D#YK_N^K[H!,D3A,-.#89FUUJ= WE17E)EU@*#F&@]D4%HPR8H0T@ MD"S(]P>%8$3M%%N*3#O1?ESL/[@L$3-U,,?IBNL*=B^V[VSZFXAV?FS:#U'W M(M&=D)0:4>I_;VC)<)1%2P29!/\ CC#VQ.E)JB\H<=>V+-T4OH6\S8G:S8.T M=\V0T8P5P]*G54,NRM\R"0]2.#[O+Q]XB%VYP[.*A=9.K^>\IV@ M!*$#-K:I+?=#4"L]6WSY7I:M$2XQ OO3B,-29>]ACQW/^\I;G,=@'O@A6$*9-@C/]V-C%:T:'0\. )BH:^X M0U'P\W,1\OAB!:\\HN!WO=HITQ,Z]6\'R5&;I#')IQ0X+4D%NWY3?X K-@0* MQ=0'HW\)$56CJ&/#4\V8",<=PPB4T<,@]9WS+[8%T(WUGKB2=T8&X\(G)1*' M)MJW^WH[K,V(^E,D7Q_0[N62ZM9G\"Y_A<5*Z$P"4_ MC*4LQ1,ZQ'X_.=F38-93"^L'X4!( !/72./_C84=2/I:])3M4/M0*B\<$_MTK7IXN+NWX-7906K24MF7K'L$?4$Q[)$LFDYNFJKUYN,)N(68$W'TD2 ^,P"'"CMF).+ MB@!K&45_U6A)8\3SES8Z;I;]@TO@"GAV3M--<54\JB&3;%]P?"%YDV6@@4&3 M]OB!ZBGA8;[ +H#> M0YD,.H2@8QC>[8XGPO@ME/+BG2"E(%KJP2/O\6)U!WL^8)^M7,1ABPF3#RN7 MT!CZ@;[U??2M?E\D;#\_&GO^E9NBR1%^+7HKGHW=$(4]$4ZGGST+KKH5%TU3 MMQB&=HHGU*++RI[BB>.%RW,IIG*4/ IX;UD:_@N)#N#S$,?!.X)S M:^?T6V M09PB.BW3\8O;$4*@_)#79&; MG=V9-V]6"619WE]T_T2QP S%ES(4&\Q0S+P0;8]-%+;42Z05!<'AE/*$>.^? M'3 6*?]$+WI#.[?I#0DU?U33SUJ"9\\E9@@6&HP]U'@1J[#\\Q/LQYY4GZ') M>/9P"P>ES17I(5N^K#,IKPH$EO&I:D0U38^?M\)G^K=<'TYK!W/KY1TT37* M3S Z&9U+A)OP0@T:GDHWR<]0"X-V.H837 E*/,7@%C1B1SHJ?-@:)$-.'M68 M ;=])UFP4MDW9M^8?>/U*_X3<<4$#86"#N#2(G'-#[W^A=62WH/R1;540=51 MKA]<3Q^QJ&*V?B*/XGZG;"2% MP>$AN/TM^>(:/C,PEA9C:<%E1\&U:@<*N_[I=/V?6UL[#JX?<:+7CZROV#:7 M4&R;ER4=Q'I;IMQ[49?XE6IS5VL8_\+:W.CE+C<+2RP?[IO&WX-#]^/'>JHK M=)>9S0R]H[R&.MVD9O/;J=1-[%J?FT7:T9HK=)<#TMT&P<%:B+3A'^_9L7N:U7K(K-P=VMU'Z^>5=9+$PBLTVRQ MV*/61MP^Z1<$)Q8!BYJUI6@&T5;DBZN-J2HN^@))&^4>-BGQK)XJ*U[.DUI' MG7%N49VQLI8ZXR4GDENA\%A9KO!XZ:5T<\^I1%Y8B*PD%"(_HPZ9ZKO74H:L M/+<,.;*MN=D*Y*!'TO(%R,K*!$$L*"ODPGC^2=H;/CBVHE\$1-1_R\C?VQ,V9$X 6?'T2 MU!NC@C#Q0RK1Q:U]K%*AI!F1C15O,K+Q^NFVIU"IID^7U 2Y (>/7)R>+ W& M Y?H?]7%J#1.%&?C5T]B%\=]4P4W/9^[E[?[^E??@2((2>NZA??S(7.67C.F MXUI/9Z"G>$(K%N,')BH?5>)/E]DK3Y?9YQ+*[.-5]D_7T2OKJZ//<1U]UB>T MC3KZ?.!WT$W-"NK1X'+F'/[78X7VRFL5VN>>*+17UEAH_[B'[Q>]+RWN;7-[[AL5MG8;' MT7,O:]J@K*EI0^Z%31N499LVS)DQ,ICP #O"0$ ?&;/+H\E(P?>@.8X2;$15 MM*K<&6!85(K@&9(:B.\RL5^.G[O&.X[%FCFZ)XH\T'[!GJ#0HKW28+L=ZG7C M3DR/+H%3[U3#Q*GD* V GJZEZWB:[:IP:L59P-D5AX]'6PR@D]FG10SZ,XH+ M3<+8^NSB+\K4XBNCX7_5R^F"ETW&UJ:3+CR:\ZCIDF1 A&4K W ; 4.Z'@:C M9X\=_DF!DB^SA"]*TL ?-1ML+S58TIT1TL+NX*F@U^W)PC,:W&@Q)_=G13]9UOW&S0)Z@*_7.X:+4_FWGV M"=.^X@ M.AB2Y@YJ,7/ND!*M<8J2,K'FSJ]/'._#!+CX@AC$_)<48IGX,8K) M&#X$Y^E<)* 0M/J*'.')]/1-^YXX:CH>6S":'C4L%M)^8/'!;))6IC4!#>Z3 MJI"DY%%H ,Q<'Y2R>&-L$KFQJ5HD4*ZN_T@B7T8I/R:EA*[>PS73,ZOMG*PT/>K10/'/@39*"0?@8OF&!&0O=[1_4 [@@3.P>8DE3[A0HLC%4JX>G)P79G,3ID;6^&CWOKZA?]$U=(G4N'%I\MVJ@< M17C)\0]VIO]<3[2/1\:P]:.[0K7C=I;\O]T/<4)LHU;K3"?CZ;_'%Z<_G8_: MW@>8)E)%@HD&^]/EVS129)+'CCY6G!GB>-/L;.=)_; M1JZ:(SM%]C30R"HHO^)Y'9S]-!C83%\)_]LQP1"Y= M=N=$\P?'*BROURC3'?F&M'B&#:?40##BH7R9H40*GF2D.0:ETD6W$_1L][MD M^D"-XVO$ULE7YN7YT_2]$,SZXZZ1-=5T.%I1F%_])9?A0&GUZ.@H[ 0Z,>@4 M:0;=Z"DOV$&R5[!7;"6>824:LU:">&67!($K/>ZWM@(#?@Q/= P2A1D[4HK= M ?Z\1W6FHZ/+G^VS^\NOXWZ6+4T39C+X^ZP[:7_]YP0LS:DOJKG@2EAE=D78 M^J3.^AP)OS,G[0:<74RAJ20S$PF80EEBA F<9,H5.<'&4LP*E:>K)VMKUY9Y M7&Q !8<,^M$OH: 'SYP<6;<]0[F*?')Y5__[TX[P.X@#3SD7FS1HK=1K+ M[[TSGCACFXJA1$P_T#E!K@ #-C/E;X%G1VS>(1S.P7DV#=AP64-K6!B,$*HK MR&8(;QO&;SO&P!#E6TB@]!X$#Q][DLBZ#*0@RT*XKBZ&H8=PVB75EFD012GG M=@^VB8)#YD,077/%W@7FT$#OGNHH)-Q.C]M'HA&$K@E>43R;I-FZ2^&A@.Y( MD1['<'](FWW]^/#K]?M8J6&70I3#Y',T>81W,7XDL %O U"DOVK4[ M?]="KSMJNX*(3SP"0RER^+HBOFY8HF4 $3KOASH1L<"$H=["%,_ @M?Z'KZO M#!5WJ.L>?1[SC%3V(LM/_*R-'Z<0(21ZUX'2(MTY?Q4'14N.]9[\;9%^6\Y' M7^F&P1X,P BV)@7-C"#0D_?/,*[,=N-@\DKPR['Z(']C49C,P2K3,&(35L#/ M+E)7[ZE8HB.6#W[M#K$:1[H 3"-+]X0BPD*I/Q 7#!FZ?AFIGUD*"CX#J@2E MX4Q3,"Y[AW)R3G$>J_,0J M,0IG^C5B*@HI.; 8_L288!#*O?8 M*H#9_ C6PMSK.\PZUF"[3(^M*Z/P/A^ MH%\4_WBOW-AC,+B-4@%E$7!O@-!B630YJ_N 6B<7@?@0_AL+,!YD52Z=^P'; M4QD8-:SQQ'-%33W,4HR5>-S!,X3W$SYH@)P0^C)ZV3 (_Z&4"IU8(E.F:[F? M$QOEFK9"1KF13R+YH8)M9" XJ(1.QHW1S8Z$C=\)DE QNHKN^R!2#.> ^0'8 M7:0MD<82T\O)IY3C3_$+/7#-7#_9]YI7&&1%O*DMY<9G<(9[E ,C$1'EN:T, MZH'BX(I#*6HNYV"7Z37:E5TNQ799;JU@BX/.MI2G5(=(8('GHQOT)0T\HAX2 M&Q$'5OA?(7P2<9.CI \<\4S5>1PU^.#'(+?X.7-#1A=,/)QJM+*\F5N#X_.X MZ"7FHK^4BUXLO'4R^HY+U)H5?#FFX!-\,E2-PB4%3\]#8A8>3OW:(?"353C" M&:Z\Z,\AT,BSKV"\*:AZAB"-W=O1:D.^9RO^(.L/9X5G) R'6;SJ?#8 M^#G1(X.S+1K9"-_NPI*1BVYY@&3Y<%7=&9[U(X\&6#WWID6)X# M7$6R\Q;$6L)2 %LR9_#@<4^M#_#/@#,L) UY*#+O"98^<@8C!JF#+3SI_$,'$S$B9^]K,Z4U7[ M,KD??KJ]'FA9CAD?=:9?OW]O'MDWM]V_FWL?+E4/44]L,9@Z^#2Z("]=.LB: M]1XX8IRZ(-BWH6'JN;'8.;(XHMV#-(E8\(0T#^*8DR5]",X@LB_$"(ES4RSL M^A)2"+'D2-.Q)(1,>,#0QKY*]@BDVC3Z0=A9OCTGDE_P!J*IF(L, M\FR_U]-HX@9+CO4S--$S$GCKZOV)>0;OQAN9->^?Z*W,?]E?>H<]JWUS70TZ M )\L'N^C#5Y;,]HWT'EXQQG]-0<:7F9F>RA;YWV4+2CUP;9$R#W"7N7\X%E8EC' M.C$,X*&//&= M#2H0(IU1J3I0-+,3W$8$DV'Y1$T.G:=Y0E%72!<.L SISI3_8%.* +@R1!NM MD P4#U6-1$S&6)H, 5F_=,?TZQJO1=5D#OM5V;ZK+/NZ^@.*O#GZSCQU2T,% MYO?\\.Q\A/X<%IU2R4W8IS=2^I&G7$"T,WC.)^C*YK18^RC+33&31/^!E3HN M1>[Q["">&=)1&/ IGI"HG PUH64+,R1KA2@7B@5+8;]7HO[@]ENH924'2'2: M6I#H%+E-V=L*5+[Y<*!\LN\1Z7F0 2$J<'AP7=N7V@ M%!O%XD&QB>VXZ4/=!^4+G$-5W53^A#.H]<,6257USH"!W*L6#$.VI77Q)"I$ M**;=55GVG%#*B=VBQHZA>ZKS('-7IAYO).=7>HDLD"?:X/K533!&ZLR,,=P1 MIG'Q$(SYH>3>0T$1')4G+&KG'3:EPO('OT(Z+P_DAJ=HABCC=A2U:X,NH%5L MBE64)=.1LC"Y[C -3Q>F2[1>]& U!S#*Y(4A]C\X$1@"'MNN(1L#44H\N3\2 MOD6T4P?=X%!4&B"M^PVPYX=!64A1//Y#1P(;*!:'^N>*EN2VI>?0 S5\Y?9_Z4.5=,<"5QCQ89_\ M;F?Z_>KV9MIS5.>KGO%3I/O7[6>]?FG76G6\1H5FGHM,G<^-J3.(;2OW1<7& MRL6*X..$%+%$=L*A#?^*TA).6]>',5Z"#(8E?%NY'5/95XS4""%$KU-Y+I>_Z[QN+2UNP1!P[>&#V M3R?R\& "O\9CD_ +_:(R)X2J/,22+RKOE4 ^L>S>X1? )=VB$]*QI*VJDJ.LQY='ZB@?7!LNR[GCX&WP+&1%7DLEH9R]9[&' .>Z'+\Y@,>?L$+M%+ M4LR!PN"P(.*<'K!8<-*V+;H]!,U$*WZ-/D6M=' M*,[4"YDRIU3F[Y,5P]:.L>ZS 2%2=$"@A'S_@2!-K57)L1+]Q#&XH)I8; N=)H5V6ZS)XXOT6]A^EDZGWA[ M1=B6$QUMTYR1=2)_VEW*7.$U#4(XY9?E7I$OCF=Q.EJA7P#; D-:T'PTTM1" MDCWY[)SZ"46#11'J<%"1[8JP\COCO0]L0VKP7MQVD]SXANJX& H"J/RB$OWBW7MQ29%/:<8B[I[/#IY_A#Q.1T86 M51"^!@A?0&V7[]XG+14UI:&*)OBRVU=[L5AKXM0/P'D*OF2&-5$R$INC\DML M)"O'3Z=UC5*;\FNB.>=,M=2B?50I0!$H@D=WA84VQ1-JF7C74D1#6,Y3O&<.$6S,%<8?*(ZV&[0O=2= MZZ'JZ(]'*1J1*,43W^Q,VZ/CP7'CU^C,J6&)U*FOJ,\1U/D0XQ;^;>*I'#0..;W8Q6Q(>6^T:F.32)AHND=X M0*1+5NBJ \TP)WBRU"7DZ0'BFZ2R,#'5H\_/?C(7?/) .:1/!0,0WS?(_1[3 ME[KXICN#_'_Z6!# %IT2Q( C#125=Z@A+50/>"/$>WP"_N9>Q_.&KNVK&"(> MZ#GX2%<_I:<'-=)1$%B5200&KWP/'$]WHR7$7 M-Z&-;0IGJ\'*X4'ZB-Z;N\;11VN?90/]R%."DAL\7NS[#Q!'?;%409KYD7W! MD([D5.,ABI9^?E/R5+X[]L*#460!\!EA-SO17SR8,?O):Q1\S5+5H!OY .?6/>90K\=MP8&=%P$P^XA+2[X5A]B\-7&RQ;HHC_K#R_PH9O1/F'K?UEG M:ES>33^[0^]NPV[WJS0E]J_&0_<,[P.S/.E)*/.>A Q32N\AL*;2]$G.C?K, MQ_#_+%FN. "PUM PN"< M3X]NPD=W&J'+?/;F_:7T^4D];5>?O\X[5R>7*E7']J79W$[Q&7:_$L M2['\>BUG4_9003YB1811VY-J]#';L?)6S"DOM!+AF^2B!.:U2,I_?:\*9@;K M@[_]WUYI+]C_2O.D0\378J'8Z8046._*[OU]>SYRK=JL$5_H)JQUR4)7%(?O M"^:6EC ]N]7"/2H'NU4NPO\ZT]'5SV%C\/.L\)>QG=WR=:78+*DOM[59Z(!) MH0\6KE"-&-H7FM<69;@[PW4][_ A^0&M7X;;Z43:B,JNL&3LOM!Z=Z9_7]Y> MGO[]UZ_#ZF#O<1T'&A,@,'!@\!IJ3=OY77$&W7>E0B5?*C?RI6KU_;P>E*JT MAMYY@K.]ZK8%DQ$AC 50D2\O_6UF'*<=Q^4 Q^7]8FD? M;.LS<%S=41PGVM/CS-O3*QUY>%B/05N*ETFZ5]>WOF&]+OSM/JCGX_-I907# M^FUH>/KCIXH7;E0X?&%""5'N#%8VJ6Y>2\?L@EY9;!\?1>&,@JF_2,$42WEX M"OZSK(;9] XS.M.!SL56[SGH;+P,G?E*-47@W%&;1[MX0=Q+W\[5K[]\N[*_ M_!C=-C=R@%SC/AU%DMY^'PU6*:E4*8L-WAP$XVJD6'B1&BD!"DOY1J&9#C7" M@$P+(!?;N*< 6=PE0";:M4;F[=HWT4C)MVG?NI>?O^D3\[RJ;^[L]H>RWDAV MS+KYG:&VG858(9FP24WTG'%D55,M-ITQE,]HJ?*+M%0C7WS>T3 !@*^' D;_ M[J)_L9U^#/TO2R&4:OEBN9)R^"=:[LK:+??TYJSQ_:)DGKFGPU](U]2UKF,5#R:J22>0% MQA1*[44*I0Q>?ZV4+]>7]OH34;<]B\J@WSW0SUG6&]; M4VC6+"8G.^Z9&KXSTO+4L[%CU$ ML3O!B;A-*;&9;B'6]NC);W>FWN6#4?ZB_?OUNYF9S4DH*JQUIO]JO1]]W;*O M^A5*[=+<.<+&FS#M'##7-$*,-KGTE5-%;O_4'\_^E)P MR2/\3M5&AF5@7U9BJ_OWT^-C_;X V(52Q^]CV54/M.] U*.%'3%R=!$*7:"L M^95R+A7D(4%>(,F_IBD8Q,S(Q;TBXN8DT:<'>X.HINP5=T>-C5PJ6(PT/L3V MPD)]_O3ML335@. /EC!ZR.ZA?X M1=\T,Y-X^Y7$&>5PK.&-U*J[>.XS Z/>N7Y=YBX5F&=:YJ*%O3[:E?\SVPVZ ML:Q)D?V?ZW$:_%U_6/SS>_=/L]Q]JM7RU6ESDKM'TYM9S:1--ZUD.UK,LUO/RK[]_GA3._OET MVMS:>I:#]2PGKN>RD=2Y]6P4\HUJ8^%Z/J9M1<=8O\0Z=EOT,SO%YG.)^W;R M3#F8*0/S07EJ6@#FW_+IJ7_PRV*0K%QT1AV2/AW(*6"X5\M5%;@RR\H&ER'ALRX>WKPH&A M5DW8P<:)U, OZ"L&CIKO!%AT59O?.P9NS+2X>?QCC0Q@M;CW^Q,1^[#8>]P:'Z_+V;Y\-CH3 O7)[WR MY\_M4Z^_]R$R;S(%7^@>+$0TGQ[3ZW*=B6^ M[O%/>7!,U'1W:/__[+UI<^)*MB[\G5^A6Z?W>7?%Q=Z(F=I]*P(#+L]V&0]5 M]<4A) &RA80U&.-?_^;*3(V(68"$\T2?;I<-4@YK'IXU(#D]%L!I*[J M(-21SW&ZB)YH(H\+ [5GUH*M#V!J.BLE,"HJ\F_=K7(16TVKK$1LZ5!EF*TV M+3(AC!L4F0T/EA19 H!ZC,Y7UD3DRL^6GF6?]%S\(4\?PLG;]8UZTJJF.PI7 M?_IX_O/X+MX41.54AGHFP MFQX>R.";9.Y-2<*XYA!C,^B(F8RMN?\D"^&$G@"#"#G% OP*0(ZR_("\=)JP M;T0]!/H(Q)0CO9TQ3Q3:FV)*85 RC)HLF+J&GC6&.?+((W!A?IW]4$!S>>J. M1G1X!H'J$KQ'XI$9ID)7YN)RP?8A:DK6@*=P@"ZD(*.NC>_NZ3#3,LDW)&_C M\%W9!7U&FQ34,4S 0ML;P N&Z#-TJA &DC;U 9[2(_NG.3[;4H_X V2""/8! MW,H#XO50J%7%D XPUG,&WXS@3#L"NK4(!9#AI%F.DAY=(8R01J=(,4N<,"F< ME09?T6 ^M:W1^9-!2H*[Q+W]F.8M'1.@;@-5(/4^(,/6"%([.06T_@&.I@IC M;Z*E3)'>T5;0P3@+_P>9'80Q9 ??S$,V(U!Y@B@: .4/%LI"6"L9!SL@K9; M+KRF0B%L IQJ(B+6.^%]ML+W1S"F?>7IXTTZTDZ*AIQ[$=.LWEM/'Z6JH@AW M^NCFK@OJ S:<03MFVCV!VOU.SPB2A%2=ZOH[YTQ!XA2HH%4#;@F'*3A!O8@.- #N40F@&TZ.M/_ MZO#\@($LPV!,/&R:S,>80 MPS.R;IY+%,@?\8PGI)R)&8(\24&U< [2=R:*1CZF#)P@5M8WB80.@Q(T.L"* ML4E"V,27!8,Y;Z:/KF%ZB6UXR/+WA^U#I,PE/"CL&;GZIJ2(!!H^:*T%!C&, M\:.<:&@P11$*#V3FA@?FO,D-4L K/8L46P]X\(Z&87L[@HH1Y,V^C+/+0$4R@34D-1$OKXUD,L6R\S&$(5U5D2!2-;HH,8$8G-';W-^6< M@GS6D548!T6-=.+_D=>XGAMQLU2/P8FOASG+UCS5E0'.[* #[2IDZ@V,BL2: M!KLA#D(R+%62Z<]T"B'.YB"*XJR1K+XY1\3889UN\^ M.LRE"9Q?W&L*T.X@,Y%D)>75N"FXKDG(5X2(SIM\ W-G(VM7:WX@W^6?]O3Q M7'FY4UO2Z?6HGV8W^^CIHWU[=%F\>WVIM8M?ON/NZ@-\&!G_:3"7.W$&6>1X M+C*1PKDUFI$DDX-A<"<>WT;F9U;X:I;S7S&'32?^7XK.'/@3V#_U]CT'0QIA,Y'=O+R:F:L_QU#H;<^^M7)3+LFF1>O?BH@(M/O%U1I]XW MO;)-AH],["(3V(4#/AT 0<$6K(L&AI^#)V1G_0.WZ $)(QC#FJ4?@]&&;HTM M'4SH93QDV7F:;8A]]/4,?NPA5S?QU//LY(6 ;4EOS#UL?,PP/Q0.G2,Q?'3F MWL&CS>,9ZH&[(P:H9_'CY0YT9!B '>H>NV>[6],71-AV <)DRBQA8OSUGV44\?'[?&^$/(2:]E)/GXI3S^:CWT115Z!\ :R/BF'0=/@RG*1"M*=P02Q$IM$R(7<)\@WWV7 M2"/&!BXGQ+.,8!HS==PG)YY"P M]%AQOS[VW_"$(Q-UDT% V0]+!H8+$K&\F M*G;&?3.E9TL1'\.6*D\?N<=^X_RE<5<;2*GANIT(RXC^-WQW-Y#RO?.&@9I- M]RJFR,E<)5!9O/!3D.7]*AOWX\;;FY&JDL:KZ[M6)O^-"XG*?/'IX[KP6^V9 MU9/'00V)RM9%_:[5Y&[JMW>_N;O;^E6[WK@[O;YJ[T9(?I894W&6['BQ4!+^ MU&V#:_05NO@X [JZZ^[IQH>J6<+*L&/PG_#;W=?3M_M($GUQ<=XT.= M+(M4W^CD\_-J\\.+#);CU\WKKE>$#\MZFK&JH. IKMS_P\]$_'%FLU)%EW5J M24D-T CWSPT%1>*N14N'^RSN7WYETTJC.%&YT?8-=&PA;]$:7^F6/%]E!,)/ MBS[CZ4.T"KW^T7,AIPFI4QB%2871>/IH7%:ECG6K5:^0PFC?73?.3ZXOFJW; M-LWC<*V?]Z=WOYE5O>L[],\ 9=>0'!WM=VYPS[=M]74#EZW,TL+D.O%M$DB0 MNOL]4,A#1:*=A;CY310OAJ772ZW&]UVUZL<_S#KS3KVWS].P,Q80J6PC6PB+ M:\YP(!#6,]6J,VRW&YA=AT-J2\VB(^6RX";.ZO6<.)53/#:<=_L&YBY-#V3G2]#" M>H X2Z[.=T!+++&VUA*+?"5;JN6SE5PA@ERGH?BX+;&9I>3!).'1X66MX?/C M@ZPT7OKEU0@OMP+AT7?S/^MWO4>]:ISNA.XB@9A*ZP$.QTQWT4M<#VVT4*UD MJ[5B-E=8GNZBQ2>E#2PK?7<5K.S9)\\D-8M'EIX[.HD9>RDV]OS)F^ PK 7L MO7?EY>KQXN3WGU^J*VA#(P"7M_AFKV)Q+5I:S^C++V/S>9NF9M^=:\;A9BM< M14=J"4T9<*(BON27CM5AB"V<2S-R>)'[E?1.%W#-84# M**FCW+ MO>DXW>?\$^T"PHEH#9(\("EK'VR8HKW@S@5;D\@IFD[BW_WT$*T&/71HT F>+OV&[9X$+/*'YK6L; MN*D1;0RO@W)M9^R=(PU+D?Y _^V'[WP@C$EB#+XJ=[NRB!L/)5D5QEBSDUIQ M6"C>L?PFD^RI *!H6@^C=^$^3EW%+7V")I :BO!R,].727O4QZ1OW92AI8TL M!3Y)[P_;''C?M'Z"THWSC E/;^K6B7[$Z_,_?()TYBYIJ(_(OUECFSD5HC@1Z^E 71!5>'U9-,I)U/Z$+*!5I\)"(@@&>;2!J.P'9H0ZV] M!5WP$$."XC1@7.?KDR&B^E+&G C+RY4AF^9+,M *N 8T8%QW\9=)5DU$YZ2."OE=&H=\Z2!7AO0;6?_38LL/F9+KQ8SRV=+" MEF1$BTIFPJ S'7MNCGDX%)P2R)D(BL$#N!&,:P/3@?0 WW4PJ+= ,G_&QR=\ M7RN_GHO32,:WJ>5H9=JV-D8SJP7Q[MO-&X=NYW'0@QR&R!4@9Y]] *7DD M197O+EVX"T3?_X[_SO_[E?L;R"O\:5 OUTW_YPZY%C8^(&M_B='<2(":+P<; MF]!QXTXH^)U'D=?-K-,QY%@A ^$=]]U.F*8X-DX7X=TT3L&'*;:VM' KYPJ; MHM2'>S'_XV5P.6Y5IU/J-J1;^2!76)-2R^N.0EM0NB'5M5[TP;E3?D-W^OKV M/#:EQ_)82,*=\FO=Z7JAW-*"L8\X\UNE.;0P,^2_$8(X>\L]*R]&NZE-#6^M MDDJ8L[E9\?JU2&+->%@V5^$1253F&S&922W$(OE++7YG4>.NKJKZ"(>F[ %: M$&X5PATS)(SI;R;QQYZHY3IY\=_8G2;#+T7FWH4O<'CC7AX8?B1Z%<&V.'O@ MCSCZ;ATN?<*OX*=*<=_;O9?[)/DF'8OG/X^=GOQQ;^=G.!93=NG:V"I"J#&H[/>W!:!S)<.-88339*"9-1V)[(TN; MN9T6ZT#&$8"4< \)^DQ4."]0OQ49;W2CUCCW2<@Y$*64(9WO-*I$6V49'$?0 MNTY&7H(\K^^I-SAI_K= &MI)$AYM4I*[BN8A]?E/Z6O65ZHQ8=;Z0;2;GX+$?.?Y6JUHYU=RGS-5^KH'@,N&<@N;L(NO+6-&;+K M1\V+,PQ9)O82O"&*_(U+/H* G^A_5=F2R7@YW/H$U2'D)XI_,;0[JB)"WYYL MT,!23S$)1+*;6&VW&ED?SK8"Z!%0'T'APDTJ<]S:.0M&3N-Z#0L9FH)I30J& M2L#?)8^!KK%36@ERW0T2?5V3/'<0_^9IJ)6TLE]0;%9DJ)V2X($\#[:D<;JE$OO%4UQC1 MNHK16 55G1+EG$AV!70OUK7P7X@["/ZA8*/="MCO4<>.8B9J=[H&9:(MP1M" MML^M6]%'++JP(#F:&CCSOGF'S!AS>Y*"?[@Y_W5\?OMK5)A:P>$5*D+M'D M MXW]\F=]5&S.?3_3)P 'K8Z)I BW:ZB*A@KQ%5BCG*"!T!]MU<'&!V!!^F# MA IQ">D4UJRO^%;(>"7)+C")#Y(BZZA8"E,FR2&P+$E.?,^!

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end XML 46 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001449349 2024-01-01 2024-09-30 0001449349 2024-11-13 0001449349 2024-09-30 0001449349 2023-12-31 0001449349 RDGL:SeriesAConvertiblePreferredStockMember 2024-09-30 0001449349 RDGL:SeriesAConvertiblePreferredStockMember 2023-12-31 0001449349 RDGL:SeriesBConvertiblePreferredStockMember 2024-09-30 0001449349 RDGL:SeriesBConvertiblePreferredStockMember 2023-12-31 0001449349 RDGL:SeriesCConvertiblePreferredStockMember 2024-09-30 0001449349 RDGL:SeriesCConvertiblePreferredStockMember 2023-12-31 0001449349 2023-01-01 2023-09-30 0001449349 2024-07-01 2024-09-30 0001449349 2023-07-01 2023-09-30 0001449349 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001449349 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001449349 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001449349 us-gaap:CommonStockMember 2022-12-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001449349 us-gaap:RetainedEarningsMember 2022-12-31 0001449349 2022-12-31 0001449349 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001449349 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001449349 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001449349 us-gaap:CommonStockMember 2023-03-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001449349 us-gaap:RetainedEarningsMember 2023-03-31 0001449349 2023-03-31 0001449349 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0001449349 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0001449349 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0001449349 us-gaap:CommonStockMember 2023-06-30 0001449349 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001449349 us-gaap:RetainedEarningsMember 2023-06-30 0001449349 2023-06-30 0001449349 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001449349 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001449349 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001449349 us-gaap:CommonStockMember 2023-12-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001449349 us-gaap:RetainedEarningsMember 2023-12-31 0001449349 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0001449349 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0001449349 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0001449349 us-gaap:CommonStockMember 2024-03-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001449349 us-gaap:RetainedEarningsMember 2024-03-31 0001449349 2024-03-31 0001449349 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-06-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-06-30 0001449349 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-06-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-06-30 0001449349 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2024-06-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember us-gaap:PreferredStockMember 2024-06-30 0001449349 us-gaap:CommonStockMember 2024-06-30 0001449349 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001449349 us-gaap:RetainedEarningsMember 2024-06-30 0001449349 2024-06-30 0001449349 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001449349 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001449349 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001449349 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001449349 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001449349 2023-01-01 2023-03-31 0001449349 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001449349 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001449349 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001449349 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001449349 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001449349 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001449349 2023-04-01 2023-06-30 0001449349 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001449349 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001449349 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001449349 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001449349 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001449349 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001449349 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001449349 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001449349 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001449349 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001449349 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001449349 2024-01-01 2024-03-31 0001449349 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001449349 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001449349 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001449349 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001449349 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001449349 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001449349 2024-04-01 2024-06-30 0001449349 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0001449349 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0001449349 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0001449349 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001449349 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001449349 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001449349 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0001449349 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0001449349 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0001449349 us-gaap:CommonStockMember 2023-09-30 0001449349 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001449349 us-gaap:RetainedEarningsMember 2023-09-30 0001449349 2023-09-30 0001449349 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0001449349 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0001449349 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0001449349 RDGL:AdditionalPaidInCapitalSeriesCPreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0001449349 us-gaap:CommonStockMember 2024-09-30 0001449349 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001449349 us-gaap:RetainedEarningsMember 2024-09-30 0001449349 us-gaap:PrivatePlacementMember 2023-01-01 2023-12-31 0001449349 us-gaap:WarrantMember 2023-12-31 0001449349 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001449349 us-gaap:WarrantMember 2024-09-30 0001449349 srt:MaximumMember us-gaap:CommonStockMember 2024-07-17 2024-07-17 0001449349 RDGL:BrachytherapyProductLineMember 2024-01-01 2024-09-30 0001449349 RDGL:RadionuclideTherapyProductLineMember 2024-01-01 2024-09-30 0001449349 us-gaap:PreferredStockMember 2024-01-01 2024-09-30 0001449349 us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001449349 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001449349 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001449349 us-gaap:StockOptionMember 2024-01-01 2024-09-30 0001449349 us-gaap:StockOptionMember 2023-01-01 2023-12-31 0001449349 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001449349 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001449349 2023-01-01 2023-12-31 0001449349 srt:ChiefExecutiveOfficerMember 2023-09-30 0001449349 RDGL:SeriesAConvertiblePreferredStockMember 2015-06-30 0001449349 RDGL:SeriesAConvertiblePreferredStockMember 2016-03-30 0001449349 RDGL:SeriesAConvertiblePreferredStockMember 2016-03-31 0001449349 RDGL:SeriesAConvertiblePreferredStockMember 2015-06-30 2015-06-30 0001449349 RDGL:SeriesBConvertiblePreferredStockMember 2018-10-10 0001449349 RDGL:SeriesBConvertiblePreferredStockMember 2018-10-10 2018-10-10 0001449349 RDGL:SeriesCConvertiblePreferredStockMember 2019-03-27 0001449349 RDGL:SeriesCConvertiblePreferredStockMember 2019-03-27 2019-03-27 0001449349 RDGL:CommonStockandWarrantsMember 2024-01-01 2024-09-30 0001449349 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001449349 us-gaap:CommonStockMember 2023-04-01 2023-04-30 0001449349 RDGL:SeriesAWarrantMember 2023-04-01 2023-04-30 0001449349 RDGL:SeriesBWarrantMember 2023-04-01 2023-04-30 0001449349 srt:MinimumMember 2023-12-31 0001449349 srt:MaximumMember 2023-12-31 0001449349 srt:MinimumMember 2024-09-30 0001449349 srt:MaximumMember 2024-09-30 0001449349 srt:MinimumMember 2022-12-31 0001449349 srt:MaximumMember 2022-12-31 0001449349 2022-01-01 2022-12-31 0001449349 srt:MinimumMember 2023-09-30 0001449349 srt:MaximumMember 2023-09-30 0001449349 us-gaap:StockOptionMember 2024-07-01 2024-09-30 0001449349 us-gaap:StockOptionMember 2024-01-01 2024-09-30 0001449349 us-gaap:StockOptionMember 2023-07-01 2023-09-30 0001449349 us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001449349 us-gaap:WarrantMember 2023-04-01 2023-04-30 0001449349 us-gaap:WarrantMember 2024-01-01 2024-01-31 0001449349 us-gaap:WarrantMember 2024-04-01 2024-04-01 0001449349 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001449349 srt:ChiefExecutiveOfficerMember RDGL:RestrictedStockUnitsMember 2024-01-01 2024-01-01 0001449349 srt:ChiefExecutiveOfficerMember RDGL:RestrictedStockUnitsMember 2024-01-01 2024-09-30 0001449349 RDGL:ConsultantsMember us-gaap:RestrictedStockUnitsRSUMember 2024-05-01 2024-05-31 0001449349 us-gaap:WarrantMember 2023-12-31 0001449349 srt:MinimumMember us-gaap:WarrantMember 2023-12-31 0001449349 srt:MaximumMember us-gaap:WarrantMember 2023-12-31 0001449349 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001449349 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001449349 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001449349 us-gaap:WarrantMember 2024-09-30 0001449349 us-gaap:WarrantMember 2022-12-31 0001449349 srt:MinimumMember us-gaap:WarrantMember 2022-12-31 0001449349 srt:MaximumMember us-gaap:WarrantMember 2022-12-31 0001449349 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001449349 us-gaap:WarrantMember 2023-09-30 0001449349 srt:MinimumMember us-gaap:WarrantMember 2023-09-30 0001449349 srt:MaximumMember us-gaap:WarrantMember 2023-09-30 0001449349 RDGL:RestrictedStockUnitsMember 2023-12-31 0001449349 RDGL:RestrictedStockUnitsMember 2024-01-01 2024-09-30 0001449349 RDGL:RestrictedStockUnitsMember 2024-09-30 0001449349 RDGL:RestrictedStockUnitsMember 2022-12-31 0001449349 RDGL:RestrictedStockUnitsMember 2023-01-01 2023-09-30 0001449349 RDGL:RestrictedStockUnitsMember 2023-09-30 0001449349 RDGL:DrMichaelKKorenkoMember RDGL:EmploymentAgreementMember 2019-06-04 2019-06-04 0001449349 RDGL:DrMichaelKKorenkoMember RDGL:EmploymentAgreementMember 2024-01-01 2024-01-01 0001449349 RDGL:DrMichaelKKorenkoMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-01-01 0001449349 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-11-12 2024-11-12 0001449349 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2024-11-12 2024-11-12 0001449349 RDGL:ExpireDecemberThirtyFirstTwoThousandAndTwentyFourMember us-gaap:SubsequentEventMember 2024-11-12 2024-11-12 0001449349 RDGL:ExpireDecemberThirtyFirstTwoThousandAndTwentyFourMember us-gaap:SubsequentEventMember 2024-11-12 0001449349 RDGL:ExpireDecemberThirtyFirstTwoThousandAndTwentySevenMember us-gaap:SubsequentEventMember 2024-11-12 2024-11-12 0001449349 RDGL:ExpireDecemberThirtyFirstTwoThousandAndTwentySevenMember us-gaap:SubsequentEventMember 2024-11-12 iso4217:USD shares iso4217:USD shares pure false --12-31 Q3 0001449349 P3Y P3Y P2Y 10-Q true 2024-09-30 2024 false 000-53497 VIVOS INC DE 80-0138937 1030 N Center Parkway Kennewick WA 99336 (509) 222-2222 Yes Yes Non-accelerated Filer true false false 417592703 1218160 1592287 5000 7000 21165 10837 1244325 1610124 1244325 1610124 48820 245004 48820 245004 48820 245004 0.001 0.001 20000000 20000000 5000000 5000000 2071007 2071007 2071007 2071007 2071 2071 8842458 8842458 5000000 5000000 200363 200363 200363 200363 200 200 290956 290956 5000000 5000000 385302 385302 385302 385302 385 385 385 385 500507 500507 500507 500507 0.001 0.001 950000000 950000000 417592703 417592703 387894033 387894033 417593 387894 75479376 73791430 -84338041 -82450781 1195505 1365120 1244325 1610124 23000 19500 5000 7000 20699 16536 3919 2301 2964 1081 7000 1310604 1205819 627152 512856 267153 214083 85400 69562 223660 300586 66551 80858 143468 132831 65123 31357 1944885 1853319 844226 694633 -1942584 -1850355 -843145 -687633 55324 31821 17882 19943 55324 31821 17882 19943 -1887260 -1818534 -825263 -667690 -1887260 -1818534 -825263 -667690 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 403860277 403860277 367112957 367112957 418629728 418629728 370541528 370541528 2071007 2071 8842458 200363 200 290956 385302 385 500507 362541518 362541 71217954 -79556028 1661044 -248318 -248318 2071007 2071 8842458 200363 200 290956 385302 385 500507 362541518 362541 71217954 -79804346 1412726 8000000 8000 632000 640000 10665 10665 515975 515975 -902526 -902526 2071007 2071 8842458 200363 200 290956 385302 385 500507 370541518 370541 72376594 -80706872 1676840 450000 450000 -667690 -667690 2071007 2071 8842458 200363 200 290956 385302 385 500507 370541518 370541 72826594 -81374562 1459150 2071007 2071 8842458 200363 200 290956 385302 385 500507 387894033 387894 73791430 -82450781 1365120 2000000 2000 126000 128000 139834 140 9342 9482 2000 2000 361500 361500 -558539 -558539 2071007 2071 8842458 200363 200 290956 385302 385 500507 390033867 390034 74290272 -83009320 1307563 11000000 11000 693000 704000 22766 22 3728 3750 16624612 16625 -16625 5000 5000 86250 86250 -503458 -503458 2071007 2071 8842458 200363 200 290956 385302 385 500507 417681245 417681 75061625 -83512778 1603105 2071007 2071 8842458 200363 200 290956 385302 385 500507 417681245 417681 75061625 -83512778 1603105 278652 279 55884 56163 295306 295 -295 500000 500 -500 -1162500 -1162 1162 361500 361500 -825263 -825263 2071007 2071 8842458 200363 200 290956 385302 385 500507 417592703 417593 75479376 -84338041 1195505 2071007 2071 8842458 200363 200 290956 385302 385 500507 417592703 417593 75479376 -84338041 1195505 -1887260 -1818534 69395 809250 965975 -2000 -3000 10328 -3996 -196184 15677 674133 988648 -1213127 -829886 10000 839000 650665 839000 660665 -374127 -169221 1592287 1706065 1218160 1536844 <p id="xdx_803_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zr4k9EzeuvAd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1: <span id="xdx_826_zVC00xlO7owf">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying condensed financial statements of Vivos Inc. (the “<i>Company</i>”) have been prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and disclosures required by accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations. These condensed financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the results of operations of the Company for the period presented. The results of operations for the nine months ended September 30, 2024, are not necessarily indicative of the results that may be expected for any future period or the fiscal year ending December 31, 2024 and should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 18, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--BusinessOverviewPolicyTextBlock_z4S1gb3Kjks2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zsmlISiELd08">Business Overview</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (“<i>SMSC</i>”). On September 6, 2006, the Company changed its name to Advanced Medical Isotope Corporation, and on December 28, 2017, the Company began operating as Vivos Inc. The Company has authorized capital of <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240930_zhzhJTg9noie" title="Common stock, shares authorized">950,000,000</span> shares of common stock (“Common Stock”), $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240930_zDcFpkuNQGL7" title="Common stock, par value">0.001</span> par value per share, and <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20240930_zkAQUiddmDNg" title="Preferred stock, shares authorized">20,000,000</span> shares of preferred stock (“Preferred Stock”), $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240930_zWztARYjKc09" title="Preferred stock, par value">0.001</span> par value per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our principal place of business is located at 1030 North Center Parkway, Kennewick, WA 99336. Our telephone number is (509) 222-2222. Our corporate website address is http://www.radiogel.com. Our Common Stock is currently quoted on the OTC Pink Marketplace under the symbol “RDGL.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device, RadioGel<sup>™</sup>, for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers, and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGel <sup>™</sup>should be classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas. Additionally, after a legal review, the Company believes that the device classification obtained from the Food and Drug Administration (“<i>FDA</i>”) Center for Veterinary Medicine is not limited to canine and feline sarcomas, but rather may be extended to a much broader population of veterinary cancers, including all or most solid tumors in animals. We expect the result of such classification and label review will be that no additional regulatory approvals are necessary for the use of IsoPet<sup>® </sup>for the treatment of solid tumors in animals. The FDA does not have premarket authority over devices with a veterinary classification, and the manufacturers are responsible for assuring that the product is safe, effective, properly labeled, and otherwise in compliance with all applicable laws and regulations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the FDA’s recommendation, RadioGel<sup>™</sup> will be marketed as “IsoPet<sup>®</sup>” for use by veterinarians to avoid any confusion between animal and human therapy. The Company already has trademark protection for the “IsoPet<sup>®</sup>” name. IsoPet<sup>® </sup>and RadioGel<sup>™</sup> are used synonymously throughout this document. The only distinction between IsoPet<sup>® </sup>and RadioGel<sup>™</sup> is the FDA’s recommendation that we use “IsoPet<sup>®</sup>” for veterinarian usage, and reserve “RadioGel<sup>™” </sup>for human therapy. Based on these developments, the Company has shifted its primary focus to the development and marketing of Isopet<sup>®</sup> for animal therapy, through the Company’s IsoPet<sup>® </sup>Solutions division.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z83RvYdfYtn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zYhJcuNy1iE7">IsoPet Solutions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospitals to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. The Company has worked with three different university veterinarian hospitals on IsoPet<sup>®</sup> testing and therapy. Washington State University treated five cats for feline sarcoma and served to develop the procedures which are incorporated in our label. They concluded that the product was safe and effective in killing cancer cells. Colorado State University demonstrated the CT and PET-CT imaging of IsoPet<sup>®</sup>. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting in November 2017.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The dogs were treated for canine soft tissue sarcoma. Response evaluation criteria in solid tumors (“<i>RECIST</i>”) is a set of published rules that define when tumors in cancer patients improve (respond), stay the same (stabilize), or worsen (progress) during treatment. The criteria were published by an international collaboration including the European Organisation for Research and Treatment of Cancer (“<i>EORTC</i>”), National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The testing at the University of Missouri met its objective to demonstrate the safety of IsoPet<sup>®</sup>. Using its advanced CT and PET equipment it was able to demonstrate that the dose calculations were accurate and that the injections perfused into the cell interstices and did not stay concentrated in a bolus. This results in a more homogeneous dose distribution. There was insignificant spread of Y-90 outside the points of injection demonstrating the effectiveness of the particles and the gel to localize the radiation with no spreading to the blood or other organs nor to urine or fecal material. This confirms that IsoPet<sup>®</sup> is safe for same day therapy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The effectiveness of IsoPet<sup>®</sup> for life extension was not the prime objective, but it resulted in valuable insights. Of the cases one is still cancer-free but the others eventually recurred since there was not a strong focus on treating the margins. The University of Missouri has agreed to become a regional center to administer IsoPet<sup>®</sup> therapy and will incorporate the improvements suggested by the testing program.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel<sup>™</sup> (under the name IsoPet<sup>®</sup>) and related services, and from licensing to private medical and veterinary clinics in the United States of America (the “<i>USA</i>”, or, the “<i>U.S.</i>”) and internationally. The Company intends to report the results from the IsoPet<sup>®</sup> Solutions division as a separate operating segment in accordance with generally accepted accounting principles (“<i>GAAP</i>”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing in July 2019, the Company recognized its first commercial sale of IsoPet<sup>®</sup>. A veterinarian from Alaska brought his cat with a re-occurrent spindle cell sarcoma tumor on his face. The cat had previously received external beam therapy, but now the tumor was growing rapidly. He was given a high dose of 400 Gray with heavy therapy at the margins. This sale met the revenue recognition requirements under Financial Accounting Standards Board (“<i>FASB</i>”) Accounting Standards Codification (“<i>ASC</i>”) Topic 606 – Revenue from Contracts with Customers (“<i>ASC 606</i>”) as the performance obligation was satisfied. The Company completed sales for an additional four animals that received the IsoPet<sup>®</sup> during 2019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our plan is to incorporate the data assembled from our work with Isopet<sup>®</sup> in animal therapy to support the Company’s efforts in the development of our RadioGel<sup>™</sup> device candidate, including obtaining approval from the FDA to market and sell RadioGel<sup>™</sup> as a Class II medical device. RadioGel<sup>™</sup> is an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals. RadioGel<sup>™</sup> is comprised of a hydrogel, or a substance that is liquid at room temperature and then gels when reaching body temperature after injection into a tumor. In the gel are small particles, less than two microns, of Y-90. Once injected, these inert particles are locked in place inside the tumor by the gel, delivering a very high local radiation dose. The radiation is beta, consisting of high-speed electrons. These electrons only travel a short distance so the device can deliver high radiation to the tumor with minimal dose to the surrounding tissue. Optimally, patients can go home immediately following treatment without the risk of radiation exposure to family members. Since Y-90 has a half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company modified its Indication for Use from skin cancel to cancerous tissue or solid tumors pathologically associated with locoregional papillary thyroid carcinoma and recurrent papillary thyroid carcinoma having discernable tumors associated with metastatic lymph nodes or extranodal disease in patients who are not surgical candidates or who have declined surgery, or patients who require post-surgical remnant ablation (for example, after prior incomplete radioiodine therapy). Papillary thyroid carcinoma belongs to the general class of head and neck tumors for which tumors are accessible by intraoperative direct needle injection. The Company’s Medical Advisory Board felt that demonstrating efficacy in clinical trials was much easier with this new indication.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the third quarter of 2024, the Company entered the market of treating exotic animals by treating a ferret. The Company also has established important contacts at zoos and used conferences to communicate the effectiveness of Precision Radionuclide Therapy <sup>TM</sup> to the zoo community.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company intends to conduct human trials internationally, initially in Southeast Asia. These trials will be initiated prior to trials in the United States, and will be conducted under a protocol consistent with and complimentary to the IDE and human trial roadmap in the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_ecustom--IntellectualPropertyPolicyTextBlock_zrm7ekMvIp5j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zPMPTDQVJum5">Intellectual Property</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our original license with Battelle National Laboratory (the “<i>Battelle License</i>”) reached its end of life in 2022. During the past several years, we have expanded our proprietary knowledge, as well as our trademark and patent protection, in anticipation of the Battelle License reaching the end of its term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our RadioGel<sup>™</sup> trademark protection is in 17 countries. We have expanded our trademark protection from RadioGel<sup>™ </sup>to now include IsoPet<sup>®</sup>. We obtained the International Certificate of Registration for ISOPET, which is the first step to file in several countries<b>.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have filed for trademark protection for the term Precision Radionuclide Therapy<sup>™.</sup> We believe this term will be increasingly important.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company received the Patent Cooperation Treaty (“<i>PCT</i>”) International Search Report on our patent application (No.1811.191). Seven of our claims were immediately ruled as having novelty, inventive step and industrial applicability. This gives us the basis to extend for many years the patent protection for our proprietary Y-90 phosphate particles utilized in Isopet<sup>®</sup> and Radiogel<sup>™</sup>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our patent team filed our particle patent in more than ten patent offices that collectively cover 63 countries throughout the world. We filed a continuation-in-part applications number 1774054 in the USA to expand the claims on our particle patent. The U.S. Patent office recently gave us the Notice of Allowance for our patent to produce our yttrium phosphate microparticles, U.S. Patent Application Serial No: 16-459,466. We also filed an amendment to correct the wording on our claims at make them consistent with the USE claims. Ref: 4207-0005; European Patent Application NO. 20 834 229.5; VIVOS INC; Our Ref: FS/53791.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We filed a hydrogel utility patent in the USA (16309:17/943,311) and internationally (16389:PCT/US22/4374) based on the last 18 months of development work to optimize our hydrogel component. These include reducing the polymer production time and increasing the output by a factor of three. We have also further reduced the level of trace contaminants to be well below the FDA guidelines.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We filed a provisional patent (Serial Number 63436562) to protect our innovative improvements in our shipping container, our vial shield, our syringe shield, and our Peltier chiller. Our objectives were to reduce shipping costs, decrease radiation exposure, and enhance sterility. These devices will be preferentially used at Mayo Clinics for human clinical studies at our IsoPet regional treatment centers. The Company filed a utility patent in the fourth quarter of 2023 for this therapy support equipment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We anticipate that Precision Radionuclide Therapy will become increasingly important in the future and expand to other isotope and other indications for use. Therefore, we filed an alternate particle utility patent (Serial number 18/152,137). We will focus our near-term effort on the Y-90 therapy, which we believe is the best beta emitter; however, we leveraged our hydrogel utility patent to incorporate other promising isotopes and compounds for a range of future applications. This includes gamma and alpha particle emitters.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have trademark protection in several countries on IsoPet<sup>®</sup>, RadioGel<sup>®</sup>, Precision Radionuclide Therapy<sup>TM</sup>, BetaGel<sup>TM</sup>, GammaGel<sup>TM</sup>, and AlphaGel<sup>TM</sup>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_ecustom--GoingConcernPolicyTextBlock_zwWWSmegA624" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zp4PRFSOsa91">Going Concern</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $<span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_iN_pn5n6_di_c20240101__20240930_z7ttWt3G2pxi" title="Current operating activities">2.5</span> million annually to maintain current operating activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_ecustom--FinancingAndStrategyPolicyTextBlock_zLwG16bVg4H4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zF7Isg9XbZmj">Financing and Strategy</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2019, the SEC qualified the Company’s offering of its Common Stock, under Regulation A of Section 3(6) of the Securities Act of 1933, as amended (the “<i>Securities Act</i>”) (“<i>Regulation A</i>”), which offering was and amended from time to time thereafter (the “<i>2019 Regulation A+ Offering</i>”). In September 2021, the SEC qualified the Company’s offering of Common Stock under Regulation A, which offering was amended from time to time thereafter (together with the 2019 Regulation A+ Offering, the “<i>Prior Regulation A+ Offerings</i>”). During the year ended December 31, 2023, $<span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zLeHPQbykMU1" title="Number of common stock shares issued. value">1,179,245</span> was raised through the sale of <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zuYh3Tr9WWJi" title="Number of common stock shares issued, shares">16,132,000</span> shares of common stock and the private placement of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYnoHksQabP" title="Number of warrants issued">18,797,000</span> warrants. During the nine months ended September 30, 2024, the Company raised $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfglflsDBElc" title="Number of common stock shares issued, value">839,000</span> through the issuance of <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7NirgtVT39h" title="Number of common stock shares issued, shares">13,000,000</span> shares of common stock and <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1LnyfFxXHne" title="Number of warrants issued">7,000,000</span> warrants. The Company’s Prior Regulation A Offerings undertaken pursuant to Regulation A+ have raised approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20240101__20240930_zimCtwJgD27f" title="Sale of common stock">6,000,000</span> from the sale of shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 17, 2024, the SEC qualified the Company’s offering under Regulation A to offer up to $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240717__20240717__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_za7sr0r8iEzk" title="Number of common stock shares issued, value">60,000,000</span> shares of its Common Stock (the “<i>July 2024 Regulation A+ Offering</i>”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is using the proceeds generated from the Prior Regulation A+ Offering and the July 2024 Regulation A+ Offering as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities. The Company may require additional funding of approximately $<span id="xdx_900_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn5n6_c20240101__20240930__srt--ProductOrServiceAxis__custom--BrachytherapyProductLineMember_zLWH7Vsf7br3" title="Current operating activities">5 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million annually to maintain current operating activities. <span id="xdx_905_ecustom--OfferingTerm_c20240101__20240930__srt--ProductOrServiceAxis__custom--BrachytherapyProductLineMember_z22I9SbJNj0g">Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, and clinical trials; (3) activate several regional clinics to administer IsoPet<sup>® </sup>across the county; (4) create an independent production center within the current production site to create a template for future international manufacturing; and (5) initiate regulatory approval processes outside of the United States. The proceeds to be raised from the Regulation A+ Offerings will be used to continue to fund this development.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise), and any requirements for additional studies (which may possibly include clinical studies). Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be: (1) the timing of any approvals; (2) the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution, and licensing of those products; and (3) the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements, as well as proceeds to be raised from the Regulation A+ Offerings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following receipt of required regulatory approvals and necessary financing to fund our working capital requirements, the Company intends to outsource material aspects of manufacturing, distribution, sales, and marketing for operations within the U.S. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses. These long-term goals are subject to the Company: (1) receiving adequate funding; (2) receiving regulatory approval for RadioGel<sup>™</sup> and other brachytherapy products; and (3) being able to successfully commercialize its brachytherapy products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s headquarters are in Northeast Washington, however, our focus on the animal therapy market has been the Northwestern sector of the U.S. The Company continues its marketing efforts on the animal therapy market and our attempts to increase the exposure to our product, and generate revenue accordingly.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2024, the Company had $<span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20240930_z0Tje3Jxa6ga" title="Cash on hand">1,218,160</span> cash on hand. There are currently commitments to vendors for products and services purchased. To continue the development of the Company’s products, the current level of cash will not be enough to cover the fixed and variable obligations of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company anticipates using the proceeds from the July 2024 Regulation A+ Offering as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the animal therapy market:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expand communication on our website, the Company’s social media presence, conferences, and journals, each intended to increase the number of certified clinics for small animal and equine therapy and to increase the number of patients.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidize some IsoPet<sup>®</sup> therapies, if necessary, to ensure that all viable candidates are treated; and.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assist a new regional clinic with their license and certification training.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the human market:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhance the pedigree of the Quality Management System.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Begin automation of product manufacturing.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fund liability insurance for human clinical studies; and.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fund human clinical studies in the US. </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development of the Company’s precision radionuclide therapy product line has been funded with proceeds from the sale of equity and debt securities, including from the Prior Regulation A+ Offerings. The Company requires additional funding of approximately $<span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn5n6_c20240101__20240930__srt--ProductOrServiceAxis__custom--RadionuclideTherapyProductLineMember_zyw9iXgBsGG7" title="Current operating activities">2.5 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million annually to maintain operating activities. <span id="xdx_90C_ecustom--OfferingTerm_c20240101__20240930__srt--ProductOrServiceAxis__custom--RadionuclideTherapyProductLineMember_zTDMR4LQ4WNh">Over the next 36 months, the Company believes it will cost approximately $8.0 to $9.0 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, clinical trials; (3) activate several regional clinics to administer IsoPet<sup>® </sup>across the U.S.; (4) create an independent production center within the current production site to create a template for future international manufacturing; and (5) initiate regulatory approval processes outside of the United States.</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The proceeds raised from the Prior Regulation A+ Offerings were used to fund this development and proceeds from the July 2024 Regulation A+ Offering will be used to continue such development efforts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The continued deployment of the precision radionuclide therapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the precision radionuclide therapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s precision radionuclide therapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or from proceeds raised from the Prior Regulation A+ Offering and from the July 2024 Regulation A+ Offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company intends to expand the indications for use in phases: first, for lymph nodes associated with thyroid cancer, secondly, cancerous lung nodules, and finally, all non-sectable solid tumors. It is anticipated that the medical community may begin to use RadioGel off-label, we will support but will not encourage that practice.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term, the Company intends to consider resuming research efforts with respect to other products and technologies, such as Gamma Gel and Alpha Gel intended to help improve the diagnosis and treatment of cancer and other illnesses. These long-term goals are subject to the Company: (1) receiving adequate funding; (2) receiving regulatory approval for RadioGel<sup>™</sup> and other precision radionuclide therapy products; and (3) being able to successfully commercialize its precision radionuclide therapy products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s headquarters are in the State of Washington., The initial focus of the animal therapy market has been the Northwestern sector of the United States. The Company has initiated marketing efforts to the animal therapy market in other regions of the United States, attempting to increase the exposure to our product and increase revenue opportunities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are currently commitments to vendors for products and services purchased. To continue the development of the Company’s products, the current level of cash will not be enough to cover the fixed and variable obligations of the Company. The Company has focused on operating on minimum overhead, including using a virtual office for the last several years and retaining experienced industry consultants available on an as needed basis. This has helped focus the capital received from the Company’s Regulation A+ Offerings on activities that enhance our objectives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is no guarantee that the Company will be able to raise additional funds or to do so on terms advantageous to the Company’s stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There can be no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--UseOfEstimates_zYSudGCihAkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zupzZDOFqrGd">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amount of revenue and expense during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zmCPqILwPVpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zmgXLbuIVYEd">Financial Statement Reclassification</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain account balances from prior periods have been reclassified in these financial statements so as to conform to current period classifications.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPBIszp9kmI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zEoEBL5XHkN7">Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company occasionally maintains cash balances in excess of the FDIC insured limit. The Company does not consider this risk to be material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z81zSue8OT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zjqGCFjLA0n3">Fair Value of Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of September 30, 2024 and December 31, 2023, the balances reported for cash, prepaid expense, accounts receivable, accounts payable, and accrued expense, approximate the fair value because of their short maturities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“<i>ASC</i>”) Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zadMuwhHUSgd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zVjj9CoTUbX9">Patents and Intellectual Property</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such <span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240930_zQoMcBcnITS5" title="Economic life of the patent">10</span>-year period and on a straight-line basis will begin once the patents have been issued and the Company begins utilization of the patents through production and sales, resulting in revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There have been no such capitalized costs in the three and nine months ended September 30, 2024 and 2023, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) filed by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet<sup>® </sup>commercially available, which it did on or about July 9, 2019. This additional patent protection will strengthen the Company’s competitive position. It is the Company’s intention to further extend this patent protection to several key countries within one year, as permitted under international patent laws and treaties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--RevenueRecognitionPolicyTextBlock_zjRUTzcrarVe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zsQUJe7Po6A7">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2014, the Financial Accounting Standards Board (“<i>FASB</i>”) issued Accounting Standard Update (“<i>ASU</i>”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated guidance effective January 1, 2018 using the full retrospective method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to perform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized revenue as they (i) identified the contracts with each customer; (ii) identified the performance obligation in each contract; (iii) determined the transaction price in each contract; (iv) were able to allocate the transaction price to the performance obligations in the contract; and (v) recognized revenue upon the satisfaction of the performance obligation. Upon the sales of the product to complete the procedures on the animals, the Company recognized revenue as that was considered the performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All revenue recognized in the three and nine months ended September 30, 2024 and 2023 relate to the procedures performed with respect to the IsoPet<sup>® </sup>therapies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zImDgD8xmLr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zwFPhXYnwR9e">Loss Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive Common Stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the periods ended in the nine months ended September 30, 2024 and 2023, the basic earnings per share equals the diluted earnings per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ziPvzJshtvr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following represent Common Stock equivalents that could be dilutive in the future as of September 30, 2024 and December 31, 2023, which include the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zTnWfM6vUcGe" style="display: none">SCHEDULE OF DILUTIVE EARNINGS PER SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49E_20240101__20240930_ztRocXUNmsn6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 30, 2024</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49A_20230101__20231231_zmRqh8gqL0Qi" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31, 2023</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zXPUPFXQxB5g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Preferred stock</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,909,570</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,909,570</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zS0XsyaNpNz4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted stock units</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,450,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z7SMWRoMkmU9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock options</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,252,809</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,252,809</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zWbPJWeulN5e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Common stock warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,100,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,134,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zTL8jO2lLsFh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total potential dilutive securities</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,262,379</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,746,379</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A8_zJ9gG5oObGO4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_ztPyi3MdZVjl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zZdckfenoRf4">Research and Development Costs</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and developments costs, including salaries, research materials, administrative expense and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930_zvfh1KjbKlcf" title="Research and development costs">66,551</span> and $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930_zPQXqE0LYHF9" title="Research and development costs">80,858</span> in research and development costs for the three months ended September 30, 2024 and 2023, respectively, and $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930_zLv3q0zPs3Te" title="Research and development costs">223,660</span> and $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930_znWSdGQO9PYg" title="Research and development costs">300,586</span> in research and development costs for the nine months ended September 30, 2024 and 2023, respectively, all of which were recorded in the Company’s operating expense noted on the statements of operations for the periods then ended.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--AdvertisingCostsPolicyTextBlock_zmsyBcBhljw1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z0SEc3JJIFtf">Advertising and Marketing Costs</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. During the three and nine months ended September 30, 2024 and 2023, the Company incurred nominal advertising and marketing costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_846_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zaHvOPlHE8jl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zjZWxcP3ciIe">Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. The Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of September 30, 2024 and December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zvdBnH4re0kc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z58iiaTowPTf">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the three and nine months ended September 30, 2024 and 2023. The Company did not have any deferred tax liability or asset on its balance sheets as of September 30, 2024 and December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the three and nine months ended September 30, 2024 and 2023, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zj7kTlEdIOwh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zSRBM4Tqk9S4">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes compensation costs under FASB ASC Topic 718, Compensation – Stock Compensation and ASU 2018-07. Companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zzRryza0dq6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zkzXiWXEVhcl">Recent Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.</span></p> <p id="xdx_857_z0WhCKkCT9md" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--BusinessOverviewPolicyTextBlock_z4S1gb3Kjks2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zsmlISiELd08">Business Overview</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (“<i>SMSC</i>”). On September 6, 2006, the Company changed its name to Advanced Medical Isotope Corporation, and on December 28, 2017, the Company began operating as Vivos Inc. The Company has authorized capital of <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240930_zhzhJTg9noie" title="Common stock, shares authorized">950,000,000</span> shares of common stock (“Common Stock”), $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240930_zDcFpkuNQGL7" title="Common stock, par value">0.001</span> par value per share, and <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20240930_zkAQUiddmDNg" title="Preferred stock, shares authorized">20,000,000</span> shares of preferred stock (“Preferred Stock”), $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240930_zWztARYjKc09" title="Preferred stock, par value">0.001</span> par value per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our principal place of business is located at 1030 North Center Parkway, Kennewick, WA 99336. Our telephone number is (509) 222-2222. Our corporate website address is http://www.radiogel.com. Our Common Stock is currently quoted on the OTC Pink Marketplace under the symbol “RDGL.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device, RadioGel<sup>™</sup>, for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers, and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGel <sup>™</sup>should be classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas. Additionally, after a legal review, the Company believes that the device classification obtained from the Food and Drug Administration (“<i>FDA</i>”) Center for Veterinary Medicine is not limited to canine and feline sarcomas, but rather may be extended to a much broader population of veterinary cancers, including all or most solid tumors in animals. We expect the result of such classification and label review will be that no additional regulatory approvals are necessary for the use of IsoPet<sup>® </sup>for the treatment of solid tumors in animals. The FDA does not have premarket authority over devices with a veterinary classification, and the manufacturers are responsible for assuring that the product is safe, effective, properly labeled, and otherwise in compliance with all applicable laws and regulations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the FDA’s recommendation, RadioGel<sup>™</sup> will be marketed as “IsoPet<sup>®</sup>” for use by veterinarians to avoid any confusion between animal and human therapy. The Company already has trademark protection for the “IsoPet<sup>®</sup>” name. IsoPet<sup>® </sup>and RadioGel<sup>™</sup> are used synonymously throughout this document. The only distinction between IsoPet<sup>® </sup>and RadioGel<sup>™</sup> is the FDA’s recommendation that we use “IsoPet<sup>®</sup>” for veterinarian usage, and reserve “RadioGel<sup>™” </sup>for human therapy. Based on these developments, the Company has shifted its primary focus to the development and marketing of Isopet<sup>®</sup> for animal therapy, through the Company’s IsoPet<sup>® </sup>Solutions division.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 950000000 0.001 20000000 0.001 <p id="xdx_840_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z83RvYdfYtn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zYhJcuNy1iE7">IsoPet Solutions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospitals to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. The Company has worked with three different university veterinarian hospitals on IsoPet<sup>®</sup> testing and therapy. Washington State University treated five cats for feline sarcoma and served to develop the procedures which are incorporated in our label. They concluded that the product was safe and effective in killing cancer cells. Colorado State University demonstrated the CT and PET-CT imaging of IsoPet<sup>®</sup>. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting in November 2017.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The dogs were treated for canine soft tissue sarcoma. Response evaluation criteria in solid tumors (“<i>RECIST</i>”) is a set of published rules that define when tumors in cancer patients improve (respond), stay the same (stabilize), or worsen (progress) during treatment. The criteria were published by an international collaboration including the European Organisation for Research and Treatment of Cancer (“<i>EORTC</i>”), National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The testing at the University of Missouri met its objective to demonstrate the safety of IsoPet<sup>®</sup>. Using its advanced CT and PET equipment it was able to demonstrate that the dose calculations were accurate and that the injections perfused into the cell interstices and did not stay concentrated in a bolus. This results in a more homogeneous dose distribution. There was insignificant spread of Y-90 outside the points of injection demonstrating the effectiveness of the particles and the gel to localize the radiation with no spreading to the blood or other organs nor to urine or fecal material. This confirms that IsoPet<sup>®</sup> is safe for same day therapy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The effectiveness of IsoPet<sup>®</sup> for life extension was not the prime objective, but it resulted in valuable insights. Of the cases one is still cancer-free but the others eventually recurred since there was not a strong focus on treating the margins. The University of Missouri has agreed to become a regional center to administer IsoPet<sup>®</sup> therapy and will incorporate the improvements suggested by the testing program.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel<sup>™</sup> (under the name IsoPet<sup>®</sup>) and related services, and from licensing to private medical and veterinary clinics in the United States of America (the “<i>USA</i>”, or, the “<i>U.S.</i>”) and internationally. The Company intends to report the results from the IsoPet<sup>®</sup> Solutions division as a separate operating segment in accordance with generally accepted accounting principles (“<i>GAAP</i>”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing in July 2019, the Company recognized its first commercial sale of IsoPet<sup>®</sup>. A veterinarian from Alaska brought his cat with a re-occurrent spindle cell sarcoma tumor on his face. The cat had previously received external beam therapy, but now the tumor was growing rapidly. He was given a high dose of 400 Gray with heavy therapy at the margins. This sale met the revenue recognition requirements under Financial Accounting Standards Board (“<i>FASB</i>”) Accounting Standards Codification (“<i>ASC</i>”) Topic 606 – Revenue from Contracts with Customers (“<i>ASC 606</i>”) as the performance obligation was satisfied. The Company completed sales for an additional four animals that received the IsoPet<sup>®</sup> during 2019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our plan is to incorporate the data assembled from our work with Isopet<sup>®</sup> in animal therapy to support the Company’s efforts in the development of our RadioGel<sup>™</sup> device candidate, including obtaining approval from the FDA to market and sell RadioGel<sup>™</sup> as a Class II medical device. RadioGel<sup>™</sup> is an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals. RadioGel<sup>™</sup> is comprised of a hydrogel, or a substance that is liquid at room temperature and then gels when reaching body temperature after injection into a tumor. In the gel are small particles, less than two microns, of Y-90. Once injected, these inert particles are locked in place inside the tumor by the gel, delivering a very high local radiation dose. The radiation is beta, consisting of high-speed electrons. These electrons only travel a short distance so the device can deliver high radiation to the tumor with minimal dose to the surrounding tissue. Optimally, patients can go home immediately following treatment without the risk of radiation exposure to family members. Since Y-90 has a half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company modified its Indication for Use from skin cancel to cancerous tissue or solid tumors pathologically associated with locoregional papillary thyroid carcinoma and recurrent papillary thyroid carcinoma having discernable tumors associated with metastatic lymph nodes or extranodal disease in patients who are not surgical candidates or who have declined surgery, or patients who require post-surgical remnant ablation (for example, after prior incomplete radioiodine therapy). Papillary thyroid carcinoma belongs to the general class of head and neck tumors for which tumors are accessible by intraoperative direct needle injection. The Company’s Medical Advisory Board felt that demonstrating efficacy in clinical trials was much easier with this new indication.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the third quarter of 2024, the Company entered the market of treating exotic animals by treating a ferret. The Company also has established important contacts at zoos and used conferences to communicate the effectiveness of Precision Radionuclide Therapy <sup>TM</sup> to the zoo community.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company intends to conduct human trials internationally, initially in Southeast Asia. These trials will be initiated prior to trials in the United States, and will be conducted under a protocol consistent with and complimentary to the IDE and human trial roadmap in the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_ecustom--IntellectualPropertyPolicyTextBlock_zrm7ekMvIp5j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zPMPTDQVJum5">Intellectual Property</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our original license with Battelle National Laboratory (the “<i>Battelle License</i>”) reached its end of life in 2022. During the past several years, we have expanded our proprietary knowledge, as well as our trademark and patent protection, in anticipation of the Battelle License reaching the end of its term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our RadioGel<sup>™</sup> trademark protection is in 17 countries. We have expanded our trademark protection from RadioGel<sup>™ </sup>to now include IsoPet<sup>®</sup>. We obtained the International Certificate of Registration for ISOPET, which is the first step to file in several countries<b>.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have filed for trademark protection for the term Precision Radionuclide Therapy<sup>™.</sup> We believe this term will be increasingly important.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company received the Patent Cooperation Treaty (“<i>PCT</i>”) International Search Report on our patent application (No.1811.191). Seven of our claims were immediately ruled as having novelty, inventive step and industrial applicability. This gives us the basis to extend for many years the patent protection for our proprietary Y-90 phosphate particles utilized in Isopet<sup>®</sup> and Radiogel<sup>™</sup>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our patent team filed our particle patent in more than ten patent offices that collectively cover 63 countries throughout the world. We filed a continuation-in-part applications number 1774054 in the USA to expand the claims on our particle patent. The U.S. Patent office recently gave us the Notice of Allowance for our patent to produce our yttrium phosphate microparticles, U.S. Patent Application Serial No: 16-459,466. We also filed an amendment to correct the wording on our claims at make them consistent with the USE claims. Ref: 4207-0005; European Patent Application NO. 20 834 229.5; VIVOS INC; Our Ref: FS/53791.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We filed a hydrogel utility patent in the USA (16309:17/943,311) and internationally (16389:PCT/US22/4374) based on the last 18 months of development work to optimize our hydrogel component. These include reducing the polymer production time and increasing the output by a factor of three. We have also further reduced the level of trace contaminants to be well below the FDA guidelines.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We filed a provisional patent (Serial Number 63436562) to protect our innovative improvements in our shipping container, our vial shield, our syringe shield, and our Peltier chiller. Our objectives were to reduce shipping costs, decrease radiation exposure, and enhance sterility. These devices will be preferentially used at Mayo Clinics for human clinical studies at our IsoPet regional treatment centers. The Company filed a utility patent in the fourth quarter of 2023 for this therapy support equipment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We anticipate that Precision Radionuclide Therapy will become increasingly important in the future and expand to other isotope and other indications for use. Therefore, we filed an alternate particle utility patent (Serial number 18/152,137). We will focus our near-term effort on the Y-90 therapy, which we believe is the best beta emitter; however, we leveraged our hydrogel utility patent to incorporate other promising isotopes and compounds for a range of future applications. This includes gamma and alpha particle emitters.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have trademark protection in several countries on IsoPet<sup>®</sup>, RadioGel<sup>®</sup>, Precision Radionuclide Therapy<sup>TM</sup>, BetaGel<sup>TM</sup>, GammaGel<sup>TM</sup>, and AlphaGel<sup>TM</sup>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_ecustom--GoingConcernPolicyTextBlock_zwWWSmegA624" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zp4PRFSOsa91">Going Concern</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $<span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_iN_pn5n6_di_c20240101__20240930_z7ttWt3G2pxi" title="Current operating activities">2.5</span> million annually to maintain current operating activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -2500000 <p id="xdx_84D_ecustom--FinancingAndStrategyPolicyTextBlock_zLwG16bVg4H4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zF7Isg9XbZmj">Financing and Strategy</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2019, the SEC qualified the Company’s offering of its Common Stock, under Regulation A of Section 3(6) of the Securities Act of 1933, as amended (the “<i>Securities Act</i>”) (“<i>Regulation A</i>”), which offering was and amended from time to time thereafter (the “<i>2019 Regulation A+ Offering</i>”). In September 2021, the SEC qualified the Company’s offering of Common Stock under Regulation A, which offering was amended from time to time thereafter (together with the 2019 Regulation A+ Offering, the “<i>Prior Regulation A+ Offerings</i>”). During the year ended December 31, 2023, $<span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zLeHPQbykMU1" title="Number of common stock shares issued. value">1,179,245</span> was raised through the sale of <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zuYh3Tr9WWJi" title="Number of common stock shares issued, shares">16,132,000</span> shares of common stock and the private placement of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYnoHksQabP" title="Number of warrants issued">18,797,000</span> warrants. During the nine months ended September 30, 2024, the Company raised $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfglflsDBElc" title="Number of common stock shares issued, value">839,000</span> through the issuance of <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7NirgtVT39h" title="Number of common stock shares issued, shares">13,000,000</span> shares of common stock and <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1LnyfFxXHne" title="Number of warrants issued">7,000,000</span> warrants. The Company’s Prior Regulation A Offerings undertaken pursuant to Regulation A+ have raised approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20240101__20240930_zimCtwJgD27f" title="Sale of common stock">6,000,000</span> from the sale of shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 17, 2024, the SEC qualified the Company’s offering under Regulation A to offer up to $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240717__20240717__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_za7sr0r8iEzk" title="Number of common stock shares issued, value">60,000,000</span> shares of its Common Stock (the “<i>July 2024 Regulation A+ Offering</i>”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is using the proceeds generated from the Prior Regulation A+ Offering and the July 2024 Regulation A+ Offering as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities. The Company may require additional funding of approximately $<span id="xdx_900_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn5n6_c20240101__20240930__srt--ProductOrServiceAxis__custom--BrachytherapyProductLineMember_zLWH7Vsf7br3" title="Current operating activities">5 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million annually to maintain current operating activities. <span id="xdx_905_ecustom--OfferingTerm_c20240101__20240930__srt--ProductOrServiceAxis__custom--BrachytherapyProductLineMember_z22I9SbJNj0g">Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, and clinical trials; (3) activate several regional clinics to administer IsoPet<sup>® </sup>across the county; (4) create an independent production center within the current production site to create a template for future international manufacturing; and (5) initiate regulatory approval processes outside of the United States. The proceeds to be raised from the Regulation A+ Offerings will be used to continue to fund this development.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise), and any requirements for additional studies (which may possibly include clinical studies). Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be: (1) the timing of any approvals; (2) the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution, and licensing of those products; and (3) the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements, as well as proceeds to be raised from the Regulation A+ Offerings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following receipt of required regulatory approvals and necessary financing to fund our working capital requirements, the Company intends to outsource material aspects of manufacturing, distribution, sales, and marketing for operations within the U.S. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses. These long-term goals are subject to the Company: (1) receiving adequate funding; (2) receiving regulatory approval for RadioGel<sup>™</sup> and other brachytherapy products; and (3) being able to successfully commercialize its brachytherapy products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s headquarters are in Northeast Washington, however, our focus on the animal therapy market has been the Northwestern sector of the U.S. The Company continues its marketing efforts on the animal therapy market and our attempts to increase the exposure to our product, and generate revenue accordingly.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2024, the Company had $<span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20240930_z0Tje3Jxa6ga" title="Cash on hand">1,218,160</span> cash on hand. There are currently commitments to vendors for products and services purchased. To continue the development of the Company’s products, the current level of cash will not be enough to cover the fixed and variable obligations of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company anticipates using the proceeds from the July 2024 Regulation A+ Offering as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the animal therapy market:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expand communication on our website, the Company’s social media presence, conferences, and journals, each intended to increase the number of certified clinics for small animal and equine therapy and to increase the number of patients.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidize some IsoPet<sup>®</sup> therapies, if necessary, to ensure that all viable candidates are treated; and.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assist a new regional clinic with their license and certification training.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the human market:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhance the pedigree of the Quality Management System.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Begin automation of product manufacturing.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fund liability insurance for human clinical studies; and.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fund human clinical studies in the US. </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development of the Company’s precision radionuclide therapy product line has been funded with proceeds from the sale of equity and debt securities, including from the Prior Regulation A+ Offerings. The Company requires additional funding of approximately $<span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn5n6_c20240101__20240930__srt--ProductOrServiceAxis__custom--RadionuclideTherapyProductLineMember_zyw9iXgBsGG7" title="Current operating activities">2.5 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million annually to maintain operating activities. <span id="xdx_90C_ecustom--OfferingTerm_c20240101__20240930__srt--ProductOrServiceAxis__custom--RadionuclideTherapyProductLineMember_zTDMR4LQ4WNh">Over the next 36 months, the Company believes it will cost approximately $8.0 to $9.0 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, clinical trials; (3) activate several regional clinics to administer IsoPet<sup>® </sup>across the U.S.; (4) create an independent production center within the current production site to create a template for future international manufacturing; and (5) initiate regulatory approval processes outside of the United States.</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The proceeds raised from the Prior Regulation A+ Offerings were used to fund this development and proceeds from the July 2024 Regulation A+ Offering will be used to continue such development efforts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The continued deployment of the precision radionuclide therapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the precision radionuclide therapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s precision radionuclide therapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or from proceeds raised from the Prior Regulation A+ Offering and from the July 2024 Regulation A+ Offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company intends to expand the indications for use in phases: first, for lymph nodes associated with thyroid cancer, secondly, cancerous lung nodules, and finally, all non-sectable solid tumors. It is anticipated that the medical community may begin to use RadioGel off-label, we will support but will not encourage that practice.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term, the Company intends to consider resuming research efforts with respect to other products and technologies, such as Gamma Gel and Alpha Gel intended to help improve the diagnosis and treatment of cancer and other illnesses. These long-term goals are subject to the Company: (1) receiving adequate funding; (2) receiving regulatory approval for RadioGel<sup>™</sup> and other precision radionuclide therapy products; and (3) being able to successfully commercialize its precision radionuclide therapy products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s headquarters are in the State of Washington., The initial focus of the animal therapy market has been the Northwestern sector of the United States. The Company has initiated marketing efforts to the animal therapy market in other regions of the United States, attempting to increase the exposure to our product and increase revenue opportunities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are currently commitments to vendors for products and services purchased. To continue the development of the Company’s products, the current level of cash will not be enough to cover the fixed and variable obligations of the Company. The Company has focused on operating on minimum overhead, including using a virtual office for the last several years and retaining experienced industry consultants available on an as needed basis. This has helped focus the capital received from the Company’s Regulation A+ Offerings on activities that enhance our objectives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is no guarantee that the Company will be able to raise additional funds or to do so on terms advantageous to the Company’s stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There can be no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1179245 16132000 18797000 839000 13000000 7000000 6000000 60000000 5000000 Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, and clinical trials; (3) activate several regional clinics to administer IsoPet® across the county; (4) create an independent production center within the current production site to create a template for future international manufacturing; and (5) initiate regulatory approval processes outside of the United States. The proceeds to be raised from the Regulation A+ Offerings will be used to continue to fund this development. 1218160 2500000 Over the next 36 months, the Company believes it will cost approximately $8.0 to $9.0 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, clinical trials; (3) activate several regional clinics to administer IsoPet® across the U.S.; (4) create an independent production center within the current production site to create a template for future international manufacturing; and (5) initiate regulatory approval processes outside of the United States. <p id="xdx_84C_eus-gaap--UseOfEstimates_zYSudGCihAkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zupzZDOFqrGd">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amount of revenue and expense during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zmCPqILwPVpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zmgXLbuIVYEd">Financial Statement Reclassification</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain account balances from prior periods have been reclassified in these financial statements so as to conform to current period classifications.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPBIszp9kmI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zEoEBL5XHkN7">Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company occasionally maintains cash balances in excess of the FDIC insured limit. The Company does not consider this risk to be material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z81zSue8OT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zjqGCFjLA0n3">Fair Value of Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of September 30, 2024 and December 31, 2023, the balances reported for cash, prepaid expense, accounts receivable, accounts payable, and accrued expense, approximate the fair value because of their short maturities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“<i>ASC</i>”) Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zadMuwhHUSgd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zVjj9CoTUbX9">Patents and Intellectual Property</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such <span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240930_zQoMcBcnITS5" title="Economic life of the patent">10</span>-year period and on a straight-line basis will begin once the patents have been issued and the Company begins utilization of the patents through production and sales, resulting in revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There have been no such capitalized costs in the three and nine months ended September 30, 2024 and 2023, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) filed by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet<sup>® </sup>commercially available, which it did on or about July 9, 2019. This additional patent protection will strengthen the Company’s competitive position. It is the Company’s intention to further extend this patent protection to several key countries within one year, as permitted under international patent laws and treaties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P10Y <p id="xdx_84B_eus-gaap--RevenueRecognitionPolicyTextBlock_zjRUTzcrarVe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zsQUJe7Po6A7">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2014, the Financial Accounting Standards Board (“<i>FASB</i>”) issued Accounting Standard Update (“<i>ASU</i>”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated guidance effective January 1, 2018 using the full retrospective method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to perform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized revenue as they (i) identified the contracts with each customer; (ii) identified the performance obligation in each contract; (iii) determined the transaction price in each contract; (iv) were able to allocate the transaction price to the performance obligations in the contract; and (v) recognized revenue upon the satisfaction of the performance obligation. Upon the sales of the product to complete the procedures on the animals, the Company recognized revenue as that was considered the performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All revenue recognized in the three and nine months ended September 30, 2024 and 2023 relate to the procedures performed with respect to the IsoPet<sup>® </sup>therapies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zImDgD8xmLr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zwFPhXYnwR9e">Loss Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive Common Stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the periods ended in the nine months ended September 30, 2024 and 2023, the basic earnings per share equals the diluted earnings per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ziPvzJshtvr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following represent Common Stock equivalents that could be dilutive in the future as of September 30, 2024 and December 31, 2023, which include the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zTnWfM6vUcGe" style="display: none">SCHEDULE OF DILUTIVE EARNINGS PER SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49E_20240101__20240930_ztRocXUNmsn6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 30, 2024</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49A_20230101__20231231_zmRqh8gqL0Qi" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31, 2023</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zXPUPFXQxB5g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Preferred stock</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,909,570</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,909,570</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zS0XsyaNpNz4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted stock units</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,450,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z7SMWRoMkmU9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock options</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,252,809</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,252,809</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zWbPJWeulN5e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Common stock warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,100,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,134,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zTL8jO2lLsFh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total potential dilutive securities</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,262,379</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,746,379</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A8_zJ9gG5oObGO4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ziPvzJshtvr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following represent Common Stock equivalents that could be dilutive in the future as of September 30, 2024 and December 31, 2023, which include the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zTnWfM6vUcGe" style="display: none">SCHEDULE OF DILUTIVE EARNINGS PER SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49E_20240101__20240930_ztRocXUNmsn6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 30, 2024</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49A_20230101__20231231_zmRqh8gqL0Qi" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31, 2023</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zXPUPFXQxB5g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Preferred stock</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,909,570</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,909,570</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zS0XsyaNpNz4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted stock units</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,450,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z7SMWRoMkmU9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock options</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,252,809</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,252,809</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zWbPJWeulN5e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Common stock warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,100,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,134,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zTL8jO2lLsFh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total potential dilutive securities</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,262,379</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,746,379</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 9909570 9909570 12000000 1450000 2252809 2252809 8100000 26134000 32262379 39746379 <p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_ztPyi3MdZVjl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zZdckfenoRf4">Research and Development Costs</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and developments costs, including salaries, research materials, administrative expense and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930_zvfh1KjbKlcf" title="Research and development costs">66,551</span> and $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930_zPQXqE0LYHF9" title="Research and development costs">80,858</span> in research and development costs for the three months ended September 30, 2024 and 2023, respectively, and $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930_zLv3q0zPs3Te" title="Research and development costs">223,660</span> and $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930_znWSdGQO9PYg" title="Research and development costs">300,586</span> in research and development costs for the nine months ended September 30, 2024 and 2023, respectively, all of which were recorded in the Company’s operating expense noted on the statements of operations for the periods then ended.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 66551 80858 223660 300586 <p id="xdx_84D_eus-gaap--AdvertisingCostsPolicyTextBlock_zmsyBcBhljw1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z0SEc3JJIFtf">Advertising and Marketing Costs</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. During the three and nine months ended September 30, 2024 and 2023, the Company incurred nominal advertising and marketing costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_846_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zaHvOPlHE8jl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zjZWxcP3ciIe">Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. The Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of September 30, 2024 and December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zvdBnH4re0kc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z58iiaTowPTf">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the three and nine months ended September 30, 2024 and 2023. The Company did not have any deferred tax liability or asset on its balance sheets as of September 30, 2024 and December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the three and nine months ended September 30, 2024 and 2023, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zj7kTlEdIOwh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zSRBM4Tqk9S4">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes compensation costs under FASB ASC Topic 718, Compensation – Stock Compensation and ASU 2018-07. Companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zzRryza0dq6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zkzXiWXEVhcl">Recent Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.</span></p> <p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zSqerUyCvvr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2: <span id="xdx_824_zO3Ylgs8HWm9">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2023, our Chief Executive Officer advanced $<span id="xdx_90C_eus-gaap--OtherLiabilities_iI_c20230930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zhcW0bhv40ne" title="Advance from officer">10,000</span> to the Company, which amount was repaid October 4, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 10000 <p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zct3ghBj30na" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3: <span id="xdx_82C_zCM8dbtRn8N9">STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has authorized <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240930_zccLp5qMn91h" title="Common stock, shares authorized">950,000,000</span> shares of Common Stock. As of September 30, 2024 and December 31, 2023, there are <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_pid_c20240930_zPQVLUyeDVWj" title="Common stock, shares issued"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240930_znHnbsWUEisj" title="Common stock, shares outstanding">417,592,703</span></span> and <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zEpjWVeiCkh6" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_z1QATgWo8rI" title="Common stock, shares outstanding">387,894,033</span></span> shares of Common Stock issued and outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has authorized <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240930_zxikNWLHYZXl" title="Preferred stock shares authorized">20,000,000</span> shares of Preferred Stock. There are currently three series of Preferred Stock outstanding; Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock. The Company’s Board of Directors is authorized to provide for the issuance of shares of Preferred Stock in one or more series, fix or alter the designations, preferences, rights, qualifications, limitations or restrictions of the shares of each series, including the dividend rights, dividend rates, conversion rights, voting rights, term of redemption including sinking fund provisions, redemption price or prices, liquidation preferences and the number of shares constituting any series or designations of such series without further vote or action by the shareholders. The issuance of Preferred Stock may have the effect of delaying, deferring or preventing a change in control of management without further action by the shareholders and may adversely affect the voting and other rights of the holders of Common Stock. The issuance of Preferred Stock with voting and conversion rights may adversely affect the voting power of the holders of Common Stock, including the loss of voting control to others.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series A Convertible Preferred Stock</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 30, 2015, a certificate of designations was filed with the Delaware Secretary of State to designate <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20150630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zX6J7XEr0B32" title="Preferred stock shares authorized">2,500,000</span> shares of the Company’s Preferred Stock as Series A Convertible Preferred Stock, par value $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20150630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zZyFH1hn6qKc" title="Preferred stock, par value">0.001</span> per share (“<i>Series A Preferred</i>”) (the “<i>Series A COD</i>”). Effective March 31, 2016, the Company amended the Series A COD, increasing the maximum number of shares of Series A Preferred from <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20160330__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zVUc2GkmMyE8" title="Preferred stock, shares authorized">2,500,000</span> shares to <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20160331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zVqvjysdW6ya" title="Preferred stock, shares authorized">5,000,000</span> shares. As of September 30, 2024 and December 31, 2023, there are <span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zJv0jikrSDnl" title="Preferred stock, shares outstanding">2,071,007</span> shares of Series A Preferred issued and outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following summarizes the current rights and preferences of the Series A Preferred:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation Preference</i>. The Series A Preferred has a liquidation preference of $<span id="xdx_901_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20150630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zjZWbgezUu2c" title="Preferred stock, liquidation preference per share">5.00</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends</i>. Shares of Series A Preferred do not have any separate dividend rights.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion</i>. Subject to certain limitations set forth in the Series A COD, each share of Series A Preferred is convertible, at the option of the holder, into that number of shares of Common Stock (the “<i>Series A Conversion Shares</i>”) equal to the liquidation preference thereof, divided by Conversion Price (as such term is defined in the Series A COD), currently $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20150630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zQ688bnJMe19" title="Conversion price, per share">4.00</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event the Company completes an equity or equity-based public offering, registered with the SEC, resulting in gross proceeds to the Company totaling at least $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20150630__20150630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zlb0cDjEuS6" title="Gross proceeds from preferred stock">5.0</span> million, all issued and outstanding shares of Series A Preferred at that time will automatically convert into Series A Conversion Shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption</i>. <span id="xdx_90B_eus-gaap--PreferredStockRedemptionTerms_c20150630__20150630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z1VPKXFKRXw3" title="Preferred stock redemption, description">Subject to certain conditions set forth in the Series A COD, in the event of a Change of Control (defined in the Series A COD), or at such time as a third party not affiliated with the Company or any holders of the Series A Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent (50%) of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series A Preferred in cash at a price per share of Series A Preferred equal to <span id="xdx_901_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_uPure_c20150630__20150630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zkepEUB8oU9l" title="Redemption percentage">100</span>% of the Liquidation Preference.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting Rights</i>. <span id="xdx_900_eus-gaap--PreferredStockVotingRights_c20150630__20150630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zNeGaXxlMy0g" title="Preferred stock voting rights, description">Holders of Series A Preferred are entitled to vote on all matters, together with the holders of Common Stock, and have the equivalent of five votes for every Series A Conversion Share issuable upon conversion of such holder’s outstanding shares of Series A Preferred. However, the Series A Conversion Shares, when issued, will have all the same voting rights as other issued and outstanding Common Stock of the Company, and none of the rights of the Series A Preferred.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation</i>. Upon any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary (a “<i>Liquidation</i>”), the holders of Series A Preferred shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the liquidation preference of the Series A Preferred before any distribution or payment shall be made to the holders of any junior securities, and if the assets of the Company are insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of the Series A Preferred shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Certain Price and Share Adjustments</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) Stock Dividends and Stock Splits. If the Company (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock equivalents; (ii) subdivides outstanding shares of Common Stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Company, then the conversion price shall be adjusted accordingly.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) Merger or Reorganization. If the Company is involved in any reorganization, recapitalization, reclassification, consolidation or merger in which the Common Stock is converted into or exchanged for securities, cash or other property than each share of Series A Preferred shall be convertible into the kind and amount of securities, cash or other property that a holder of the number of shares of Common Stock issuable upon conversion of one share of Series A Preferred prior to any such merger or reorganization would have been entitled to receive pursuant to such transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series B Convertible Preferred Stock</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 10, 2018, a certificate of designation was filed with the Delaware Secretary of State to designate <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20181010__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zNXvKCAicu9i" title="Preferred stock shares authorized">5,000,000</span> shares of our Preferred Stock as Series B Convertible Preferred Stock, par value $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20181010__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zrOwdXTLOLO9" title="Preferred stock, par value">0.001</span> per share (“<i>Series B Preferred</i>”) (the “<i>Series B COD</i>”). As of September 30, 2024 and December 31, 2023, there are <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zrhHRP3OEnA8" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zWXomsP5xuKi" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zj5i9wUf5lK5" title="Preferred stock, shares outstanding"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zQncCNU38NV6" title="Preferred stock, shares outstanding">200,363</span></span></span></span> shares of Series B Preferred issued and outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following summarizes the current rights and preferences of the Series B Preferred:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation Preference</i>. The Series B Preferred has a liquidation preference of $<span id="xdx_909_eus-gaap--PreferredStockLiquidationPreference_iI_c20181010__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zvhfBxXVi65" title="Preferred stock, liquidation preference per share">1.00</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends</i>. Shares of Series B Preferred do not have any separate dividend rights.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion</i>. Subject to certain limitations set forth in the Series B COD, each share of Series B Convertible is convertible, at the option of the holder, into that number of shares of Common Stock (the “<i>Series B Conversion Shares</i>”) equal to the liquidation preference thereof, divided by the Conversion Price (as such term is defined in the Series B COD), currently $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20181010__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zAWOMzDNDbf" title="Conversion price per share">0.08</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption</i>. <span id="xdx_902_eus-gaap--PreferredStockRedemptionTerms_c20181010__20181010__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zhiGZ6yDJd5" title="Preferred stock redemption, description">Subject to certain conditions set forth in the Series B COD, in the event of a Change of Control (defined in the Series B COD), or at such as a third party not affiliated with the Company or any holders of the Series B Convertible shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent (50%) of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Preferred in cash at a price per share of Series B Preferred equal to <span id="xdx_908_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_uPure_c20181010__20181010__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zfeqfbCUo3Dk" title="Redemption percentage">100</span>% of the Liquidation Preference</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting Rights</i>. <span id="xdx_907_eus-gaap--PreferredStockVotingRights_c20181010__20181010__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zF6PbtsSGvk7" title="Voting percentage">Holders of Series B Preferred are entitled to vote on all matters, together with the holders of Common Stock, and have the equivalent of two votes for every Series B Conversion Share issuable upon conversion of such holder’s outstanding shares of Series B Preferred. However, the Series B Conversion Shares, when issued, will have the same voting rights as other issued and outstanding shares of Common Stock of the Company, and none of the rights of the Series A Preferred.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation</i>. Upon any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary (a “<i>Liquidation</i>”), the holders of Series B Preferred shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the liquidation preference of the Series B Preferred before any distribution or payment shall be made to the holders of any junior securities, and if the assets of the Company are insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of the Series B Preferred shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Certain Price and Share Adjustments</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) Stock Dividends and Stock Splits. If the Company (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock equivalents; (ii) subdivides outstanding shares of Common Stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Company, then the conversion price shall be adjusted accordingly.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) Merger or Reorganization. If the Company is involved in any reorganization, recapitalization, reclassification, consolidation or merger in which the Common Stock is converted into or exchanged for securities, cash or other property than each share of Series B Preferred shall be convertible into the kind and amount of securities, cash or other property that a holder of the number of shares of Common Stock issuable upon conversion of one share of Series B Preferred prior to any such merger or reorganization would have been entitled to receive pursuant to such transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series C Convertible Preferred Stock</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 27, 2019, a certificate of designation was filed with the Delaware Secretary of State to designate <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20190327__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zpFqnC7YZ2Ll" title="Preferred stock shares authorized">5,000,000</span> shares of our Preferred Stock as Series C Convertible Preferred Stock, par value $<span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20190327__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_ztmXvJwLZyaf" title="Preferred stock, par value">0.001</span> per share (“<i>Series C Preferred</i>”) (the “<i>Series C COD</i>”). As of September 30, 2024 and December 31, 2023, there were <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zRVq7tnOt3gc" title="Preferred stock shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_z1On5srRFrzg" title="Preferred stock shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zcvOs9zdeQt8" title="Preferred stock shares outstanding"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zmqXgsFd53A6" title="Preferred stock shares outstanding">385,302</span></span></span></span> shares of Series C Preferred issued and outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following summarizes the current rights and preferences of the Series C Preferred:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation Preference</i>. The Series C Preferred has a liquidation preference of $<span id="xdx_904_eus-gaap--PreferredStockLiquidationPreference_iI_c20190327__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zhLaoRCCqdQ2" title="Preferred stock, liquidation preference per share">1.00</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends</i>. Shares of Series C Preferred do not have any separate dividend rights.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion</i>. Subject to certain limitations set forth in the Series C COD, each share of Series C Preferred is convertible, at the option of the holder, into that number of shares of Common Stock (the “<i>Series C Conversion Shares</i>”) equal to the liquidation preference thereof, divided by Conversion Price (as such term is defined in the Series C COD), currently $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20190327__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zxT2q0ir0ZYi" title="Conversion price per share">0.08</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series C Preferred will only be convertible at any time after the date that the Company shall have amended its Certificate of Incorporation to increase the number of shares of Common Stock authorized for issuance thereunder or effect a reverse stock split of the outstanding shares of Common Stock by a sufficient amount to permit the conversion of all Series C Preferred into shares of Common Stock (“<i>Authorized Share Approval</i>”) (such date, the “<i>Initial Convertibility Date</i>”), each share of Series C Preferred shall be convertible into validly issued, fully paid and non-assessable shares of Common Stock on the terms and conditions set forth in the Series C COD under the definition “<i>Conversion Rights</i>”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption</i>. <span id="xdx_90C_eus-gaap--PreferredStockRedemptionTerms_c20190327__20190327__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zafzgbdGQj8b" title="Preferred stock redemption, description">Subject to certain conditions set forth in the Series C COD, in the event of a Change of Control (defined in the Series C COD), or at such time as a third party not affiliated with the Company or any holders of the Series C Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent (50%) of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series C Preferred in cash at a price per share of Series C Preferred equal to <span id="xdx_90D_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_uPure_c20190327__20190327__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zubOKEbvHCbi" title="Redemption percentage">100</span>% of the Liquidation Preference</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting Rights</i>. <span id="xdx_90A_eus-gaap--PreferredStockVotingRights_c20190327__20190327__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zNIOyOkl4qpg" title="Voting percentage">Holders of Series C Preferred are entitled to vote on all matters, together with the holders of Common Stock, and have the equivalent of thirty-two votes for every Series C Conversion Share issuable upon conversion of such holder’s outstanding shares of Series C Preferred. However, the Series C Conversion Shares, when issued, will have the same voting rights as other issued and outstanding shares of Common Stock of the Company, and none of the rights of the Series C Preferred.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation</i>. Upon any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary (a “<i>Liquidation</i>”), the holders of Series C Preferred shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the liquidation preference of the Series C Preferred before any distribution or payment shall be made to the holders of any junior securities, and if the assets of the Company are insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of the Series C Preferred shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Certain Price and Share Adjustments</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) Stock Dividends and Stock Splits. If the Company (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock equivalents; (ii) subdivides outstanding shares of Common Stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Company, then the conversion price shall be adjusted accordingly.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) Merger or Reorganization. If the Company is involved in any reorganization, recapitalization, reclassification, consolidation or merger in which the Common Stock is converted into or exchanged for securities, cash or other property than each share of Series C Preferred shall be convertible into the kind and amount of securities, cash or other property that a holder of the number of shares of Common Stock issuable upon conversion of one share of Series C Preferred prior to any such merger or reorganization would have been entitled to receive pursuant to such transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common and Preferred Stock Issuances</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common and Preferred Stock Issuances - 2024</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From January 1, 2024 through September 30, 2024, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockandWarrantsMember_zqiNMjeOeev5" title="Number of shares issued">13,000,000</span> shares of Common Stock and warrants to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDJiMguMv2N9" title="Warrant purchase">7,000,000</span> shares of Common Stock pursuant to the Regulation A+ Offerings for cash proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20240101__20240930_zo7BuOSbWzKc" title="Proceeds from issuance or sale of equity">839,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20240930_z1dBzliOPFpi" title="Issued for services, shares">441,252</span> shares of Common Stock for services rendered valued at $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240101__20240930_zMDqKXtRsmia" title="Issued for services, value">69,395</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company issued <span id="xdx_905_ecustom--StockIssuedDuringPeriodSharesStockOptionsWarrantExercised_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSkvpLMUfc52" title="Issued for common stock warrant exercise">16,919,918</span> shares of Common Stock in the cashless exercise of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zktzzA5EseRj" title="Issued for cashless exercise, warrants">25,034,000</span> warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company settled <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6LPtRtOLYA3" title="Issued for common stock RSU">500,000</span> RSUs for Common Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adjusted their common shares for vested RSUs in prior periods that were cancelled.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common and Preferred Stock Issuances – 2023</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2023, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230401__20230430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zV9IRJKeshoh" title="Number of shares issued">8,000,000</span> shares of Common Stock, <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230401__20230430__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantMember_zVUP3UaJcLR2" title="Number of shares issued">2,665,000</span> Series A warrants and <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230401__20230430__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantMember_z2uHxNKmSVSc" title="Number of shares issued">8,000,000</span> Series B warrants in their Regulation A+ Offerings for $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230401__20230430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkagTukUVwO4" title="Number of shares issued, value">640,000</span>. The Company sold the warrants for $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_c20230401__20230430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWWQpHYmarke" title="Proceeds from issuance of warrants">10,665</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 950000000 417592703 417592703 387894033 387894033 20000000 2500000 0.001 2500000 5000000 2071007 5.00 4.00 5000000.0 Subject to certain conditions set forth in the Series A COD, in the event of a Change of Control (defined in the Series A COD), or at such time as a third party not affiliated with the Company or any holders of the Series A Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent (50%) of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series A Preferred in cash at a price per share of Series A Preferred equal to 100% of the Liquidation Preference. 1 Holders of Series A Preferred are entitled to vote on all matters, together with the holders of Common Stock, and have the equivalent of five votes for every Series A Conversion Share issuable upon conversion of such holder’s outstanding shares of Series A Preferred. However, the Series A Conversion Shares, when issued, will have all the same voting rights as other issued and outstanding Common Stock of the Company, and none of the rights of the Series A Preferred. 5000000 0.001 200363 200363 200363 200363 1.00 0.08 Subject to certain conditions set forth in the Series B COD, in the event of a Change of Control (defined in the Series B COD), or at such as a third party not affiliated with the Company or any holders of the Series B Convertible shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent (50%) of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Preferred in cash at a price per share of Series B Preferred equal to 100% of the Liquidation Preference 1 Holders of Series B Preferred are entitled to vote on all matters, together with the holders of Common Stock, and have the equivalent of two votes for every Series B Conversion Share issuable upon conversion of such holder’s outstanding shares of Series B Preferred. However, the Series B Conversion Shares, when issued, will have the same voting rights as other issued and outstanding shares of Common Stock of the Company, and none of the rights of the Series A Preferred. 5000000 0.001 385302 385302 385302 385302 1.00 0.08 Subject to certain conditions set forth in the Series C COD, in the event of a Change of Control (defined in the Series C COD), or at such time as a third party not affiliated with the Company or any holders of the Series C Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent (50%) of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series C Preferred in cash at a price per share of Series C Preferred equal to 100% of the Liquidation Preference 1 Holders of Series C Preferred are entitled to vote on all matters, together with the holders of Common Stock, and have the equivalent of thirty-two votes for every Series C Conversion Share issuable upon conversion of such holder’s outstanding shares of Series C Preferred. However, the Series C Conversion Shares, when issued, will have the same voting rights as other issued and outstanding shares of Common Stock of the Company, and none of the rights of the Series C Preferred. 13000000 7000000 839000 441252 69395 16919918 25034000 500000 8000000 2665000 8000000 640000 10665 <p id="xdx_804_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zjA0U4ZVDWwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4: <span id="xdx_823_zTPmk2fCY3lc">COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes in the financial statements compensation related to all stock-based awards, including stock options and warrants, based on their estimated grant-date fair value. The Company has estimated expected forfeitures and is recognizing compensation expense only for those awards expected to vest. All compensation is recognized by the time the award vests.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zI5iWtTWPSy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following schedule summarizes the changes in the Company’s stock options:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_z7QAnE1odNL6" style="display: none">SCHEDULE OF CHANGES IN STOCK OPTION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options Outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average<br/> Remaining</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number Of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price<br/> Per Share</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual<br/> Life</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate<br/> Intrinsic Value</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center">Exercise <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price<br/> Per Share</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-decoration: underline"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine Months Ended September 30, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 1, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240930_zB3HnxKZAd4b" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right" title="Number of Options Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,252,809</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930__srt--RangeAxis__srt--MinimumMember_zBUxGs4hQev" title="Exercise Price Per Share Outstanding Beginning Balance">0.024</span>-<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930__srt--RangeAxis__srt--MaximumMember_zdqBIrZQjIF5" title="Exercise Price Per Share Outstanding Beginning Balance">0.04</span> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zSK8sNext9f7" title="Weighted Average Remaining Contractual Life (in years) Outstanding">5.70</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20240930_zVabgmm7IoHl" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78,886</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice_iS_c20240101__20240930_zMqnO64CedNl" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right" title="Weighted Average Exercise Price Per Share Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240930_zkcuKgit0zj6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240930_zwcq1IMlBI7j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1067">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--WeightedAverageExercisePricePerShareOptionsGranted_c20240101__20240930_zoICNn1UfCC8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1069">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240101__20240930_zHH5pd7IatCf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1071">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240930_zcymJmQSkqW" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1073">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_ecustom--WeightedAverageExercisePricePerShareOptionsExercised_c20240101__20240930_zE5jKytvK5r6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Options exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1075">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired/canceled</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20240101__20240930_zDc85928pIxg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1077">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20240930_zrs8yVdXp5ae" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1079">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_ecustom--WeightedAverageExercisePricePerShareOptionsExpired_c20240101__20240930_zPW9hlkDTgrk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Options expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1081">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at September 30, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240930_zd2LBy222Rwd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,252,809</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930__srt--RangeAxis__srt--MinimumMember_ziFvyCAgCV03" title="Weighted Average Exercise Price Per Share Outstanding Ending">0.024</span>-<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930__srt--RangeAxis__srt--MaximumMember_zmEy9x4u1p0l" title="Weighted Average Exercise Price Per Share Outstanding Ending">0.04</span> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930_zwLLZKcV92Wi" title="Weighted Average Remaining Contractual Life (in years) Outstanding">4.95</span> years </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20240101__20240930_zP7vRhzSpYw5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">284,567</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice_iE_c20240101__20240930_zUJUollWNxzd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at September 30, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20240930_zsT2AUfRXuBc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,252,809</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisablePrice_iE_c20240101__20240930__srt--RangeAxis__srt--MinimumMember_zieELlyXEOe8" title="Exercise Price Per Share Exercisable">0.024</span>-<span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisablePrice_iE_c20240101__20240930__srt--RangeAxis__srt--MaximumMember_zZFgnwPbxXQg" title="Exercise Price Per Share Exercisable">0.04</span> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930_z8Nr64UrnKX7" title="Weighted Average Remaining Contractual Life (in years) Exercisable">4.95</span> years </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20240101__20240930_z6YZXRvVZ3x2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">284,567</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricePerShares_iE_c20240101__20240930_zjiz1yyaWbp6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-decoration: underline"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine Months Ended September 30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 1, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230930_zh7btokCg678" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,252,809</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_zrF2MFa9vnNf" title="Exercise Price Per Share Outstanding Beginning Balance">0.024</span>-<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_z0PH3E6E2Kia" title="Exercise Price Per Share Outstanding Beginning Balance">0.04</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zboKphuEdpf2" title="Weighted Average Remaining Contractual Life (in years) Outstanding">6.70</span> years </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20230101__20230930_zXmUxrDZj0J6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,032</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice_iS_c20230101__20230930_zxz1ajunZsLd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230101__20230930_zJQ0exisrAsj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1119">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230930_zM7wKjfjT06l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1121">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_ecustom--WeightedAverageExercisePricePerShareOptionsGranted_c20230101__20230930_zDg9A1wIfb1d" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1123">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230101__20230930_zPBn3NyCwtKl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1125">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230930_zSTcnOhZaDIg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1127">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_ecustom--WeightedAverageExercisePricePerShareOptionsExercised_c20230101__20230930_zxQgVwMrMNE9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Options exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1129">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired/canceled</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230101__20230930_z3AUnICao4Q5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1131">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230930_zW9xTRDZz8Fd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1133">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_ecustom--WeightedAverageExercisePricePerShareOptionsExpired_c20230101__20230930_zjjKnGj8HDn2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Options expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1135">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at September 30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930_zR7tAoeIHoE4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,252,809</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_zMWi17Tn7RQ4" title="Weighted Average Exercise Price Per Share Outstanding Ending">0.024</span>-<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_zdsizubs7c8" title="Weighted Average Exercise Price Per Share Outstanding Ending">0.04</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_z5wz0ATg0qqi" title="Weighted Average Remaining Contractual Life (in years) Outstanding">5.95</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20230101__20230930_zrgU7nRZbMx6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65,819</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice_iE_c20230101__20230930_zwnvVmmDtdt2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at September 30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230930_zDMrMTz0NWoi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,252,809</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisablePrice_iE_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_zvab6pOeqD42" title="Exercise Price Per Share Exercisable">0.024</span>-<span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisablePrice_iE_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_zJN0D82ez7pc" title="Exercise Price Per Share Exercisable">0.04</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_zzmtdc2MNxki" title="Weighted Average Remaining Contractual Life (in years) Exercisable">5.95</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20230101__20230930_zCTEhO8HqQs8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65,819</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricePerShares_iE_c20230101__20230930_zEczQvH7psYl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AF_zrpsiEGtJnq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three and nine months ended September 30, 2024 and the three and nine months ended September 30, 2023, the Company recognized $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20240701__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzOnfBLu65u" title="Stock based compensation"><span id="xdx_909_eus-gaap--ShareBasedCompensation_c20240101__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8eAIb2xclek" title="Stock based compensation"><span id="xdx_904_eus-gaap--ShareBasedCompensation_c20230701__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zh32G3vXox86" title="Stock based compensation"><span id="xdx_908_eus-gaap--ShareBasedCompensation_c20230101__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGlf2sidH33" title="Stock based compensation">0</span></span></span></span> of stock-based compensation expense related to the vesting of stock options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zWGv1XGz5oB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following schedule summarizes the changes in the Company’s stock warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zRYnJ5p1tl7b" style="display: none">SCHEDULE OF CHANGES IN STOCK WARRANTS </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants Outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average<br/> Remaining</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number Of<br/> Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per Share</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual<br/> Life</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate<br/> Intrinsic Value</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price<br/> Per Share</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-decoration: underline"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine Months Ended September 30, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 1, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZCKcqrvJix1" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,134,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zqU0dxYdQbBf" title="Exercise Price Per Share Warrants Outstanding Beginning">0.06</span>-<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zg4UC99gs7E3" title="Exercise Price Per Share Warrants Outstanding Beginning">0.10</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOkTjSwY5S5g" title="Weighted Average Remaining Contractual Life Warrants Outstanding Ending">3.54</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zEV6SoPYFD5a" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1179">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_ecustom--WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable_iS_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zj23JVoAau5c" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0827</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zHtlTecpfFp1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zVY844jWhHzb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share Warrants granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.075</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_ecustom--ExcercisePriceWarrantsGrantedMinimum_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zVI9IWomr0Ra" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ztCy47qEbUXc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25,034,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKlVp4ZR4eU7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share Warrants exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1191">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redeemed</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWHikc8iRlGc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants redeemed"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(500,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zxL8TYa3ghEg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share Warrants exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1195">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired/cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLCUxMrMyQkb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1197">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zN1pJXPS5RI" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share Warrants expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1199">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at September 30, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGYRt9DrbWqf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,100,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjx3pZS4iB4l" title="Exercise Price Per Share Warrants Outstanding Ending">0.075</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKV5Apvb5zO7" title="Weighted Average Remaining Contractual Life Warrants Outstanding Ending">3.25</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmXtHRS5EYuh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">717,660</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_ecustom--ExercisePriceMinimum_iE_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zIFC09GaUCIj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.075</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at September 30, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zssjhOt2Hv24" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,100,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisablePrice_iE_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zgJ0dnDPWBMc" title="Exercise Price Per Share Warrants Exercisable Ending">0.075</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwzP3Hj3IOz8" title="Weighted Average Remaining Contractual Life Warrants Exercisable">3.25</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zo25QfhJbI9j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">717,660</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_ecustom--WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable_iE_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zc9vtoyrxhJ5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.075</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-decoration: underline"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine Months Ended September 30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 1, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQLkRmlJtkt6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,737,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zWFxb4LkiKL2" title="Exercise Price Per Share Warrants Outstanding Beginning">0.06</span>-<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z2MyTZBy96Ea" title="Exercise Price Per Share Warrants Outstanding Beginning">0.10</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLGiyxCRjLV3" title="Weighted Average Remaining Contractual Life Warrants Outstanding Ending">1.52</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3VtQM8ySPi7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1229">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_ecustom--WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable_iS_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRHUJcpYuCnd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.09</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmHAg0jwCDZ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,665,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRJd5c27zn92" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share Warrants granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0775</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_ecustom--ExcercisePriceWarrantsGrantedMinimum_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zd9CMtb2vtll" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1237">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redeemed</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zBHcJ6RG4ck1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants redeemed"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(500,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3eLp4q7mBL6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share Warrants exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1241">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired/cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkYCcy99NDUl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,237,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4h9VF5LtHRa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share Warrants expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1245">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at September 30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLmQfnKFXl7h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,665,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_znP8iSisZeEc" title="Exercise Price Per Share Warrants Outstanding Ending">0.06</span>-<span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z5ZZGSqr4qNh" title="Exercise Price Per Share Warrants Outstanding Ending">0.10</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4E8OdQkoYn3" title="Weighted Average Remaining Contractual Life Warrants Outstanding Ending">1.91</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9oW2iSD0tzk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,573</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_ecustom--ExercisePriceMinimum_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zS3yQAKA3hJ2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.079</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at September 30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8exKRY0ys23" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,665,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisablePrice_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z6CB8EteG5pb" title="Exercise Price Per Share Warrants Exercisable Ending">0.06</span>-<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisablePrice_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zV9yDVfkhD6" title="Exercise Price Per Share Warrants Exercisable Ending">0.10</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zTZY58Y7yo13" title="Weighted Average Remaining Contractual Life Warrants Exercisable">1.91</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zaujllN8Vhj4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,573</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_ecustom--WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLDb7igNL6B7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.079</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A3_zCXLnOH1lmrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each option/warrant is estimated using the Black-Scholes valuation model. The following assumptions were used for the periods as follows:</span></p> <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zCE6mXLfYDyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zqcIA0s3ZSD4" style="display: none">SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td id="xdx_49D_20240101__20240930_z10n2mJXYpD7" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td id="xdx_49F_20230101__20230930_zZJIfLwK1Tn3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2024 </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2023 </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c20240101__20240930_zu0qf4s8fuOc" title="Expected term"><span style="-sec-ix-hidden: xdx2ixbrl1273">-</span></span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c20230101__20230930_z0W8UbcJn276" title="Expected term"><span style="-sec-ix-hidden: xdx2ixbrl1275">-</span></span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_ze7AjR22ji36" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1277">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1278">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_zmNU1cLwA408" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1280">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1281">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_zTiagAlYZEjf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1283">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1284">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> <p id="xdx_8A7_znDQ9KlDu1zj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company granted <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230401__20230430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOK3n4eynJWk" title="Number of Shares, warrants granted">10,665,000</span> warrants in their Reg A+ funding in April 2023, with an exercise price of $<span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20230401__20230430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4XFlcyeLJb3" title="Exercise price per share warrants granted">0.0775</span> and a <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20230401__20230430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrfuCmeuhggd" title="Weighted average remaining contractual term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl1290">three-year</span></span> term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company granted <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUsxDz2MS7Kh" title="Number of Shares, warrants granted">2,000,000</span> warrants in their Regulation A+ Offering in January 2024, with an exercise price of $<span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zIntpMxVj7K8" title="Exercise price per share warrants granted">0.075</span> and a <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20240101__20240131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLY89iUhY8ak" title="Weighted average remaining contractual term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl1296">three-year</span></span> term and <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240401__20240401__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzypDluJp8Ql" title="Number of Shares, warrants granted">5,000,000</span> warrants with the same terms on April 1, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company issued <span id="xdx_900_ecustom--StockIssuedDuringPeriodSharesStockOptionsWarrantExercised_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZLk2qYF1r1j" title="Number of shares issued">16,919,918</span> shares of Common Stock in the cashless exercise of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAeY1yXwVk1h" title="Number of Shares, Warrants exercised">25,034,000</span> warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restricted Stock Units</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zwouTXxMx2k4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following schedule summarizes the changes in the Company’s restricted stock units:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zlce7oPnXXDd" style="display: none">SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number Of Shares</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average<br/> Grant Date Fair Value</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline"><span style="font-family: Times New Roman, Times, Serif">Nine Months Ended September 30, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at January 1, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20240930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zoD26xMD1ire" style="width: 16%; text-align: right" title="Number of Shares, RSU's Beginning balance"><span style="font-family: Times New Roman, Times, Serif">1,450,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240101__20240930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zzhsDgtYENAh" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif">0.09</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20240930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zpM1u6nw1Xyd" style="text-align: right" title="Number of Shares, RSU's granted"><span style="font-family: Times New Roman, Times, Serif">21,050,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20240930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zvXZe78PFpP3" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's granted"><span style="font-family: Times New Roman, Times, Serif">0.077</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Vested</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20240930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zMKD2gYv04Ih" style="text-align: right" title="Number of Shares, RSU's vested"><span style="font-family: Times New Roman, Times, Serif">(10,500,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20240930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zuq0BkHIpUq7" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's vested"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1316">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20240930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zDsWoDnZ0xth" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, RSU's forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1318">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20240930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zZc4BuxtkC4i" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1320">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Outstanding at September 30, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20240930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zDlkAQDwMW3" style="text-align: right" title="Number of Shares, RSU's Ending balance"><span style="font-family: Times New Roman, Times, Serif">12,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20240930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zgf1gstdWm24" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif">0.08</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline"><span style="font-family: Times New Roman, Times, Serif">Nine Months Ended September 30, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Outstanding at January 1, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20230930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zueayxQaIpwd" style="text-align: right" title="Number of Shares, RSU's Beginning balance"><span style="font-family: Times New Roman, Times, Serif">10,262,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20230930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zVgwBq5niIpa" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif">0.08</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zqwFgsVzNCFi" style="text-align: right" title="Number of Shares, RSU's granted"><span style="font-family: Times New Roman, Times, Serif">2,900,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zhuo1q4G9Gk" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's granted"><span style="font-family: Times New Roman, Times, Serif">0.091</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Vested</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20230930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zJhVjmvwbvSd" style="text-align: right" title="Number of Shares, RSU's vested"><span style="font-family: Times New Roman, Times, Serif">(10,725,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230101__20230930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zSfgJijD47l7" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's vested"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1336">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20230930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zyxVPIG8crhc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, RSU's forfeited"><span style="font-family: Times New Roman, Times, Serif">(262,500</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20230930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zkOAGRcstEb5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1340">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding at September 30, 2023</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zA1gNlLiwBf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, RSU's Ending balance"><span style="font-family: Times New Roman, Times, Serif">2,175,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20230930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_z8WQjwN9Edo5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif">0.09</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AA_zBDcViCsgZfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2024 and 2023, the Company recognized $<span id="xdx_90B_eus-gaap--RestrictedStockExpense_c20240101__20240930_zW6G6QvvuAr4" title="Restricted stock expense vesting">809,250</span> and $<span id="xdx_90B_eus-gaap--RestrictedStockExpense_c20230101__20230930_zM5NQ7mnP5R9" title="Restricted stock expense vesting">965,975</span> in expense related to the vesting of its restricted stock units. As of September 30, 2024, the Company had $<span id="xdx_90A_ecustom--RestrictedStockExpensesYetToBeRecognized_c20240101__20240930_zW9HiaDGfqP6" title="Restricted stock expenses yet to be recognized">951,595</span> worth of expense yet to be recognized for restricted stock units not yet vested.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 1, 2024, the Company granted <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20240101__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zY8wSFQYwRk6" title="Number of shares, RSU's granted">20,000,000</span> restricted stock units to its Chief Executive Officer as part of his new employment agreement that vest in four equal installments over a <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20240101__20240101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_z3oGiYXnKny5" title="Vest period::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl1354">two-year</span></span> period beginning February 1, 2024. During the nine months ended September 30, 2024, <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20240930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zJCWWT97G2ob" title="Restricted stock units vested">10,500,000</span> of these restricted stock units vested. In May 2024, the Company granted <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240501__20240531__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zIU7mNyE7GW3" title="Number of restricted shares unit granted">1,050,000</span> restricted stock units to consultants that vest through December 31, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zI5iWtTWPSy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following schedule summarizes the changes in the Company’s stock options:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_z7QAnE1odNL6" style="display: none">SCHEDULE OF CHANGES IN STOCK OPTION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options Outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average<br/> Remaining</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number Of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price<br/> Per Share</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual<br/> Life</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate<br/> Intrinsic Value</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center">Exercise <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price<br/> Per Share</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-decoration: underline"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine Months Ended September 30, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 1, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240930_zB3HnxKZAd4b" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right" title="Number of Options Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,252,809</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930__srt--RangeAxis__srt--MinimumMember_zBUxGs4hQev" title="Exercise Price Per Share Outstanding Beginning Balance">0.024</span>-<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930__srt--RangeAxis__srt--MaximumMember_zdqBIrZQjIF5" title="Exercise Price Per Share Outstanding Beginning Balance">0.04</span> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zSK8sNext9f7" title="Weighted Average Remaining Contractual Life (in years) Outstanding">5.70</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20240930_zVabgmm7IoHl" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78,886</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice_iS_c20240101__20240930_zMqnO64CedNl" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right" title="Weighted Average Exercise Price Per Share Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240930_zkcuKgit0zj6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240930_zwcq1IMlBI7j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1067">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--WeightedAverageExercisePricePerShareOptionsGranted_c20240101__20240930_zoICNn1UfCC8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1069">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240101__20240930_zHH5pd7IatCf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1071">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240930_zcymJmQSkqW" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1073">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_ecustom--WeightedAverageExercisePricePerShareOptionsExercised_c20240101__20240930_zE5jKytvK5r6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Options exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1075">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired/canceled</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20240101__20240930_zDc85928pIxg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1077">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20240930_zrs8yVdXp5ae" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1079">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_ecustom--WeightedAverageExercisePricePerShareOptionsExpired_c20240101__20240930_zPW9hlkDTgrk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Options expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1081">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at September 30, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240930_zd2LBy222Rwd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,252,809</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930__srt--RangeAxis__srt--MinimumMember_ziFvyCAgCV03" title="Weighted Average Exercise Price Per Share Outstanding Ending">0.024</span>-<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930__srt--RangeAxis__srt--MaximumMember_zmEy9x4u1p0l" title="Weighted Average Exercise Price Per Share Outstanding Ending">0.04</span> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930_zwLLZKcV92Wi" title="Weighted Average Remaining Contractual Life (in years) Outstanding">4.95</span> years </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20240101__20240930_zP7vRhzSpYw5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">284,567</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice_iE_c20240101__20240930_zUJUollWNxzd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at September 30, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20240930_zsT2AUfRXuBc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,252,809</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisablePrice_iE_c20240101__20240930__srt--RangeAxis__srt--MinimumMember_zieELlyXEOe8" title="Exercise Price Per Share Exercisable">0.024</span>-<span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisablePrice_iE_c20240101__20240930__srt--RangeAxis__srt--MaximumMember_zZFgnwPbxXQg" title="Exercise Price Per Share Exercisable">0.04</span> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930_z8Nr64UrnKX7" title="Weighted Average Remaining Contractual Life (in years) Exercisable">4.95</span> years </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20240101__20240930_z6YZXRvVZ3x2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">284,567</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricePerShares_iE_c20240101__20240930_zjiz1yyaWbp6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-decoration: underline"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine Months Ended September 30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 1, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230930_zh7btokCg678" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,252,809</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_zrF2MFa9vnNf" title="Exercise Price Per Share Outstanding Beginning Balance">0.024</span>-<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_z0PH3E6E2Kia" title="Exercise Price Per Share Outstanding Beginning Balance">0.04</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zboKphuEdpf2" title="Weighted Average Remaining Contractual Life (in years) Outstanding">6.70</span> years </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20230101__20230930_zXmUxrDZj0J6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,032</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice_iS_c20230101__20230930_zxz1ajunZsLd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230101__20230930_zJQ0exisrAsj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1119">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230930_zM7wKjfjT06l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1121">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_ecustom--WeightedAverageExercisePricePerShareOptionsGranted_c20230101__20230930_zDg9A1wIfb1d" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1123">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230101__20230930_zPBn3NyCwtKl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1125">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230930_zSTcnOhZaDIg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1127">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_ecustom--WeightedAverageExercisePricePerShareOptionsExercised_c20230101__20230930_zxQgVwMrMNE9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Options exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1129">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired/canceled</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230101__20230930_z3AUnICao4Q5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1131">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230930_zW9xTRDZz8Fd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1133">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_ecustom--WeightedAverageExercisePricePerShareOptionsExpired_c20230101__20230930_zjjKnGj8HDn2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Options expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1135">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at September 30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930_zR7tAoeIHoE4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,252,809</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_zMWi17Tn7RQ4" title="Weighted Average Exercise Price Per Share Outstanding Ending">0.024</span>-<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_zdsizubs7c8" title="Weighted Average Exercise Price Per Share Outstanding Ending">0.04</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_z5wz0ATg0qqi" title="Weighted Average Remaining Contractual Life (in years) Outstanding">5.95</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20230101__20230930_zrgU7nRZbMx6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65,819</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice_iE_c20230101__20230930_zwnvVmmDtdt2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at September 30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230930_zDMrMTz0NWoi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,252,809</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisablePrice_iE_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_zvab6pOeqD42" title="Exercise Price Per Share Exercisable">0.024</span>-<span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisablePrice_iE_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_zJN0D82ez7pc" title="Exercise Price Per Share Exercisable">0.04</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_zzmtdc2MNxki" title="Weighted Average Remaining Contractual Life (in years) Exercisable">5.95</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20230101__20230930_zCTEhO8HqQs8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65,819</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricePerShares_iE_c20230101__20230930_zEczQvH7psYl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 2252809 0.024 0.04 P5Y8M12D 78886 0.04 2252809 0.024 0.04 P4Y11M12D 284567 0.04 2252809 0.024 0.04 P4Y11M12D 284567 0.04 2252809 0.024 0.04 P6Y8M12D 16032 0.04 2252809 0.024 0.04 P5Y11M12D 65819 0.04 2252809 0.024 0.04 P5Y11M12D 65819 0.04 0 0 0 0 <p id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zWGv1XGz5oB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following schedule summarizes the changes in the Company’s stock warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zRYnJ5p1tl7b" style="display: none">SCHEDULE OF CHANGES IN STOCK WARRANTS </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants Outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average<br/> Remaining</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number Of<br/> Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per Share</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual<br/> Life</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate<br/> Intrinsic Value</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price<br/> Per Share</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-decoration: underline"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine Months Ended September 30, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 1, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZCKcqrvJix1" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,134,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zqU0dxYdQbBf" title="Exercise Price Per Share Warrants Outstanding Beginning">0.06</span>-<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zg4UC99gs7E3" title="Exercise Price Per Share Warrants Outstanding Beginning">0.10</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOkTjSwY5S5g" title="Weighted Average Remaining Contractual Life Warrants Outstanding Ending">3.54</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zEV6SoPYFD5a" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1179">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_ecustom--WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable_iS_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zj23JVoAau5c" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0827</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zHtlTecpfFp1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zVY844jWhHzb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share Warrants granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.075</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_ecustom--ExcercisePriceWarrantsGrantedMinimum_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zVI9IWomr0Ra" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ztCy47qEbUXc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25,034,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKlVp4ZR4eU7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share Warrants exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1191">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redeemed</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWHikc8iRlGc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants redeemed"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(500,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zxL8TYa3ghEg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share Warrants exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1195">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired/cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLCUxMrMyQkb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1197">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zN1pJXPS5RI" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share Warrants expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1199">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at September 30, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGYRt9DrbWqf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,100,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjx3pZS4iB4l" title="Exercise Price Per Share Warrants Outstanding Ending">0.075</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKV5Apvb5zO7" title="Weighted Average Remaining Contractual Life Warrants Outstanding Ending">3.25</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmXtHRS5EYuh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">717,660</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_ecustom--ExercisePriceMinimum_iE_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zIFC09GaUCIj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.075</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at September 30, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zssjhOt2Hv24" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,100,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisablePrice_iE_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zgJ0dnDPWBMc" title="Exercise Price Per Share Warrants Exercisable Ending">0.075</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwzP3Hj3IOz8" title="Weighted Average Remaining Contractual Life Warrants Exercisable">3.25</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zo25QfhJbI9j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">717,660</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_ecustom--WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable_iE_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zc9vtoyrxhJ5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.075</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-decoration: underline"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine Months Ended September 30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 1, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQLkRmlJtkt6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,737,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zWFxb4LkiKL2" title="Exercise Price Per Share Warrants Outstanding Beginning">0.06</span>-<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z2MyTZBy96Ea" title="Exercise Price Per Share Warrants Outstanding Beginning">0.10</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLGiyxCRjLV3" title="Weighted Average Remaining Contractual Life Warrants Outstanding Ending">1.52</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3VtQM8ySPi7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1229">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_ecustom--WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable_iS_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRHUJcpYuCnd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.09</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmHAg0jwCDZ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,665,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRJd5c27zn92" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share Warrants granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0775</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_ecustom--ExcercisePriceWarrantsGrantedMinimum_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zd9CMtb2vtll" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1237">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redeemed</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zBHcJ6RG4ck1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants redeemed"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(500,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3eLp4q7mBL6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share Warrants exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1241">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired/cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkYCcy99NDUl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,237,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4h9VF5LtHRa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Per Share Warrants expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1245">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at September 30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLmQfnKFXl7h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,665,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_znP8iSisZeEc" title="Exercise Price Per Share Warrants Outstanding Ending">0.06</span>-<span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z5ZZGSqr4qNh" title="Exercise Price Per Share Warrants Outstanding Ending">0.10</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4E8OdQkoYn3" title="Weighted Average Remaining Contractual Life Warrants Outstanding Ending">1.91</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9oW2iSD0tzk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,573</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_ecustom--ExercisePriceMinimum_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zS3yQAKA3hJ2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.079</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at September 30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8exKRY0ys23" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,665,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisablePrice_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z6CB8EteG5pb" title="Exercise Price Per Share Warrants Exercisable Ending">0.06</span>-<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisablePrice_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zV9yDVfkhD6" title="Exercise Price Per Share Warrants Exercisable Ending">0.10</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zTZY58Y7yo13" title="Weighted Average Remaining Contractual Life Warrants Exercisable">1.91</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zaujllN8Vhj4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,573</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_ecustom--WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLDb7igNL6B7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.079</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 26134000 0.06 0.10 P3Y6M14D 0.0827 7000000 0.075 25034000 -500000 8100000 0.075 P3Y3M 717660 0.075 8100000 0.075 P3Y3M 717660 0.075 26737500 0.06 0.10 P1Y6M7D 0.09 10665000 0.0775 -500000 11237500 25665000 0.06 0.10 P1Y10M28D 150573 0.079 25665000 0.06 0.10 P1Y10M28D 150573 0.079 <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zCE6mXLfYDyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zqcIA0s3ZSD4" style="display: none">SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td id="xdx_49D_20240101__20240930_z10n2mJXYpD7" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td id="xdx_49F_20230101__20230930_zZJIfLwK1Tn3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2024 </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2023 </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c20240101__20240930_zu0qf4s8fuOc" title="Expected term"><span style="-sec-ix-hidden: xdx2ixbrl1273">-</span></span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c20230101__20230930_z0W8UbcJn276" title="Expected term"><span style="-sec-ix-hidden: xdx2ixbrl1275">-</span></span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_ze7AjR22ji36" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1277">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1278">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_zmNU1cLwA408" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1280">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1281">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_zTiagAlYZEjf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1283">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1284">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> 10665000 0.0775 2000000 0.075 5000000 16919918 25034000 <p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zwouTXxMx2k4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following schedule summarizes the changes in the Company’s restricted stock units:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zlce7oPnXXDd" style="display: none">SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number Of Shares</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average<br/> Grant Date Fair Value</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline"><span style="font-family: Times New Roman, Times, Serif">Nine Months Ended September 30, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at January 1, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20240930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zoD26xMD1ire" style="width: 16%; text-align: right" title="Number of Shares, RSU's Beginning balance"><span style="font-family: Times New Roman, Times, Serif">1,450,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240101__20240930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zzhsDgtYENAh" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif">0.09</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20240930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zpM1u6nw1Xyd" style="text-align: right" title="Number of Shares, RSU's granted"><span style="font-family: Times New Roman, Times, Serif">21,050,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20240930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zvXZe78PFpP3" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's granted"><span style="font-family: Times New Roman, Times, Serif">0.077</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Vested</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20240930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zMKD2gYv04Ih" style="text-align: right" title="Number of Shares, RSU's vested"><span style="font-family: Times New Roman, Times, Serif">(10,500,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20240930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zuq0BkHIpUq7" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's vested"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1316">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20240930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zDsWoDnZ0xth" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, RSU's forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1318">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20240930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zZc4BuxtkC4i" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1320">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Outstanding at September 30, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20240930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zDlkAQDwMW3" style="text-align: right" title="Number of Shares, RSU's Ending balance"><span style="font-family: Times New Roman, Times, Serif">12,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20240930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zgf1gstdWm24" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif">0.08</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline"><span style="font-family: Times New Roman, Times, Serif">Nine Months Ended September 30, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Outstanding at January 1, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20230930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zueayxQaIpwd" style="text-align: right" title="Number of Shares, RSU's Beginning balance"><span style="font-family: Times New Roman, Times, Serif">10,262,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20230930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zVgwBq5niIpa" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif">0.08</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zqwFgsVzNCFi" style="text-align: right" title="Number of Shares, RSU's granted"><span style="font-family: Times New Roman, Times, Serif">2,900,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zhuo1q4G9Gk" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's granted"><span style="font-family: Times New Roman, Times, Serif">0.091</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Vested</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20230930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zJhVjmvwbvSd" style="text-align: right" title="Number of Shares, RSU's vested"><span style="font-family: Times New Roman, Times, Serif">(10,725,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230101__20230930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zSfgJijD47l7" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's vested"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1336">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20230930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zyxVPIG8crhc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, RSU's forfeited"><span style="font-family: Times New Roman, Times, Serif">(262,500</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20230930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zkOAGRcstEb5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1340">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding at September 30, 2023</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zA1gNlLiwBf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, RSU's Ending balance"><span style="font-family: Times New Roman, Times, Serif">2,175,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20230930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_z8WQjwN9Edo5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif">0.09</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 1450000 0.09 21050000 0.077 10500000 12000000 0.08 10262500 0.08 2900000 0.091 10725000 262500 2175000 0.09 809250 965975 951595 20000000 10500000 1050000 <p id="xdx_807_eus-gaap--CommitmentsDisclosureTextBlock_zcMz1OuCg7C" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5: <span id="xdx_82C_zzOAd2Xgcycj">COMMITMENT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 4, 2019, the Company entered into an Executive Employment Agreement (“<i>Employment Agreement</i>”) with Dr. Michael K. Korenko, the Company’s Chief Executive Officer. <span id="xdx_903_ecustom--AgreementTermDescription_c20190604__20190604__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrMichaelKKorenkoMember_z4KgK0ZJBwHf" title="Agreement term description">The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement. On December 31, 2020, the Company extended the Employment Agreement through December 31, 2021 while renegotiating terms of a new Employment Agreement. On May 3, 2021, the Company and the Chief Executive Officer agreed the terms of a new Employment Agreement with an effective date of January 1, 2021 that has a term of three years and expired December 31, 2023. The Company renewed the Employment Agreement for a term of two years expiring December 31, 2025.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the terms of the Employment Agreement effective January 1, 2024, the Company shall pay to Dr. Korenko a base compensation of $<span id="xdx_90C_eus-gaap--OfficersCompensation_c20240101__20240101__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrMichaelKKorenkoMember_zJ8nji3KPTmj" title="Compensation amount">295,500</span>. In addition, there is a discretionary bonus to be earned in the amount of $<span id="xdx_90C_ecustom--DiscretionaryBonus_c20240101__20240101__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrMichaelKKorenkoMember_zta4hVhpoMI9" title="Discretionary bonus">10,000</span> per quarter upon the satisfaction of conditions to be determined by the Board of Directors of the Company. In addition, the Company granted Dr. Korenko <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20240101__us-gaap--TypeOfArrangementAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DrMichaelKKorenkoMember_zc6TilJxaDWi" title="Granted restricted stock units">20,000,000</span> restricted stock units on January 1, 2024 that vest over the <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20240101__20240101__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrMichaelKKorenkoMember_zsfomRTKh0ne" title="Vest period">two year</span> period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement. On December 31, 2020, the Company extended the Employment Agreement through December 31, 2021 while renegotiating terms of a new Employment Agreement. On May 3, 2021, the Company and the Chief Executive Officer agreed the terms of a new Employment Agreement with an effective date of January 1, 2021 that has a term of three years and expired December 31, 2023. The Company renewed the Employment Agreement for a term of two years expiring December 31, 2025. 295500 10000 20000000 P2Y <p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_z3GJBogvSUO9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6: <span id="xdx_820_zKVi857VXYE1">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On November 12, 2024, the Company entered into agreements for the issuance of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241112__20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMtBBJzY1tjh" title="Number of share issued">11,950,000</span> shares of common stock for $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241112__20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRMA8jyaP0j3" title="Number of share issued, value">1,434,000</span> under the Regulation A+. The Company additionally entered into agreements for the sale of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241112__20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQUjAtwwFox9" title="Number of share issued">11,950,000</span> warrants, <span id="xdx_904_ecustom--WarrantsPercentage_dp_c20241112__20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ExpireDecemberThirtyFirstTwoThousandAndTwentyFourMember_zDtuX4ys9cd7" title="Warrants percentage">30</span>% of which expire December 31, 2024 at an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ExpireDecemberThirtyFirstTwoThousandAndTwentyFourMember_ziNMmLmTyTW8" title="Warrants exercise price">0.01</span> and <span id="xdx_903_ecustom--WarrantsPercentage_dp_c20241112__20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ExpireDecemberThirtyFirstTwoThousandAndTwentySevenMember_z03nACRSzW45" title="Warrants percentage">70</span>% of which expire December 31, 2027 at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ExpireDecemberThirtyFirstTwoThousandAndTwentySevenMember_zJ363lHbATVf" title="Warrants exercise price">0.15</span> for $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241112__20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zExMe9vH220i" title="Number of share issued, value">11,950</span> which were not part of the Regulation A+. The shares and warrants will be issued upon receipt of fully executed agreements and receipt of all funds.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></p> 11950000 1434000 11950000 0.30 0.01 0.70 0.15 11950